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Almost one century has passed since the discovery of the first antibiotic drug, yet bacterial 
infections remain a major threat to public health. Two alarming trends have been observed in the 
last decades: While no truly novel antibiotic drugs were developed, the emergence and spread of 
antimicrobial resistance dramatically increased. Therefore, a rational use of the existing antibiotic 
drugs is crucial. One key pillar of rational antibiotic treatment is the choice of an appropriate dosing 
regimen resulting in adequate antibiotic exposure at the site of infection. In special patient 
populations, such as critically ill patients or morbidly obese patients, appropriate dosing is 
particularly challenging since these patients commonly show certain patient-specific 
characteristics altering antibiotic exposure. 
The objective of the present thesis was to leverage pharmacometric modelling and simulation 
approaches in order to (i) enhance the understanding of the pharmacokinetics of antibiotic drugs in 
special patient populations, but also of the variability in the microdialysis technique – as the method 
of choice to determine drug exposure at target site, (ii) to evaluate and optimise antibiotic dosing 
regimens via adequate antibiotic exposure, and (iii) to translate the research results into the clinics 
supporting future therapeutic decisions. The thesis focused on the two antibiotic drugs ‘linezolid’ 
(Project I, II) and ‘meropenem’ (Project III, IV) in the selected special populations of ‘obese 
surgical patients’ and ‘critically ill patients’, respectively. 
Project I characterised the pharmacokinetics (PK) of linezolid in plasma as well as at the target site 
(interstitial space fluid of s.c. adipose tissue, representing a common location of infections) in obese 
compared to nonobese surgical patients: The distribution of linezolid to the target site was delayed 
and exposure was reduced compared to plasma. The body size descriptor ‘lean body weight’ 
together with the obesity status of the patient were identified as factors which had an impact on 
linezolid PK. Both factors led to lower exposure in obese patients compared to nonobese patients, 
with a particularly pronounced difference at the target site. Interestingly, also anaesthesia and the 
related haemodynamic changes were found to impact linezolid PK, which resulted in reduced 
linezolid tissue fluid distribution and excretion. In addition to the PK-related findings, Project I 
characterised the variability in the microdialysis technique by integrating all available 
microdialysis data into the pharmacometric model and by dissecting and quantifying various levels 
of variability (interpatient, intercatheter, intracatheter). While the interpatient variability was 
almost fully explained by the obesity status of the patient, the quantified inter- and intracatheter 
variability highlighted the importance of special care in the performance of microdialysis 
(calibration of catheter, placement of catheter etc.).  
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Project II, a simulation analysis, applied the developed pharmacometric model of linezolid to 
assess standard linezolid dosing regarding the attainment of effective linezolid exposure (i.e. 
attainment of a predefined PK/Pharmacodynamic target). In the setting of perioperative infection 
prophylaxis, single standard linezolid dosing only resulted in effective target site exposure for 
susceptible pathogens and/or for surgical procedures of short durations. Overall, an increase in the 
risk of ineffective exposure was observed with increasing body size. In the setting of acute therapy, 
standard linezolid dosing was related to high risk of ineffective linezolid exposure at the target site, 
partly even for susceptible pathogens and/or in plasma. Increasing the daily dose (from 1200 mg 
to 2400 mg) clearly reduced the risk of ineffective exposure. In general, also prolongation of the 
infusion duration (from 30 min to 4 h) or shortening of the dosing interval (from 12 h to 8 h) 
reduced the risk of ineffective exposure, yet, less pronounced than the intensification of the daily 
dose. For resistant pathogens, none of the investigated dosing alterations resulted in effective 
linezolid exposure, neither in obese nor in nonobese patients. 
Project III and IV characterised the PK of meropenem in a heterogenous critically ill patient 
population with severe infections. A large PK variability was observed between patients, which 
was to a large extent explained by the wide disparity in the patient characteristics: creatinine 
clearance (according to Cockcroft and Gault, CLCRCG), body weight and serum albumin 
concentration. Of these three characteristics, CLCRCG showed by far the strongest impact on the 
(non)-attainment of effective meropenem exposure. Patients with normal or augmented renal 
function were at highest risk of ineffective exposure. Increasing the daily dose of meropenem, but 
particularly increasing the infusion duration (from 30-min to 3-h prolonged and/or continuous 
infusion regimens) reduced the risk of ineffective exposure.  
In order to translate the findings into the clinics, two easy-to-use tools – the ‘MeroRisk Calculator’ 
and the ‘3-level dosing algorithm’ – were developed. By providing a simple and intuitive interface, 
both tools enable the application of the pharmacometric modelling and simulation results by health 
care professionals. The MeroRisk calculator is an Excel® tool, which allows assessing the risk of 
ineffective exposure when administering standard meropenem dosing, by considering a patient’s 
CLCRCG and the susceptibility of the identified/suspected pathogen. The 3-level dosing algorithm 
provides an intuitive dosing overview, which recommends dosing regimens likely to result in 
effective exposure. The algorithm is based on a patient’s CLCRCG, considers four different levels 
of knowledge about the infecting pathogen and for the first time the uncertainty in the underlying 
pharmacometric model for selection of meropenem dosing regimens.  
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To conclude, the present thesis contributed to a better understanding of the PK of clinically relevant 
antibiotic drugs in special patient populations and identified patient- and surgery-specific 
influencing factors altering antibiotic exposure in plasma and at the target site. By assessing the 
adequacy of standard and alternative antibiotic dosing regimens and translating the results into 
easy-to-use tools for clinical application, the present thesis has taken substantial steps towards 
therapeutic decision support to combat bacterial infections in the context of model-informed 
precision dosing. Future clinical studies are required to evaluate the tools with respect to clinical 
efficacy and safety before widespread application of the tools in clinical practice.  
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Zusammenfassung 
Seit der Entdeckung des ersten Antibiotikums ist fast ein Jahrhundert vergangen, dennoch stellen 
bakterielle Infektionen weiterhin eine ernsthafte Bedrohung für die öffentliche Gesundheit dar. In 
den letzten Jahrzehnten wurden zwei alarmierende Trends beobachtet: Während keine neuartigen 
Antibiotika entwickelt wurden, nahm das Auftreten und die Verbreitung von 
Antibiotikaresistenzen dramatisch zu. Daher ist eine rationale Anwendung der aktuell vorhandenen 
Antibiotika von entscheidender Bedeutung. Eine wichtige Säule in der rationale 
Antibiotikatherapie ist die Wahl eines geeigneten Dosierungsschematas, welches in einer 
adäquaten Antibiotikaexposition am Infektionsort resultiert. In speziellen Patientenpopulationen 
wie Intensiv- oder krankhaft adipösen Patienten ist eine geeignete Dosierung besonders 
herausfordernd, da diese Patienten häufig bestimmte patientenspezifische Merkmale aufweisen, 
welche die Antibiotikaexposition verändern.  
Ziel der vorliegenden Arbeit war es, pharmakometrische Modellierungs- und Simulationsansätze 
zu nutzen, um (i) das Verständnis der Pharmakokinetik von Antibiotika in speziellen 
Patientenpopulationen, aber auch der Variabilität in der Mikrodialysetechnik - als Methode der 
Wahl zur Bestimmung der Arzneistoffexposition am Wirkort – zu verbessern, (ii) die 
Antibiotikadosierung im Hinblick auf eine adäquate Antibiotikaexposition zu evaluieren und zu 
optimieren und (iii) die Forschungsergebnisse in die Klinik zu übertragen, um zukünftige klinische 
Dosierungsentscheidungen zu unterstützen. Die Arbeit konzentrierte sich auf die zwei Antibiotika 
‚Linezolid‘ (Projekt I, II) und ‚Meropenem‘ (Projekt III, IV) in den speziellen Populationen der 
‚adipösen chirurgischen Patienten‘ bzw. der ‚Intensivpatienten‘. 
In Projekt I wurde die Pharmakokinetik (PK) von Linezolid im Plasma sowie am Wirkort 
(Interstitialflüssigkeit des s.c. Fettgewebes, welche einen häufigen Infektionsort darstellt) in 
adipösen im Vergleich zu nicht-adipösen chirurgischen Patienten charakterisiert: Die Verteilung 
von Linezolid zum Wirkort war verzögert und die Exposition im Vergleich zum Plasma verringert. 
Die Körpermassenkennzahl ‚Lean Body Weight‘ wurde zusammen mit dem Adipositasstatus des 
Patienten als Einflussfaktoren für die PK von Linezolid identifiziert. Beide Faktoren führten in 
adipösen Patienten zu einer geringeren Linezolidexposition verglichen mit nicht-adipösen 
Patienten, wobei der Unterschied am Wirkort besonders ausgeprägt war. Interessanterweise zeigten 
auch die Anästhesie und die damit verbundenen hämodynamischen Veränderungen einen Einfluss 
auf die PK von Linezolid, was zu einer verminderten Gewebsverteilung und Ausscheidung von 
Linezolid führte. Neben den Ergebnissen zur Pharmakokinetik charakterisierte Projekt I zusätzlich 
die Variabilität in der Mikrodialysetechnik, indem alle verfügbaren Mikrodialysedaten in das 
pharmakometrische Modell integriert und verschiedene Variabilitätsniveaus (Inter-Patienten, 
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Inter-Katheter, Intra-Katheter) separiert und quantifiziert wurden. Während die Inter-Patienten 
Variabilität fast vollständig furch den Adipositasstatus des Patienten erklärt wurde, betonte die 
quantifizierte Inter- und Intra-Katheter Variabilität die Wichtigkeit einer besonderen Sorgfalt bei 
der Durchführung der Mikrodialyse (Kalibrierung des Katheters, Platzierung des Katheters usw.). 
Projekt II, eine Simulationsstudie, nutzte das entwickelte pharmakometrische Linezolidmodell um 
die Standarddosierung von Linezolid hinsichtlich des Erreichens einer effektiver Linezolid 
Exposition (d.h., Erreichen eines vordefinierten PK/Pharmakodynamischen Zielwertes) zu 
evaluieren. In der perioperativen Infektionsprophylaxe führte die einmalige Standarddosierung von 
Linezolid nur im Falle von empfindlichen Krankheitserregern und/oder chirurgischen Eingriffen 
von kurzer Dauer mit hoher Wahrscheinlichkeit zu einer effektiven Exposition am Wirkort. 
Insgesamt wurde ein höheres Risiko für ineffektive Exposition mit zunehmender Körpermasse 
beobachtet. In der Akuttherapie war die Standarddosierung von Linezolid mit einem hohen Risiko 
für ineffektiven Linezolidexposition am Wirkort verbunden, teilweise sogar für empfindliche 
Krankheitserreger und/oder im Plasma. Die Erhöhung der Tagesdosis von Linezolid (von 1200 mg 
auf 2400 mg), verringerte das Risiko einer ineffektiven Exposition deutlich. Im Allgemeinen 
verringerten auch eine Verlängerung der Infusionsdauer (von 30 min auf 4 h) oder eine Verkürzung 
des Dosierungsintervalls (von 12 h auf 8 h) das Risiko einer ineffektiven Exposition, jedoch 
weniger ausgeprägt als die Intensivierung der Tagesdosis. Bei resistenten Erregern führte keine der 
untersuchten Dosierungsänderungen zu effektiver Linezolid Exposition, weder bei adipösen noch 
bei nicht-adipösen Patienten. 
Projekt III und IV charakterisierten die PK von Meropenem in einer heterogenen Population von 
Intensivpatienten mit schweren Infektionen. Es wurde eine hohe PK-Variabilität zwischen den 
Patienten beobachtet, die sich zu einem Großteil durch starke Unterschiede in 
Patienteneigenschaften erklären ließ: Kreatinin-Clearance (gemäß Cockcroft und Gault, CLCRCG), 
Körpergewicht und Serumalbumin-Konzentration. Von diesen drei Charakteristika zeigte die 
CLCRCG bei weitem den stärksten Einfluss auf das (Nicht-)Erreichen einer effektiven 
Meropenemexposition. Patienten mit normaler oder erhöhter Nierenfunktion zeigten das höchste 
Risiko einer ineffektiven Exposition. Die Erhöhung der Tagesdosis von Meropenem, insbesondere 
aber die Verlängerung der Infusionsdauer (von 30-min auf 3-h prolongierte und/oder 
kontinuierliche Infusionsschemata) verringerten das Risiko einer ineffektiven Exposition.  
Um die Ergebnisse in die Klinik zu übertragen, wurden zwei einfach zu bedienende Tools 
entwickelt - der ‚MeroRisk Calculator‘ und der ‚3-stufige Dosierungsalgorithmus‘. Durch eine 
simple und intuitive Benutzeroberfläche ermöglichen beide Tools die Anwendung der 
pharmakometrischen Modellierungs- und Simulationsergebnisse durch Fachpersonal im 
Gesundheitswesen. Der MeroRisk Calculator ist ein Excel®-Tool, mit welchem das Risiko einer 
ineffektiven Exposition bei Verabreichung einer Standarddosierung von Meropenem beurteilt 
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werden kann, indem die CLCRCG des Patienten und die Empfindlichkeit des 
identifizierten/vermuteten Erregers berücksichtigt werden. Der 3-stufige Dosierungsalgorithmus 
bietet eine intuitive Dosierungsübersicht, welche Dosierungsschemata empfiehlt, die mit hoher 
Wahrscheinlichkeit zu einer effektiven Exposition führen. Der Algorithmus basiert auf der 
CLCRCG des Patienten, berücksichtigt vier verschiedene Wissensniveaus über den infektiösen 
Erreger, sowie erstmals die Unsicherheit in dem zugrunde liegenden pharmakometrischen Modell 
für die Auswahl von Dosierungsschemata. 
Zusammenfassend hat die vorliegende Arbeit zu einem besseren Verständnis der PK von zwei 
klinisch relevanten Antibiotika in speziellen Patientenpopulationen beigetragen und patienten- und 
operationsspezifische Einflussfaktoren identifiziert, welche die Antibiotikaexposition im Plasma 
und am Wirkort verändern. Durch die Beurteilung der Angemessenheit von Standard- und 
alternativen Antibiotika-Dosierungsschemata und der Translation der Ergebnisse in einfach zu 
nutzende Tools für die klinische Anwendung hat die vorliegende Arbeit wesentliche Schritte in 
Richtung einer therapeutischen Entscheidungshilfe zur Bekämpfung bakterieller Infektionen, im 
Kontext von modellgestützte Präzisionsdosierung, unternommen. Zukünftige klinische Studien 
sind erforderlich, um die Tools im Hinblick auf die klinische Wirksamkeit und Sicherheit zu 
bewerten, bevor sie in der klinischen Praxis eingesetzt werden. 
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Almost one century has passed since the discovery of the first antibiotic drug, and yet bacterial 
infections remain a major threat to public health [7]. As reported by the World Health Organisation 
(WHO), worldwide 3 million deaths were caused by lower respiratory infections in 2016 [8]. 
Certain subgroups of patient populations (‘special patient populations’) are particular vulnerable 
to infections: For instance, critically ill patients frequently suffer from severe infections (e.g. sepsis 
or septic shock), which are related to high mortality rates up to 60% [9–17]. The ‘golden age’ of 
antibiotic drug discovery lasted from 1940 to 1962; in the last three decades, however, no truly 
novel antibiotics have been developed [18–20]. Beyond that, the emergence and spread of 
antimicrobial resistance has been increasing, a natural process which, however, can be accelerated 
by inappropriate use of antibiotic drugs [21–24]. Fortunately, global awareness of the threat of 
infectious diseases is greater than ever and different national and internal action plans have been 
proposed. These stress not only the need of reinvigorating the antibiotic value change, but also 
highlight the importance of a more rational use of existing antibiotic drugs [19,25–28].  
 Key pillars of rational antibiotic treatment 
Key pillars of rational  antibiotic treatment 
Apart from developing novel antibiotic compounds, a rational use of the currently available 
antibiotic drugs is of vital importance to optimise the therapeutic outcome of the patients, to reduce 
the emergence of antimicrobial resistance and to preserve the antibiotics for future use [29]. 
Rational antibiotic treatment in human health comprises four key pillars (Figure 1.1 A) which will 
be outlined hereinafter.  
(1) The first pillar is the appropriate indication [30,31]. As highlighted by the WHO and the 
Antimicrobial Stewardship Working Groups of the International Society of Chemotherapy, 
evidence-based prescribing of antibiotics should be the standard of care, i.e. the prescription of 
antibiotic drugs should be based on clear suspicion or evidence of a bacterial infection [29,31]. 
Unnecessary use of antibiotics, e.g. for the treatment of viral infections, should be avoided. 
(2) The second pillar is the appropriate choice of the antibiotic, i.e. choosing an antibiotic drug 
which shows antibacterial efficacy against the causative pathogen based on the antibiotic’s 
spectrum of antibacterial activity. Microbiological diagnostics based on appropriate  
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microbiological samples before administration of the antibiotic can support an appropriate choice 
[31]. Yet, especially for vulnerable populations, such as critically ill patients, a prompt initial 
empirical antibiotic treatment is indicated [31,32]. The selection of the empirical treatment should 
be guided by e.g. local epidemiological data on microbiology and susceptibility patterns and a 
single patient’s medical history (e.g. previous infections, recent administration of antibiotics) 
[31,32]. Once the causative pathogen is identified based on microbiological diagnostics the 
antibiotic treatment should be adapted to target the pathogen most effectively [33].  
(3) The third pillar is the appropriate timing of the antibiotic therapy. For critically ill patients, 
studies revealed an association between each hour delay in the initiation of an appropriate antibiotic 
treatment and an increase in the mortality in presence of sepsis or septic shock [34–36]. Thus, 
appropriate antibiotic treatment is required as early as possible. The ‘International Guidelines for 
Management of Sepsis and Septic Shock’ by the Surviving Sepsis Campaign recommends the 
initiation of antibiotic therapy within the first hour after the diagnosis of sepsis or septic shock [37]. 
 
Figure 1.1: Four key pillars of rational antibiotic treatment (A) and the three determinants of adequate drug 
exposure (B). 
Abbreviations: C: Concentration; MIC: Minimum inhibitory concentration. 
(4) The fourth pillar is the appropriate dosing of the antibiotic drug resulting in adequate exposure 
at the site of infection where the pathogen is located [31,33]. Even if the infection is caused by a 
pathogen which is susceptible against the selected antibiotic drug (first and second pillar) and the 
treatment is initiated promptly (third pillar) antibiotic therapy might fail due to an inappropriately 
selected selected dosing regimen resulting in ineffective drug exposure. Previous studies have 
linked adequate antibiotic exposure to an improved clinical success [38–40]. Furthermore, 
appropriate dosing is also essential for prevention of emergence and spread of antimicrobial 
resistance in treated an future patients [41,42]. As illustrated in Figure 1.1 B, adequate antibiotic 
exposure depends on the triangular relationship between the antibiotic drug, the pathogen and the 
patient. In the following sections different aspects of the four key pillars for a rational antibiotic 
treatment will be further elucidated. 
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 Target site pharmacokinetics utilising the microdialysis technique 
Target site pharmacokinetics ut ilis ing  the microdialys is technique  
As already indicated in section 1.1, the attainment of adequate antibiotic exposure at the site of 
infection where the pathogen is located (i.e. the ‘target site’) is crucial for antibacterial efficacy 
[43,44]. Thus, reliable characterisation of the antibiotic target site pharmacokinetics (PK) is 
essential. In that regard, three key aspects need to be considered:   
(1) Several studies indicated substantial differences between tissue and plasma antibiotic PK, 
regarding exposure but also regarding kinetics (i.e. the shape of the drug concentration-time 
profile), both representing important determinants of the antibacterial effect [45–51]. The target 
site PK is determined by the distribution of the drug from the plasma to the respective tissue, which 
in turn may depend on both drug-specific and patient-specific characteristics [52]. While drug-
specific characteristics include physicochemical properties (e.g. lipophilicity), molecular size and 
plasma protein binding, patient-specific characteristics include alterations in blood flow/perfusion, 
capillary density, fluid shifts etc. The PK differences between tissue and plasma PK, as well as the 
fact that pathogens are mostly located in the extravascular space, i.e. outside the blood [53,54], 
highlight the value of characterising antibiotic exposure in the respective tissue of interest.  
(2) It is important to note that tissue is not a uniform matrix but consists of cells (intracellular 
space) and the interstitial space fluid (ISF) surrounding the cells (extracellular space). The vast 
majority of pathogens is localised in extracellular body fluids, only very few pathogens reside 
intracellularly [40,44]. Furthermore, intra- and extracellular antibiotic concentrations within one 
tissue may vary considerably: For instance, betalactam antibiotics exclusively distribute into the 
ISF [55], while quinolones show intracellular accumulation [56]. To reliably determine the 
antibiotic exposure at the target site, a quantification of the drug concentration in the respective 
tissue compartment is of interest, rather than in the homogenate of the tissue.  
(3) It is well known that only the unbound drug concentration is the driver of the pharmacological 
effect of a drug [57–59]. Thus, the focus should lie on characterising unbound, not total drug 
concentrations at the target site.  
One method that combines the three aforementioned key aspects is the microdialysis, a minimally 
invasive sampling technique which can be used to determine antibiotic drug concentrations directly 
at the target site.   
Historical aspects of microdialysis. The microdialysis methodology has its origin in the early 
mid-1980s. While in the first years the focus was on studying neurotransmitter release in the brain, 
from 1990 on, microdialysis was increasingly used to characterise tissue fluid distribution of drugs 
in various therapeutic areas (e.g. neurology, dermatology, oncology and infectiology [60]) but also 
of endogenous compounds (e.g. cytokines [61]). Particularly in the field of infectiology, several 
clinical microdialysis studies have been performed to assess the distribution of the antibiotics into 
the ISF of the tissue of interest (e.g. subcutaneous (s.c.) adipose, muscle, skin, lung, brain, liver, 
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kidney, bone, eye [62]). Today, microdialysis has been recognised by regulatory agencies as a 
suitable method to determine drug concentrations in non-homogenate tissues (European Medicines 
Agency (EMA): ‘Guideline on the use of Pharmacokinetics and Pharmacodynamics in the 
Development of Antibacterial Medicinal Products’ [63]).  
Microdialysis technique. The microdialysis employs the principle of dialysis, e.g. the passive 
diffusion of water and small solutes across a semipermeable membrane [64] and is graphically 
illustrated in Figure 1.2 A.  
 
Figure 1.2: Illustration of microdialysis (A) and retrodialysis (B), exemplified for the ISF of s.c. adipose 
tissue. 
Adipose tissue: consists of adipocytes (yellow), blood vessel (red) and ISF (white); Microdialysis system: consist of 
syringe/pump, catheter with semipermeable membrane and microvial; Green circles: Drug molecules; Blue arrows: Direction 
of perfusion flow.   
Abbreviations: ISF: Interstitial space fluid; s.c.: subcutaneous.  
For microdialysis sampling, a microdialysis catheter is inserted into the tissue fluid of interest (e.g. 
ISF, used as example in the subsequent text of this section) and constantly perfused with a drug-
free physiological solution, the so-called ‘perfusate’ [60]. If drug molecules become available in 
the ISF of the tissue, they will diffuse through the semipermeable membrane at the tip of the 
catheter along the concentration gradient into the drug-free perfusion fluid in the catheter. Due to 
the molar mass cut-off of the semipermeable membrane, which typically ranges from 6 to 100 kDa 
(typical: 20 kDa), only unbound drug molecules will diffuse via the membrane [65]. The drug-
containing fluid, the so-called ‘microdialysate’, is collected for a defined collection time interval 
in the microvial and its drug concentration is subsequently quantified. As the catheter is constantly 
perfused with the perfusate, an equilibrium at the semipermeable membrane will never be achieved. 
Consequently, the drug concentration in the microdialysate (𝐶𝑀𝑖𝑐𝑟𝑜𝑑𝑖𝑎𝑙𝑦𝑠𝑎𝑡𝑒), only represents a 
fraction of the actual ISF drug concentration (𝐶𝐼𝑆𝐹), termed ‘relative recovery’(𝑅𝑅) (Eq. 1.1). 𝑅𝑅 = 𝐶𝑀𝑖𝑐𝑟𝑜𝑑𝑖𝑎𝑙𝑦𝑠𝑎𝑡𝑒𝐶𝐼𝑆𝐹  ( Eq. 1.1) 
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In order to determine the relative recovery, which can be used to transform the measured 
microdialysate drug concentrations into the actual ISF drug concentrations, an in vivo calibration 
of every single catheter is required. Different methods have been proposed to estimate the relative 
recovery, yet the most widely accepted calibration approach is the so-called ‘retrodialysis’ also 
known as ‘reverse dialysis of the drug’ or ‘delivery’ [66].  
Retrodialysis technique. In contrast to the microdialysis setting, during retrodialysis, the catheter 
is perfused with a solution containing a defined concentration of the drug of interest, the so-called 
‘retroperfusate’ (Figure 1.2 B). The drug molecules will diffuse through the semipermeable 
membrane along the concentration gradient into the ISF of the tissue. The fluid leaving the catheter, 
the so-called ‘retrodialysate’ will be collected in the microvial and the remaining drug 
concentration quantified. By knowing the drug concentration that enters (retroperfusate, 𝐶𝑅𝑒𝑡𝑟𝑜𝑝𝑒𝑟𝑓𝑢𝑠𝑎𝑡𝑒) and leaves the catheter (retrodialysate, 𝐶𝑅𝑒𝑡𝑟𝑜𝑑𝑖𝑎𝑙𝑦𝑠𝑎𝑡𝑒), the loss via the 
membrane, also referred to as ‘relative delivery’ (𝑅𝐷), can be computed (Eq. 1.2). 
𝑅𝐷 = 𝐶𝑅𝑒𝑡𝑟𝑜𝑝𝑒𝑟𝑓𝑢𝑠𝑎𝑡𝑒 − 𝐶𝑅𝑒𝑡𝑟𝑜𝑑𝑖𝑎𝑙𝑦𝑠𝑎𝑡𝑒 𝐶𝑅𝑒𝑡𝑟𝑜𝑝𝑒𝑟𝑓𝑢𝑠𝑎𝑡𝑒  ( Eq. 1.2) 
This calibration method relies on the assumption that the loss (i.e. 𝑅𝐷) during retrodialysis equals 
the gain (i.e. 𝑅𝑅) during microdialysis sampling (Eq. 1.3). Hence, the experimentally determined 
relative delivery for a given catheter is equal to its unknown relative recovery and can be used to 
convert the microdialysate concentration into the actual ISF concentrations (𝐶𝐼𝑆𝐹) (Eq. 1.4, i.e. 
rearranging Eq. 1.1.  𝑅𝐷 = 𝑅𝑅 ( Eq. 1.3) 
𝐶𝐼𝑆𝐹 = 𝐶𝑀𝑖𝑐𝑟𝑜𝑑𝑖𝑎𝑙𝑦𝑠𝑎𝑡𝑒𝑅𝑅  ( Eq. 1.4) 
In the following of the thesis, solely the term ‘relative recovery’ will be used to describe the loss 
during retrodialysis and the gain during microdialysis.   
Parameters impacting relative recovery. The relative recovery is dependent on several 
parameters, including system-specific parameters, such as flow rate, temperature and composition 
of perfusate, molar mass cut-off and surface of the semipermeable membrane, but also drug-
specific parameters, such as molar mass or adsorbing characteristics of the drug to the material of 
the catheter or the tubing material [66,67]. Hence, in vitro investigations prior to the clinical study 
are recommended to determine optimal conditions for the in vivo micro- and retrodialysis [60]. In 
addition, also patient-specific parameters have been described to influence the relative recovery. 
First of all, it is well known that the in vitro relative recovery is typically higher than the in vivo 
relative recovery, which is why in vivo retrodialysis is required for catheter calibration [65]. This 
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has been explained by different movement rates of the molecules in the ISF of the tissue in vivo, 
compared to the in vitro situation in which a buffer solution is used to mimic the ISF [60]: While 
in the buffer solution the molecules can freely move, in the ISF of the tissue, tortuosity caused by 
cellular structures in the extracellular matrix and connectivity of the spaces, results in a longer 
diffusion path of the molecules to reach the semipermeable membrane [60,65]. Furthermore, 
different relative recovery values have been described for the same drug for different tissues, 
presumably related to physiological characteristics of each tissue [68]. Furthermore, intracerebral 
microdialysis studies identified the clearance of an analyte from the site of measurement, by 
cellular uptake, to impact the relative recovery [69–71].  
 Special patient populations 
Special  patie nt populations  
Whether an antibiotic dosing regimen will result in adequate drug exposure also depends on the 
patient who is treated with the antibiotic drug (Figure 1.1 B). Patient-specific characteristics such 
as physiological factors (e.g. age), pathophysiological factors (e.g. renal impairment), or genetic 
factors (e.g. genotype), but also comedications, comorbidities or environmental factors may impact 
the PK of the antibiotic drug and hence influence drug exposure. In the following, the two special 
patient populations ‘obese surgical patients’ and ‘critically ill patients’ will be introduced as the 
key populations of the present thesis. The focus is set on the clinical relevance of antibiotic 
treatment in these patient groups and on special characteristics which might impact drug PK. 
1.3.1 Obese surgical patients 
Worldwide, the number of obese patients, i.e. patients characterised with an excessive 
accumulation of fat that may impair their health (according to WHO: BMI>30 kg/m2 [72]), has 
dramatically increased in the recent decades [73]. According to WHO, from 1975 to 2016, the 
prevalence of obesity has almost tripled, with 13% of the adult population worldwide being obese 
in 2016 [72].  
Clinical relevance of antibiotic treatment. Emerging data indicate an association between 
obesity and the risk and outcome of infections [74,75]. In particular for surgical interventions, 
various prospective and retrospective studies have demonstrated an increased risk of postoperative 
wound infections and associated morbidity and mortality in obese patients compared to nonobese 
patients [76–81]. One type of surgery increasingly used in the obese population is the bariatric 
surgery, or ‘weight loss surgery’, which is suggested for obese patients not responding to non-
surgical treatments and showing a BMI of ≥40 kg/m2 or ≥35 kg/m2, the latter in combination with 
one or more obesity-associated serious diseases [81–83]. In addition to a significant and sustainable 
weight loss, bariatric surgery has been associated with an improvement of obesity-related 
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comorbidities and a reduction in mortality [84–88]. Given the increased risk of surgical site 
infections and associated morbidity and mortality in the obese population, perioperative antibiotic 
infection prophylaxis has been recommended for bariatric surgery [81]. Yet, the selection of an 
appropriate dosing regimen remains challenging, considering that a variety of 
(patho-)physiological changes related to obesity and/or the performed surgery might impact the 
antibiotic PK and thus drug exposure.   
Special characteristics. In an obese person, both fat mass (FM) and lean body weight (LBW) are 
increased compared to a nonobese person, with LBW accounting for 20%-40% of the excess of 
body weight [89,90]. The increase in body size has been linked to an increased volume of 
distribution for various lipophilic and hydrophilic drugs; yet, different body size descriptors (e.g. 
total body weight, adjusted body weight) have been identified as determinant [90,91]. Furthermore, 
cardiac output has been shown to be increased in obese patients resulting in an increased blood 
flow to the organs; however, the blood flow into the adipose tissue has been described to be reduced 
[91–93]. The increase in blood flow to eliminating organs (e.g. kidney, liver) together with the 
increase in organ size, might result in an increased drug clearance [90,93]. Yet, obese patients 
frequently suffer from obesity-related comorbidities (e.g. diabetic nephropathy, hepatic 
dysfunctions), which on the other hand might impair the excretion capacity of the eliminating 
organs [90]. Furthermore, obesity has been suggested to impact the activity of different cytochrome 
P450 (CYP) enzymes, yet the direction of impact appears to be isozyme-specific [94–96].   
In obese patients undergoing a surgical intervention, also surgery-related factors might impact the 
drug PK, however, limited information is available to date. Anaesthesia has been discussed to alter 
the blood flow to eliminating organs or to impact enzyme activities, which in turn potentially alter 
drug elimination [97,98]. In addition, post-surgical pathophysiological changes have been 
described, e.g. the occurrence of renal impairment, which might impact the clearance of renally 
excreted drugs [99]. 
1.3.2 Critically ill patients 
The special patient population of critically ill patients is a highly vulnerable patient population, 
characterised by severe or life-threatening illness that is associated with profound 
pathophysiological changes requiring an intensive and specialised care, aggressive medical 
interventions and intensive monitoring [100,101].   
Clinical relevance of antibiotic treatment. Infections in critically ill patients remain a major 
concern, due to high prevalence (~50% [17]) and high mortality rates: For instance, for severe 
infections such as sepsis or septic shock, mortality rates in intensive care units (ICU) reach up to 
60%. [9–17]. There are two major challenges in the antibiotic treatment of critically ill patients. 
Firstly, infections are typically caused by less susceptible pathogens compared to infections in non-
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critically ill patients on general wards [101]. For instance, in Germany, for the carbapenem 
antibiotic meropenem, considerably higher minimum inhibitory concentration (MIC; 
Section 1.4.1.1) values were overserved for pathogens detected in patients on the ICU compared 
to non-ICU patients: The MIC90 values (i.e. MIC value required to inhibit the growth of 90% of 
isolates) for all pathogens combined, were 8 mg/L and 1 mg/L, respectively [102]. The second 
major challenge is related to the high heterogeneity of patient-specific characteristics observed in 
ICU patients, which might result in high PK variability, making the selection of an appropriate 
dosing regimen more difficult.  
Special characteristics. Critically ill patients are commonly characterised by a combination of 
diverse pathophysiological alterations. Haemodynamic changes, towards hyperdynamic 
circulation, are frequently observed in critically ill patients [103]. This characteristic has been 
discussed to be related to the systemic inflammatory response syndrome, which is observed in 
various clinical conditions, e.g. sepsis, burns, major surgeries [104,105]. The systemic 
inflammation might lead to decreased vascular resistance and increased cardiac output, which 
together with treatment interventions (e.g. fluid resuscitation, vasopressors), might cause the 
hyperdynamic state [101,106]. The related increase in blood flow to the eliminating organs, might 
result in increased drug clearance. In terms of kidney, this phenomenon is called ‘augmented renal 
clearance’, which has been described to be related to the clearance of renally excreted drugs 
[101,106]. Apart from the haemodynamic changes, critically ill patients might show altered fluid 
balance as a result of various factors. The systemic inflammatory response syndrome can lead to 
endothelial cell damage and increased vascular permeability, resulting in the so-called ‘third 
spacing’, an extravasation of fluid into the interstitial space of the tissues [101,107]. To avoid 
hypotension, fluid resuscitation is typically administered in the clinics, which might lead to further 
fluid shift into the interstitial space. This altered fluid balance might impact the drug distribution, 
particularly of hydrophilic drugs [101,108,109]. The increased vascular permeability might not 
only result in an extravasation of fluid, but also in a leakage of albumin into the ISF, which is 
discussed as the main cause of hypoalbuminemia, a frequently observed characteristic of critically 
ill patients [110,111]. The reduced serum albumin concentrations might result in a higher fraction 
of unbound drug in plasma, thereby increasing drug distribution and/or clearance, particularly of 
highly protein-bound drugs [112]. Furthermore, organ dysfunction(s) of one or multiple organs are 
frequently observed in critically ill patients and are one of the major causes of mortality in the 
critically ill patient group [113,114]. Especially when drug eliminating organs such as kidney or 
liver are affected (i.e. renal or hepatic impairment), the drug clearance may be reduced [101]. In 
the presence of organ failure, critically ill patients might require extracorporeal organ support: e.g. 
renal replacement therapy (RRT) for kidney support or extracorporeal membrane oxygenation 
(ECMO) for lung support [101,115]. RRT has been described to potentially impact the drug 
clearance; however, the impact seems to be highly variable and depend on various factors, such as 
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RRT-related characteristics (e.g. mode, filter type, blood flow rate) as well as drug-related 
physicochemical and PK characteristics (e.g. lipophilicity, protein binding) [101,116–119]. ECMO 
is a relatively new organ support procedure, which seems to have a less pronounced impact on the 
PK when compared to the influence of the critically illness itself [120]. Yet, clinical and nonclinical 
investigations are currently ongoing to better characterise the impact of ECMO on drug PK 
[121,122]. 
 Antibiotic pharmacokinetics/pharmacodynamics and key 
antibiotic drugs 
Antibiotic pharmacokinetics/pharmacodynamics and key antibiotic drugs  
As described before, the adequacy of antibiotic drug exposure depends on the antibiotic drug itself 
(Figure 1.1): While on the one hand the PK characteristics of the drug and the patient-specific 
characteristics (Section 1.3) determine the achieved drug exposure, the pharmacokinetic/ 
pharmacodynamic (PK/PD) relationship of the antibiotic drug and the susceptibility of the 
pathogen, defines the adequacy of antibiotic exposure with respect to the antibacterial efficacy. 
This chapter provides an introduction in the general concepts of PK/PD relationships of antibiotics 
(Section 1.4.1), followed by an introduction in the key antibiotic drugs of the present thesis 
(Section 1.4.2). 
1.4.1 Pharmacokinetics/pharmacodynamics of antibiotic drugs 
The PK/PD relationship of an antibiotic agent represents the key determinant of antibacterial 
efficacy and is characterised by the triangular relationship between the antibiotic drug exposure 
(i.e. PK), the in vitro antibacterial activity of the antibiotic (i.e. MIC) and the effect of the antibiotic 
(e.g. clinical cure) [117,123]. This relationship is typically described by so-called ‘PK/PD targets’. 
Before elucidating PK/PD targets in more detail, the minimum inhibitory concentration and the 
PK/PD indices will be introduced.  
1.4.1.1 Minimum inhibitory concentration and breakpoints  
A well-established standard measure to describe antibacterial activity of an antimicrobial agent 
against a pathogen is the MIC, which can be determined in vitro by susceptibility testing methods 
(discussed in detail elsewhere [124–126]). The MIC is defined as the concentration of an antibiotic 
drug that prevents visible growth of the bacterium under defined conditions [127,128]. Hence, it 
provides valuable information on the susceptibility of a pathogen against the antibiotic drug: The 
higher the MIC value, the less susceptible the pathogen against the antibiotic agent. In contrast to 
other in vitro PD models (e.g. static/dynamic time-kill curve experiments [129]), the MIC has the 
advantage of a relatively simple determination, only requiring a single measurement after a defined 
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time point. Accordingly, the MIC reflects a snapshot of antimicrobial activity at one single time 
point, however, does not provide information on the growth-kill behaviour of the pathogen over 
time [129,130]. Despite the relatively simple determination, a routine determination of the MIC in 
the clinics is still rare – even in the vulnerable ICU setting [131]. Beyond that, susceptibility 
categories (see below) are frequently reported instead of MIC values [131].  
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) reports MIC 
distributions of microorganisms based on MIC data originating from worldwide sources [132] and 
classifies isolates depending on their MIC values for a given antimicrobial agent into three 
categories ‘susceptible at normal dosing’ (S category), ‘susceptible at increased exposure’ 
(I category) and ‘resistant’ (R category) in order to provide information about the likelihood of 
therapeutic success [4]. To that end, species-specific MIC breakpoints are defined for an 
antimicrobial agent, separating the three abovementioned categories for a specific microorganism: 
‘S breakpoint’ (separates isolates of the S and I category), ‘R breakpoint’ (separates isolates of the 
I and R category) [5,133]. In case species-specific MIC breakpoints do not exist for a given 
microorganism, non-species related PK/PD breakpoints (likewise: S and R breakpoints) of the 
antimicrobial agents are provided [5,134]. Although the MIC breakpoints represent a simple way 
of assessing the potential likelihood of therapeutic success in the clinics, the individual PK of a 
patient is not considered in the evaluation, which may be of particular importance for special patient 
populations that are oftentimes characterised by highly altered pharmacokinetics (Section 1.3). 
1.4.1.2 PK/PD indices and targets  
In contrast to the MIC breakpoints, which only consider 
the susceptibility of the pathogen for assessment of dosing 
adequacy, so-called ‘PK/PD indices’ and their ‘PK/PD 
targets’ additionally consider the pharmacokinetics of a 
patient. For antibiotic agents, different patterns of 
antibacterial activity have been observed: Concertation-/ or 
time-dependent antibacterial activity with or without 
prolonged persistent effects [129,135]. Depending on the 
pattern of antibacterial activity of antibiotic agents, three 
major PK/PD indices have been described which best 
relate to antibacterial activity (Figure 1.3): (i) Cmax/MIC, 
i.e. the ratio of the maximum drug concentration and the MIC, (ii) AUC/MIC, i.e. ratio of the area 
under the drug concentration-time profile and the MIC, (iii) T>MIC, i.e. the time period that the drug 
concentration exceeds the MIC [129,135]. These PK/PD indices are typically determined using 
dose fractionation studies in in vitro or in vivo animal models [136] and are usually related to 24-h 
treatment period and derived for the unbound – also referred to as free – drug concentration (i.e. 
 
Figure 1.3: Graphical illustration of 
antibiotic PK/PD indices. 
Abbreviations: AUC: Area under the curve; 
Cmax: Maximum concentration; MIC: 
Minimum inhibitory concentration; T>MIC: 
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fAUC/MIC, fCmax/MIC, fT>MIC; f indicates free drug concentration).  
While the PK/PD indices describe the relationship between a PK measure (e.g. AUC, Cmax) and a 
PD measure (MIC) which is driving the efficacy, the PK/PD target provides information of the 
magnitude of the PK/PD index required for the desired efficacy of the antibiotic drug, which could 
for instance be the reduction in bacterial load, bacterial eradication, clinical cure or survival [129]. 
PK/PD targets can be derived from in vitro models or in in vivo studies both in animals or in 
patients, which have been shown to be overall in good agreement [135]. Today, PK/PD targets 
present a valuable tool to support the identification of an appropriate dosing regimen for newly 
developed antibiotic drugs in drug discovery and development in pharmaceutical industry, but 
particularly also for the dosing selection of already approved antibiotic drugs for the treatment of 
special patient populations in clinical practice [129,137]. How PK/PD targets can be utilised to 
identify appropriate dosing regimens is introduced in section 2.4.3. 
1.4.2 Key antibiotic drugs 
In the following, the key antibiotic drugs of the present thesis, linezolid and meropenem, will be 
introduced with respect to spectrum of activity, indication, dosing, PK, PK/PD targets and safety. 
1.4.2.1 Linezolid 
Spectrum of activity, indications and dosing regimens. Linezolid is the first representative of 
the class of oxazolidinone antibiotics and was approved for clinical use in 2000 [129,138]. 
Linezolid interferes with the protein biosynthesis of the pathogens by targeting the bacterial 
ribosomes. In contrast to other antibiotics interfering with the protein biosynthesis, linezolid 
inhibits the initiation of the bacterial translation in a very early step by blocking the formation of 
70S initiation complex [139]. This unique mechanism of action avoids cross-resistances with most 
of the other commonly used antibiotic groups [138]. Linezolid displays antibacterial activity 
against the vast majority of clinically relevant gram-positive pathogens, including multidrug 
resistant strains such as Methicillin-resistant Staphylococcus aureus (MRSA) or Vancomycin-
resistant Enterococcus (VRE) [138,140]. In light of this favourable spectrum of activity, linezolid 
treatment plays an important role in the ICU setting, given the high prevalence of infections caused 
by multidrug resistant gram-positive pathogens and the high mortality rates following severe 
infections [10]. Linezolid is approved for the treatment of nosocomial and community-acquired 
pneumonia and skin and soft tissue infections [139]. The approved standard dosing regimen for 
adults includes 600 mg linezolid administered either orally or as short-term intravenous (i.v.) 




Pharmacokinetics. Linezolid is a small molecule (molar mass: 337 mg/L [141]) with slight 
lipophilic character (logDpH7.4=0.64 [142]). The bioavailability of linezolid is nearly 100% and is 
not significantly affected by food intake, thus oral and i.v. formulations are considered equivalent 
[45,139,143]. Linezolid shows a relatively low plasma protein binding (~10-30%, concentration-
independent) and has been shown to distribute into different tissues (e.g. epithelial lining fluid of 
the lung [129,138,139,144]). The volume of distribution of linezolid approximates to total body 
water (~40-50 L [139,145,146]). Linezolid clearance comprises both renal and nonrenal clearance 
[144]. The renal clearance of linezolid is relatively low (average 40 mL/min), which indicates 
tubular reabsorption [144,145]. The nonrenal clearance accounts for 65% of the total linezolid 
clearance and includes metabolism of the morpholine ring by oxidation. Linezolid is metabolised 
to two major inactive (i.e. without significant antibacterial activity) metabolites: The 
aminoethoxyacetic acid metabolite (metabolite A) and the hydroxyethyl glycine metabolite 
(metabolite B), the latter being the predominant metabolite in humans [139,144,147]. Yet, the 
metabolic pathways are not fully understood. For metabolite B, in vitro studies indicated that the 
formation is mediated by a chemical oxidation mechanism rather than by enzymatic oxidation 
[144,148]. Based on the presumed non-enzymatic metabolism in vitro, it is hypothesised that the 
oxidation in vivo may proceed throughout the entire body [147]. As for the parent substance, the 
two main metabolites are primarily excreted via the urine (proportion of dose under steady-state 
conditions: 30%, 10% and 40% as parent substance, metabolite A and B, respectively) and 
additionally to a small extent in faeces (3% and 6% as metabolite A and B, respectively [144]).  
PK/PD targets. Previous in vitro investigations as well as in vivo studies in animals and in patients 
have been performed to define a PK/PD index that best correlates with the antimicrobial efficacy 
of linezolid [149–152]. The investigations revealed two relevant PK/PD indices for linezolid, 
AUC/MIC and T>MIC. For instance, Andes et al. demonstrated in an in vivo neutropenic mice model 
with thigh infections, for an AUC24/MIC ratio of 82.9 (mean, SD=57.3), bacteriostatic activity 
against Staphylococcus (S.) aureus [150]. Sanberg et al., who investigated the activity of linezolid 
against S. aureus in vitro and in vivo in a mice peritonitis model, associated fAUC24/MIC of 100 
together with fT>MIC of 100% with an improved infection outcome [149]. In an in vivo rat model 
with Streptococcus (S.) pneumoniae, Gentry-Nielson et al. related the two PK/PD targets 
fAUC24/MIC>147 and fT>MIC>39% to favourable outcomes [151]. Rayner et al. investigated clinical 
linezolid PK/PD data originating from critically ill patients, regarding a correlation with clinical 
success (bacterial eradication and clinical cure) [153]. According to the data, an increased clinical 
success was observed for T>MIC of around 85% in patients with bacteraemia as well as for 
AUC24/MIC values of 80-120 in patients with bacteraemia, skin and soft tissue infections and lower 
respiratory tract infections.  
Safety. The most common adverse drug reactions associated with linezolid treatment are diarrhoea, 
headache and nausea [144]. However, especially after long-term linezolid treatment, rare but 
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serious adverse drug reactions have been described, that include thrombocytopenia, peripheral and 
optic neuropathy, and lactic acidosis [129,154,155]. 
1.4.2.2 Meropenem 
Spectrum of activity, indications and dosing regimens. Meropenem is a broad-spectrum 
carbapenem betalactam antibiotic, which exhibits bactericidal activity by inhibiting the synthesis 
of the bacterial cell wall via binding to and inactivation of the penicillin-binding protein [156]. 
Meropenem is active against both gram-negative and gram-positive pathogens, including less 
susceptible pathogens, e.g. Pseudomonas (P.) aeruginosa, Acinetobacter spp., as well as extended-
spectrum β-lactamase and AmpC-producing Enterobacteriaceae [157]. It is therefore frequently 
used to treat severe bacterial infections in critically ill patients [158]. Meropenem is approved for 
the treatment of e.g. complicated skin and soft tissue infections, complicated intra-abdominal 
infections, severe pneumonia or complicated urinary tract infections [33]. For these indications, 
the approved standard dosing regimens for adults (intact renal function) include 500 mg or 
1000 mg administered as short-term infusions every 8 h (q8h); for other indications (e.g. 
meningitis), doses up to 2000 mg are recommended [157]. For patients with creatinine clearance 
(CLCR) ≤50 mL/min, dose adjustment is suggested, e.g. for patients with CLCR
 
of 10–25 mL/min, 
half of the indicated dose every 12 h (q12h) is recommended [157].  
Pharmacokinetics. Meropenem is a hydrophilic molecule (logDpH7.4=-4.36 [157]) with low molar 
mass (383 g/mol [159]) and with a very low plasma protein binding of 2% [160]. It is excreted 
primarily via the kidneys (98%, 2% via faeces [157]), predominantly by glomerular filtration, but 
also by active tubular secretion via organic anion transporters (OAT) (namely OAT1 and OAT3 
[161,162]). While the major proportion of the dose is excreted as parent substance (~70%), the 
remaining proportion is nearly completely excreted renally as inactive beta-lactam ring-opened 
metabolite (28%), which is likely to be formed by the renal dehydropeptidase-1 [157,158]. 
Meropenem has been shown to be readily dialysable and effectively removed by RRT [157].   
PK/PD target. As a β-lactam antibiotic, meropenem shows time-dependent activity; i.e. its 
antimicrobial efficacy is linked to the time that meropenem concentrations exceed the MIC value 
of a pathogen (T>MIC) [163]. Various investigations focused on the identification of a respective 
PK/PD target value. For instance, Craig (results reported by Drusano [164]) and Ong et al. [165], 
who investigated the activity of meropenem against Escherichia (E.) coli and P. aeruginosa in a 
mouse thigh infection model, associated fT>MIC of 40% with a maximum bacterial kill activity. In 
a clinical study by Crandon et al., clinical success and survival in patients with P. aeruginosa 
ventilator-associated pneumonia were linked to fT>MIC of 19.2% and 47.9%, respectively [166]. 
Furthermore, Li et al. associated the attainment of the target fT>MIC of 54% to microbiological 
response in patients with lower respiratory tract infections [167]. For febrile neutropenic patients 
with bacteraemia, Ariano et al. demonstrated an increased clinical response rate of 80% when 
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fT>MIC was 76–100% [168]. Furthermore, McKinnon et al. demonstrated a significantly increased 
clinical cure and bacteriological eradication for the target T>MIC of 100%, in patients with serious 
bacterial infections treated with betalactam antibiotics [169].   
Additional in vitro [42,170] and in vivo investigations [167,169] for meropenem and other 
betalactam antibiotics suggested an improved antibiotic efficacy for drug concentrations that 
achieved ~5 (range: 4-6.3) times the MIC value during the dosing interval.  
Safety. Overall, meropenem shows a relatively good safety profile [171]. Most commonly 
occurring adverse events include diarrhoea, rash and nausea/vomiting [157]. For high meropenem 
exposure, an increased risk of developing neuro- and nephrotoxicity has been described (minimum 
concentrations>64.2 mg/L and 44.5 mg/L, respectively [172]).  
 Pharmacometrics and its application towards therapeutic 
decision support in infectious diseases 
Pharmacometrics and its application towards therape utic decision support in infectious  diseases  
First introduced in the 1970s, the science 
of pharmacometrics constitutes a research 
area, combining disciplines such as 
pharmacology, medicine, clinical 
pharmacy, mathematics, statistics and 
computational methods (Figure 1.4).  
Pharmacometrics develops and applies 
quantitative mathematical and statistical 
modelling and simulation approaches with 
the overall aim to better understand and 
characterise a system (e.g. a patient) and 
to identify, describe, quantify and predict 
the relationships between the system, a 
drug and/or a disease [173,174]. Thereby, 
the focus is on elucidating the interactions between the dosing schedule of the drug, the drug 
concentration-time profile (pharmacokinetics, ‘what the body does to the drug’), the drug effect-
time profile (pharmacodynamics, ‘what the drug does to the body’) and the therapeutic outcome or 
disease progression [173], by means of pharmacometric models (overview on pharmacometric 
modelling concepts: Section 2.1).   
In pharmaceutical industry, ‘model-informed drug discovery and development’ has become an 
increasingly important field, which supports an accelerated, efficient and cost-effective 
development of safe and effective drugs [173,175–179]. The application of pharmacometric 
 
Figure 1.4: Multidisciplinarity of pharmacometrics. 
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modelling and simulation approaches spans across all stages of pharmaceutical drug development, 
ranging from drug discovery over pre-clinical and clinical drug development to life cycle 
management [176,177] and is encouraged by regulatory agencies, such as the EMA or US Food 
and Drug Administration (FDA) [180,181]. While in the past, dosing regimens in the drug label 
focused mostly on the average patient, today, regulatory agencies started to adjust the labelled 
dosing for certain patient subpopulations, based on pharmacometric analyses, when a supportive 
database is available [180,182]. Yet, in phase III studies, the enrolment of patients is typically 
restricted by patient-specific characteristics (i.e. inclusion/exclusion criteria [183]). Thus, the 
collected data is likely to not fully reflect the diversity of the ‘real-world’ patient population, which 
will use the approved drug in clinical practice. Special patient subgroups might show patient-
specific characteristics outside the eligibility criteria of phase III studies, which could however 
alter the PK and/or PD and therefore demand dose adjustment [184].  
A commonly used strategy to select an appropriate dosing regimen after therapy initiation in 
clinical practice is therapeutic drug monitoring (TDM), which is based on collected PK blood 
samples [185]. TDM is applied since the early 1970s and was historically employed to reduce 
toxicity rather than to improve efficacy, for drugs with a narrow therapeutic range (e.g. 
aminoglycosides) [186]. However, in light of the emergence of antimicrobial resistance, TDM is 
more frequently used also for the rarely toxic betalactam antibiotics, with the primary aim to 
improve efficacy by attaining adequate antibiotic exposure [186,187]. In the critically ill patient 
group, TDM of betalactam antibiotics is of particular importance [186,187], as the patients exhibit 
highly altered PK, tend to be infected with less susceptible pathogens, and show high mortality 
rates up to 60% related to severe infections (Section 1.3.2; [9–15,101,102,186,187]).  
Beyond that, in the recent years pharmacometric modelling and simulation has gained increasing 
attention in clinical practice with respect to dosing individualisation: The new and promising 
concept of ‘model-informed precision dosing’, aims to apply pharmacometric models, mostly so-
called ‘nonlinear mixed-effects’ (NLME) models (Section 2.3), in order to individualise drug 
dosing based on patient-specific characteristics [182,188,189]. Model-informed precision dosing 
can also be applied in situations in which no PK blood sample is available as the pharmacometric 
model together with patient-specific characteristics can be used to predict the PK of a patient. Thus, 
it enables individualised dosing recommendations already prior to the initiation of drug therapy. In 
the field of antiinfectives, the ‘probability of target attainment’ (PTA) analysis has proven to be a 
powerful concept to assess the adequacy of antiinfective dosing regimens and to ultimately support 
the selection of appropriate dosing regimens (for further details on PTA see Section 2.4.3; 
[129,190]). The PTA analysis, which has also been recommended by EMA [63], allows to assess 
various dosing regimens (e.g. altering dose, infusion duration, dosing frequencies etc.) with respect 
to the attainment of existing PK/PD targets (Section 1.4.1.2) for a given patient-pathogen 
combination and, based on the results, to select the most appropriate dosing regimen. Thereby, 
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pharmacometric modelling and simulation provides an important tool for model-informed 
precision dosing at bedside with the ultimate potential to support therapeutic decisions. 
 Objectives 
Objectives 
To date, the identification of appropriate antibiotic dosing regimens remains a major challenge in 
our health care system. An appropriate antibiotic dosing regimen resulting in adequate antibiotic 
exposure at the site of infection (i.e. the target site) is an essential prerequisite for antibacterial 
efficacy and related therapeutic outcome in the patients as well as prevention of emergence and 
spread of antimicrobial resistance. A sampling technique to determine the drug exposure directly 
at the target site is the microdialysis, a rather new method which still requires basic research to be 
better characterised. Adequate antibiotic exposure depends on the antibiotic drug as well as on the 
susceptibility of the pathogen causing the infection. In addition, patient-specific characteristics may 
impact antibiotic exposure, which is of particular importance for special patient populations (e.g. 
critically ill or obese patients), who exhibit altered patient-specific characteristics (e.g. impaired 
organ function or altered body composition). Consequently, an adjustment of the antibiotic dosing 
regimen for special patient populations might be required to attain adequate antibiotic exposure. 
Today, even for routinely used antibiotic drugs the relation between patient, pathogen and 
antibiotic drug as well as the implications on the dosing regimens have not yet fully been assessed 
and the translation of the results into clinical application is lacking.  
The central objective of the present thesis was to leverage pharmacometric approaches in order to: 
• enhance the understanding of the PK of antibiotic drugs in special patient populations, but 
also of the variability in the microdialysis sampling technique, 
• evaluate and, if needed, optimise antibiotic dosing regimens in special patient populations 
via an adequate antibiotic exposure, and to 
• translate the research results back into the clinical practice to ultimately support future 
therapeutic decisions. 
Thereby, the present thesis covered objectives within the research categories ‘basic research’, 
‘applied research’ and ‘translational research’ as depicted in Figure 1.5.  
In the following, a detailed description of the project-specific objectives is provided. For each 
objective the respective research category is stated as well as the motivation/research question 




Figure 1.5: Graphical overview of the central objectives of the present thesis and their research categories. 
The three coloured outer triangles summarise the objectives (dark blue font) and respective research categories (black font, i.e. 
basic, applied and translational research) of the present thesis; the inner white triangle depicts the approach employed to achieve 
these objectives. 
Project I: Characterisation of linezolid plasma and target site exposure in obese and nonobese 
surgical patients, including the evaluation of the microdialysis methodology.  
Research category: Basic research 
• Why? The objective of the project was to (i) better characterise the PK of total and 
unbound linezolid in plasma and of unbound linezolid at the site at risk of wound 
infection (i.e., target site: interstitial space fluid of subcutaneous adipose tissue) and to 
(ii) identify and quantify the impact of patient- and/or surgery-specific factors on the 
PK of linezolid. In addition, this project focused on (iii) the evaluation of variabilities 
in the microdialysis technique as the method of choice to determine target site 
exposure. 
• How? The project employed the NLME modelling and approach to develop a joint 
model which simultaneously describes PK- and methodology-related aspects, plasma 
and target site PK and includes patient- and surgery-specific characteristics impacting 
the PK of linezolid. The project further aimed to apply this model by performing 
deterministic and stochastic simulations to explore the PK of linezolid in plasma 
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compared to target site and for patients with varying patient- and surgery-specific 
characteristics.  
Project II: Evaluation and optimisation of linezolid dosing regimens for infection prophylaxis and 
acute therapy in obese and nonobese surgical patients. 
Research category: Applied research 
• Why? This project aimed to evaluate the adequacy of standard linezolid dosing in the 
setting of infection prophylaxis and acute infection therapy. For acute therapy, this 
project further sought to assess alternative linezolid dosing regimens in order to 
optimise linezolid dosing. 
• How? The project utilised the NLME PK model (developed in Project I) for stochastic 
Monte Carlo (MC) simulations, in order to evaluate the probability of PK/PD target 
attainment in plasma and at the target site for standard and alternative linezolid dosing 
regimens. 
Project III: Development of a risk assessment tool to evaluate standard meropenem dosing in 
critically ill patients with respect to ineffective meropenem exposure. 
Research category: Basic research  
• Why? The first objective of this project was to assess the impact of renal function on 
meropenem exposure. 
• How? The project developed a regression model to quantify the relationship between 
renal function and meropenem exposure. 
Research category: Applied research 
• Why? The second objective of this project was to evaluate the adequacy of standard 
meropenem dosing for critically ill patients with respect to renal function. 
• How? The project used stochastic MC simulations to assess the probability of PK/PD 
target attainment in dependence of renal function. 
Research category: Translational research 
• Why? The third objective of this project was to develop a tool to assess the risk of 
ineffective meropenem exposure after standard meropenem dosing for an individual 
patient.  
• How? The project translated the results from the regression model and the risk 




Project IV: Development of a dosing algorithm to identify effective meropenem dosing regimens 
for critically ill patients. 
Research category: Basic research  
• Why? First, this project aimed to better characterise meropenem exposure in critically 
ill patients, to identify clinical determinants of PK and to assess and quantify their 
impact on meropenem exposure.  
• How? The project employed the NLME modelling approach including a systematic 
analysis of various patient-specific factors as potential determinants of PK variability 
and applied the developed NLME PK model by performing deterministic simulations 
of meropenem exposure. 
Research category: Applied research 
• Why? Second, this project sought to evaluate the adequacy of standard meropenem 
dosing, to identify major clinical determinants of in-/effective exposure and to assess 
alternative meropenem dosing regimens in order to optimise meropenem treatment. 
• How? The project employed stochastic MC simulations including the uncertainty in 
the parameters of the NLME PK model, in order to evaluate the probability of PK/PD 
target attainment and the cumulative fraction of response following standard and 
alternative meropenem dosing regimens. 
Research category: Translational research 
• What? Third, this project aimed to develop a dosing algorithm suggesting improved 
meropenem dosing regimens for the critically ill patient population already at start of 
treatment based on the level of knowledge about the pathogen. 
• How? The project translated the results of probability of the PK/PD target attainment 





 Pharmacometric modelling and simulation concepts 
Pharmacometric modelling and sim ulation concepts  
Pharmacometrics, which was introduced in section 1.5 comprises different concepts, which can be 
categorised into bottom-up and top-down approaches (Figure 2.1). While bottom-up approaches 
are typically built upon prior knowledge of the system, i.e. the patient (e.g. anatomy, patho-
/physiology) and the drug (e.g. physicochemical properties), top-down approaches are based on 
(non-)clinical data. In the PK setting, for instance, these clinical data can be drug concentrations 
determined over time in plasma, tissue or other matrices. Top-down approaches are further 
classified as (i) non-compartmental or compartmental approaches and (ii) individual or population 
approaches.   
 
Figure 2.1: Overview of different pharmacometric approaches. 
The blue coloured text and arrows highlight the nonlinear mixed-effects approach and its categorisation into the pharmacometric 
approaches, as the most relevant pharmacometric approach of the present thesis.   
Abbreviations: PBPK: Physiologically based pharmacokinetic(s). 
For the analysis of PK data, compartmental approaches are typically applied, in which the body is 
assumed to consist of ‘compartments’ representing kinetically homogeneous regions of the body  
Pharmacometric modelling and simulation concepts  
21 
to which the drug can distribute [173,191]. In a one-compartment model the body is assumed to 
behave like a single kinetically homogeneous compartment, whereas in a two-compartment model 
the body is assumed to comprise two kinetically heterogeneous compartments which drug 
molecules reach: The central compartment (typically comprising blood and highly perfused regions 
of the body, e.g. kidneys) and the peripheral compartment (typically comprising less perfused 
regions of the body, e.g. adipose tissue).   
As implied by the name, individual approaches focus on the analysis of available data on the level 
of the individual, whereas the focus of population approaches is on analysing data of more than 
one individual on the level of the population of individuals [192]. In order to describe the data of a 
population, the naïve pooling approach can be used, which jointly analyses the data of all 
individuals, without considering which data belongs to which individual; hence, this approach 
results in loss of information on the variability between the patients. In contrast, by using the two-
stage approach, the data of each individual are analysed separately (stage 1) and afterwards 
descriptive summary statistics are computed to describe the central tendency in the population as 
well as the variabilities between the patients (stage 2; Appendix 7.3.1). This method requires a rich 
and balanced data situation in each patient, which is often limited in clinical studies. Furthermore, 
this approach has been shown to overestimate the variability between the patients, as only one level 
of variability is considered [192]. The population method of choice, which overcomes the 
drawbacks discussed above, is the nonlinear mixed-effects (NLME) modelling approach. In 
contrast to the two-stage approach, NLME modelling is also applicable in case of a limited and 
unbalanced data situation (e.g. few patients with rich and few patients with sparse data), as it 
simultaneously analyses the data of all individuals and thereby allows to ‘borrow’ information from 
the other individuals in the population to ‘fill gaps’ in the sampling schedule of single individuals 
[191]. This method allows to describe the central tendency in the population as well as to dissect 
and quantify different levels of variability (e.g. between the patients or residual variability), which 
represents a major strength of this approach. Furthermore, NLME modelling aims at identifying 
patient-specific characteristics (so-called ‘covariates’), which explain the observed variability and 
form the basis for e.g. dose individualisation, to ultimately support therapeutic decisions [191]. The 
NLME approach was primarily used in this work and is described in more detail in section 2.3. 
The pharmacometric modelling and simulation analysis starts from data which can be of different 
nature (e.g. PK, PD, additional patient-specific data) and can originate from different sources (e.g. 
pre-clinical experiments, clinical studies). The general steps of a typical pharmacometric modelling 
and simulation workflow for the nonlinear mixed-effects approach are illustrated in Figure 2.2 and 
will be further elucidated in the first part of the method chapter (Sections 2.2-2.4). Additional 
project-specific methodological details and clinical data will be described in the second part 




Figure 2.2: Typical pharmacometric modelling and simulation workflow, illustrated for the nonlinear mixed-
effects modelling approach. 
Abbreviations: ESDA: Exploratory statistical data analysis; EGDA: Exploratory graphical data analysis. 
 Data management and exploratory data analysis 
Data management and exploratory data analysis  
Data management (i.e. dataset generation and checkout) and exploratory statistical and graphical 
data analyses are crucial steps for the subsequent modelling and simulation analyses.  
2.2.1 Dataset generation 
To analyse the data in the respective pharmacometric modelling and simulation software, a specific 
dataset structure is required. In the following, the focus will be on NONMEM®, the main software 
used for modelling and simulation analyses in the present thesis. All data to be used in the analysis 
need to be combined into one dataset with numerical data records only [193,194]. This can be, for 
instance, information on drug dosing history (e.g. dose and dosing time point), PK and PD sampling 
(e.g. measurement and sampling time point) or patient-specific information (e.g. demographics or 
clinical chemistry data). Data originating from a single individual need to be contiguous and 
arranged chronologically. NONMEM®-specific (required and optional) data items are to be 
specified dependent on the data situation (e.g. required: ID=individual identifier; DV=dependent 
variable; optional: MDV=missing dependent variable; CMT=compartment [193,194]). Apart from 
bringing the data in a software-specific dataset structure, dataset generation also comprises 
handling of missing data or data below the lower limit of quantification for e.g. drug concentration 
or covariate measurements. Different strategies exist [195–198], of which the ones applied in the 
projects are discussed in the respective sections (Project I: Section 2.6.3.1, Project IV: 
Section 2.9.2.1). Note that in the following, the term ‘imputation’ is defined as the replacement of 
a missing planned observation, whereas the term ‘interpolation’ is defined as the derivation of a 
new value within two planned observations.  
Using programming software combined with version control allows to document and track all 
changes made to the original dataset (Section 2.5).  
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2.2.2 Dataset checkout 
In order to evaluate the dataset for plausibility and completeness, as well as to detect implausible 
or erroneous values, different dataset checkout procedures are typically performed and documented 
[193]. ‘Cross column checks’ are applied to evaluate whether the combination of dataset items is 
plausible. ‘Index plots’ graphically display each data item versus ID and are hence useful to 
evaluate completeness, implausible values etc. but also give the first impression of special 
characteristics of the datasets and the value ranges between and within individuals. Project-specific 
dataset checkout procedures are described in the respective sections (Project I: Section 2.6.3.2, 
Project IV: Section 2.9.2.2)  
2.2.3 Exploratory data analysis 
Prior to the actual model development, an extensive exploratory data analysis is typically 
performed, comprising both statistical and graphical data analysis [193]. Statistical analyses aim at 
revealing characteristics (e.g. distributional) of the data and discovering possible trends and 
relationships. For this purpose, different numerical and graphical statistical outputs are generated, 
such as descriptive summary statistics (Appendix 7.3.1) in a tabular format, graphical illustration 
of frequency distributions (histograms) or bivariate scatter plots.   
The aim of the graphical analyses is to detect potential trends in the relationship between dependent 
variable (e.g. drug concentration, drug effect) and independent variable (e.g. time, covariate), 
which will be analysed in the modelling step. In addition, it aims at exploring potential model 
structures that might be suitable to describe the data (e.g. number of disposition phases, delay etc.). 
For these purposes, diverse plots of dependent variable versus independent variable are generated: 
(i) for all patients, stratified by individual or for the typical patient (e.g. geometric mean of drug 
concentration vs. time), (ii) stratified by covariates, sampling matrix, dosing etc., (iii) on linear, 
semilogarithmic or logarithmic scale.  
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As described previously (Section 2.1), a nonlinear mixed-effects model is a hierarchical 
mathematical framework that allows to analyse the data of all individuals of a population 
simultaneously [199]. The term ‘nonlinear’ implies that the dependent variable (e.g. drug 
concentration) is related via a nonlinear function to the model parameters (e.g. clearance) and 
independent variables (e.g. time, dose). The term ‘mixed-effects’ refers to the parameterisation of 
the model, which consists of fixed and random-effects parameters, estimated simultaneously during 
the modelling procedure. Fixed-effects parameters are assumed to be constant in a population, 
while random-effects vary among individuals. The following sections provide further information 
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on the components (Section 2.3.1), parameter estimation (Section 2.3.2) and selection and 
evaluation (Section 2.3.3) of nonlinear mixed-effects models. 
2.3.1 Model components 
NLME models comprise three major components (Figure 2.3 A; [193]): (i) the structural submodel, 
(ii) the statistical submodel, and (iii) the covariate submodel. The structural and statistical 
submodel form the base model, which completes together with the covariate model the full NLME 
model. This section aims to provide a general and mathematical overview of the submodels; a 
detailed description of the model building strategy is provided for the different projects that applied 
NLME modelling, in the respective chapters (Project I: Section 2.6.4.2, Project IV: Section 2.9.3). 
 
Figure 2.3: Components of nonlinear mixed-effects models (A), sketch of structural one-compartment model 
(B), and typical drug concentration-time profile (C) for i.v. bolus administration. 
Abbreviations: CL: Clearance; D: Dose; i.v.: Intravenous; NLME: Nonlinear mixed-effects; V: Volume of distribution. 
2.3.1.1 Structural submodel  
The structural submodel describes the typical behaviour (‘central tendency’) of the dependent 
variable versus the independent variable. In case of PK data this could be the typical drug 
concentration-time profile in plasma of the population and for PD data the typical concentration of 
an inflammation marker changing over time of the population.   
As discussed previously (Section 2.1), for PK models on which this work focused, compartment 
models are typically used to describe the drug concentration over time [191,199]. Exemplified for 
the simplest case of a compartment model – a one-compartment model (single i.v. bolus input, 
first-order elimination, Figure 2.3 B) – the typical drug concentration-time profile C(t) can be 
described by the following exponential equation Eq. 2.1 and is exemplarily depicted in 
Figure 2.3 C. 
𝐶(𝑡) = 𝐷𝑉 ∙ 𝑒− 𝜃𝐶𝐿𝜃 𝑉  ∙ 𝑡 ( Eq. 2.1) 
In Eq. 2.1, the drug concentration (𝐶) is a function of the administered dose (𝐷), time (𝑡) and the 
two fixed-effects PK parameters clearance (𝜃𝐶𝐿) and volume of distribution (𝜃 𝑉). The structural 
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submodel is typically described by a system of ordinary differential equations (ODEs) [200]. The 
concentration-time profile in Eq. 2.1 is the solution of the following ODE (Eq. 2.2) taking into 
account that the amount (𝐴) over time (𝑡) is 𝐴(𝑡) = 𝐶(𝑡) ∙ 𝑉: 𝑑𝐴𝑑𝑡 = −𝐶𝐿𝑉 ∙ 𝐴 ( Eq. 2.2) 
A more general mathematical representation of the structural model based on 𝑖 individuals and 𝑗 observations can be expressed as depicted in Eq. 2.3, assuming that there is no discrepancy 
between observations and model predictions (i.e. no residual unexplained variability: 
Section 2.3.1.2; [201,202]). 𝑌𝑖𝑗 = 𝑓(𝜙𝑖 , 𝑥𝑖𝑗) ( Eq. 2.3) 
In Eq. 2.3, 𝑌𝑖𝑗 is the dependent variable of the 𝑖𝑡ℎ individual corresponding to the 𝑗𝑡ℎ observation. 
The nonlinear function (𝑓) represents the structural model and is dependent on the vector of 
structural model parameters of the 𝑖𝑡ℎ individual 𝜙𝑖 (e.g. clearance) and the known study design 
variables 𝑥𝑖𝑗 (e.g. dose, sampling time).  
Note that the fixed-effects-parameters can be used to describe different processes, e.g. PK-related, 
PD-related and dependent on the type of model also system-related processes (e.g. a microdialysis 
system integrated in the NLME model, Section 2.6.4.1). 
2.3.1.2 Statistical submodel 
In addition to the typical behaviour, which is captured by the structural submodel, the statistical 
submodel describes and quantifies different levels of variability observed in the data. Hence, it 
allows to describe the individual behaviour of the dependent variable versus the independent 
variable. The statistical submodel comprises different levels of variability, depending on the 
available data (Figure 2.3 A): Interindividual and interoccasion variability in the model parameters 
on individual level (e.g. clearance) as well as residual unexplained variability in the dependent 
variable on observation level (e.g. drug concentration [193]).  
Interindividual variability  
The interindividual variability (IIV) quantifies unexplained deviations of the individual parameter 
value (Empirical Bayes estimate, EBE) from the typical model parameter. For PK models, IIV is 
typically implemented on the model parameters using an exponential relationship (Eq. 2.4) [199]. 
Hence, the model parameters are assumed to follow a log-normal distribution which prevents them 
from taking negative and thus physiologically implausible values.  
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𝜙𝑖𝑘 = 𝜃𝑘 ∙ 𝑒𝜂𝑖𝑘          𝜂𝑘~𝑁(0,𝜔𝑘2) ( Eq. 2.4) 
In Eq. 2.4, the structural model parameter of the 𝑖𝑡ℎ individual and the 𝑘𝑡ℎ parameter (𝜙𝑖𝑘) is 
defined by the typical value of the 𝑘𝑡ℎ parameter in the population (𝜃𝑘) and the individual impact 
of the patient (𝑒𝜂𝑖𝑘). The random-effects parameters 𝜂𝑖𝑘 of all individuals 𝑖 (𝜂𝑘) are assumed to 
follow a normal distribution with a mean of zero and a variance of the estimated random-effects 
parameter 𝜔𝑘2.  
The variance and covariance estimates are provided in the omega matrix Ω [202]. In Eq. 2.5, the 
omega matrix is depicted in lower triangular form for an example with three IIV parameters. 
Ω = (𝜔1,12𝜔1,2 𝜔2,22𝜔1,3 𝜔2,3 𝜔3,32 ) ( Eq. 2.5) 
In the omega matrix (Ω), the diagonal elements (highlighted in blue) represent the variances (𝜔𝑘2) 
of the parameters 𝑘=1,2,3; the off-diagonal elements represent the covariances between the 
corresponding variances, e.g. 𝜔1,2 = 𝑐𝑜𝑣(𝜔1,12 , 𝜔2,22 ) . In the NONMEM® software, off-diagonal 
elements are assumed to be zero, unless explicitly defined and estimated using the so-called ‘omega 
block’ statement [193]. 
When reporting random-effects parameters, the variance 𝜔𝑘2 is typically converted to the 
coefficient of variation (CV) for easier interpretation. For log-normally distributed parameters the 
CV can be computed as follows [199,203] (Eq. 2.6): 
𝐶𝑉,% =  √𝑒𝜔𝑘2 − 1 ∙ 100 ( Eq. 2.6) 
Covariances are typically reported as correlation coefficient 𝜌 which can be derived as follows 
Eq. 2.7: 
𝜌1,2,% =  𝑐𝑜𝑣(𝜔1,12 , 𝜔2,22 )√𝜔1,12 ∙ √𝜔2,22 ∙ 100 = 𝜔1,2√𝜔1,12 ∙ √𝜔2,22 ∙ 100 ( Eq. 2.7) 
Interoccasion variability 
In case of multiple observations of the dependent variable on more than one occasion, an additional 
level of variability, the interoccasion variability (IOV), can be quantified. IOV accounts for 
unexplained deviations of the individual parameter value at each occasion from the typical 
individual model parameter. Similar to IIV, IOV is typically implemented on the model parameters 
using an exponential model (Eq. 2.8):  
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𝜙𝑖𝑘𝑞 = 𝜃𝑘 ∙ 𝑒𝜂𝑖𝑘+𝜅𝑖𝑘𝑞         𝜂𝑘~𝑁(0,𝜔𝑘2)        𝜅𝑘~𝑁(0, 𝜋𝑘2) ( Eq. 2.8) 
In Eq. 2.8, the structural model parameter of the 𝑖𝑡ℎ individual, the 𝑞𝑡ℎ occasion and the 𝑘𝑡ℎ 
parameter (𝜙𝑖𝑘𝑞) is defined by the typical value of the 𝑘𝑡ℎ parameter for the population (𝜃𝑘), the 
impact of the individual (𝑒𝜂𝑖𝑘) and the impact of the occasion (𝑒𝜅𝑖𝑘𝑞). The random-effects 
parameters 𝜂𝑖𝑘 of all individuals 𝑖 (𝜂𝑘) as well as the random-effects parameters 𝜅𝑖𝑘𝑞 of all 
individuals 𝑖 at all occasions 𝑞 (𝜅𝑘) are assumed to follow a normal distribution with a mean of 
zero and a variance of 𝜔𝑘2 and 𝜋𝑘2, respectively. Similar to IIV, IOV is typically reported as CV and 𝜋𝑘2 can be converted using Eq. 2.6. 
Both levels of variability (IIV and IOV) can be implemented on any fixed-effects parameter in the 
model (e.g. PK-related, PD-related, but also system-related parameters as exemplified in Project I 
for the ‘Relative Recovery’ parameter: Section 3.1.2.2).  
Residual unexplained variability  
In addition to the variability in the PK parameters (IIV and IOV) residual unexplained variability 
(RUV) can be quantified on the level of the dependent variable. RUV might originate from different 
sources of variability, such as (i) imprecision of the bioanalytical assay used to measure the 
dependent variable, (ii) erroneous documentation of the independent variable (e.g. dosing or 
sampling time points) or (iii) model misspecification. RUV describes the deviation of the observed 
dependent variable from the model predicted concentration (Eq. 2.9): 𝑌𝑖𝑗 = 𝑓(𝜙𝑖, 𝑥𝑖𝑗) + 𝜀𝑖𝑗       𝜀~𝑁(0, 𝜎2) ( Eq. 2.9) 
In Eq. 2.9, 𝜀𝑖𝑗 describes the discrepancy between the observation of the 𝑖𝑡ℎ individual at the 𝑗𝑡ℎ 
observation (𝑌𝑖𝑗) and the model prediction (𝑓(𝜙𝑖, 𝑥𝑖𝑗)). The random-effects parameters 𝜀𝑖𝑗 of all 
individuals 𝑖 and all observations 𝑗 (𝜀) are assumed to be normally distributed with a mean of zero 
and a variance of the estimated random-effects parameter 𝜎2. The variance and covariance 
estimates of RUV are provided in the sigma matrix Σ [202]. 
RUV can be implemented into the NLME model using different models, e.g. an additive, 
proportional or combined RUV model [193]. The example provided above (Eq. 2.9) illustrates an 
additive RUV model, in which the variance is assumed to be constant over the full range of model 
predictions. In contrast, the proportional RUV model (Eq. 2.10) assumes a variance that is 
proportional to the magnitude of the model prediction, i.e. for low model predictions the variance 
is relatively small, while for higher model predictions the variance increases. The two RUV models 
can be combined in the ‘combined RUV model’ (Eq. 2.11), capturing both an additive component 
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that dominates at lower model predictions and a proportional component that dominates at higher 
model predictions. 𝑌𝑖𝑗 = 𝑓(𝜙𝑖, 𝑥𝑖𝑗) ∙ (1 + 𝜀𝑖𝑗)       𝜀𝑖𝑗~𝑁(0, 𝜎2) ( Eq. 2.10) 
𝑌𝑖𝑗 = 𝑓(𝜙𝑖, 𝑥𝑖𝑗) ∙ (1 + 𝜀𝑝𝑟𝑜𝑝,𝑖𝑗) + 𝜀𝑎𝑑𝑑.𝑖𝑗        𝜀𝑝𝑟𝑜𝑝,𝑖𝑗~𝑁(0, 𝜎𝑝𝑟𝑜𝑝2)  𝜀𝑎𝑑𝑑,𝑖𝑗~𝑁(0, 𝜎𝑎𝑑𝑑2) 
( Eq. 2.11) 
 
When reporting the RUV, for the additive RUV component oftentimes the standard deviation is 
chosen, which has the same unit as the dependent variable; for the proportional RUV component 
the dimensionless CV is typically derived (Eq. 2.6).   
In case of data collected from different ‘sources’ e.g. different studies, different matrices or 
different sampling techniques, separate RUV models can be implemented (Section 3.1.2.2).  
2.3.1.3 Covariate submodel  
The implementation of covariates into the model is one of the key objectives of pharmacometric 
modelling and is typically performed after the development of the base model.   
When implementing the covariates into a NLME model, the vector of the fixed-effects model 
parameters of the 𝑖𝑡ℎ individual (𝜙𝑖) is described by the following equation (Eq. 2.12): 𝜙𝑖 = 𝑔(𝛩, Ζ𝑖) ( Eq. 2.12) 
In Eq. 2.12, 𝜙𝑖 is defined by the covariate function 𝑔, which described the relationship between 
the vector of the fixed-effects parameters (𝛩) and the vector of the observed covariate values (Ζ𝑖) of 
the 𝑖𝑡ℎ individual.  
Covariates can be categorised into continuous covariates (e.g. creatinine clearance) and categorical 
covariates (e.g. sex). Dependent on the number of categories, categorical covariates can be further 
classified in dichotomous covariates (i.e. two categories: e.g. sex) and multiple categorical 
covariates. Multiple categorical covariates in turn can be categorised into ordered (e.g. renal 
function categories: severely impaired, moderately impaired, mildly impaired, normal, augmented) 
or not ordered covariates (e.g. sepsis cause: pneumonia, peritonitis, urosepsis, soft tissue infection). 
Dependent on the number of values recorded during the observation period, covariates can be 
further classified into single-measured (one value available per individual) or longitudinally 
measured covariates (multiple values available per individual), in the latter case one also speaks of 
time-varying covariates. Dependent on the type of covariate, different ways of implementing 
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covariate-parameter relationships into the NLME model exist.  
In the following, examples for the covariate function 𝑔 (Eq. 2.12) are provided that can be used to 
implement continuous covariates on a structural model parameter 𝜃𝑘 [193]: Linear, piecewise 
linear and power relationships, as well as a linear relationships in case of time-varying continuous 
covariates. For reasons of simplicity, all examples are provided under the assumption that only one 
covariate impacts the PK of the structural parameter 𝜃𝑘 (i.e. 𝑍 vector contains only one element). 
Furthermore, in the examples the covariate effects are centred to the median covariate value in the 
population (𝑍𝑚𝑒𝑑𝑖𝑎𝑛) [193].  
Given a linear covariate-parameter relationship (Eq. 2.13), the structural model parameter 
linearly increases or decreases over the full range of observed covariate values. 𝑔(𝜃𝑖𝑘 , 𝑍𝑖) = 𝜃𝑘 ∙ (1 + 𝜃𝑍 ∙ (𝑍𝑖 − 𝑍𝑚𝑒𝑑𝑖𝑎𝑛)) ( Eq. 2.13) 
Eq. 2.13 provides an example for a linear form of function 𝑔. The  𝑘𝑡ℎ fixed-effects parameter of 
the 𝑖𝑡ℎ individual with a specific covariate value 𝑍𝑖 (𝜃𝑖𝑘) is defined by the  𝑘𝑡ℎ fixed-effects 
parameter for the median covariate value 𝑍𝑚𝑒𝑑𝑖𝑎𝑛 in the population (𝜃𝑘) and the covariate effect 
(𝜃𝑧), which describes the fractional change of 𝜃𝑘 per unit deviation of the covariate value 𝑍𝑖 from 
the median covariate value 𝑍𝑚𝑒𝑑𝑖𝑎𝑛. 
In a piecewise linear covariate-parameter relationship (Eq. 2.14), for different ranges of a 
covariate (‘pieces’) different linear covariate-parameter relationships (i.e. with different slopes) are 
observed. In the following equation (Eq. 2.14), a two-spline relationship (also referred to as 
hockey-stick relationship) is provided: For this specific example, the model parameter increases 
linearly up to a specific estimated covariate value (inflection point, 𝜃𝐼𝑁𝐹) and is constant for 
covariate values greater than this value: 
If 𝑍𝑖 < 𝜃𝐼𝑁𝐹:  𝑔(𝜃𝑖𝑘 , 𝑍𝑖) = 𝜃𝑘 ∙ (1 + 𝜃𝑍 ∙ (𝑍𝑖 − 𝑍𝑚𝑒𝑑𝑖𝑎𝑛)) 
If 𝑍𝑖 ≥ 𝜃𝐼𝑁𝐹:  𝑔(𝜃𝑖𝑘 , 𝑍𝑖) = 𝜃𝑘 ∙ (1 + 𝜃𝑍 ∙ ( 𝜃𝐼𝑁𝐹 − 𝑍𝑚𝑒𝑑𝑖𝑎𝑛)) ( Eq. 2.14) 
 
In addition to linear covariate-parameter relationships, nonlinear relationships, such as the power 
covariate-parameter relationship (Eq. 2.15), can be used. This type of relationship allows high 
flexibility as it can describe a variety of different relationships, depending on the estimated 
coefficient parameter (𝜃𝑧). 
𝑔(𝜃𝑖𝑘, 𝑍𝑖) = 𝜃𝑘 ∙ ( 𝑍𝑖𝑍𝑚𝑒𝑑𝑖𝑎𝑛)𝜃𝑍 ( Eq. 2.15) 
Alternatively, for body size descriptors the principle of allometry [204] can be applied in which 
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the coefficient parameter in Eq. 2.15 is set to 0.75 for clearance parameters and to 1 for volumes 
of distribution parameters.  
In case of time-varying continuous covariates two extended linear relationships have been 
proposed by Wählby et al. [205]. ‘Extended Wählby model 1’ defines separate covariate-parameter 
relationships between and within individuals (Eq. 2.16). ‘Extended Wählby model 2’ includes an 
additional interindividual random-effects parameter on the covariate effect and thus allows the 
covariate effect to differ between individuals (Eq. 2.17).  𝑔(𝜃𝑖𝑘 , 𝑍𝑖) = 𝜃𝑘 ∙ (1 + 𝜃𝐵𝑍 ∙ (𝐵𝑍𝑖 − 𝐵𝑍𝑚𝑒𝑑𝑖𝑎𝑛) + 𝜃𝐷𝑍 ∙ (𝑍𝑖 − 𝐵𝑍𝑖)) ( Eq. 2.16) 
𝑔(𝜃𝑖𝑘 , 𝑍𝑖) = 𝜃𝑘 ∙ (1 + 𝜃𝑍 ∙ 𝑒𝜂𝑍 ∙ (𝑍𝑖 − 𝑍𝑚𝑒𝑑𝑖𝑎𝑛)) ( Eq. 2.17) 
In Eq. 2.16, 𝑍𝑖, 𝐵𝑍𝑖  and 𝐵𝑍𝑚𝑒𝑑𝑖𝑎𝑛 represent a value of the covariate 𝑍 for the individual 𝑖, the 
individuals baseline value and the median baseline value in the population, respectively. 𝜃𝐵𝑍 and 𝜃𝐷𝑍 are the estimated interindividual and intraindividual covariate-parameter relationships.   
In Eq. 2.17, 𝜂𝑍 is the estimated interindividual random-effects parameter on the covariate-
parameter relationship 𝜃𝑍.  
As described above, in addition to continuous covariates, categorical covariates exist that can be 
implemented into the NLME model by e.g. estimating separate parameters for each category or by 
using a fractional change model. The latter is demonstrated for an example of a covariate with 
two potential categories (CAT=1, 2) in the following equation (Eq. 2.18): 
If CAT=1: 𝜃𝑘,𝐶𝐴𝑇=1 = 𝜃𝑘 
If CAT=2: 𝜃𝑘,𝐶𝐴𝑇=2 = 𝜃𝑘 ∙ (1 + 𝜃𝑍) ( Eq. 2.18) 
 
In Eq. 2.18, 𝜃𝑘  is the fixed-effects parameter in case of the first covariate category (CAT=1), which 
is usually the category with the higher number of observations in the dataset. 𝜃𝑍 defines the 
fractional change of 𝜃𝑘, in case of the second covariate category (CAT=2). 
The covariate model building strategies typically start with the pre-selection of potential 
covariate candidates based on different criteria, e.g. graphical evaluation (by assessment of the 
relationship between a covariate and the individual structural and random-effects PK parameters), 
prior knowledge from publications or clinical interest. Afterwards the pre-selected candidates are 
investigated within the NLME model. Here, different approaches exist which can be selected based 
on the question of the analysis and data situation (e.g. stepwise covariate model building, full 
covariate modelling, LASSO, mechanistic implementation), which have been described in detail 
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elsewhere [204,206–210]. The covariate model building strategies applied in this work are in more 
detail described in the respective sections (Project I: Section 2.6.4.2, Project IV: Section 2.9.3.2). 
Combining the three submodels as described above, results in the following general mathematical 
equation for NLME models (Eq. 2.19): 𝑌𝑖𝑗 = 𝑓((𝑔(𝛩𝑖, 𝑍𝑖), 𝜂𝑖 , 𝜅𝑖), 𝑥𝑖𝑗), 𝜀𝑖𝑗   ( Eq. 2.19) 
2.3.2 Parameter estimation 
NLME modelling aims at identifying parameter estimates that best match the observed data, both 
on population and on individual level. Parameter estimation is typically carried out using the 
maximum likelihood estimation approach, in order to find the set of parameters which maximises 
the likelihood of observing the data given the model (Eq. 2.20). These parameters are referred to 
as maximum likelihood estimates.  
ℒ𝑖(𝜃, 𝜔2, 𝜎2 |𝑌𝑖) = 𝑝(𝑌𝑖|𝜃, 𝜔2, 𝜎2) =∏ℒ(𝑛𝑗=1 𝜃,𝜔2, 𝜎2|𝑌𝑖𝑗) ( Eq. 2.20) 
In Eq. 2.20, ℒ𝑖 denotes the individual contributions to the likelihood of observing the data 𝑌𝑖 of 
every 𝑖𝑡ℎ individual given the model parameters 𝜃,𝜔2, 𝜎2. The variable 𝑝 represents the 
corresponding probability density function. 
In NONMEM® the so-called ‘objective function value’ (OFV) is used which is defined as minus 
twice the natural logarithm of the likelihood (Eq. 2.21) and hence minimised during parameter 
search (best fit = maximum likelihood = minimum OFV) [199].  
𝑂𝐹𝑉 = −2ℒℒ = −2 ∙ log(ℒ(𝜃, 𝜔2, 𝜎2 |𝑌)) =∑−𝑛𝑖=1 2 ∙ log(ℒ𝑖(𝜃, 𝜔2, 𝜎2 |𝑌𝑖)) ( Eq. 2.21) 
Computation of the likelihood for nonlinear mixed-effect models is challenging and cannot be 
solved analytically [211]. That is why the OFV has to be approximated numerically, for which a 
variety of different estimation methods exist [211,212]. In the present work, the first-order 
conditional expectation (FOCE) method including the interaction option in NONMEM® was 
applied. The FOCE method is a gradient-based linearisation algorithm that approximates the 
likelihood by applying Laplace transformation and Taylor series expansion. The additional use of 
the interaction option allows for interaction between the interindividual random-effects (𝜂) and 
residual random-effects (𝜀) parameters. The FOCE method uses an iterative procedure to determine 
the likelihood. First the likelihood is evaluated for the set of initial parameter estimates. Then, in 
the second iteration, the parameters are updated in the direction in which the likelihood increases, 
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i.e. the OFV decreases. This is repeated until convergence criteria are met and the maximum 
likelihood, i.e. the minimum OFV is found [211,213].  
While the estimation method returns the population parameters, the individual parameter estimates 
(Empirical Bayes estimates, EBEs) are typically obtained in second post-hoc estimation step (also 
referred to as Bayes or conditional estimation step) [199,214]. In the FOCE method, this post-hoc 
estimation step is performed after each iteration step. The Bayes objective function is used to derive 
the EBSs for each individual by balancing the posterior and prior term (Eq. 2.22; [199,215]):  
𝑂𝐹𝑉𝐵𝑎𝑦𝑒𝑠 = 𝑃𝑟𝑖𝑜𝑟 + 𝑃𝑜𝑠𝑡𝑒𝑟𝑖𝑜𝑟 = ∑ (𝜃𝑘,𝐸𝐵𝐸 − 𝜃𝑘,𝑝𝑜𝑝)2𝜔𝑘2𝑚𝑘=1 +∑(𝑌𝑖𝑗 − 𝑌𝑖?̂?)2𝜎2𝑛𝑗=1  ( Eq. 2.22) 
In Eq. 2.22, the prior term is described as the sum of the squared deviation of the 𝑘𝑡ℎ individual 
parameter (𝜃𝑘,𝐸𝐵𝐸) from the 𝑘𝑡ℎ population parameter (𝜃𝑘,𝑝𝑜𝑝), weighted by the respective 𝑘𝑡ℎ 
interindividual random-effects parameter (𝜔𝑘2). The posterior term is defined as the sum of the 
squared deviation of the observed data for the 𝑖𝑡ℎ individual and 𝑗𝑡ℎ observation (𝑌𝑖𝑗) from the 
predicted data for the 𝑖𝑡ℎ individual and 𝑗𝑡ℎ observation (𝑌𝑖?̂?), weighted by the residual random-
effects parameter (𝜎2). 
2.3.3 Model evaluation and discrimination 
A crucial part of the model development process is the evaluation and assessment of the 
appropriateness of a developed model given a dataset, with the aim to evaluate the model (‘model 
evaluation’) and select the most appropriate model from a collection of models under consideration 
(‘model discrimination’) [216]. Depending on the dataset used for the evaluation of the model, 
evaluation methods can be classified in ‘internal’ and ‘external’. While for the internal methods 
the evaluation is based on the dataset that has already been used for the development of the model, 
for external methods a dataset from another source (e.g. experiment or clinical study) is used. 
Additional common classifications comprise (1) ‘basic’ and ‘advanced’ according to the 
complexity of the method (e.g. computational time), (2) ‘numerical’ and ‘graphical’ according to 
the representation of the technique, and (3) ‘data-based’ and ‘simulation-based’ according to the 
basis of the evaluation. Important model evaluation techniques will be discussed in detail in the 
following, highlighting the allocation to the aforementioned classifications. 
2.3.3.1 Goodness-of-fit plots 
Classification of technique: ‘internal’, ‘basic’, ‘graphical’, ‘data-based’ 
Goodness-of-fit (GOF) plots represent commonly used basic evaluation plots that are visually 
assessed to evaluate an NLME model with a special focus on the structural and residual variability 
Nonlinear mixed-effects modelling  
33 
submodel. These plots are typically based on the observed dependent variable (observations), the 
predicted dependent variable (predictions) both for the population and the individual as well as on 
the differences between observations and predictions (residuals). Also, individual-/occasion-
specific random-effects parameters and empirical Bayes estimates are assessed. The most 
important GOF plots are introduced in the following. 
Observations versus predictions 
Observations are plotted against both the population predictions (PRED) and the individual 
predictions (IPRED) and the scattering around the line of identity (intercept=0, slope=1) is 
evaluated. In case of an appropriate goodness-of-fit, data points show a symmetric scattering, 
without any systematic deviations that would suggest a model misspecification. In addition, the 
magnitude of spread of the data points around the line of identity is assessed. Considering the 
interindividual differences in the model parameters, observations versus PRED is expected to show 
a spread around the line of identity. For IPRED, however, the data points should be narrowly 
distributed around the line of identity. These plots are evaluated for the full population, for 
population subgroups and on an individual level. 
Residuals 
As the residuals depend on the absolute magnitude of the observations/predictions, the residuals 
are commonly weighted in order to use them for model evaluation [199]. The weighing of the 
residuals is dependent on the estimation algorithm used. In case of the FOCE algorithm in the 
NONMEM® software, which was applied in the present thesis, conditional weighted residuals are 
recommended which have been shown to adequately reflect model adequacy [193,217].  
The distribution of conditional weighted residuals (CWRES) versus the independent variable and 
PRED is typically assessed (i.e. in case of PK: time and drug concentration, respectively). The 
plots are evaluated with respect to occurrence of a systematic trend as well as the magnitude of 
spread around the reference line (intercept=0, slope=0), for the full population and stratified by 
individual patients and patient subgroups. 
Individual predictions 
Per individual, the observations (i.e. in case of PK: drug concentrations) are graphically displayed 
against the independent variable (i.e. in case of PK: time) and overlaid with the respective PRED 
and IPRED (‘individual predictions’). While PRED should display the central tendency in the 
population, IPRED should be as close as possible to the observations.  
Distribution of random-effects and Empirical Bayes estimate 
Distribution of individual-/occasion-specific random-effects (i.e. IIV: η or IOV: κ) and EBEs are 
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evaluated by histograms. Individual-/occasion-specific random-effects should approximate a 
normal distribution with a mean not significantly different from zero. A binormal distribution, for 
instance, might indicate a dichotomous covariate which is not yet implemented in the model, but 
is dividing the population into two distinct patient subgroups. The width of the distribution 
indicates the unexplained variability and should be rather small.   
The distribution of the EBEs is dependent on the model used for implementation of the random-
effects into the NLME model; in case of an exponential model structure (Eq. 2.4), EBEs are log-
normally distributed.  
2.3.3.2 Parameter precision  
Classification of technique: ‘internal’, ‘basic’, ‘numerical’, ‘data-based’ 
Within the NONMEM® software, estimates of the precision of the model parameters can be 
requested ($COVARIANCE). In this case, after the minimisation routine is complete, NONMEM® 
is postprocessing the output from the estimation step (Section 2.3.2) and providing as additional 
output the complete variance-covariance matrix of the estimates [193,194]. The standard errors 
(SE) of the model parameters can be derived by taking the square root of the diagonal elements of 
the matrix. For the sake of an easier interpretation of the parameter precision, SE are usually 
reported as relative standard errors (RSE, Eq. 2.23, Eq. 2.24). When reporting random-effects 
parameters as %CV instead of the estimated variance – which is typically the case (Section 2.3.1.2) 
– the RSE can be transformed into the approximate standard deviation scale (Eq. 2.25, [193]). In 
the following equations the computation of the RSE for fixed-effects parameters 𝜃, Eq. 2.2) and 
the random-effects parameters (exemplarily represented for 𝜔2: Eq. 2.24, Eq. 2.25) are provided. 
For other levels of random-effects parameters (e.g. IOV: 𝜋2, RUV: 𝜎2) complementary formulas 
are used. Of note, in this thesis RSE of random-effects parameters were reported on standard 
deviation scale unless stated otherwise.  
𝑅𝑆𝐸𝜃, % = 𝑆𝐸𝜃𝜃 ∙ 100 ( Eq. 2.23) 𝑅𝑆𝐸𝜔𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑠𝑐𝑎𝑙𝑒2 , % = 𝑆𝐸𝜔2𝜔2 ∙ 100 ( Eq. 2.24) 
𝑅𝑆𝐸𝜔𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑠𝑐𝑎𝑙𝑒2 , % = 𝑆𝐸𝜔22 ∙ 𝜔2 ∙ 100 ( Eq. 2.25) 
Assuming a normal distribution of the parameters, 95% CI can be derived as exemplarily shown 
for the kth fixed-effects parameters 𝜃 in the following equation (Eq. 2.26):  
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𝐿𝑜𝑤𝑒𝑟 𝑙𝑖𝑚𝑖𝑡 𝑜𝑓 95%𝐶𝐼 =  𝜃𝑘 − (𝑆𝐸 ∙ 1.96) 𝑈𝑝𝑝𝑒𝑟 𝑙𝑖𝑚𝑖𝑡 𝑜𝑓 95%𝐶𝐼 = 𝜃𝑘 + (𝑆𝐸 ∙ 1.96) ( Eq. 2.26) 
 
1.96 corresponds to the 97.5th percentile of the normal distribution and can thus be used to derive 
the lower limit (2.5th percentile) and the upper limit (97.5th percentile) of the 95% CI. 
In addition to the parameter precision derived by NONMEM®, more advanced evaluation 
techniques exist which allow to derive confidence intervals for the model parameters of interest, 
without assuming a distribution of the parameter (e.g. bootstrap: Section 2.3.3.5, log-likelihood 
profiling: Section 2.3.3.4, [218]). 
2.3.3.3 Shrinkage 
Classification of technique: ‘internal’, ‘basic’, ‘numerical’, ‘data-based’ 
If little and less informative individual information is available in the model building dataset, the 
individual parameters (i.e. EBEs) tend to shrink towards the typical fixed-effects parameter values, 
i.e. the variance in the EBEs decreases. This phenomenon is illustrated in Eq. 2.22, in which in 
case of sparse individual data situations, the posterior term of the formula gets smaller compared 
to the prior term and hence the population parameter values are given more weight than the data of 
the individual. This phenomenon is termed 𝜂-shrinkage and is described with the following 
equation (Eq. 2.27; [219]):  
𝜂 − 𝑠ℎ𝑟𝑖𝑛𝑘𝑎𝑔𝑒 = 1 − 𝑆𝐷𝐸𝐵𝐸𝜂√𝜔2 ∙ 100 ( Eq. 2.27) 
In Eq. 2.27, 𝑆𝐷𝐸𝐵𝐸𝜂 is the standard deviation of the individual values of the EBEs of 𝜂, 𝜔2 is the 
estimated variance of 𝜂. Of note, shrinkage values ≥20%-30%, can impact diagnostic plots based 
on EBEs (e.g. EBE versus covariates plots) and can thus result in a misinterpretation of the plots 
and unreliable conclusions. 
Similarly to 𝜂-shrinkage, in case of sparse data, the distribution of the individual weighted residuals 
(IWRES, Eq. 2.28) distribution shrinks towards zero as well; this is called 𝜀-shrinkage (Eq. 2.29, 
[219]).  
𝐼𝑊𝑅𝐸𝑆 = (𝑌𝑖𝑗  − ?̂?𝑖𝑗)√𝜎2  ( Eq. 2.28) 𝜀 − 𝑠ℎ𝑟𝑖𝑛𝑘𝑎𝑔𝑒 = 1 − 𝑆𝐷𝐼𝑊𝑅𝐸𝑆 ( Eq. 2.29) 
Here, 𝑌𝑖𝑗 is the observed dependent variable of the 𝑖𝑡ℎ individual at each time point 𝑗, ?̂?𝑖𝑗  is the 
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respective model predicted dependent variable, 𝜎2 is the estimated variance of 𝜀, and 𝑆𝐷𝐼𝑊𝑅𝐸𝑆 is 
the standard deviation of the IWRES. 
2.3.3.4 Log-Likelihood profiling 
Classification of technique: ‘internal’, ‘advanced’, ‘graphical’, ‘data-based’ 
Log-likelihood profiling (also called OFV profiling, objective function mapping or sensitivity 
analysis) is a technique which can be used to evaluate the precision and identifiability of model 
parameters. The parameter of interest is fixed to different values close to the final estimate and the 
remaining parameters are re-estimated. By computing the difference in the OFV between the 
original model and the re-estimated models, a log-likelihood (OFV) profile is generated which is 
typically graphically evaluated. Differences in the OFV equal to 3.84 represent the 95% confidence 
limits, assuming that the difference of the likelihood is approximately 𝑥2 distributed. In addition, 
the log-likelihood profile of the parameter of interest can be investigated for global and local 
minima.  
2.3.3.5 Bootstrap 
Classification of technique: ‘internal’, ‘advanced’, ‘numerical’, ‘data-based’ 
Bootstrap is a technique which can be applied to evaluate the precision and accuracy of the model 
parameters as well as the model robustness. This section will focus on the non-parametric 
bootstrap, which was applied in this thesis. By repeated random sampling with replacement from 
the original dataset on individual level, replicate datasets are created, each with the same size as 
the original dataset. The number of bootstrap replicates is dependent on the purpose of the 
bootstrap; e.g. to derive the CI, ≥1000 samples are recommended [220]. Using the re-sampled 
datasets, the model parameters are then re-estimated. The median of the new parameter estimates 
is compared with the estimate obtained with the original dataset, in order to assess the accuracy 
(bias; Eq. 2.30); by computing the 95% CI of the new parameter estimates the parameter precision 
can be evaluated. 𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑏𝑖𝑎𝑠,% = 𝑃𝑜𝑟𝑖𝑔,𝑘 − 𝑃𝑏𝑠,𝑘𝑃𝑜𝑟𝑖𝑔,𝑘 ∙ 100 ( Eq. 2.30) 
Here, 𝑃𝑜𝑟𝑖𝑔,𝑘 is the original estimate of the kth model parameter and 𝑃𝑏𝑠 the median of the respective 
parameters in the bootstrap replicates.  
A measure for model robustness is the convergence rate, which is calculated as the percentage of 
models in the bootstrap replicates that converged during the parameter estimation process.  
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2.3.3.6 Case deletion diagnostics  
Classification of technique: ‘internal’, ‘advanced’, ‘graphical’, ‘data-based’ 
Case deletion diagnostics (also called jackknife, leave-one-out technique or leverage analysis) is a 
technique which aims at detecting individuals, groups of individuals or observations that show a 
substantial influence on the parameter estimates and thus also evaluates the model robustness and 
stability of the parameter estimates. In the following, the procedure is exemplified for case deletion 
diagnostic on the individual level. Each individual is deleted one-by-one from the dataset and the 
model parameters re-estimated based on the reduced datasets. The new parameter estimates are 
graphically compared with the original estimates and their 95% CIs. If the parameter lies outside 
the 95% CI of the original estimate the individual is considered influential. It is recommended to 
further investigate whether the individual shows distinctive characteristics which might explain the 
differences to the rest of the population. 
2.3.3.7 Visual predictive checks 
Classification of technique: ‘internal’, ‘advanced’, ‘graphical’, ‘simulation-based’ 
The visual predictive check (VPC) is an important simulation-based evaluation technique which 
aims to assess the predictive performance of the NLME model. More concretely, by comparing 
percentiles derived from the distribution of observations with percentiles derived from the 
distribution of stochastic simulations (Section 2.4.2), the model’s capability to reproduce the 
central tendency as well as the variability in the observed data is assessed. Typically, a large 
number of stochastic simulations (n=1000 replicates in this thesis) is performed and the 5th, 50th 
and 95th percentiles of the observations and of each simulation replicate (i.e. median and 90% 
prediction interval) are derived. The percentiles of the observations are graphically compared with 
the median and the 95% CI of the percentiles of the simulations. A stratification of the VPC by e.g. 
patient subgroups or sampling matrices (e.g. plasma and microdialysate) can be used to evaluate 
the predictive model performance with respect to the stratification variables. For assessment of the 
covariate submodel, the VPC can be displayed using the covariate as independent variable, which 
allows to evaluate the predictive performance of the model across the full covariate range.  
2.3.3.8 Prediction errors  
Classification of technique: ‘internal/external’, ‘advanced’, ‘numerical’, ‘simulation-based’ 
Another way of assessing the predictive performance of the model is to compare the observed 
dependent variable with the model predicted dependent variable by calculating prediction errors. 
Prediction errors allow evaluating both accuracy (e.g. prediction error (PE); Eq. 2.31) and precision 
(e.g. absolute prediction error (APE); Eq. 2.32) of the model and can be assessed either as absolute 
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value (unit of dependent variable; Eq. 2.31-Eq. 2.32: left) or as relative value (in percent; Eq. 2.31-
Eq. 2.32: right).  
𝑃𝐸𝑖𝑗 = ?̂?𝑖𝑗 − 𝑌𝑖𝑗                      𝑅𝑃𝐸𝑖𝑗 = ?̂?𝑖𝑗 − 𝑌𝑖𝑗𝑌𝑖𝑗 ∙ 100 ( Eq. 2.31) 𝐴𝑃𝐸𝑖𝑗 = |𝑃𝐸𝑖𝑗|                              𝑅𝐴𝑃𝐸𝑖𝑗 = |𝑅𝑃𝐸𝑖𝑗|  ( Eq. 2.32) 
In Eq. 2.31, 𝑌𝑖𝑗 is the observed dependent variable of the 𝑖𝑡ℎ individual at each time point 𝑗, ?̂?𝑖𝑗  is 
the respective model predicted dependent variable.   
To provide an overall measure of precision and accuracy, the mean or median of the prediction 
errors over all predictions can be reported. Computation for a subset of predictions only, allows to 
evaluate the predictive performance of the model for this specific subset (e.g. a specific phase of a 
drug concentration-time profile).  
2.3.3.9 Objective function value and Akaike information criterion 
Classification of technique: ‘internal’, ‘basic’, ‘numerical’, ‘data-based’ 
As introduced in section 2.3.2 the objective function value (OFV) is defined as twice the natural 
logarithm of the likelihood. The likelihood ratio test is a statistical test which is commonly used to 
compare the OFV of two nested models. Two models are termed ‘nested’ if the parameters of one 
model (M1) represent a subset of the parameters of the other model (M2), i.e. M1 can be obtained 
by setting one or more parameter(s) of M2 to the null hypothesis values(s) [193,199]. For instance, 
the more complex model M2 could be a covariate model and M1 the respective base model. Since 
the OFV of a model is defined as minus twice the logarithm of the likelihood (Section 2.3.2), the 
likelihood ratio test can be used to evaluate the difference between the two OFV values of the two 
nested models (likelihood ratio, LR; Eq. 2.33):  𝐿𝑅 = 𝑂𝐹𝑉𝑀2 − 𝑂𝐹𝑉𝑀1           𝐿𝑅~𝑋2(𝑑𝑓 = 𝛥𝑛𝑝) ( Eq. 2.33) 
The LR is assumed to be 𝑥2 distributed; the degrees of freedom (𝑑𝑓) are defined as the difference 
in the number parameters between the more complex model M2 and the model M1 (𝛥𝑛𝑝). The LR 
is compared to the defined test statistic, 
which is dependent on the specified 
significance level 𝛼 and the 𝑑𝑓. If the 
LR is larger than the statistics, the M2 
model results in a statistically 
significant improved description of the 
analysed data. Table 2.1 summarises 
Table 2.1: Values of the 𝑥2 distribution, for selected 
significant levels (𝛼 values) and degrees of freedom (𝑑𝑓). 𝒅𝒇 𝒙𝟐 value (=test statistic) 𝛼=0.1 𝛼=0.05 𝛼=0.01 𝛼=0.001 
1 2.71 3.84 6.64 10.8 
2 4.60 5.99 9.21 13.8 
3 6.25 7.82 11.3 16.3 
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test statistics selected dependent on the model development step (e.g. covariate forward inclusion: 
α=0.05, 𝑑𝑓=1, 𝑥2 value=3.84). 
For comparison of ‘non-nested’ models the Akaike information criterion (𝐴𝐼𝐶) can be employed 
which is computed as follows (Eq. 2.34):  𝐴𝐼𝐶 = −2𝐿𝐿 + 2 · 𝑛𝑝       ( Eq. 2.34) 
In Eq. 2.34, −2𝐿𝐿 refers to the OFV of the model and 𝑛𝑝 to the total number of parameters in the 
model, which can be considered as penalising term for larger models. When comparing two 
models, the model with the lower AIC value is deemed to provide the better description of the data 
and is thus selected [202].  
 Simulations 
Sim ulations  
Simulations constitute a vital and powerful tool during the NLME model development process (for 
simulation-based model evaluation and discrimination, Section 2.3.3), but even more importantly 
after the model development. Simulations, as application of the NLME model, can be utilised to 
explore and better understand the system and relationship between patient, disease and drug, to 
assess ‘what-if’ scenarios, e.g. ‘Which drug exposure is attained in a patient if the dose is increased 
by 2-fold?’ or ‘Which dosing regimen results in adequate PK/PD target attainment for a critically 
ill patient with severe renal impairment?’ and to ultimately support therapeutic decisions 
[173,221]. Simulations can be classified into deterministic (non-stochastic) and stochastic 
simulations, which are selected depending on the research question [173]. The following section 
discusses the two types of simulations and introduces the ‘probability of target attainment’ analysis, 
a simulation-based approach commonly used to assess the adequacy of antibiotic dosing [63,163]. 
2.4.1 Deterministic simulations 
Deterministic simulations are used to visualise the typical behaviour of the dependent variable over 
the independent variable considering the design variables. In case of simulations of PK, which will 
be focused on in this section, this could be the typical drug concentration-time profile for a given 
dosing regimen and covariate combination. Deterministic simulations are based on the fixed-
effects parameters only and do not consider random-effects parameters [173]. This type of 
simulation represents a valuable tool to gain a better understanding of e.g. the interactions between 
the drug and the patient, by evaluating the typical drug exposure for specific covariate 
combinations but also the typical drug exposure resulting from a specific dosing regimen.  
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2.4.2 Stochastic simulations 
Stochastic simulations, or Monte Carlo (MC) simulations, are used to visualise the behaviour in a 
population of individuals. In contrast to deterministic simulations not only fixed-effects but also 
random-effects parameters are considered in these simulations [173]. Depending on the research 
question, different levels of model variability can be considered in the simulations (i.e. PK 
variabilities IIV and IOV, but additionally also RUV, Eq. 2.19). For a defined set of design 
variables, a large population (typically n=1000 individuals) is generated by randomly sampling 
from the respective variability distributions. This type of simulation can be utilised to assess the 
variability of the drug exposure for a defined set of design variables. Moreover, in the field of 
antiinfective therapy, MCs form the basis for the probability of target attainment analysis, which 
is discussed in the following (Section 2.4.3).  
2.4.3 Probability of target attainment and cumulative fraction of response 
analysis  
As described before (Section 1.5), the probability of target attainment analysis (PTA) has become 
a powerful concept to assess the adequacy of antiinfective dosing regimens and to ultimately 
support dosing regimen selection [129,190]. In this type of analysis, the drug concentration-time 
profiles of a population of individuals (typically n=1000 patients), generated via stochastic MC 
simulations applying a NLME PK model (Figure 2.4 top), are evaluated with respect to the 
attainment of a predefined PK/PD target (e.g. 50%fT>MIC). The PTA is derived by computing the 
percentage of simulated patients achieving the respective target (Figure 2.4 bottom). A PTA of 
90%, i.e. 900 of 1000 patients attaining the target, is considered as adequate therapy [63]. 
Typically, the PTA is derived over a range of MIC values of interest but can also be assessed 
dependent on e.g. covariates implemented in the model. A PTA analysis can be used to e.g. identify 
patients at risk for ineffective exposure when administering the standard dosing regimen, but also 
to identify superior dosing regimens by evaluating alternative dosing regimens.  
Based on the results of the PTA analysis, the cumulative fraction of response (CFR) can be derived, 
which additionally considers the MIC distribution of the bacteria of interest. Hence, the CFR can 
be applied when aiming to evaluate the probability of target attainment for a given pathogen 
without knowledge on the specific MIC value in a patient or a patient population. The CFR can be 
computed according to the following equation (Eq. 2.35): 
𝐶𝐹𝑅 = ∑𝑃𝑇𝐴𝑖𝑛𝑖=1 ∙ 𝑓𝑖 ( Eq. 2.35) 
in which 𝑖 represents the index of MIC values ranked from lowest to highest MIC value of a 
population of pathogens, 𝑃𝑇𝐴𝑖 the PTA of each MIC value and 𝑓𝑖 the fraction of the respective 
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MIC value of the MIC distribution [222]. Information on the MIC distribution is collected in 
databases such as the EUCAST database [4].  
 
Figure 2.4: Graphical illustration of a typical PTA workflow.  
Exemplified for drug administration via i.v. infusion, a two-compartment PK model, the PK/PD index T>MIC and PTA across 
different MIC values.  
Abbreviations: CL: Clearance; MC: Monte Carlo; MIC: Minimum inhibitory concentration; PK/PD: Pharmacokinetic/ 
Pharmacodynamic; PTA: Probability of target attainment; Q: Intercompartmental clearance; V1: Central volume of distribution; 






This section summarises the software used in the present work (Table 2.2) as well as key 
functionalities and packages applied in the respective software (Table 2.3). 
Table 2.2: Software used in the present thesis.  
Software Version  Reference Used in 
projects: 
NONMEM®  7.3 Icon Development Solutions, Ellicott City, MD, USA. 
(www.iconplc.com/innovation/nonmem) 
I, II, IV 
PsN 4.4.0-4.6.0 Uppsala University, Uppsala, Sweden. 
(uupharmacometrics.github.io/PsN) [223] 
I, II, IV 
Pirana  2.8.1-2.9.6 Pirana Software & Consulting BV  
(www.pirana-software.com) [224] 
I, II, IV 
R  3.1.2-3.5.0 The project for statistical computing. Vienna, Austria. 
(www.CRAN.R-project.org) 
I, II, III, IV 
R Studio 0.98.1091-
1.1.447 
Integrated development environment for R, Boston, MA. 
(www.rstudio.org) 
I, II, III, IV 
Microsoft® Office 
Excel®  
2016 Microsoft Corporation, Redmond, Washington, USA. III 
Abbreviations: PsN: Pearl speaks NONMEM. 
Table 2.3: Key functionalities and packages used in the respective software (Table 2.2). 
Software Functionalities, packages  Used in projects: 
PsN vpc functionality 
bootstrap functionality  
llp functionality  
cdd functionality 
sse functionality  
scm functionality 
I, IV  
I, IV  
I, IV 
I, IV  
IV  
I, IV 
R  ggplot2 package  
xpose4 package 
Git version control  
I, II, III, IV 




Visual basics for application  III 
Abbreviations: vpc: Visual predictive check; llp: Log-likelihood profiling; cdd: Case deletion diagnostics; sse: Stochastic 
simulation and estimation; scm: Stepwise covariate model-building. 
Computationally intensive modelling and simulation activities were partly performed on the high-
performance computing cluster ‘Soroban’ by the Freie Universitaet Berlin [225]. 
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 Project I: Characterisation of linezolid plasma and target site 
exposure in obese and nonobese surgical patients, including the 
evaluation of the microdialysis methodology 
Linezolid plasma and target site exposure in obese and nonobese surgical patie nts  
2.6.1 Clinical study design  
A prospective, open-label, parallel group, controlled single-centre clinical trial was conducted at 
the University Hospital of Leipzig, Germany, with the aim to assess the antibiotic treatment with 
four antibiotic drug combinations in obese and nonobese surgical patients (treatment group 1: 
linezolid and meropenem; 2: tigecycline; 3: cephazolin and metronidazole; 4: fosfomycin and 
piperacillin/tazobactam) [226]. The clinical study was approved by the ethics committee of Leipzig 
University, Germany (121/13-ff) and the Federal Institute for Drugs and Medical Devices of 
Germany (BfArM) and was registered in the European Clinical Trials Database (EudraCT number: 
2012-004383-22).  
In total, 120 obese and nonobese patients were to be enrolled in the clinical study, i.e. 30 patients 
per treatment group, each comprising 15 obese (=index group) and 15 nonobese patients (=control 
group). The current work focused on treatment group 1, more specifically, the treatment with the 
antibiotic linezolid. Criteria for inclusion comprised an age ≥18 years, an abdominal surgical 
intervention with a need of antibiotic prophylaxis, written informed consent and a BMI of 
≥35 kg/m² and <30 kg/m² in the index group and the control group, respectively. Exclusion criteria 
included treatment with study medication ≤72 h before surgery, known allergic reactions against 
one of the study drugs, pregnancy or breastfeeding (for detailed information on inclusion and 
exclusion criteria see Appendix Table S1). Obese and nonobese patients were matched according 
to sex and age (maximum accepted age difference: ±5 years).  
Anaesthesia was performed according to local clinical standards either by balanced anaesthesia 
with propofol and sufentanil or remifentanil followed by desflurane/isoflurane/sevoflurane, or by 
total intravenous anaesthesia (TIVA). All patients received a single standard dose of the antibiotic 
linezolid (600 mg as 30-min i.v. infusion), 30 min to 1 h before the surgical incision (Figure 2.5). 
Concurrently, all patients received meropenem as well as an analgesic drug (half of the patients: 
acetaminophen, the remaining half: metamizole).  
The PK of linezolid was monitored over 8 h, i.e., depending on the duration of the surgery, PK 
samples could be collected during anaesthesia (intra-anaesthetic, anaesthesia status=‘ON’) or after 
anaesthesia (post-anaesthetic, anaesthesia status=‘OFF’). The planned blood sampling time points 
were as follows: 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h and 8 h after start of the linezolid infusion 
(Figure 2.5) and were collected via an arterial line which is often used during surgery to monitor 
blood pressure and analyse arterial blood gasses [227]. In addition, microdialysate samples were 
collected in the ISF of the s.c. adipose tissue. For this purpose, per patient, two microdialysis 
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catheters, identical in construction (CMA 63 microdialysis probe, membrane length 30 mm, cut-
off 20,000 Da, CMA, Kista, Sweden), were inserted into the s.c. adipose tissue of each upper arm, 
90 min before start of linezolid dosing. The catheters were perfused with 0.9% NaCl solution using 
a flow rate of 2 µL/min. After this 90-min equilibration period, microdialysis samples were 
collected during the following planned sampling intervals: 0-30 min, 30 min-1 h, 1-1.5 h, 1.5-2 h, 
2-3 h, 3-4 h, 4-5 h, 5-6 h, 6-7 h, 7-8 h after start of the linezolid infusion (Figure 2.5). 
Subsequently, after flushing and equilibration for 5 min, the catheters were calibrated using the 
retrodialysis technique (Section 1.2). For this purpose, the catheter was perfused with the 
retroperfusate (planned linezolid concentration of 150 mg/L) and up to two retrodialysate samples 
were collected per catheter. While for the first 14 enrolled patients one retrodialysis period over 
30 min was scheduled, for the following 16 patients a double retrodialysis was performed (with 
collection intervals à 15 min) – following the suggestions from a concurrently performed in vitro 
investigation [228]. The exact sampling time points and collection intervals were recorded by the 
medical staff.  
 
Figure 2.5: Clinical study design and PK sampling schedule (modified from [226]).  
Black arrow: Surgical incision; Blue arrow/bar: Start/duration of 30-min linezolid infusion; Dark green arrows: Blood 
sampling time points; Light green arrows: Blood samples in which unbound linezolid concentrations were determined via 
ultrafiltration; Grey bars: Catheter equilibration/flushing periods; Red bars: Microdialysis collection intervals; Blue bars: 
Retrodialysis collection intervals.  
In addition to the PK samples, patient- and surgery-specific information were recorded 
(Section 2.6.4.2: Covariate model development): After obtaining the written informed consent to 
participate, baseline characteristics, such as sex, age, body height, total body weight and laboratory 
data were collected. On the day of surgery, information on e.g. the surgery (e.g. indication, type, 
duration), anaesthesia and intubation were recorded. Furthermore, perioperative arterial blood 
pressure and heart rate were routinely monitored and reported longitudinally for each patient during 
the PK monitoring period. 
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2.6.2 Bioanalytical quantification 
PK samples were analysed at the Department of Pharmacology, University of Regensburg, 
Regensburg, Germany. For 3 of the 8 blood samples per patient, ultrafiltration was performed to 
characterise the protein binding of linezolid. The 3 blood samples were selected around 30 min, 
3 h and 8 h, i.e. at high (30 min=Cmax), medium (3 h) and low (8 h) drug concentrations, with the 
aim to assess a potential concentration-dependency in protein binding. Linezolid concentrations in 
all matrices (plasma, ultrafiltrate, microdialysate, retroperfusate, retrodialysate) were quantified 
using HPLC methods coupled with spectrometric detection [228]. 
2.6.3 Data management and exploratory data analysis 
All steps of data management and exploratory data analysis were encoded in R in a generalisable 
way, allowing to use the scripts as a basis for the analysis of other study drugs of all different 
treatment groups (Section 2.6.1; [226]). 
2.6.3.1 Dataset generation 
A NONMEM® compatible dataset was generated as outlined in section 2.2.1. Given the variety of 
the available PK data (plasma, ultrafiltrate, microdialysate, retrodialysate, retroperfusate; 
Section 2.6.1), additional data items (e.g. FLAG: to specify the PK sampling matrix; CMT: to 
specify the compartment for the respective matrix; CIN: to specify the retroperfusate concentration; 
TIN: to specify the length of the dialysate collection interval) were added. Furthermore, additional 
events (rows) were added to modify the status of a microdialysate compartment, utilised to 
integrate microdialysate concentrations as part of an advanced integrated dialysate-based 
modelling approach (Section 2.6.4.1; [229]). At the start of each collection interval, the respective 
compartment (example: µD compartment represents compartment 3) was ‘turned on’ (EVID=2, 
CMT=3), thereby initiating the integration over the microdialysate (µD) concentration-time 
profile. At the end of the collection interval, the compartment was ‘switched off’ and ‘reset’ 
(EVID=2, CMT=-3). Depending on the desired structure of the NLME model, the dataset was 
adjusted accordingly. In addition, different body size descriptors (BMI; LBW: lean body weight; 
FM: fat mass; IBW: ideal body weight; ABW: adjusted body weight) and haemodynamic markers 
(MAP: mean arterial pressure, COLZ: cardiac output according to Liljestrand and Zander [3]) were 
added to the dataset, which were computed as described in Appendix 7.3.2 and Appendix 7.3.4, 
respectively.  
The full final dataset for the 30 patients consisted of 110 columns and 2607 rows. For illustration 
an exemplary subset of the dataset used for the final NLME model, is provided for a generic patient 
in Appendix 7.4.1. 
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Handling of missing data: Imputation  
In case of available microdialysis data, but missing catheter calibration data via retrodialysis (i.e. 
missing RR estimates to the transform microdialysate into ISF concentrations), imputation of 
retrodialysis data was performed based on identified impact factors on the RR value 
(Section 3.1.1.2). More specifically, considering the need of raw retrodialysate and -perfusate 
concentrations in the dataset underlying the dialysate-based integral modelling, not the RR value 
itself was imputed, but the respective retrodialysate and -perfusate concentrations. As 
retroperfusate concentration, the originally planned concentration (i.e. 150 mg/L; Section 2.6.1) 
was imputed. The associated retrodialysate concentration was derived on the basis of the RR value 
(determined based on the quantified impact factors; Section 3.1.1.2) and the originally planned 
retroperfusate concentration (Eq. 1.2).  
2.6.3.2 Dataset checkout  
In addition to the performed cross column checks and index plots (Section 2.2.2.), newly developed 
individual graphical evaluation plots were generated to assess the sampling schedule of micro- and 
retrodialysis with respect to plausibility (Appendix Figure S1).  
2.6.3.3 Exploratory data analysis 
Prior to NLME modelling, available PK and additional patient-specific data were analysed 
according to the exploratory statistical and graphical data analysis procedures described in 
section 2.2.3. The current project focused on the evaluation of the different types of PK data with 
respect to exposure. For this purpose, different PK matrices (e.g. plasma versus ISF), different 
patients (e.g. obese versus nonobese) and microdialysate data collected with different catheters (i.e. 
catheter 1 versus catheter 2) were analysed. Apart from exposure evaluation, the PK data were 
analysed with regard to choosing a potential PK model (e.g. number of disposition phases, 
nonlinearity, tissue fluid distribution). Furthermore, patient- and surgery-specific characteristics 
such as body size (e.g. BMI, LBW, FM, IBW, ABW) and anaesthesia status and haemodynamic 
markers (e.g. MAP, COLZ) were assessed (e.g. their distribution; section 2.2.3).  
2.6.4 Nonlinear mixed-effects modelling 
2.6.4.1 Integrated dialysate-based modelling approach for microdialysis data 
Two NLME different modelling approaches for analysing data obtained from microdialysis 
experiments have been described which differ in the complexity, the underlying assumptions and 
the output of the data analysis: The ‘mid-time approach’ and the ‘integrated dialysate-based 
modelling approach’ [229–231]. The mid-time approach represents a simple stepwise analysis 
approach that requires data transformation prior to modelling. More concretely, microdialysate 
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concentrations are converted into ISF concentrations based on the relative recovery values obtained 
from the retrodialysis calibration. As the name of this approach implies, the derived ISF 
concentrations are assigned to the mid-time point of the collection interval for modelling purposes. 
Hence, this method makes assumptions regarding the time point of the microdialysate observation 
and assumes an error-free relative recovery.  
The integrated dialysate-based modelling approach was first proposed by Tunblad et al. for animal 
data [229] and Minichmayr and Schaeftlein et al. at our department for humans [45,230] and was 
applied in the present thesis. In contrast to the mid-time approach, this more advanced modelling 
approach analyses all available PK data including the untransformed micro- and retrodialysate data 
(‘dialysate-based’) simultaneously. Consequently, this approach does not require any data 
transformation prior to modelling. The relative recovery factor is estimated based on the 
retroperfusate and retrodialysate concentrations according to Eq. 1.2 and is used to transform 
microdialysate concentrations into ISF concentrations (Figure 2.6 A).  
 
Figure 2.6: Illustration of the integrated dialysate-based modelling approach.  
A: Snapshot of full structural NLME model, which illustrates the use of all available PK data (𝐶µ𝐷 , 𝐶𝑅𝑃, 𝐶𝑅𝐷) and the estimation 
of the RR value within the model, which converts 𝐶µ𝐷 into 𝐶𝐼𝑆𝐹. Solid/Dashed arrows: Indicate mass transfer/no mass transfer. 
B: Microdialysate and ISF concentration-time profiles, which illustrate the integration over the profile for a defined collection 
interval 𝑇𝑖𝑛𝑡.   
Abbreviations: CISF: ISF concentration; 𝐶µD: Microdialysate concentration; 𝐶𝑅𝐷: Retrodialysate concentration;  𝐶𝑅𝑃: Retro-
perfusate concentration; ISF: Interstitial space fluid; PK: Pharmacokinetic; RR: Relative recovery; t: Time; Tint: Time interval.  
This is done within the model, by integrating the linezolid concentration-time profile over the 
collection interval using the underlying PK model (Eq. 2.3; Figure 2.6 B), thus not requiring any 
assumptions regarding the sampling time points.  
𝐶µ𝐷[𝑡𝑗, 𝑡𝑗+1] = ∫ 𝐶𝐼𝑆𝐹(𝑡) ∙ 𝑅𝑅 𝑑𝑡𝑡𝑗+1𝑡𝑗 /(𝑡𝑗+1  −  𝑡𝑗) ( Eq. 2.36) 
In Eq. 2.36, the microdialysate concentration (𝐶µ𝐷[𝑡𝑗, 𝑡𝑗+1] , 𝑗 ∈ {1,… , 𝑛 − 1}) is defined by the 
integral of the ISF concentration-time profile (𝐶𝐼𝑆𝐹(𝑡)) multiplied by the relative recovery value 
(𝑅𝑅) over the collection interval (𝑇𝑖𝑛𝑡  =  [𝑡𝑗, 𝑡𝑗+1]), which is then divided by the duration of the 
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microdialysate collection (𝑡𝑗+1  − 𝑡𝑗). To realise this computation in NONMEM®, concentrations 
are ‘accumulated’ (i.e. ‘integrated’) in a separate compartment, as commonly used for e.g. AUC 
calculations (Appendix 7.4.2).  
2.6.4.2 Model development strategy  
Given the PK data collected in different matrices, 
the NLME model was developed in a stepwise 
sequential procedure (Figure 2.7). In brief, a base 
model was developed based on the total plasma 
concentrations (step 1), which was extended by 
the unbound plasma concentrations determined 
via ultrafiltration (step 2). The microdialysate 
concentrations together with the respective 
retroperfusate and dialysate concentration data of 
one of the catheters were then added (step 3) and 
subsequently the data of both catheters (step 4). 
Finally, a covariate analysis was performed with a 
special focus on body size descriptors and 
surgery-specific characteristics (step 5). Further 
details are provided in the following sections.  
Base model development: Plasma (steps 1-2)  
Base model development started from 
investigating total plasma concentrations and 
aimed to characterise the plasma PK of linezolid 
(step 1). Based on the results of the exploratory 
analysis and prior knowledge from previously 
published literature, different structural linezolid 
disposition models (one-, two-compartment) were 
investigated. IIV was implemented using the ‘full 
approach’, i.e. the diagonal random-effects 
parameters were implemented on all PK 
parameters simultaneously using an exponential 
model (Eq. 2.4). IIV parameters were assessed 
and removed in a stepwise backward deletion 
procedure until none of the remaining IIV 
parameters met any of the following exclusion 
Figure 2.7: Model development strategy. The 
numbered arrows represent the steps of the model 
development procedure (for further information see 
text, section 2.6.4.2). 
Abbreviations: 𝐶𝑃_𝑡𝑜𝑡: Total plasma concentrations;  𝐶𝑃_𝑢: Unbound plasma concentrations; 𝐶𝑅𝐷: Retrodialysate 
concentration; 𝐶𝑅𝑃: Retroperfusate concentration;  𝐶µD: Microdialysate concentration; µD: Microdialysate. 
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criteria: Precision (≥50% RSE), η-shrinkage (≥30%) and magnitude of IIV (≤10%CV). Additional 
covariance between the IIV parameters was assessed using the OMEGA BLOCK functionality in 
NONMEM® (Section 2.3.1.2) and was implemented if correlation coefficient 𝜌≥75% (Eq. 2.7). 
RUV was investigated using additive (Eq. 2.9), proportional (Eq. 2.10) and combined (Eq. 2.11) 
variability models. 
Next, to characterise the protein binding of linezolid, unbound plasma concentrations were 
integrated in the model and an additional ‘fraction unbound’ (fu) parameter was estimated, which 
linearly scaled total to unbound linezolid concentrations (step 2). An additional IIV parameter on 
the estimated fu parameter as well as separate RUV for the unbound plasma concentrations were 
evaluated. In the resulting plasma model for total and unbound linezolid concentrations, different 
clearance (CL) models were assessed on the basis of the results of the exploratory data analysis 
and prior knowledge from previously published literature:  
• Linear CL 
• Concentration-dependent clearance:  
o Nonlinear Michaelis-Menten CL 
o Parallel linear and nonlinear Michaelis-Menten CL 
o Nonlinear CL using an empirical inhibition compartment [45,146] 
• Time-varying CL dependent on surgery-specific characteristics: 
o Anaesthesia status 
o Intubation status 
o Haemodynamic markers 
Base model development: Plasma and target site (steps 3-4) 
The successfully developed plasma base model was extended by the PK data of one of the 
microdialysis catheters (i.e. its microdialysate, retroperfusate and retrodialysate concentrations) 
using the integrated dialysate-based modelling approach (Section 2.6.4.1), in order to evaluate the 
kinetics of tissue fluid distribution (step 3). Different structural models, assuming different 
distribution kinetics, were assessed:  
• Model A: Rapid negligible distribution of linezolid from plasma to ISF (i.e. target site), 
i.e. rapid equilibrium between plasma and ISF:  
Assignment of ISF to the central compartment of the plasma base model and estimation of 
an additional tissue scaling factor 
• Model B: Delayed distribution of linezolid from plasma to the target site, with ISF data 
showing similar kinetics of linezolid transfer as the peripheral compartment of the plasma 
base model:   
Assignment of ISF to the already existing peripheral compartment of the plasma base 
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model and estimation of an additional tissue scaling factor 
• Model C: Delayed distribution of linezolid from plasma to the target site; with ISF data 
showing different kinetics of linezolid transfer than the peripheral compartment of the 
plasma base model:   
Assignment of ISF to a second separate peripheral compartment and estimation of two 
additional PK parameters of this compartment (intercompartmental clearance and the 
volume of distribution)  
Apart from the exploratory graphical data analysis, the appropriateness of distribution model A 
was assessed by evaluating the applicability of an already existing pooled NLME PK model for 
linezolid, which had ISF assigned to the central compartment [45]. For this purpose, concentration-
time profiles of obese and nonobese patients were predicted using the final PK parameters 
estimated in the pooled population PK model [45] based on an overweight diabetic (BMImedian=31 
kg/m2) and a healthy population (BMImedian=23 kg/m2), respectively. Final model parameter 
estimates and individual data were used for Bayesian estimation of individual PK parameters 
(Section 2.3.2; MAXEVAL=0 functionality in NONMEM®). Model adequacy was assessed by 
goodness-of-fit plots (Section 2.3.3.1), visual predictive checks (Section 2.3.3.7) and calculation 
of prediction errors (Section 2.3.3.8).   
For the three structural models (A-C), IIV was investigated on the additional PK- and 
methodology-related parameters and separate RUV parameters assessed for the micro- and 
retrodialysate concentrations. Furthermore, the links of the unbound ISF concentrations with the 
total or the unbound plasma concentrations were investigated, respectively.  
After identification of an appropriate structural model, the data of the second catheter was 
integrated instead of the first catheter and subsequently in addition to the first catheter, with the 
aim of identifying different levels of catheter variability in the microdialysis technique (step 4). 
After replacing the data of catheter 1 by the data of catheter 2, all model parameters were re-
estimated and compared to the parameters of the previous model based on data from catheter 1. 
Thereafter, the data of both catheters were simultaneously analysed and different levels of 
variability in the microdialysis technique dissected and quantified: Intercatheter variability (based 
on 2 catheters/patient) and intracatheter variability (based on 1-2 retrodialysis assessments 
/catheter).  
Covariate model development (step 5) 
The covariate model development aimed to identify covariates that explained microdialysis 
methodology- and PK-related variability between the patients. For the PK-related variability, the 
analysis focused on the investigation of body size descriptors and surgery-specific characteristics. 
Body size was pre-investigated using the following three approaches:  
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• Approach 1: Analysis of the categorical covariate ‘obesity’ using the automated stepwise 
covariate model building procedure scm in PsN [223]. 
• Approach 2: Analysis of continuous body size descriptors (total body weight (WT), BMI, 
ABW, IBW, LBW) and additional pre-selected covariate candidates (sex; ASAT: aspartate 
aminotransferase; ALAT: alanine aminotransferase; GGT: gamma-glutamyl-transferase; 
bilirubin; CLCRCG_LBW: Creatinine clearance estimated according to Cockcroft and Gault 
using LBW [2]) using the automated stepwise covariate model building procedure scm in 
PsN [223]. Preselection was performed based on graphical evaluation and prior knowledge 
from publications (Section 2.3.1.3). 
• Approach 3: Analysis of body size using a mechanistic implementation according to 
Huisinga et al. [210] and Holford et al. [204]. 
Approach 3 aimed to more mechanistically implement body size into the NLME model by 
separating total body weight into LBW and FM, which are jointly used as covariates on the PK 
parameters. The respective proportional impact of LBW and FM on the PK parameters are 
estimated in the models and are specific for the drug and the PK parameter. In case of a hydrophilic 
drug, LBW might be an appropriate covariate to describe volume of distribution or clearance, while 
for lipophilic drugs, an additional impact of FM is likely [204]. Both models (i.e. Huisinga et al. 
(Eq. 2.37) and Holford et al. (Eq. 2.38)) use the same approach, but different parameterisations.  
𝜃𝑖𝑘 = 𝜃𝑘,𝑟𝑒𝑓 ∙ ((1 − 𝑅) ∙ 𝐿𝐵𝑊𝑖𝐿𝐵𝑊𝑟𝑒𝑓 + 𝑅 ∙ 𝐹𝑀𝑖𝐹𝑀𝑟𝑒𝑓) ( Eq. 2.37) 𝑁𝐹𝑀𝑖 = 𝐿𝐵𝑊𝑖 + 𝑓𝑓𝑎𝑡 ∙ 𝐹𝑀𝑖 𝑁𝐹𝑀𝑟𝑒𝑓 = 𝐿𝐵𝑊𝑟𝑒𝑓 + 𝑓𝑓𝑎𝑡 ∙ 𝐹𝑀𝑟𝑒𝑓 
𝜃𝑖𝑘 = 𝜃𝑘,𝑟𝑒𝑓 ∙ 𝑁𝐹𝑀𝑖𝑁𝐹𝑀𝑟𝑒𝑓 
( Eq. 2.38) 
 
In both models, 𝜃𝑖𝑘 represents the typical 𝑘th PK parameter for the 𝑖th individual 𝐿𝐵𝑊𝑖-𝐹𝑀𝑖 
combination; 𝜃𝑘,𝑟𝑒𝑓 represents the typical 𝑘th PK parameter for the reference 𝐿𝐵𝑊𝑟𝑒𝑓-𝐹𝑀𝑟𝑒𝑓 
combination. In the model by Huisinga et al. (Eq. 2.37), the estimated parameter 𝑅 defines the 
proportional impact of LBW and FM on 𝜃𝑘, if e.g. 𝑅=0.5, doubling the FM would have the same 
impact on 𝜃𝑘 as doubling LBW. The individual LBW and FM (𝐿𝐵𝑊𝑖, 𝐹𝑀𝑖) are centred around the 
reference values (𝐿𝐵𝑊𝑟𝑒𝑓, 𝐹𝑀𝑟𝑒𝑓). In the model by Holford et al. (Eq. 2.38), a new body size 
descriptor ‘normalised fat mass’ (𝑁𝐹𝑀) is introduced, which is defined by the estimated parameter 𝑓𝑓𝑎𝑡 representing the fraction of 𝐹𝑀 which is added to 𝐿𝐵𝑊. Similar to the model by Huisinga et 
al., the individual 𝑁𝐹𝑀 (𝑁𝐹𝑀𝑖) is centred around the reference 𝑁𝐹𝑀 (𝑁𝐹𝑀𝑟𝑒𝑓).   
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Based on the results of the three covariate pre-investigations performed, a stepwise covariate 
analysis strategy was developed in order to identify the final covariate model for body size 
(Appendix Table S5). For evaluation of the surgery-specific impact on the PK of linezolid, the 
categorical covariate ‘anaesthesia status’ and the continuous haemodynamic markers were assessed 
(heart rate, MAP, CO) using fractional change (Eq. 2.18) and linear (Eq. 2.13) covariate-parameter 
relationships, respectively. 
After having included all identified covariates into the model, the final model refinement step 
focused on the reassessment of the RUV model structures for the different sampling matrices and 
the centring of the covariate effects around typical covariate values. 
2.6.4.3 Model evaluation and discrimination 
A combination of evaluation approaches (goodness-of-fit plots, VPCs (n=1000 simulations, 
stratified by sampling matrix and/or obesity status of the patient)), assessment of parameter 
plausibility and precision) was used for model evaluation. In case of competing models, OFV 
values were compared using the likelihood ratio test or AIC values. In addition, for the final model, 
the following advanced evaluation techniques were used:   
• Non-parametric bootstrap (n=1000 replicate datasets) to assess accuracy and precision of 
the parameter estimates as well as model robustness (evaluating the convergence rate) 
• Case-deletion diagnostics (on patient level) to evaluate model robustness and the presence 
of influential individuals 
Details on the abovementioned evaluation techniques are summarised in section 2.3.3. 
2.6.5 Simulations: Exploration of linezolid exposure 
To further explore the PK of linezolid after standard dosing, the final NLME PK model was applied 
by simulating linezolid concentration-time profiles in different body fluids and for different patient 
characteristics. With regard to body fluids, the analysis focused on the comparison of the total and 
the unbound linezolid concentrations in plasma with ISF concentrations in the s.c. adipose tissue. 
Patient characteristics were selected according to the covariates identified in the final NLME PK 
model.   
The first analysis aimed at analysing specific plausible covariate combinations, representing typical 
patients of the study population (Table 2.4 A). Deterministic and stochastic simulations were 
performed (n=1000 patients; Sections 2.4.1-2.4.2). In the second analysis, the impact of body size 
on linezolid exposure was further evaluated. More precisely, the body size descriptor(s) identified 
in the NLME PK model, were varied over a broad range with the remaining covariates set to the 
representative values in the population, and the resulting linezolid concentration-time profiles were 
assessed using deterministic simulations (Table 2.4 B). In both analyses, simulations were 
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performed for standard linezolid i.v. dosing (600 mg as 30-min infusion) administered as single 
dose, but also as multiple doses (q12h) for the first 24 h of treatment. 
Table 2.4: Patients used for exposure simulations. 
 A: Typical obese and nonobese patients during and after anaesthesia (used for simulation analysis 1) 
Characteristics Typical patients 











Sex1 female female female female 
Body weight2 [kg] 119 65 119 65 
Body height2 [m] 1.65 1.67 1.65 1.67 
MAP2 [mmHg] 71.7 66.7 91.7 83.3 
Anaesthesia status3 ON  ON OFF OFF 
BMI4 [kg/m2] 43.7 23.3 43.7 23.3 
LBW4 [kg] 56.7 41.7 56.7 41.7 
 
B: Patients with varying LBW6 during surgery (used for simulation analysis 2). 
Characteristics Patients with LBW6 [kg] of: 
35 40 45 50 55 60 65 70 75 808 
Sex1 |───────────────────── fe  le ─────────────────────| 
Anaesthesia status3 |───────────────────── ON  ───────────────────────| 
Body height2 [m] |───────────────────── 1.65  ──────────────────────| 
MAP2 [mmHg] |───────────────────── 69.2  ──────────────────────| 
Body weight5 [kg] 50.1 61.8 75.4 91.7 111 135 166 205 258 334 
BMI5 [kg/m2] 18.4 22.7 27.7 33.7 40.8 49.6 61.0 75.3 94.8 122 
Obesity status7 0 0 0 1 1 1 1 1 1 1 
 
Symbols ‘|─── xxx ───|’: indicate that same value of a characteristic was used for all patients.  
Grey shading: indicates which characteristics were derived or back-calculated from observed characteristics (i.e. 
characteristics not shaded in grey).   
1Assigned to most frequently observed sex in the population (i.e. female; Section 3.1.1.1).  
2Assigned to median of the respective female patient population.  
3Indicates whether patient is under anaesthesia (intra-anaesthetic, ‘ON’) or thereafter (post-anaesthetic, ‘OFF’). 
4Derived based on the observed characteristics not shaded in grey.   
5For illustration back-calculated from LBW (Eq. 7.11) and the observed characteristics not shaded in grey.   
6LBW as the body size descriptor(s) identified in the NLME PK model (Section 3.1.2.2).  
7For illustration derived from BMI (0: nonobese, i.e. BMI<30 kg/m2; 1: obese, i.e. BMI≥30 kg/m2).    
8Extraploated for female patient population (i.e. LBW of 80 kg was not observed); but observed for male patient population. 




 Project II: Evaluation and optimisation of linezolid dosing 
regimens for infection prophylaxis and acute therapy in obese and 
nonobese surgical patients 
Linezolid dos ing regimens in obese and nonobese surgical  patie nts  
The NLME PK model which was developed in Project I was applied to assess the adequacy of 
linezolid dosing regimens in the setting of infection prophylaxis and acute infection therapy for 
patients with different clinical characteristics and pathogen susceptibilities.  
In this paragraph a general description of the analysis approach is provided, while in the following 
two subsections 2.7.1 and 2.7.2, a more detailed description is provided for the setting of infection 
prophylaxis and acute infection therapy, respectively. In general, to assess the adequacy of 
linezolid dosing regimens, for each specific covariate combination and dosing regimen, linezolid 
concentration-time profiles were simulated for 1000 patients using stochastic MC simulations 
(Section 2.4.2) considering IIV in the PK parameters. To assess the attainment of ‘effective 
exposure’, the PTA (Section 2.4.3, technical details are described in more detail below) was 
evaluated for the PK/PD target of 95%fT>MIC (considering non-achievability of 100%fT>MIC due to 
single dose treatment and the delayed distribution of linezolid into ISF). PTA was evaluated for 
the MIC values 0.5 , 1 , 2 , 4 mg/L (the latter two, representing non-species related as well as 
species related EUCAST S and R breakpoints of relevant pathogens, e.g. S. aureus, Enterococcus 
spp. and α-haemolytic Streptococcus spp. [5]). A PTA of ≥90% (i.e., 900 of 1000 patients achieving 
the PK/PD target [63]) was considered adequate. 
2.7.1 Simulations: Evaluation of standard linezolid dosing for infection 
prophylaxis 
In order to evaluate standard linezolid dosing for the setting of infection prophylaxis during 
surgery, PTA was assessed for three different incision-suture durations, i.e. times between incision 
and suture (2 h, 4 h, 6 h), based on unbound linezolid concentrations in the ISF of the s.c. adipose 
tissue (as a potential site of infection) following a single standard linezolid dose (600 mg, as 30-
min i.v. infusion, 30 min before incision). As the analysis focused on assessing different incision-
suture durations, the analysis was performed for the typical ‘intra-anaesthetic’ obese and nonobese 
patient of the study population (Table 2.4 A) as well as for varying values of body size descriptor(s) 
identified in the NLME PK model (Table 2.4 B).  
2.7.2 Simulations: Evaluation and optimisation of linezolid dosing for acute 
therapy 
In order to evaluate and, if needed, optimise linezolid dosing regimens for the setting of acute 
infection therapy, PTA was assessed for the first 24 h of treatment based on unbound linezolid 
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concentrations in the ISF of the s.c. adipose tissue as well as in plasma following standard but also 
alternative linezolid dosing regimens. Compared to standard linezolid dosing, the seven 
alternatives comprised dosing regimens with an intensified daily dose and/or a prolonged infusion 
duration and/or a shortened dosing interval (Table 2.5),. Throughout this project an informative 
code ‘XYZ’ was used to indicate the dosing regimens: In this code X represents the type of infusion, 
Y the administered daily dose in gram and Z the dosing interval in hours (e.g. for the standard 
linezolid dosing regimen: SI1.212; here, SI indicates the short-term infusion of a 1.2 g daily dose 
which is divided into two 0.6 g doses administered every 12 h).  
Table 2.5: Evaluated i.v. dosing regimens of linezolid. 
Daily dose [mg]  Short-term infusion (SI)  
over 30 min 
Prolonged infusion (PI) 
over 4 h  
1200 SI1.212:  600 mg  q12h  
(=standard dosing regimen) 
PI1.212:  600 mg  q12h 
1800 SI1.812:  900 mg  q12h PI1.812:  900 mg  q12h 
1800 SI1.88:  600 mg  q8h PI1.88:  600 mg  q8h 
2400 SI2.412:  1200 mg  q12h PI2.412:  1200 mg  q12h 
Abbreviations: PI: Prolonged infusion; SI: Short-term infusion, q8h: Every 8 hours; q12h: Every 12 hours. 
The PTA analyses were performed for the eight investigated dosing regimens (Table 2.5), for 
different typical patients (Table 2.4 A) as well as for varying values of body size descriptor(s) 
identified in the NLME PK model (Table 2.4 B). Based on these analyses, the impact of dosing 
alterations (1. intensification of the daily dose, 2. prolongation of the infusion duration, 
3. shortening of the dosing interval) on the PTA was assessed, both the actual magnitude of PTA 
as well as the attainment of adequate PTA (i.e. PTA≥90%).  
To evaluate the general impact of the dosing alteration, the investigated dosing regimens were 
grouped together and compared with respect to the overall frequency of attaining adequate PTA: 
Grouping was based on the dosing characteristics of interest, e.g. in case of the dosing alteration 
‘intensification of daily dose’, the regimens with the same daily dose were grouped together. In 
order to allow the assessment of the univariate impact of the dosing alteration of interest, grouping 
was performed for dosing regimens for which corresponding dosing regimens existed, i.e. dosing 
regimens which varied in the dosing characteristics of interest (e.g. varying daily dose), but were 
comparable with respect to the two remaining characteristics (e.g. same infusion duration and 
dosing interval). To give an example, to assess the general impact of the dosing alteration 
‘intensification of daily dose’ on the attainment of adequate PTA, the two dosing regimens with 
the daily dose of 1200 mg (SI1.212, PI1.212) were compared to the two corresponding 1800 mg 
regimens (SI1.812, PI1.812) and the two corresponding 2400 mg regimens (SI2.412, PI2.412). The 
two regimens with the shortened dosing interval (SI1.88 and PI1.88) were not included in the 
comparison, as no corresponding regimens with the daily dose of 1200 mg and 2400 mg were 
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investigated (Table 2.5). In addition to the assessment of the general impact of dosing alteration, 
the impact was further elucidated for selected types of dosing regimens or in selected matrices (i.e. 
plasma or ISF). For example, in case of the dosing alteration ‘intensification of daily dose’, the 
impact was separately assessed for short-term (SI1.212 vs. SI1.812 vs. SI2.412) and prolonged 
infusion regimens (PI1.212 vs. PI1.812 vs. PI2.412) as well as separately in plasma an in ISF. A 
detailed overview of all investigated scenarios is provided in the Appendix, Table S9.  
In addition to the impact of dosing regimen alteration on the PTA, the impact of the identified body 
size descriptor(s) on the PTA was elucidated. Lastly, a dosing overview was created, summarising 
the short-term and prolonged dosing regimens resulting in adequate PTA either in plasma only or 
both in plasma and in the ISF of the s.c. adipose tissue, for varying values of body size descriptor(s) 
and the four investigated MIC values. 
 Project III: Development of a risk assessment tool to evaluate 
standard meropenem dosing in critically ill patients with respect 
to ineffective meropenem exposure 
Risk assessment too l for standard meropenem dosing in critically  il l patie nts  
2.8.1 Clinical study design 
This prospective observational study was conducted at three intensive care units within the 
Department of Anaesthesiology, University Hospital, Ludwig-Maximilians-Universitaet (LMU) 
Munich, Germany. The study protocol (ClinicalTrials.gov Identifier: NCT01793012) was 
approved by the Institutional Review Board of the Medical Faculty of the LMU Munich, Germany. 
Criteria for inclusion comprised the presence of severe infection (confirmed or suspected by 
clinical assessment), an age ≥18 years and treatment with meropenem (including possible de-
escalation; clinical assessment independent from the study). Patients were excluded in case of a 
planned hospitalisation <4 days or meropenem administration >48 h prior to study start. Written 
informed consent to participate was obtained from all patients or their legal representatives.   
All patients received standard doses of meropenem as 30-min i.v. infusions every 8 h (Figure 2.8). 
Multiple blood samples were collected for the quantification of meropenem concentrations over a 
study period of 4 days via an arterial line which is commonly used in critically ill patients to 
monitor blood pressure and analyse arterial blood gasses [227,232]. Intensive sample collection 
was performed during all three dosing intervals of study day 1 and during the first dosing interval 
of study days 2–4. An additional single meropenem minimum concentration (Cmin) sample before 
the next dose was collected for the third dosing interval of days 2 and 3. The planned sampling 
time points per intensively monitored dosing interval were as follows: 15 min, 30 min, 1.5 h, 4 h, 
and 8 h (immediately prior to next dose; Cmin) after the start of infusion (Figure 2.8).   
Risk assessment tool for standard meropenem dosing in critically ill patients  
57 
 
Figure 2.8 Clinical study design (A) and sampling schedule of intensively monitored meropenem (MER) 
dosing intervals (B) (modified from [233]).  
A: Blue arrows: Start of 30-min meropenem infusions; Dark green bars: Intensively monitored meropenem dosing intervals; 
Light green bars: Monitored meropenem dosing interval with minimum concentration sample only; Orange triangles: 
Determinations of serum creatinine for the estimation of creatinine clearance   
B: Blue arrows/bars: Start/duration of 30-min meropenem infusion; Green arrows: Sampling times (0.25, 0.5, 1.5, 4, 8 h after 
start of infusion).  
Abbreviations: MER: Meropenem; PK: Pharmacokinetic.  
The exact sampling time points were recorded by the medical staff. In addition to the PK samples, 
patient-specific data such as diagnosis, demographics, disease scores and laboratory data (e.g., 
serum creatinine) were recorded during the study period (Table S2). Furthermore, pathogens 
identified in specimens collected from the patients (between 3 days before and 3 days after the 
study period) were recorded. 
2.8.2 Bioanalytical quantification 
Blood samples were immediately sent to the Institute of Laboratory Medicine, University Hospital, 
LMU Munich, Germany and centrifuged. Serum samples were stored at −80°C until total 
meropenem serum concentration was quantified by using a validated liquid chromatography-
tandem mass spectrometry method described previously [234]. Briefly, six-fold deuterated 
meropenem was used as an internal standard, and validation revealed good analytical performance, 
with an inaccuracy of less than or equal to ±4% relative error and imprecision ≤6%CV. 
2.8.3 Exploratory data analysis  
PK and additional patient-specific data were analysed using exploratory statistical and graphical 
methods as outlined in section 2.2.3. This project further focused on the evaluation of the 
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variability of meropenem concentrations as described in the following.   
To quantify inter- and intraindividual variability of meropenem serum concentrations, measured 
Cmin values at the end of the dosing interval were first analysed as observed, irrespective of the 
actual heterogeneous sampling time points or administered doses. Interindividual variability was 
evaluated by an exploratory statistical summary analysis of all available Cmin values; for description 
of intraindividual variability, the ratios of the maximum (max.) and minimum (min.) Cmin values (𝐶min_max𝐶min_min) of all dosing intervals monitored within a patient were statistically summarised. 
Summary statistics included median, range, 95% CI and %CV.   
Second, in order to exclude a potential impact of dose- and sampling time point-related variability 
on meropenem Cmin, dose-normalised meropenem concentrations (to a dose of 1000 mg, assuming 
linear PK) at two specific time points (4 h (C4h) and 8 h (C8h) after start of infusion) were calculated 
and the variability evaluated as described above. C4h and C8h values were determined by linear 
regression (if ≥3 available data points) or linear interpolation (if 2 available data points) of the 
logarithmised meropenem concentrations in the declining phase of each concentration-time profile. 
In case of a coefficient of determination (r2) of <0.9, being associated with two distinct phases in 
the declining part of the concentration-time profile, a separate linear interpolation/regression was 
performed for each of these phases. 
2.8.4 Pharmacokinetic/Pharmacodynamic analysis 
On the PK side, this analysis focused on a regression model to quantify the impact of renal function 
on meropenem exposure (Section 2.8.4.1). PK was then linked to PD, by performing a PTA 
analysis, in order to assess the probability of achieving effective meropenem exposure after 
standard meropenem dosing and to evaluate the impact of renal function on this probability 
(Section 2.8.4.2). 
2.8.4.1 Regression model: Impact of renal function on meropenem exposure 
To investigate the impact of renal function on meropenem exposure, creatinine clearance estimated 
according to Cockcroft and Gault (CLCRCG [2]) was related to C4h and C8h values. This was done 
(i) at patient level by using the median individual CLCRCG of a patient and (ii) at sample level by 
using all single observed CLCRCG values of all patients. For all patients not undergoing CRRT 
(continuous renal replacement therapy), the relation between CLCRCG and C8h values (𝐶8ℎ=α ∙ 1𝐶𝐿𝐶𝑅𝐶𝐺𝛽) was quantified by weighted linear least squares regression in double logarithmic 
scale (Eq. 2.39), i.e.: 
Risk assessment tool for standard meropenem dosing in critically ill patients  
59 
log(𝐶8ℎ, 𝑜𝑏𝑠) = 𝑎 + 𝑏 ∙ log(𝐶𝐿𝐶𝑅𝐶𝐺) + 𝜀, ( Eq. 2.39) 
in which 𝑎 = log(𝛼) , 𝑏 = −𝛽 (for further details see Section 2.8.5.1). The residual variability 𝜀 
represented the difference between the logarithmised observed 𝐶8ℎ, 𝑜𝑏𝑠 values and the 
logarithmised model-predicted typical 𝐶8ℎ, 𝑝𝑟𝑒𝑑  values and was assumed to be normally distributed 
with variance ?̂?𝜀2 proportional to 𝐶𝐿𝐶𝑅𝐶𝐺. 
2.8.4.2 PK/PD target attainment analysis: Evaluation of standard meropenem dosing 
To evaluate the achievement of effective meropenem serum concentrations, PK/PD target 
attainment was assessed for a broad MIC range from 0.25 mg/L to 8 mg/L, with a special focus on 
MIC=2 mg/L and MIC=8 mg/L as EUCAST MIC S and R breakpoints for relevant bacteria, such 
as Enterobacteriaceae, Pseudomonas spp. or Acinetobacter spp. [5]. Due to the negligible protein 
binding of meropenem (2%), total meropenem serum concentrations were used for all analyses 
[63,160]. The PK/PD target 100%T>MIC (i.e. meropenem concentrations exceeding 1x the MIC for 
the entire dosing interval) was selected [235,236]. In accordance with other studies, 50%T>4xMIC 
(i.e. meropenem concentration exceeding 4 x the MIC value for half of the dosing interval) was 
chosen as a second target [237–239]. To evaluate the attainment of the PK/PD targets 100%T>MIC, 
the predicted C8h values of each dosing interval were evaluated regarding the achievement of 1 x 
MIC breakpoints for all patients not undergoing CRRT (non-CRRT). Similarly, for the target 
50%T>4xMIC, the predicted C4h values of each dosing interval were evaluated regarding the 
attainment of 4 x the MIC breakpoints for all non-CRRT patients. Dosing was considered adequate 
if the PK/PD target was attained in ≥90% of the monitored dosing intervals [41].  
To assess the impact of renal function, target attainment at sample level was stratified by the 
following classes of renal function (RF) based on CLCRCG [104,240,241]: Severely impaired RF: 
15-29 mL/min; moderately impaired RF: 30-59 mL/min; mildly impaired RF: 60-89 mL/min; 
normal RF: 90-129 mL/min; augmented RF: ≥130 mL/min.  
2.8.5 Risk assessment tool 
A Microsoft Excel® tool for the risk assessment of PK/PD target non-attainment based on the renal 
function was developed for the PK/PD target 100%T>MIC. The quantified CLCRCG-C8h relationship 
for non-CRRT patients (Section 2.8.4.1) was implemented in order to derive the typical 
meropenem C8h value for a specific CLCRCG. In addition, to determine the range of probable C8h 
values for a patient cohort with a specific CLCRCG, the 95% prediction interval (PI) around this 
relationship was provided [242]. Furthermore, the computation of the risk of target non-attainment 
for given CLCRCG and MIC values was implemented in the Microsoft Excel® tool.  
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2.8.5.1 Mathematical basis  
The model-predicted typical value was denoted by log(𝐶8ℎ, 𝑝𝑟𝑒𝑑) = ?̂? + ?̂? ∙ log(𝐶𝐿𝐶𝑅𝐶𝐺) (â, b̂ are 
estimated regression model parameters). The regression variability parameter ?̂?𝑟𝑒𝑔2  was determined 
from ?̂?, ?̂? and due to heteroscedasticity varying with the value of 𝐶𝐿𝐶𝑅𝐶𝐺. The prediction 
variability ?̂?2 around the typical 𝐶8ℎ, 𝑝𝑟𝑒𝑑  value consisted of the sum of two components: The 
regression variability ?̂?𝑟𝑒𝑔2  and the residual variability ?̂?𝜀2. To obtain prediction intervals and the 
risk of target non-attainment from the prediction variability ?̂?2, standardised residuals were utilised 
(part of the classic theory of linear models [242]). The standardised residuals log(𝐶8ℎ, 𝑜𝑏𝑠)−log(𝐶8ℎ, 𝑝𝑟𝑒𝑑)?̂?2  are t-distributed with 𝑛 − 2 degrees of freedom, with 𝑛 being the number 
of data points used in the regression analysis.  
The 95% PI and risk of PK/PD target non-attainment P(𝐶8ℎ, 𝑝𝑟𝑒𝑑 ≤ MIC) were then derived from 
quantiles 𝑞𝛼𝑡𝑛−2 and the cumulative distribution function 𝐹𝑡𝑛−2 of the t-distribution (Eq. 2.40, 
Eq. 2.41), i.e. 95% 𝑃𝐼 = [𝐶8ℎ, 𝑝𝑟𝑒𝑑 ∙ 𝑒𝑥𝑝(?̂? ∙ 𝑞 0.025𝑡𝑛−2 ) ;  𝐶8ℎ, 𝑝𝑟𝑒𝑑 ∙ 𝑒𝑥𝑝(?̂? ∙ 𝑞 0.975𝑡𝑛−2 )]  ( Eq. 2.40) 
and 𝑃(𝐶8ℎ, 𝑝𝑟𝑒𝑑 ≤ 𝑀𝐼𝐶) = 𝐹𝑡𝑛−2 ( 𝑙𝑛(𝑀𝐼𝐶) − 𝑙𝑛(𝐶8ℎ, 𝑝𝑟𝑒𝑑)?̂? ). ( Eq. 2.41) 
 Project IV: Development of a dosing algorithm to identify 
effective meropenem dosing for critically ill patients 
Dosing algorit hm to identify effective meropenem dos ing for critically il l patients  
2.9.1 Clinical study design  
Project IV was based on data from the same clinical study as Project III. For further details on the 
design of the clinical study as well as the bioanalytical quantification refer to section 2.8.1 and 
section 2.8.2 respectively.  
2.9.2 Data management and exploratory data analysis  
2.9.2.1 Dataset generation 
The NONMEM® compatible dataset was generated as outlined in section 2.2.1. Based on the 
observed patient-specific characteristics, further covariates were computed, e.g. creatinine 
clearance was estimated according to the Cockcroft and Gault equation (CLCRCG [2]; Appendix 
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7.3.3) on the basis of daily measured serum creatinine (Jaffé assay) as well as measurements from 
urine collected over 24 h (CLCRUC; Appendix 7.3.3). For the patient-specific characteristics 
additional columns were added to the dataset, indicating missing planned observations, and 
imputed or interpolated values. The final full dataset for the 48 patients consisted of 394 columns 
and 3052 rows. 
Handling of missing covariate data: Imputation and interpolation  
Overall only 3.07% of the planned covariate observations were missing. For each characteristic 
(e.g. body weight), observations were available in at least 80.5% of the planned observation time 
points (Appendix Table S2). Missing information of longitudinally measured continuous 
covariates were imputed at planned observation time points using two imputation strategies, i.e. 
stepwise (Strategy A) and a linear strategy (Strategy B; Formula: Appendix 7.3.5). 
• For missing covariate values between two available covariate values of an individual: 
Strategy A: Imputation of the last available covariate value of the respective individual 
(‘last observation carried forward’) 
Strategy B: Imputation of the covariate value derived from linear interpolation between the 
two covariate values of the respective individual 
• For missing values without a following covariate value measured at a later time point 
within an individual:   
Strategy A/B: Imputation of the last available covariate value of the respective individual 
(‘last observation carried forward’)  
• For missing values without a preceding covariate value measured at an earlier time point 
within an individual:   
Strategy A/B: Imputation of the first available covariate value of the respective individual 
(‘next observation carried backward’) 
The same strategies were used for interpolation of additional time points in the dataset in between 
the observation time points. A graphical illustration of the imputation and interpolation strategies 
is provided in the Appendix Figure S2. 
2.9.2.2 Dataset checkout 
The dataset checkout was performed using index plots and cross column checks as outlined in 
section 2.2.1. To the basic index plots of all covariates, reference ranges as well as the median in 
the population were added (Appendix Figure S3). In addition, the data subset of three randomly 
selected patients was evaluated manually for correctness and completeness by comparison with the 
originally received raw data. For the longitudinally measured covariates, the imputation and/or 
interpolation was graphically assessed based on individual plots displaying the covariate over time. 
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2.9.2.3 Exploratory data analysis 
In addition to the exploratory data analysis described for Project III in section 2.8.3, this project 
further focused on the evaluation of the PK data with respect to choosing a potential NLME PK 
model (e.g. number of disposition phases). 
2.9.3 Nonlinear mixed-effects pharmacokinetic modelling 
2.9.3.1 Base model development strategy 
Based on the results of the exploratory data analysis and prior knowledge from previously 
published literature, different structural PK disposition models (one-, two-, three-compartment) 
with zero-order input and first-order elimination were investigated, parameterised in terms of 
clearance and volume of distribution parameters. Random-effects parameters IIV and IOV were 
implemented in the model following the ‘stepwise approach’ i.e. the random-effects parameters 
were implemented successively/one at a time on a PK parameter. This implementation continued 
until no further random-effects parameter fulfilled the following three inclusion criteria: precision 
(<50% RSE), shrinkage (<30%) and magnitude of IIV (>10%CV). IIV and IOV were implemented 
using exponential models and hence assuming log-normal distribution of individual PK parameters 
per occasion (Eq. 2.8). The implementation of IOV was assessed by defining as occasion: (i) study 
day (i.e. ≤4 occasions/patient), or (ii) intensively monitored dosing interval (including also the 
additional single Cmin values prior to the intensively monitored interval; i.e. ≤6 occasions/patient). 
The random-effects parameter RUV was investigated using additive (Eq. 2.9), proportional 
(Eq. 2.10) and combined (Eq. 2.11) variability models. 
2.9.3.2 Covariate model development strategy  
Prior to covariate model development, a pre-analysis was performed based on the model covariate 
CLCRCG to compare and to select one of the two imputation/interpolation strategies 
(Section 2.9.2.1). The selected imputation/interpolation strategy was used in the actual covariate 
model development as default strategy for all longitudinally measured continuous covariates and 
reassessed in a refinement step at the end of the covariate model development (see below: step 6). 
For covariate model development a systematic semi-automated stepwise strategy was used 
(Figure 2.9). In step 1, the 41 non-CRRT patients were selected as database for the covariate model 
development and the parameters of the base model re-estimated for this subset. In step 2, covariate 
candidates were preselected from 58 available patient-specific criteria (Appendix Table S2) based 
on (i) graphical evaluation, assessing the relationship between a covariate at study start and the 
individual structural and random-effects PK parameters, (ii) prior knowledge from publications 
and (iii) clinical interest. In step 3, a systematic semi-automated stepwise forward-inclusion 
procedure was used to develop the full covariate model. For the forward-inclusion steps, the scm 
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functionality in PsN [223] was used and preselected 
covariates were implemented on all PK parameters for 
which IIV had been included in the base model. For 
continuous covariates (e.g. CLCRCG), linear (Eq. 2.13) 
and power covariate-parameter relationships (Eq. 2.15) 
were investigated, and for categorical covariates (e.g. 
sex), a fractional change in the respective parameter 
was estimated (Eq. 2.18). Ordered categorical 
covariates with ≥9 categories (e.g. heart rate extracted 
from the APACHE II score [1]) were handled as 
continuous covariates. After each step, the five 
covariate-parameter relationships leading to the 
statistically most significant improvement of the model 
(i.e. leading to the highest drop in the objective function 
value, OFV) were identified. The respective covariates 
were further evaluated regarding reduction of 
unexplained variability (if not stated otherwise, given as 
relative value on variance scale), precision of the 
estimate quantifying the covariate effect, clinical 
relevance (evaluated by the magnitude of change of the 
respective structural PK parameter across the 90% CI of 
the respective covariate values of the first study day) 
and biological plausibility. The covariate best fulfilling 
these criteria was included in the model, followed by 
the next step of the forward-inclusion procedure. This 
process was repeated until no additional significant 
covariate (ΔOFV≥3.84, α=0.05, df=1) was identified, 
leading to the full covariate model. In step 4, this full 
covariate model was further refined: Alternative 
covariates describing similar clinical characteristics 
(e.g. CLCRCG versus CLCRUC, total versus lean body 
weight) and alternative covariate classifications (e.g. 
for multiple ordered covariates) were investigated. 
Furthermore, an additional inclusion of interoccasion variability (IOV) was assessed, leading to 
the refined full covariate model which comprised all quantifiable levels of variability, a prerequisite 
for the subsequent backward deletion. In step 5, i.e. the backward deletion step, all covariates were 
excluded that reduced ≤5% of the unexplained variability associated with the respective population 
 
Figure 2.9: Covariate model development 
strategy. The numbers in the arrows represent 
the steps of the model development procedure 
(for further information see text, section 
2.9.3.2) (modified from [243]). 
Abbreviations: CRRT: Continuous renal replacement 
























         
           
     






parameter, i.e. the population parameter variability (PPV, computed as sum of variances of IIV and 
IOV [191]). This was accomplished by individual exclusion of the covariates from the full 
covariate model and assessment of the increase in PPV. Subsequently, a stepwise deletion of 
covariates was performed based on the precision of the parameter quantifying the covariate effect 
and – if similar magnitudes of precision – statistical significance. This backward deletion procedure 
was performed until all covariates fulfilled the prerequisites of precision (RSE<50%) and statistical 
significance (ΔOFV≥6.64, α=0.01, df=1), leading to the final covariate model. In step 6 the final 
covariate model was refined by defining the centring of covariate relationships as well as evaluating 
the interpolation strategy of longitudinally measured continuous covariates, by comparing (i) linear 
with stepwise interpolation in the dataset (Section 2.9.2.1) and (ii) linear interpolation in the dataset 
with and additional linear interpolation between observations of covariates also within the 
NONMEM® script. Besides, alternative functional covariate-parameter relationships for 
continuous covariates (e.g. piecewise linear relationship; Eq. 2.14), the ‘extended Wählby model 1’ 
for continuous time-varying covariates (Eq. 2.16) and the statistical submodel were reinvestigated, 
leading to the refined final covariate model. In step 7, the applicability of the covariate-parameter 
relationships for the CRRT subpopulation (n=7) was evaluated: Model parameters were estimated 
based on the data of CRRT patients and compared with the parameter estimates of the non-CRRT 
patients. 
2.9.3.3 Model evaluation and discrimination 
For model evaluation and discrimination, a similar procedure was used as described for Project I 
(Section 2.6.4.3). In brief, a combination of graphical and numerical basic evaluation techniques 
was used for model evaluation and discrimination. For the final NLME PK model, additional 
advanced techniques were applied: VPC (n=1000 simulations, with time or covariates as 
independent variables), non-parametric bootstrap (n=1000 replicate datasets) and case-deletion 
diagnostics (on patient level). Details on the evaluation techniques are summarised in section 2.3.3. 
2.9.4 Simulations: Evaluation and optimisation of meropenem exposure and 
dosing regimens  
The developed NLME PK model was used for deterministic simulations to explore and better 
understand meropenem exposure after standard meropenem dosing (Section 2.4.1). Furthermore, 
stochastic simulations were performed to assess the adequacy of meropenem exposure after 
standard meropenem dosing and alternative dosing regimens (Section 2.9.4.2), to evaluate and if 
needed optimise meropenem dosing regimens.  
  
Dosing algorithm to identify effective meropenem dosing for critically ill patients  
65 
2.9.4.1 Evaluation of meropenem exposure  
To evaluate the plasma pharmacokinetics of meropenem after standard meropenem dosing, 
deterministic exposure simulations were performed for varying patient characteristics. The patient 
characteristics were selected according to the covariates identified in the final NLME PK model 
and were univariately varied to assess their impact on the meropenem concentration-time profile 
(Table 2.6).  
Table 2.6: Patient characteristics used for deterministic exposure simulations 
Assess impact 
of 
Identifier Patient characteristics* 
CLCRCG [mL/min] WT [kg] ALB [g/dL] 
CLCRCG 1 min: 24.8 med: 70 med: 2.8 
2 med: 80.8 med: 70 med: 2.8 
3 max1: 154 med: 70 med: 2.8 
WT 4 med: 80.8 min: 44 med: 2.8 
5 med: 80.8 med: 70 med: 2.8 
6 med: 80.8 max: 140 med: 2.8 
ALB 7 med: 80.8 med: 70 min: 1.7 
8 med: 80.8 med: 70 med: 2.8 
9 med: 80.8 med: 70 max: 3.8 
*Univariately varied patient characteristic values are highlighted in bold. 1Inflection point of CLCRCG-CL relationship 
(=154 mL/min) is displayed instead of maximum CLCRCG, given the constant meropenem CL for higher CLCRCG values 
(Appendix Figure S30).  
Abbreviation: ALB: Serum albumin concentration; CL: Clearance; CLCRCG: Creatinine clearance estimated according to 
Cockcroft and Gault [2]; max: Maximum; med: Medium; min: Minimum, WT: Total body weight. 
2.9.4.2 Evaluation and optimisation of meropenem dosing regimens 
This section provides a general description of the analysis approach; more detailed information is 
provided in the subsequent subsections. In order to evaluate the adequacy of standard meropenem 
dosing, PTA and CFR (Section 2.4.3, technical details described in more detail below) were 
evaluated for patients with different clinical characteristics and levels of available pathogen 
information. The impact of single covariates on the PTA was investigated by varying one covariate 
while fixing the remaining ones to the median value in the population (univariate covariate 
variation). Considering the available covariate ranges in the critically ill population, additionally 
‘worst’- and ‘best-case’ covariate combinations were assessed for standard meropenem dosing 
(multivariate covariate variation). Based on the results of the uni- and multivariate covariate 
variation, vital determinants for PTA/CFR were determined.  
In a second step, PTA and CFR analyses were performed for seven alternative dosing regimens for 
varying values of the identified vital covariates. Compared to standard linezolid dosing, the 
alternative dosing regimens consisted of an intensified or reduced daily dose and/or a prolonged or 
continuous infusion duration (Table 2.7).  
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Table 2.7: Evaluated i.v. dosing regimens of meropenem (modified from [243]). 
Daily dose 
[mg]  
Short-term infusion (SI)  
over 30 min 
Prolonged infusion (PI) 
over 3 h  
Continuous infusion (CI) 
over 24 h 
2000 SI212:  1000 mg  q12h PI212:  1000 mg  q12h -- 
3000 or 
3412.51 
SI38:  1000 mg  q8h 
(=standard dosing regimen) 
PI38:  1000 mg  q8h CI32:  3000 mg  q24h 
following an initial loading 
dose of 500 mg over 30 min 
6000 or 
68751 
SI68:  2000 mg  q8h PI68:  2000 mg  q8h CI62:  6000 mg  q24h 
following an initial loading 
dose of 1000 mg over 30 
min 
1For CI treatment at day 1, the initial loading dose is included; 2Consider to renew the infusion solution dependent on the drug 
concentration twice or thrice daily (see supplement of article [244]) to ensure the stability of meropenem  
Abbreviations: CI: Continuous infusion; PI: Prolonged infusion; SI: Short-term infusion, q8h: Every 8 hours; q12h: Every 
12 hours; q24h: Every 24 hours. 
Throughout this project an informative code ‘XYZ’ was used to indicate the different dosing 
regimens: In this code, X represents the type of infusion, Y the administered daily dose in gram 
and Z the dosing interval in hours (e.g. for the standard meropenem dosing regimen: SI38; here, SI 
indicates the short-term infusion of a 3 g daily dose which is divided into three 1 g doses 
administered every 8 h). For continuous infusion regimens the simplified dosing code ‘XY’ was 
used. A detailed description on the applied PK/PD target and the PTA and CFR analyses is 
provided below. 
PK/PD target 
The PK/PD target 100%fT>MIC (i.e., unbound meropenem serum concentrations exceeding the MIC 
for 100% of the 24-h period) has been suggested in literature for betalactam treatment in critically 
ill patients  [235,236]. In the present work, total meropenem concentrations (T>MIC) were evaluated 
due to the negligibly low protein binding of meropenem (2%, [63,160]). Furthermore, given the 
non-achievability of 100%T>MIC when starting the i.v. infusion on the first day of therapy the 
attainment of 98%T>MIC was assessed, i.e. allowing for a 2% period within 24 h (=30 min), for the 
increasing part of the concentration-time profile, to reach the MIC concentration. For the evaluation 
of continuous-infusion regimens a stricter target 98%T>4xMIC was selected [42]. The attainment of 
the predefined PK/PD target was defined as ‘effective exposure’.  
Probability of target attainment analysis 
For each specific covariate combination and dosing regimen (i.e. standard and alternative dosing 
regimens), meropenem plasma concentration-time profiles were simulated for 500 patients over 
four treatment days using stochastic MC simulations (Section 2.4.2) considering IIV and IOV in 
the PK parameters. The PTA (Section 2.4.3) was computed for treatment day 1 (i.e. start of therapy) 
and treatment day 4 (i.e. presumably at steady-state) across the full MIC range from 0.002 to 
512 mg/L [132]. A PTA of ≥90% (i.e., 450 of 500 patients achieving the PK/PD target [63]) was 
Dosing algorithm to identify effective meropenem dosing for critically ill patients  
67 
considered adequate. To incorporate PK model parameter uncertainty, each MC simulation was 
repeated 1000 times using the PK parameter sets obtained from a non-parametric bootstrap and the 
respective PTA values derived (sse functionality in PsN [223,245]). A PTA of ≥90% for the 
5th percentile of the 1000 computed PTA values was considered a dosing regimen ‘reliably’ 
attaining ‘effective exposure’.  
Cumulative fraction of response 
Based on the PTA results, the CFR (Section 2.4.3) was derived for five pathogens commonly 
encountered in ICUs (P. aeruginosa, Acinetobacter spp., E. coli, Enterobacter (E.) cloacae, 
Klebsiella (K.) pneumonia [246]). For the two least susceptible pathogens, P. aeruginosa and 
Acinetobacter spp., the CFR was separately calculated for the MIC distribution of the isolates 
belonging to the S category (MIC≤2 mg/L) and of the isolates belonging to the I category (MIC>2 
and ≤8 mg/L). A dosing regimen achieving a CFR of ≥90% [63] for the 5th percentile of the 1000 
computed CFR values was considered a dosing regimen ‘reliably’ attaining ‘effective exposure’.  
2.9.5 Development of a dosing algorithm 
Based on the results of the PTA and CFR analyses (Section 2.9.4.2; PK/PD target for SI and PI: 
98%T>MIC, for CI: 98%T>4xMIC), a tabular dosing overview was generated in the R software, 
considering CLCRCG of the patient (10-154 mL/min) and the level (L) of knowledge about the 
pathogen:  
• ‘Level 1’ (L1): pathogen unknown, 
• ‘Level 2’ (L2): pathogen known,  
• ‘Level 3(-MIC)’ (L3(-MIC)): pathogen and susceptibility category known,  
• ‘Level 3(+MIC)’ (L3(+MIC)): MIC value known. 
L1 and L3(+MIC) were based on the PTA results for the predefined non-species-related EUCAST 
PK/PD breakpoints for meropenem (S: 2 mg/L, R: 8 mg/L [5]) and a broad MIC range (0.004-
16 mg/L), respectively. L2 and L3(-MIC) were based on the results of the CFR analyses for the full 
MIC distribution and the MIC distribution of the isolates belonging to the S and I category of the 
pathogens, respectively. Per CLCRCG-pathogen/susceptibility combination, the lowest effective SI, 





 Project I: Characterisation of linezolid plasma and target site 
exposure in obese and nonobese surgical patients, including the 
evaluation of the microdialysis methodology 
Linezolid plasma and target site exposure in obese and nonobese surgical patie nts  
3.1.1 Exploratory data analysis  
3.1.1.1 Patient characteristics 
As specified in the study protocol, 30 patients - 15 obese and 15 nonobese - were enrolled 
(Table 3.1). Considering the matching criteria sex and age, the two subgroups were highly 
comparable, with 87% females, a median age of 52 and 50 years and a median body height of 1.65 
and 1.69 m for the obese and nonobese population, respectively. In contrast and as expected, body 
size was very diverse, with median BMI values of 45 and 24 kg/m2 for the obese and nonobese 
patients, respectively. Overall, the 30 patients covered a large range of body size, from normal 
weight up to severe obesity (i.e. obesity class III, [247]), indicated by BMI values ranging from 
20.5-81.5 kg/m2 and LBW values from 34.9-84.8 kg (Figure 3.1 A, B; frequency distribution of 
additional body size descriptors: Appendix Figure S4).  
 
Figure 3.1: Frequency distributions of body size descriptors (A: BMI; B: LBW) and a haemodynamic marker 
(C: MAP) of obese (red) and nonobese (green) patients. 
C: Summary statistics based on individual median observed intra-anaesthetic data and post-anaesthetic data, respectively. 
Colour coding: Red: Obese patients; Green: Nonobese patients.  
Abbreviations: BMI: Body mass index; LBW: Lean body weight; MAP: Mean arterial pressure.  
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Table 3.1: Patient-specific and surgery-specific characteristics of (obese and nonobese) patients. 






Continuous  Median P0.05-P0.95 Median P0.05-P0.95 Median P0.05-P0.95 
Age [years] 51.5 32.4-63.1 52.0 35.6-62.9 50.0 33.1-62.6 
Body height [m] 1.66 1.57-1.78 1.65 1.53-1.80 1.69 1.59-1.78 
Total body weight [kg] 101 60.0-170 121 104-196 65.0 57.6-81.2 
BMI [kg/m2] 32.6 21-60.6 44.7 39.3-68.3 23.6 20.6-26.8 
LBW [kg] 51.9 34.9-61.2 56.7 50.3-83.6 43.7 38.5-79.2 
FM [kg] 41.0 17.9-93.3 64.6 51.9-115 22.5 15.5-30.9 
CLCRCG_LBW [mL/min] 63.4 38.0-105 72.3 36.0-113 55.8 41.2-81.5 
Incision-suture duration [h] 2.81 2.38-3.57 2.78 2.35-3.55 2.90 2.55-4.32 
Anaesthesia duration [h] 4.22 2.55-7.94 4.08 3.39-5.52 4.78 2.49-8.27 
Intubation duration [h] 4.08 2.37-7.52 3.88 2.94-5.33 4.43 2.40-7.90 
Heart rate1 [min-1] 71.2 56.6-87.3 71.5 60.0-86.9 71.0 57.1-84.8 
• Intra-anaesthetic 65.2 53.9-84.1 65.0 57.2-83.0 65.5 53.8-85.3 
• Post-anaesthetic 80.0 61.0-99.5 79.0 61.5-97.4 81.5 61.0-99.0 
MAP1 [mmHg] 75.4 65.8-91.1 76.7 69.5-102 72.5 64.5-85.4 
• Intra-anaesthetic 72.7 62.0-91.7 72.5 62.3-85.8 75.0 62.6-93.2 
• Post-anaesthetic 85.0 70.7-103 96.7 77.0-110 81.2 71.1-93.6 
COLZ1 [L/min] 20.9 15.7-29.2 23.7 15.6-30.7 20.6 16.1-23.9 
• Intra-anaesthetic 19.6 13.8-26.6 20.2 13.1-27.3 19.3 15.1-26.3 
• Post-anaesthetic 26.2 18.3-39.8 26.2 19.8-39.6 24.9 18.4-33.0 
Categorical  Number (%) Number (%) Number (%) 
Sex, female 26 (86.7) 13 (86.7) 13 (86.7) 
Type of anaesthesia       
• Balanced 27 (90.0) 13 (86.7) 14 (93.3) 
• TIVA 3 (10.0) 2 (13.3) 1 (6.67) 
1Time-varying characteristics: Summary statistics based on individual median of observed intra-anaesthetic data and post-
anaesthetic data, respectively.  
Abbreviations: BMI: Body mass index; CLCRCG_LBW: Creatinine clearance estimated according to Cockcroft and Gault [2] using 
LBW; COLZ: Cardiac output estimated according to Liljestrand and Zander (unadjusted) [3]; FM: Fat mass; LBW: Lean body 
weight; MAP: Mean arterial pressure; P0.05-P0.95: 5th percentile - 95th percentile; TIVA: Total intravenous anaesthesia. 
All patients underwent abdominal surgery: While the obese population underwent bariatric surgery 
(i.e. obesity was the indication), the main surgery indication for the nonobese group was cancer 
(75%, e.g. cervical carcinoma). The median duration of surgery (i.e. time from incision to suture) 
was 2.8 h, while the median duration for anaesthesia was 50% longer (median duration: 4.2 h). 
Most of the patients received balanced anaesthesia (90% of patients, Table 3.1). As expected, the 
routinely monitored time-varying markers HR, MAP and COLZ indicated reduced haemodynamics 
during anaesthesia compared to the post-anaesthetic period, e.g. HR increased from 65 to 80 min-1 
and MAP from 73 to 85 mmHg (Table 3.1 C; Appendix Figure S4). In general, haemodynamic 
markers were higher in obese compared to nonobese patients. 
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3.1.1.2 Linezolid dosing and sampling 
A single linezolid dose (600 mg as 30-min i.v. infusion) was administered 30 min before surgical 
incision (=median; 5th-95th percentile: 11.5-46.2 min). In total, 1009 linezolid measurements were 
available for subsequent NLME modelling, comprising total plasma concentrations (n=239), 
unbound plasma concentrations (n=90), microdialysate concentrations collected with the two 
catheters in the s.c. adipose tissue (n=296+295), as well as retrodialysate concentrations 
(n=43+46). Thus, only very few of the planned linezolid measurements (~1.4%) were missing 
(Section 2.6.1). Only for one catheter in one obese patient, the retrodialysis and hence the RR value 
was missing completely, which required imputation in order to make use of the available 
microdialysate data of the respective catheter (Section 2.6.3.1: Handling of missing data). A strong 
impact of the obesity status on the RR was detected, which was used for imputation (i.e. median 
RR of the obese patients was imputed, Appendix Figure S5 B).  
3.1.1.3 Linezolid concentrations  
The evaluation of the exposure of linezolid in different PK matrices revealed highest exposure for 
total plasma concentrations, followed by unbound plasma concentrations and ISF concentrations 
in s.c. adipose tissue (Figure 3.2 A.1, A.2). Unbound plasma concentrations were approximately 
15% lower than the total plasma concentrations, indicating a fraction unbound of ~85%. This 
magnitude was observed and consistent over the full investigated concentration range, independent 
from the obesity status and seemed to show only low variability between the patients (Appendix 
Figure S6, r2=0.994). When comparing the kinetics of linezolid in the different body fluids, a slight 
time delay in the Cmax value was observed for ISF compared to plasma (Figure 3.2 A.1; tmax: 1.25 h 
vs. 0.5 h for ISF (mid time of microdialysis collection interval) and plasma, respectively).   
Stratification of the concentration-time profiles by obesity status showed lower drug concentrations 
for obese than nonobese patients especially in the initial phase, both for plasma 
(Figure 3.2 B.1, B.2) and ISF (Figure 3.2 C.1). The comparison of the individual ISF 
concentration-time profiles determined concurrently using the two microdialysis catheters, showed 
very similar exposure for some patients, but larger differences for others (Appendix Figure S7). 
Yet, these differences showed no systematic pattern but seemed to randomly occur between 
patients and catheters. Overall, the two catheters demonstrated very similar typical ISF 
concentration-time profiles (Figure 3.2 C.2).  
The linezolid concentration-time profiles also gave first insights into the NLME PK model 
structure. Firstly, the biphasic disposition in the semilogarithmic plasma concentration-time profile 
of most patients suggested a two-compartment disposition model (Figure 3.2 B.2). Secondly, an 
additional third phase was detected in the terminal elimination phase, which showed – opposite to 
the expectations from a three-compartment model – a steeper decline than the previous phase. 




Figure 3.2: Linezolid concentration-time profiles stratified by sampling matrix (A.1, A.2), obesity status 
(B.1, B.2, C.1) and microdialysis catheter (C.2). 
A: Individual (A.1; nprofiles=106) and typical concentration-time profiles (A.2) for total (dark blue; nprofiles=30) and unbound 
linezolid in plasma (light blue; nprofiles=30) and unbound linezolid in ISF of the s.c. adipose tissue (red; nprofiles=46).  
B: Typical (B.1) and individual (B.2) total linezolid plasma concentration-time profiles for obese (red; nprofiles=15) and nonobese 
patients (green) on linear (B.1) and semilogarithmic scale (B.2; nprofiles=15).  
C: Typical linezolid ISF concentration-time profiles for obese (npatients=15) and nonobese (npatients=15) patients (C.1: red and 
green, respectively) and catheter 1 and catheter 2 (C.2: circle and triangle, respectively). ISF concentrations are displayed at the 
mid time of the respective collection intervals.  
Typical profiles: Geometric mean concentrations including geometric standard deviation (error bars) are depicted at median 
sampling time point.  
Abbreviations: ISF: Interstitial space fluid; s.c.: Subcutaneous.  
This finding indicated nonlinearity in the PK, more precisely a terminal increase in clearance 
parameter. The occurrence of nonlinearity was observed at linezolid concentrations of ~2-10 mg/L 
and at the end of anaesthesia in approximately half of the patients (Appendix Figure S8). Thirdly, 
Results 
72 
the delayed Cmax values in ISF compared to plasma indicated that ISF concentrations should rather 
be allocated to a peripheral delayed compartment than the central compartment. 
3.1.2 Nonlinear mixed-effects model 
This section focuses on the applied stepwise NLME model development (3.1.2.1), followed by a 
description of the developed final NLME model (3.1.2.2) and the results of the model evaluation 
(3.1.2.3).  
3.1.2.1 Model development 
An overview of the single steps of the model development is illustrated in form of a workflow in 
Figure 3.3. The models selected in the single steps are highlighted with a green frame. In the 
following, this comprehensive workflow is described in more detail. 
Base model development: Plasma (steps 1-2) 
In step 1, a base model was developed for the observed total linezolid plasma concentrations. A 
two-compartment disposition model parameterised in terms of clearance (CL), volumes of 
distribution (central, peripheral: V1, V2) and intercompartmental clearance (Q) was selected as the 
structural model, as it adequately described the trajectory of the total plasma concentrations. The 
one-compartment model was inferior to the two-compartment model, as indicated by the apparent 
misspecifications in the basic goodness-of-fit plots (Appendix Figure S9) and the significantly 
higher OFV value (ΔOFV:+71.9, df=2, α<0.001). For instance, the graphical assessment of 
CWRES versus population predictions demonstrated a U-shape (e.g. underprediction for low and 
high population predicted values), indicating the need of an additional compartment to adequately 
describe the data (Appendix Figure S9 A.2).   
IIV was quantifiable for all PK parameters. The IIV parameters were relatively precisely estimated 
(≤26.1% RSE) and indicated moderate to higher variability between the patients (≤68.9%CV). The 
exclusion of IIV on Q – as the parameter with the highest RSE – was tested but resulted in reduced 
model predictivity. Hence, the selected statistical IIV submodel included variability on all four PK 
parameters. Covariance between the IIV parameters was found to be 𝜌≤74.4% and was thus not 
included in the model. The graphical evaluation of residuals versus population predictions 
illustrated a fan-shaped pattern, which indicated the need of a RUV model in which the variance is 
proportional to the magnitude of the model prediction (Appendix Figure S10 A). This was 
confirmed when implementing and investigating the different RUV models: The solely additive 
RUV model was markedly inferior compared to the proportional and combined model 
(ΔOFV≥13.9). The proportional and combined model both adequately described the data. With 
respect to OFV, the combined model was slightly superior over the proportional model 
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(ΔOFV=9.1). Considering the moderate precision of the estimated additive term (36% RSE) and 
the comparably good results in the goodness-of-fit evaluations (Appendix Figure S10), the 
proportional RUV was finally selected as the statistical RUV submodel in this step, which is in line 
with the principle of parsimony. Even though most model evaluation techniques revealed adequate 
model performance, the ‘CWRES versus time’ plot showed an undulating pattern, indicating a 
potential model misspecification (Appendix Figure S10 C). An additional evaluation suggested a 
relation between the occurrence of the undulating pattern and the observed nonlinearity in the 
concentration-time profiles, which was not yet considered in the structural model of the total 
plasma data only (Appendix Figure S11).   
In step 2, the available unbound plasma concentrations were integrated into the model by assigning 
them to the central compartment and estimating an additional fu parameter. IIV on fu was assessed 
within the model and was found to be negligibly small (0.3%CV), confirming the results from the 
exploratory analysis (Section 3.1.1.3). Thus, for parsimony reasons, IIV on fu was not included in 
the NLME plasma model. Additionally, a separate proportional RUV was estimated for the 
unbound plasma concentrations.   
Within the developed NLME model for total and unbound linezolid plasma concentrations the 
observed nonlinearity in the terminal phase of the linezolid concentration-time profiles 
(Figure 3.2 B.2) was investigated by implementation of different nonlinear clearance models, 
assuming either a concentration dependence of the clearance parameter or a time variation based 
on surgery-specific characteristics. In contrast to linear clearance, all investigated nonlinear 
clearance models showed an improved model performance, which is discussed in more detail in 
the following. Six ‘anaesthesia models’ were assessed, assuming different patterns of linezolid 
clearance over time after the end of the anaesthesia (Figure 3.3, model equations: Appendix 
Figure S12). The model, which described a time-dependent increase of clearance according to an 
ordinary Emax model (Figure 3.3 Step 1, ‘Time-varying CL’: top row, middle panel; Appendix 
Figure S12 C), was selected as the most adequate anaesthesia model based on the reduction of the 
observed pattern of the ‘CWRES versus time’ plot, the precise and plausible parameter estimates 
as well as the plausible assumption of a functional change of clearance (Appendix Figure S13 C, 
Table S3 Model B). The six nonlinear anaesthesia models were reassessed using the end of 
intubation instead of the end of anaesthesia as the starting time point for the change in clearance. 
The results were very similar given the high correlation between the two time points (r2=0.997). 
The ‘anaesthesia model’ was chosen over the ‘intubation model’ due to slightly better parameter 
precision. In addition to the anaesthesia and intubation status, the continuous time-varying 
haemodynamic marker heart rate was assessed as an impact factor for clearance. Within the 
NONMEM® script, heart rate was linearly interpolated between the available observations and a 




Figure 3.3: Results of model development: steps 1-3 (based on model development strategy, section 2.6.4.2) 
[continued on next page].  
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Figure 3.3 [continued]: Results of model development: steps 4-5 and final NLME PK model. 
Colour coding in model sketches: Blue: PK-related; Green: Microdialysis methodology-related; Pink: Body size descriptors; 
Orange: Anaesthesia/MAP. Symbols in model sketches: Solid/Dashed arrows: Indicate mass transfer/no mass transfer.   
Abbreviations: ABW: Adjusted body weight; ANAE: Anaesthesia; CL: Clearance; CLu: CL of unbound linezolid; CMT: 
Compartment; 𝐶𝑃_𝑡𝑜𝑡: Total plasma concentrations; 𝐶𝑃_𝑢: Unbound plasma concentrations; 𝐶𝑅𝐷: Retrodialysate concentration; 𝐶𝑅𝑃: Retroperfusate concentration; 𝐶µD: Microdialysate concentration; COLZ: Cardiac output estimated according to Liljestrand 
and Zander [3]; fu: Fraction unbound; IIV: Interindividual variability; i.v.: Intravenous; Km: Michaelis-Menten constant; Km,u: 
Km of unbound linezolid; LBW: Lean body weight; MAP: Mean arterial pressure; NLME: Nonlinear mixed-effects; OBE: 
Obesity; Q, Q2: Intercompartmental clearance parameters between CMT 1 and 2, and between CMT 1 and 3, respectively; Qu: 
Q of unbound linezolid; RR: Relative recovery; RUV: Residual unexplained variability; tANAE_STOP: Time of anaesthesia end; 
scm: Stepwise covariate model-building; TF: Tissue factor; V1, V2, V3: Volume of distribution parameters of central and two 
peripheral CMTs; V1,u, V2,u: V1, V2 of unbound linezolid; Vmax: Maximum elimination rate; Vmax,u: Vmax of unbound linezolid.  
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Compared to the sole linear clearance model, the ‘heart rate model’ was superior (ΔOFV=-28.2, 
df=1, α<0.001); however, it only led to a slight reduction of the undulating pattern in the ‘CWRES 
versus time’ plot (Appendix Figure S13 B, Table S3 D). Hence, the ‘anaesthesia model’ was still 
considered as the most adequate time-varying nonlinearity model.   
In addition to time-varying clearance models, concentration-dependent clearance models were 
assessed: Comparing the concentration-dependent nonlinear Michaelis-Menten model with the 
combined linear and nonlinear Michaelis-Menten model, the latter demonstrated better model 
performance as indicated by the significantly lower OFV value (ΔOFV=-276, df=1, α<0.001). The 
implementation of an empirical inhibition compartment (describing a time- and concentration-
dependent clearance; Appendix Figure S14) was not supported by the data, as indicated by the rate 
transfer parameter into the empirical inhibition compartment, which was estimated to be close to 
0, as well as the increase in the AIC value compared to the linear clearance model (ΔAIC=+8.06). 
Consequently, the parallel linear and nonlinear Michalis-Menten model was considered as the most 
adequate concentration-dependent model (Appendix Figure S13 D, Table S3 C). 
The two most adequate nonlinearity models (time-varying anaesthesia model and concentration-
dependent parallel linear/nonlinear Michaelis-Menten model) were compared by evaluating GOF 
plots, VPCs, individual clearance estimates versus time and deterministic simulations. Both models 
illustrated good model predictivity and performance given the observed data, however, resulted in 
different predictions when extrapolating to altered linezolid dosing regimens (Appendix 
Figure S15). At this stage, the Michaelis-Menten model was included in the plasma base model, as 
this type of clearance model had been identified for linezolid before [248]. Yet, a reassessment of 
the time-varying impact of the surgery-specific characteristics was performed during the covariate 
analysis, after having all available PK information (also target site exposure) included into the 
model (Section 3.1.2.1: Covariate model development (step 5)).  
Base model development: Plasma and target site (steps 3-4) 
In step 3, the PK data collected with one of the microdialysis catheters was integrated into the 
model by three different distribution kinetics models (Figure 3.3 Step 3: Model A-C). Model A, 
which was investigated by external evaluation of an already existing NLME PK model [45], did 
not satisfactorily capture the distribution process from plasma into ISF in the obese/nonobese 
population. Evaluation of goodness-of-fit plots, VPCs and high relative prediction errors revealed 
that the initial concentrations were less well captured than those measured in the elimination phase 
(Appendix Figure S16). While an overprediction was observed for the initial microdialysate 
concentrations, an underprediction was apparent for the plasma concentrations. This confirmed the 
results of the exploratory analysis, which already indicated a delayed distribution of linezolid 
(Section 3.1.1.3).   
A graphical comparison of the deterministic simulations of the individual linezolid concentration-
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time profiles in the peripheral compartment of the plasma model showed similar kinetics as the 
observed microdialysis data and hence suggested that Model B might be suitable to describe the 
tissue fluid distribution (Appendix Figure S17). This was confirmed when investigating both 
delayed distribution models (Model B and C) in the NLME model. Model C was not supported by 
the data as demonstrated by its poor predictivity for the retrodialysate concentrations (Appendix 
Figure S18 B.4.a, B.4.b), the imprecisely estimated parameters of the additional peripheral 
compartment (V3: 49.3, Q2: 49.1% RSE), and the low values of the parameters (V3: 1.59 L, Q2: 
2.16 L/h). With Model B, however, plausible and precisely estimated parameters were obtained 
with an adequate predictivity for all matrices (Appendix Figure S18 A). Thus, Model B, assigning 
the ISF concentrations of the s.c. adipose tissue to the peripheral compartment and estimating an 
additional scaling factor (‘tissue factor’, TF), was integrated in the joint NLME model, which 
enabled the description of target site exposure. The statistical submodel was extended by additional 
IIV parameters for the TF and the RR. Unbound ISF concentrations were linked to the unbound 
concentrations in the peripheral compartment of the model to allow a better physiological 
interpretation of the TF. 
In step 4, re-estimation of all parameter estimates based on the PK data of the second catheter 
resulted in very similar parameter estimates, justifying the joint modelling of the data of both 
catheters. For the joint model including data from both catheters, a second microdialysate 
compartment was added describing the concentrations determined with the second microdialysis 
catheter. Both microdialysate compartments were linked via the RR parameter to the ISF 
concentrations. The RR parameter allowed to implement and hence to dissect ‘intercatheter 
variability’ which was estimated based on the PK data of the two catheters, and ‘intracatheter 
variability’ which was estimated based on the PK data of the two retrodialysis assessments 
performed for half of the catheters (Section 2.6.1). In NONMEM®, this was achieved by encoding 
the inter- and intracatheter variability parameters as additional hierarchical levels of random-effects 
parameters (like ‘interoccasion variability’ (Eq. 2.8)). Overall, the final base NLME model 
adequately described the data, however, for the ‘CWRES versus time’ plot, a remaining undulating 
pattern in the microdialysate data was observed (Appendix Figure S19 A.1).  
Covariate model development (step 5) 
The difference in the RR values of obese and nonobese patients, which had already been observed 
in the exploratory analysis (Appendix Figure S5 B), was assessed within the model by investigating 
the obesity status (i.e. obese/non-obese) and continuous body size descriptors (e.g. body weight) 
as covariates on the RR parameter. Obesity was found to be by far the best predictor of RR, almost 
completely explaining the interindividual variability on the RR (reduction of unexplained IIV on 
RR from 14.8%CV to 0.3%CV). Hence, obesity was implemented in the NLME base model by 
estimating a separate typical RR value for obese and nonobese patients, and IIV on RR was 
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removed (Appendix Table S4).  
The three pre-investigations performed to assess the impact of body size (+ additional pre-selected 
covariates) on the PK of linezolid, identified a potential influence of body size on the PK 
parameters V1, V2, Q and TF (Section 2.6.4.2: Covariate model development (step 5)). This was 
further investigated and confirmed in a comprehensive stepwise covariate analysis, for which the 
strategy was developed based on the results of the pre-investigations (Appendix Table S5). In brief 
body size was first investigated (i) as categorical (i.e. obesity) and continuous covariates (according 
to Holford et al. [204]: total body weight, LBW and NFM; Eq. 2.38), (ii) with and without 
allometric scaling and (iii) with combinedly and separately estimated NFM for the volume and 
clearance parameters, respectively. A following step assessed renal function markers (serum 
creatinine, CLCRCG_LBW) on the clearance parameters. Furthermore, following a one-by-one 
backward deletion of the selected covariates, the need of obesity as an additional impact factor for 
PK parameters was evaluated in addition to the impact of body size. The stepwise comprehensive 
evaluation identified the obesity status as a predictor of TF and LBW as an adequate predictor for 
V1 and V2 and Q (allometric implementation). No body size descriptor was identified as a covariate 
on the linezolid clearance parameters (Appendix Table S6). Detailed information on the results of 
the stepwise covariate analysis are summarised in the Appendix, Table S7.  
The investigation of the surgery-specific characteristics as predictors of linezolid clearance and 
tissue fluid distribution resulted in the three following models, which were further compared 
(Appendix Table S8):  
• Model 1: Including the anaesthesia status on the clearance parameter Vmax and on TF 
• Model 2: Including the two haemodynamic markers MAP and COLZ as continuous time-
varying covariates on total clearance (i.e. sum of linear and nonlinear clearance) and on 
TF, respectively 
• Model 3: Including the anaesthesia status on TF and MAP on total clearance 
Model 3 was superior to the two other models with respect to reduction in unexplained IIV and/or 
the precision of the parameter estimates (Appendix Table S8). Furthermore, this model almost fully 
explained the undulating pattern in the ‘CWRES versus time’ plot of the microdialysate data 
(Appendix Figure S19 B.1) and was hence implemented in the NLME model.  
In a final refinement step, proportional RUV models were selected for all measurement matrices. 
In addition, all implemented covariate effects of continuous covariates were centred to the median 
value of the investigated population.  
3.1.2.2 Final joint nonlinear mixed-effects model 
A sketch of the final joint NLME model of linezolid is provided at the bottom of Figure 3.3 and 
captures the following aspects: (i) total (i.e. bound + unbound) and unbound linezolid plasma and 
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unbound linezolid target site PK, (ii) PK in patients with varying body size/obesity status 
(highlighted in pink), (iii) intra-anaesthetic and post-anaesthetic PK (orange), as well as (iv) PK-
related and microdialysis methodology-related aspects (blue and green, respectively). The 
NONMEM® model script of the joint NLME model is provided in Appendix 7.4.2 and the 
respective PK parameters are summarised in Table 3.2, using the same colour coding as in the 
model sketch.  
In summary, the final model was a two-compartment model with an unbound volume of 
distribution of 50 L and parallel linear and nonlinear Michaelis-Menten clearance (average 
unbound CL over monitored time period of 8 h: 8.92 L/h). The ISF of the s.c. adipose tissue was 
identified to be part of the peripheral compartment and an additional TF was estimated to scale the 
concentrations in the peripheral compartment to the ISF concentrations. The TF was lower for the 
obese patients (54%) than for the nonobese patients (69%), thus resulting in lower target site 
exposure in the obese population. The obesity status of the patient was additionally found to impact 
RR, with a lower value for obese than nonobese patients (37.5% vs. 57.5%). The continuous body 
size descriptor LBW was identified as an impact factor for volume of distribution parameters (V1, 
V2) and Q according to allometric principles [204]: The volume of distribution parameters linearly 
scaled with LBW (allometric exponent: 1), i.e. increasing the LBW by 50% (e.g. 50 kg vs. 75 kg) 
also increased the volume of distribution of unbound linezolid by 50% (e.g. 48.5 L vs. 72.8 L). The 
parameter Q scaled with body weight to the power of 0.75 (=allometric exponent), i.e. increasing 
the LBW by 50% (e.g. 50 kg vs. 75 kg) increased the unbound Q of linezolid by 35.5% (e.g. 60.7 
L/h vs. 82.2 L/h). In addition, the anaesthesia status of the patients and the haemodynamic marker 
MAP were found to impact the TF and the total (i.e. linear + nonlinear) CL of unbound linezolid, 
respectively. During anaesthesia, the TF was 13.6% lower than after anaesthesia; an increase of 
MAP of 10 mmHg led to an increase in total CL by 8%. The inclusion of the aforementioned 
covariates considerably decreased the unexplained interindividual and method-related variability 
compared to the base model (IIV on variance scale (IIVVar) V2: -68.6%, IIVVar TF: -55.0%, IIVVar 
CL: -50.5%, IIVVar V1: -40.1%, IIVVar Km: -38.9%; IIVVar Q: -20.5%, IIVVar RR: -99.95%; 
Table 3.2 and Table S4).  
The dissected variabilities in the microdialysis technique, i.e. intercatheter- and intracatheter 
variability on the RR parameter, showed similar magnitudes with 26%CV and 27%CV, 
respectively. Residual unexplained variability was estimated separately for the matrices plasma 
(total plasma concentrations), ultrafiltrate (unbound plasma concentrations) and microdialysate. 
For the retrodialysate concentrations, RUV was fixed to the bioanalytical assay imprecision 
(1.9%CV [249]), to facilitate a separation of intracatheter variability and RUV. Total and unbound 
plasma concentrations showed similar magnitudes of RUV (total: 4.76%CV; unbound: 4.56%CV), 
while RUV for microdialysate was approximately twice as high as RUV for plasma (13.3%CV). 
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Table 3.2: Parameter estimates of final joint NLME model of linezolid in obese and nonobese surgical 
patients. PK parameter estimates for unbound linezolid and derived parameters for total linezolid, 
microdialysis methodology-related parameter estimates, as well as bootstrap results are displayed.  
Parameter [unit] Final model  Bootstrap3 





Median 95% CI 
OFV -247.45 -- -285.61 [-676.94, 116.23] 
 
Fixed-effects parameters 
θ CLu [L/h] 3.32 (30.7) 2.84 3.47 [1.56, 5.61] 
θ Vmax,u [mg/h] 45.9 (21.8) 39.3 45.2 [20.6, 65.6] 
θ Km,u [mg/L] 2.93 (23.8) 2.51 2.68 [0.464, 5.57] 
θ MAP_CLTot4, % 0.805 (41.0) -- 0.793 [0. 251, 1.49] 
 
θ V1,u [L]5 17.0 (8.20) 14.6 17.0 [14.5, 20.3] 
θ Qu [L/h]5 62.4 (9.00) 53.4 62.1 [51.4, 74.8] 
θ V2,u [L]5 33.4 (4.60) 28.6 33.4 [29.8, 36.1] 
θ fu, % 85.6 (0.700) -- 85.6 [84.5, 86.9] 
 
θ TFOBE,u, % 54.1 (7.30) -- 54.3 [47.1, 63.4] 
θ TFNOBE,u, % 69.0 (5.70) -- 69.0 [61.2, 76.8] 
 
θ ANAE_TF7, % -13.6 (19.5) -- -13.7 [-19.0, -8.86] 
θ RROBE, % 37.5 (7.80) -- 37.4 [32.1, 43.6] 
θ RRNOBE, % 57.5 (4.70) -- 57.6 [52.2, 63.4] 
 
Interindividual and method variability parameters, %CV 
ω  Lu 66.7 (32.3) -- 63.1 [32.9, 128] 
ω Km,u 74.4 (48.8) -- 74.4 [31.6, 2520] 
ω V1,u 42.1 (11.6) -- 41.3 [32.6, 50.3] 
ω Qu 46.8 (17.7) -- 44.6 [31.1, 60.3] 
ω V2,u 16.7 (23.6) -- 15.8 [8.64, 23.0] 
 
ω  Fu 14.8 (22.9) -- 13.5 [7.32, 18.8] 
ω  N E_ F 82.2 (22.3) -- 78.0 [49.3, 127] 
ωIntercatheter RR 26.1 (19.5) -- 25.1 [16.7, 33.8]  
ωIntracatheter RR 27.2 (10.4) -- 27.0 [21.8, 32.0] 
 
Residual variability parameters, %CV 
prop 𝐶𝑃_𝑡𝑜𝑡 4.76 (12.9) -- 4.67 [3.59, 5.89] 
prop 𝐶𝑃_𝑢 4.56 (12.7) -- 4.49 [3.22, 5.62] 
prop 𝐶µ𝐷 13.3 (6.50) -- 13.3 [11.6, 15.0] 
prop 𝐶𝑅𝐷 1.9 FIX8 -- 1.9 FIX8 -- 
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1RSE of random-effects parameter estimates ω and  are reported on approximate standard deviation scale; 2Total parameter = 
Unbound parameter estimate ∙ fu; 3Convergence rate of non-parametric bootstrap (n=1000): 92%;4Change of clearance per 
mmHg deviation of MAP from 75 mmHg (linear MAP-CLTot,u relationship); 5Allometrically scaled with LBW (exponent of 1 
and 0.75 for V1/V2 and Q, respectively) and centred to median in overall population (51.9 kg); 6Post-anaesthetic TFu; 7Intra-
anaesthetic change of TF; 8Fixed to interassay variability [228].  
Colour coding: Refers to the colours used in the model sketch (Figure 3.3); Blue: PK-related parameters; Green: microdialysis-
methodology-related parameters; Pink: Body size impact; Orange: Anaesthesia/MAP impact.  
Abbreviations: ANAE_TFu: Anaesthesia effect on TFu; CI: Confidence interval; CLu: CL of unbound linezolid; CLTot,u: Total 
clearance of unbound linezolid; CMT: Compartment; 𝐶𝑃_𝑡𝑜𝑡: Total plasma concentrations; 𝐶𝑃_𝑢: Unbound plasma 
concentrations; 𝐶𝑅𝐷: Retrodialysate concentration; 𝐶𝑅𝑃: Retroperfusate concentration; 𝐶µD: Microdialysate concentration; CV: 
Coefficient of variation (calculated for random-effects parameters according to Eq. 2.6); fu: Fraction unbound; Km,u: Michaelis-
Menten constant of unbound linezolid; LBW: Lean body weight; MAP: Mean arterial pressure; MAP_CLTot,u: Effect of MAP on 
CLTot,u; NLME: Nonlinear mixed-effects; OBE: Obesity; Qu: Intercompartmental clearance of unbound linezolid; RSE: Relative 
standard error; RROBE, RRNOBE: Relative recovery for obese and nonobese patients; TFOBE,u, TFNOBE,u: Tissue factor of unbound 
linezolid for obese and nonobese patients; V1,u, V2,u: Volume of distribution parameters of central and peripheral CMTs of 
unbound linezolid; Vmax,u: Maximum elimination rate of unbound linezolid; θ: Fixed-effects parameter; 𝜔: Random-effects 
parameter: Interindividual variability; 𝜎: Random-effects parameter: Residual unexplained variability. 
3.1.2.3 Model evaluation 
Standard goodness-of-fit plots indicated adequate model predictions as shown by the symmetric 
and narrow distribution of observed versus predicted linezolid concentrations around the line of 
identity (Figure 3.4 A, B) and CWRES around the 0 reference line (Figure 3.4 C, D). The 
undulating pattern in the CWRES versus time plot, which had been observed for the base model 
without covariates and linear clearance was almost not present anymore, both for plasma and 
microdialysate data (Figure 3.4 D.1, D.2). The non-parametric bootstrap confirmed model 
robustness (convergence rate=92%) and accurately estimated parameter as indicated by the median 
of the bootstrap replicates, which were overall very similar to the estimates of the developed model. 
The 95% confidence intervals derived from the bootstrap replicates included the point estimates of 
the parameters, did not include 0, and were overall narrow which indicated statistical significance 
and precisely estimated parameters. Only the random-effect parameter IIV on the Michaelis-
Menten constant Km showed a comparably high upper limit of the confidence interval. A log-
likelihood profiling of this parameter indicated a steep increase in OFV for parameter values lower 
than the one resulting in the observed OFV minimum, whereas for higher parameter values the 
change in OFV was rather flat (95% CI: 33.4-320%CV, Appendix Figure S20). The visual 
predictive checks indicated good predictive model performance for the three different matrices 
(Figure 3.4 E). Case deletion diagnostics on individual level revealed that none of the newly 
obtained parameter estimates fell outside the 95% confidence intervals of the final model parameter 






Figure 3.4: Basic goodness-of-fit plots (A-D) and VPC (n=1000 simulations, E) for the final NLME PK 
model for microdialysate concentrations (left panel; 1), total plasma concentrations (middle panel; 2), 
unbound plasma concentrations (right panel; 3).  
A, B: Circles: Observed vs. population predicted (A) and individual predicted linezolid concentrations (B) for obese (red) and 
nonobese patients (green); Triangles: Microdialysate concentrations of the second catheter. Black line: Line of identity; Grey 
line: Loess smoother [250].   
C, D: Circles: Conditional weighted residuals vs. population predicted linezolid concentrations (C) and time (D) for obese (red) 
and nonobese patients (green); Triangles: Microdialysate concentrations of the second catheter. Lines: Reference lines at y=0; 
Grey lines: Loess smoothers [250].  
E: Circles: Observed linezolid concentrations; Lines: 5th, 95th percentile (dashed), 50th percentile (solid) of the observed (blue) 
and simulated (green) data. Green shaded areas: 95% confidence interval around 5th, 50th and 95th percentile of simulated data. 
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3.1.3 Simulations: Exploration of linezolid exposure 
Deterministic and stochastic exposure simulations for standard linezolid dosing illustrated 
substantially lower linezolid drug concentrations in ISF of the s.c. adipose tissue than in plasma 
(especially around Cmax) as well as a delayed distribution into the tissue fluid, as indicated by the 
Cmax value, which was reached later in ISF than in plasma (Figure 3.5 A). The difference in the 
concentrations between the two matrices was most pronounced in obese patients (Figure 3.5 A: 
red, orange), resulting from the reduced tissue fluid penetration in the obese patient population 
(Table 3.2). Furthermore, a strong impact of body size on linezolid exposure was observed. Obese 
patients (Figure 3.5 B: red) showed markedly lower linezolid exposure compared to nonobese 
patients (Figure 3.5 B: green). This difference was detected both in plasma and in ISF and was 
particularly high in ISF and around the Cmax value.  
 
Figure 3.5: Simulated unbound linezolid concentration-time profiles for selected typical patients following 
standard linezolid dosing (600 mg, 30-min i.v. infusion, q12h). 
A: Median (line), 5th and 95th percentile (shaded areas) of stochastic simulations (n=1000) of the unbound linezolid 
concentration-time profiles in plasma (solid) and ISF of the s.c. adipose tissue (dashed) for 4 typical patients over the first 8 h. 
B: Typical linezolid concentration-time profile (i.e. deterministic simulation) of an exemplary obese and nonobese intra-
anaesthetic patient over 24 h.  
C: Typical linezolid concentration-time profile (i.e. deterministic simulation) of an exemplary intra-anaesthetic and post-
anaesthetic obese patient over 24 h.  
Dashed horizontal line: Exemplary MIC value of 2 mg/L(non-species-related EUCAST PK/PD S breakpoint [251]).   
Colour coding: Red: Obese and intra-anaesthetic patient; Dark green: Nonobese and intra-anaesthetic patient; Orange: Obese 
and post-anaesthetic patient; Light green: Nonobese and post-anaesthetic patient (for detailed information on patient 
characteristics see Table 2.4 A).  
Abbreviations: EUCAST: European Committee on Antimicrobial Susceptibility Testing; ISF: Interstitial space fluid; i.v.: 




An additional influence of the anaesthesia status and the MAP on the linezolid concentrations was 
observed, yet less pronounced than for body size. An intra-anaesthetic patient with a lower MAP 
value (Figure 3.5 C: red) showed slightly higher plasma concentrations in the terminal phase of the 
concentration-time profile than a post-anaesthetic patient with a higher MAP value (Figure 3.5 C: 
orange), reflecting the impact of MAP on linezolid clearance. For ISF, however, exposure was 
lower for the intra-anaesthetic patients, resulting from the reduced tissue factor during anaesthesia. 
Univariate deterministic exposure simulations for varying LBW showed a strong impact of body 
size on the linezolid concentration-time profile, which was particularly pronounced for the 
maximum concentrations and the concentrations in the early declining part of the profile 
(Figure 3.6). Maximum linezolid plasma concentrations for a typical patient with a low LBW value 
of 35 kg (i.e. body weight of 50.1 kg for a 1.65 m tall female patient) were ~2-fold higher than for 
a patient with a very high LBW of 80 kg (i.e. body weight of 334 kg for a 1.65 m tall female patient) 
(26.3 and 12.7 mg/L for first dose, respectively; Figure 3.6 A). In the later phase of the dosing 
interval (>8 h), an inverse trend was observed, with the high-LBW patient (80 kg) reaching ~2-
fold higher linezolid plasma concentrations at 12 h after start of infusion, compared to the low-
LBW patient (35 kg) (1.74 and 0.826 mg/L for first dose, respectively; Figure 3.6 A).  
 
Figure 3.6: Simulated unbound linezolid concentration-time profiles in plasma (A) and ISF of the s.c. 
adipose tissue (B) for patients with varying LBW, following standard linezolid dosing (600 mg, 30-min i.v. 
infusion, q12h). 
All other covariates in the NLME PK model were set to median values of the patient population (for detailed information on 
patient characteristics see Table 2.4 B).  
Dashed horizontal line: Exemplary MIC value of 2 mg/L (non-species-related EUCAST PK/PD S breakpoint [251]).  
Abbreviations: LBW: Lean body weight; Further abbreviation see Figure 3.5. 
Similar trends were also observed for ISF (Figure 3.6 B). Here, the differences in the maximum 
linezolid concentrations of obese and nonobese patients was even more marked than for plasma, 
resulting from the reduced tissue factor in obese patients (in this example, LBW ≥50 kg – i.e. body 
weight ≥91.7 kg and BMI=33.7 kg/m2 for a 1.65 m tall female patient – was defined as obese 
patients due to BMI ≥30 kg/m2; Table 2.4 B). Maximum ISF linezolid concentrations were ~2.5-
fold lower for the high-LBW (80 kg) patient compared to the low-LBW patient (35 kg) (9.08 and 
3.23 mg/L for first dose, respectively), while linezolid ISF concentrations at 12 h after the start of 
infusion were ~1.5-fold higher (0.892 and 0.602 mg/L for first dose, respectively; Figure 3.6 B).  
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 Project II: Evaluation and optimisation of linezolid dosing 
regimens for infection prophylaxis and acute therapy in obese and 
nonobese surgical patients 
Linezolid dos ing regimens in obese and nonobese surgical  patie nts  
3.2.1 Simulations: Evaluation of standard linezolid dosing for infection 
prophylaxis 
For the prophylactic setting of linezolid dosing (600 mg, as 30-min i.v. infusion, 30 min before 
incision), the results of the PTA analysis (PK/PD taget 95%fT>MIC, assessed for incision-suture 
duration) for the site of a potential wound infection (i.e. ISF of the s.c. adipose tissue) are 
summarised in Table 3.3 for the typical obese (BMI=43.7 kg/m2) and nonobese (BMI=23.3 kg/m2) 
intra-anaesthetic patient. For illustration, the underlying stochastic exposure simulations for these 
two patients are depicted in Figure 3.7.  
Table 3.3: Probability of target (95%fT>MIC) attainment for different typical patients for infection 
prophylaxis.  
PTA is given for ISF of the s.c. adipose tissue following a single standard linezolid dose (600 mg, 30-min i.v. infusion) in a 
typical obese and non-obese intra-anaesthetic patient for selected MIC values and incision-suture durations. 
MIC [mg/L] Incision-suture 
duration [h] 
Probability of target attainment, % 
“obese & intra-anaesthetic”1 “non-obese & intra-anaesthetic”1 
0.5 
2 99.6 99.8 
4 99.3 99.7 
6 98.7 98.7 
1 
2 98.8 99.5 
4 98 99 
6 92.8 96.4 
2 
2 90.1 97.9 
4 80.6 95.8 
6 51.8 81 
4 
2 25.5 83.1 
4 9.1 59.6 
6 1 25 
1Detailed information on patient characteristics: Table 2.4 A.  
Colour coding: Green: PTA≥90%, Yellow: PTA 80-<90%, Orange: PTA>50-<80%, Red: PTA≤50%  
Abbreviations: fT>MIC: Time period that unbound drug concentration exceeds the MIC; ISF: Interstitial space fluid; s.c.: 
Subcutaneous. 
Overall, the following three trends were observed: (i) PTA increased with decreasing MIC value, 
(ii) PTA increased with decreasing incision-suture duration and (iii) PTA was higher for nonobese 
than for obese patients. More precisely, standard linezolid dosing resulted in adequate target 
attainment (i.e. PTA ≥90%) for both the typical obese and nonobese patient for MIC values 
≤1 mg/L and incision-suture durations up to 6 h. For MIC=2 mg/L, however, PTA was adequate 
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only for the incision-suture duration of 2 h for the obese patient and 4 h for the nonobese patient. 
In case of even higher MIC values (≥4 mg/L), standard dosing did not result in adequate PTA for 
any of the investiagated incision-suture durations and patients. 
 
Figure 3.7: Stochastic simulations (n=1000) of the unbound linezolid concentration-time profiles in the ISF 
of the s.c. adipose tissue for the typical obese (A) and nonobese (B) intra-anaesthetic patient following a 
single standard dose of linezolid (600 mg, 30-min. i.v. infusion). 
Lines: Horizontal solid: MIC=4 mg/L; Horizontal long dashed: MIC=2 mg/L; Horizontal short-dashed: MIC=1 mg/L; 
Horizontal dotted=0.5 mg/L; Vertical black: Incision time; Vertical grey: Incision-suture duration of 2 h, 4 h, 6 h.  
Colour coding: Red: Obese and intra-anaesthetic patient; Green: Nonobese and intra-anaesthetic patient (for detailed 
information on patient characteristics see Table 2.4 A)  
Abbreviations: ISF: Interstitial space fluid; i.v.: Intravenous; MIC: Minimum inhibitory concentration; PK/PD: 
Pharmacokinetic/Pharmacodynamic; R: Resistant. 
Similar trends were observed when evaluating the PTA over a broad range of LBW values for an 
intra-anaesthetic patient (Figure 3.8). While for MIC ≤1 mg/L, adequate PTA was reached for the 
full investigated LBW range (35-80 kg; i.e. body weight of 50.1-334 kg for a 1.65 m tall female 
patient), for MIC=2 mg/L, PTA was only adequate for incision-suture durations of 2 and 4 h in the 
lower investigated LBW range (LBW ≤50 and ≤45 kg, respectively; i.e. body weight ≤111 kg and 
≤75.4 kg, respectively, for a 1.65 m tall female patient; Figure 3.8). For MIC=4 mg/L, none of the 
LBW values reached adequate PTA: While PTA was yet relatively high for the incision-suture 
duration of 2 h and low LBW (e.g. 88.3% for LBW=35 kg, i.e. body weight of 46.7 kg for a 1.65 m 
tall female patient), for high LBW values PTA declined markedly (e.g. 4.5%, for LBW=80 kg; 
Figure 3.8). 
3.2.2 Simulations: Evaluation and optimisation of linezolid dosing for acute 
therapy 
For linezolid standard dosing in the setting of acute infection therapy (SI1.212: 600 mg, as 30-min 
i.v. infusion, q12h), the results of the PTA analysis (PK/PD taget 95%fT>MIC) for the initial phase 
of treatment (i.e first 24 h) are summarised in Figure 3.9 A.1-A.2 for varying LBW values, both 
for unbound linezolid concentrations in plasma and in ISF of the s.c. adipose tissue 
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Figure 3.8: Probability of target (PTA; 95%fT>MIC) attainment versus LBW depicted for full PTA range 
(A: 0-100%) and selected PTA range (B: 90-100%).  
PTA evaluated in ISF of the s.c. adipose tissue following a single standard linezolid dose (600 mg, 30-min i.v. infusion) for 
infection prophylaxis. PTA is provided for varying LBW values, for selected MIC values, and incision-suture durations. All 
other covariates in the NLME PK model were set to median values of the patient population (for detailed information on patient 
characteristics see Table 2.4 B).   
Vertical line: LBW obesity threshold of 47.1 kg (translating into the BMI obesity threshold of 30 kg/m2 for a 1.65 m tall female 
patient).  
Colour coding (shaded areas): Green: PTA≥90%, Yellow: PTA 80-<90%, Orange: PTA>50-<80%, Red: PTA≤50%.  
Abbreviations: fT>MIC: Time period that unbound drug concentration exceeds the MIC; ISF: Interstitial space fluid; LBW: 
Lean body weight; MIC: Minimal inhibitory concentration; PTA: Probability of target attainment; s.c.: Subcutaneous. 
This analysis revealed adequate PTA (i.e. PTA ≥90%) after 24 h of standard linezolid treatment, 
only in plasma for the lowest investigated MIC value (0.5 mg/L) and the upper range of LBW 
(LBW ≥60 kg, i.e. body weight of ≥135 kg for a 1.65 m tall female patient; Figure 3.9 A.1). In ISF, 
none of the investigated combinations of MIC value (0.5, 1, 2, 4 mg/L) and LBW value (35-80 kg) 
reached adequate PTA (Figure 3.9 A.2).   
In the following the impact of the of dosing regimen alterations (intensification of the daily dose: 
Section 3.2.2.1, prolongation of the infusion duration: Section 3.2.2.2, shortening of the dosing 
interval: Section 3.2.2.3) and LBW on the PTA (Section 3.2.2.4) is elucidated as well as an 
overview of adequate dosing regimens (Section 3.2.2.5) is provided. The underlying raw results of 
the PTA analyses are provided in the Appendix chapter (Appendix Figure S21 and Table S10); 
additionally, deterministic simulations of the linezolid concentration-time profiles resulting from 
the different dosing regimens are provided for graphical illustration (Appendix Figure S22). 
3.2.2.1 Impact of intensification of daily dose on the PTA  
The intensification of the total daily dose (DD) overall clearly improved the attainment of adequate 
PTA (i.e. PTA ≥90%). Increasing the daily dose for the q12h infusion regimens by 50% (i.e. from 
1200 mg to 1800 mg) enhanced the attainment of adequate PTA by 3.56-fold. Doubling the daily 
dose (i.e. from 1200 mg to 2400 mg) even increased the achievement of adequate PTA by 5.43-
fold. More precisely, the impact of the daily dose on the attainment of adequate PTA was more 
pronounced for short-term than prolonged infusion regimens as well as for ISF compared to 
plasma. Raw results are provided in the Appendix, Table S12. 
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Comparing the actual magnitude of the PTA, also revealed a clear increase in PTA with 
intensification of the daily dose (Figure 3.9).  
 
Figure 3.9: Probability of target (95%fT>MIC) attainment vs. LBW in plasma (1) and ISF of the s.c. adipose 
tissue (2), for standard linezolid dosing SI1.212 (A) and the two alternative dosing regimens with intensified 
daily dose SI1.812 (B) and SI2.412 (C). 
All other covariates in the NLME PK model were set to median values of the patient population (for detailed information on 
patient characteristics see Table 2.4 B). PTA results of all eight investigated dosing regimens: Appendix Figure S21. 
Deterministic simulations of unbound linezolid concentration-time profiles in plasma and ISF for the eight different dosing 
regimens: Appendix Figure S22.  
Vertical line: LBW obesity threshold of 47.1 kg (translating into the BMI obesity threshold of 30 kg/m2 for a 1.65 m tall female 
patient).  
Dosing regimens: SI1.212: 600 mg 30-min i.v. infusion, q12h; SI1.812: 900 mg 30-min i.v. infusion, q12h; SI2.412: 1200 mg 
30-min i.v. infusion, q12h.   
Colour coding (shaded areas): Green: PTA≥90%, Yellow: PTA 80-<90%, Orange: PTA>50-<80%, Red: PTA≤50%.  
Abbreviations: fT>MIC: Time period that unbound drug concentration exceeds the MIC; ISF: Interstitial space fluid; LBW: Lean 
body weight; q8h: Every 8 h; q12h: Every 12 h; MIC: Minimum inhibitory concentration; s.c.: Subcutaneous. 
  
Linezolid dosing regimens in obese and nonobese surgical patients 
89 
While, for instance, for the short-term dosing regimen with standard daily dose of 1200 mg 
(SI1.212), PTA in plasma was only 43.3% (‘red’ area; Figure 3.9 A.1) for LBW of 50 kg and a MIC 
value of 2 mg/L, PTA increase to 80.8% (‘yellow’ area; Figure 3.9 B.1) for the daily dose of 
1800 mg and even up to 90.6% (‘green’ area, Figure 3.9 C.1) for a daily dose of 2400 mg. 
3.2.2.2 Impact of prolongation of infusion duration on the PTA 
Prolongation of the infusion duration (INF) overall improved the attainment of adequate PTA (i.e. 
PTA ≥90%). The investigated prolonged infusion regimens (INF=4 h) resulted 16.5% more often 
in adequate PTA compared to the investigated short-term infusion regimens (INF=30 min). More 
precisely, the superiority of the prolonged over the short-term infusion regimens was more 
pronounced for standard than intensified daily doses: While for standard daily dose (1200 mg) the 
prolongation of the infusion interval led to a 3.20-fold improvement in the attainment of adequate 
PTA, for the intensified daily doses of 1800 mg and 2400 mg, a 1.38-fold and 1.07-fold 
improvement was reached, respectively. In addition, the impact of the prolongation of infusion 
duration on the attainment of adequate PTA differed between q12h and q8h dosing regimens: For 
the q12h dosing regimens (𝜏=12 h), the prolongation of the dosing interval clearly improved the 
attainment of adequate PTA by 32.4% compared to short-term regimens. However, for the q8h 
dosing regimens (𝜏=8 h) the prolongation of the infusion duration showed no impact on the 
attainment of adequate PTA. Furthermore, the impact of the prolongation of infusion duration on 
the attainment of adequate PTA also differed between plasma and ISF: While, in plasma prolonged 
infusion regimens resulted 24.3% more often in adequate PTA than short-term regimens; in ISF, 
the attainment of adequate PTA was comparable between prolonged and short-term infusion 
regimens. Raw results are provided in the Appendix, Table S13.  
Assessing the impact of the prolongation of the infusion duration on the actual magnitude of PTA, 
overall showed an improvement in PTA (Figure 3.10). For some investigated combinations an 
inverse impact was observed with prolongation of the infusion duration resulting in reduced PTA 
compared to the corresponding short-term infusion regimens (Figure 3.10; Appendix Figure S21). 
This was in general the case for higher MIC values and/or high LBW values and was particularly 
pronounced in ISF. While, for example, the PTA in ISF for the prolonged regimen PI1.212 and the 
low MIC value of 0.5 mg/L was superior to the standard dosing (SI1.212) up to LBW values of 
70 kg, it was inferior for higher LBW values (LBW ≥75 kg; Figure 3.10). For the higher MIC value 




Figure 3.10: Probability of target (95%fT>MIC) attainment vs. LBW in plasma (1) and ISF of the s.c. adipose 
tissue (2), for standard linezolid dosing SI1.212 (A) and one selected alternative dosing regimen with 
prolonged infusion duration PI1.812 (B).  
Dosing regimens: SI1.212: 600 mg 30-min i.v. infusion, q12h; PI1.212: 600 mg 4-h i.v. infusion, q12h.  
For further information and abbreviations see Figure 3.9. 
3.2.2.3 Impact of shortening of dosing interval on the PTA 
Shortening the dosing interval (𝜏) overall improved the attainment of adequate PTA (i.e. 
PTA ≥90%). The investigated q8h infusion regimens (𝜏=8 h) resulted 33.3% more often in 
adequate PTA compared to the investigated corresponding q12h infusion regimens (𝜏=12 h). In 
general, the superiority was more pronounced for short-term than for prolonged infusion regimens: 
While for short-term infusions, the shortening of the dosing interval increased the attainment of 
adequate PTA by ~1.58-fold, for prolonged infusions the increase was ~1.15-fold. In addition, the 
impact of shortening the dosing interval on the attainment of adequate PTA was stronger in plasma 
than in ISF, with a ~1.38-fold and ~1.24-fold improvement, respectively. Raw results are provided 
in the Appendix, Table S14.  
Assessing the impact of shortening the dosing interval on the actual magnitude of PTA, an overall 
improvement in PTA was observed (Figure 3.11); yet, for some MIC-LBW combinations an 
inverse impact was observed with shortening of dosing intervals (𝜏=8 h) resulting in a reduction of 
PTA compared to standard dosing intervals (𝜏=12 h) (Figure 3.11; Appendix Figure S21).  
Linezolid dosing regimens in obese and nonobese surgical patients 
91 
 
Figure 3.11: Probability of target (95%fT>MIC) attainment vs. LBW in plasma (1) and ISF of the s.c. adipose 
tissue (2), for standard linezolid dosing SI1.212 (A) and one selected alternative dosing regimen with 
prolonged infusion duration PI1.812 (B).  
Dosing regimens: SI1.212: 600 mg 30-min i.v. infusion, q12h; SI1.88: 600 mg 30-min i.v. infusion, q8h.  
For further information and abbreviations see Figure 3.9. 
In general, this impact was observed for higher MIC values and/or high LBW values and was 
particularly pronounced in ISF. For example, the PTA in ISF for the q8h infusion regimen SI1.88 
and the MIC value of 1 mg/L was higher compared to the q12h infusion regimen SI1.812 over the 
full investigated LBW range (i.e. 35-80 kg; Figure 3.11). For the higher MIC value of 2 mg/L, 
however, the q8h infusion regimen showed a higher magnitude of PTA values compared to the 
q12h infusion regimens up to LBW values of 50 kg, while for higher LBW values (≥55 kg) an 
inverse relation was observed. 
3.2.2.4 Impact of lean body weight on the PTA 
As indicated in the previous sections, the relationship between LBW and PTA was influenced by 
the MIC value and various determinants of linezolid exposure (Appendix Figure S22), namely, the 
LBW value, the matrix of interest (i.e. plasma, ISF) and the type of dosing regimen (daily dose, 




Figure 3.12: Probability of target (95%fT>MIC) attainment vs. LBW in plasma (1) and ISF of the s.c. adipose 
tissue (2), for four different MIC values (A-D) and eight different linezolid dosing regimens.  
Dosing regimens: SI1.212: 600 mg 30-min i.v. infusion, q12h; SI1.812: 900 mg 30-min i.v. infusion, q12h; SI1.88: 600 mg 30-
min i.v. infusion, q8h; SI2.412: 1200 mg 30-min i.v. infusion, q12h; PI1.212: 600 mg 4-h i.v. infusion, q12h; PI1.812: 900 mg 4-
h i.v. infusion, q12h; PI1.88: 600 mg 4-h i.v. infusion, q8h; PI2.412: 1200 mg 4-h i.v. infusion, q12h.  
For further information and abbreviations see Figure 3.9. 
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Jointly assessing all investigated combinations (Figure 3.12) indicated the following general 
tendencies:  
i. for lower MIC values and/or lower LBW values a positive LBW-PTA relationship was 
detected, i.e. an increase in LBW improved the PTA, 
ii. for higher MIC values and/or higher LBW values a negative LBW-PTA relationship 
was observed, i.e. an increase in LBW reduced the PTA,  
iii. the change from a positive to a negative LBW-PTA relationship occurred earlier (i.e. 
at lower MIC and/or LBW values) 
a. in ISF compared to plasma,  
b. for lower compared to the corresponding higher daily doses,  
c. for prolonged compared to the corresponding short-term infusion regimens, and  
d. for q8h compared to the corresponding q12h infusion regimens.   
These tendencies will be elucidated by selected examples in the following. Tendency i-ii: While, 
for instance, for a low MIC value of 0.5 mg/L the PTA in plasma increased with increasing LBW 
(Figure 3.12 A.1), for a higher MIC value of 4 mg/L, the PTA decreased for some dosing regimens 
(e.g. SI1.88; Figure 3.12 D.1). In addition, at lower LBW values ≤50 kg, the PTA in plasma 
increased for the dosing regimen SI1.812, while the PTA decreased for higher LBW values ≥55 kg 
(Figure 3.12 D.1). Tendency iiia: While in plasma only at a MIC value of 4 mg/L a clear decline 
in PTA with increasing LBW was observed for some of the dosing intervals (e.g. SI1.88; 
Figure 3.12 D.1), in ISF already at a MIC value of 1 mg/L a clear negative LBW-PTA relationships 
was observed (e.g. SI1.88; Figure 3.12 B.2). In addition, in plasma a positive PTA-LBW 
relationship was revealed up to LBW values of 70 kg for the dosing regimen SI2.412 and MIC value 
of 4 mg/L (Figure 3.12 D.1), whereas in ISF a positive relationship was only detected up to a LBW 
value of 40 kg (Figure 3.12 D.2). Tendency iiib: While for the low-dose regimen SI1.212 a positive 
LBW-PTA relationship was only observed up to MIC values of 1 mg/L in plasma, for the high-
dose regimen SI2.412 the positive LBW-PTA relationship was detected up to MIC values of 
2 mg/L. Furthermore, for the dosing regimen SI1.812 a positive PTA-LBW relationship was 
revealed up to LBW values of 59 kg for a MIC of 4 mg/L in plasma, whereas the high-dose regimen 
SI2.412 demonstrated a positive relationship up to a LBW value of 70 kg. Tendency iiic: While the 
PTA for the standard short-term infusion regimen SI1.212 increased up to a LBW value of 70 kg in 
plasma and for a MIC value of 4 mg/L, the PTA of the corresponding prolonged infusion regimen 
PI1.212 only increased up to a LBW value of 55 kg. Tendency iiid: The PTA for the q12h infusion 
regimen PI1.812 increased up to a LBW value of 50 kg and decreased for LBW values ≥55kg; the 
PTA of the corresponding q8h regimen PI1.88, however, declined over the full investigated LBW 
range (i.e. 35-80 kg). 
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3.2.2.5 Dosing overview 
A tabular overview of dosing regimens resulting in adequate PTA (i.e. PTA ≥90%) is provided in 
Table 3.4 and shall be explained in the following (example provided in parenthesis for illustration): 
Given the information on sex (female) and total body weight (110 kg) of a patient, the 
corresponding LBW (~55 kg) can be computed (Appendix Section 7.3.2: Eq. 7.11). In addition to 
the patient-specific LBW the pathogen-specific MIC value is required (1 mg/L). In a next step it 
needs to be defined whether adequate PTA is aimed for in plasma only or both in plasma and ISF 
of the s.c. adipose tissue (plasma&ISF). Based on this information short-term and/or prolonged 
dosing regimens can be identified resulting in adequate PTA (SI2.412, PI2.412).  
Table 3.4: Overview of adequacy of different dosing regimens to attain PK/PD target (95%fT>MIC) for 
varying LBW in plasma (A) or both in plasma and ISF (B) [continued on next page].  
Results given for selected short-term and prolonged dosing regimens, selected MIC values and varying LBW values. Dosing 
regimens resulting in adequate PTA for plasma (A) or plasma and ISF (B) are highlighted with . 
MIC [mg/L] LBW [kg]1 
Dosing regimens3 
A: …r  ul   g     d qu    P A2  
in plasma 
B: …r  ul   g     d qu    P A2  
in plasma and ISF 
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Table 3.4 [continued]. 
MIC [mg/L] LBW [kg]1 
Dosing regimens3 
A: …r  ul   g     d qu    P A2  
in plasma 
B: …r  ul   g     d qu    P A2  
in plasma and ISF 


































































35 none   
 
 none none 
40 none   
  
none none 
45 none   
  
none none 
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none none 
65   
  
 
   
none none 
70   
  
 
   
none none 















35 none none none none 
(…) none none none none 
80 none none none none 
1All other covariates in the NLME PK model were set to median values of the patient population (for detailed information on 
patient characteristics see Table 2.4 B). 2Adequate PTA is defined as PTA ≥90%, for the PK/PD target 95%fT>MIC (for detailed 
information on PTA see Table S10); 3Dosing regimens: SI1.212: 600 mg 30-min i.v. infusion, q12h; SI1.812: 900 mg 30-min i.v. 
infusion, q12h; SI1.88: 600 mg 30-min i.v. infusion, q8h; SI2.412: 1200 mg 30-min i.v. infusion, q12h; PI1.212: 600 mg 4-h i.v. 
infusion, q12h; PI1.812: 900 mg 4-h i.v. infusion, q12h; PI1.88: 600 mg 4-h i.v. infusion, q8h; PI2.412: 1200 mg 4-h i.v. infusion, 
q12h.   
Horizontal dashed line: Separates obese from nonobese patients according to LBW obesity threshold of 47.1 kg (translating 
into the BMI obesity threshold of 30 kg/m2 for a 1.65 m tall female patient).  
Abbreviations: fT>MIC: Time period that unbound drug concentration exceeds the MIC; ISF: Interstitial space fluid; LBW: Lean 
body weight; PL: Plasma; PTA: Probability of target attainment; s.c.: Subcutaneous. 
Overall, in contrast to standard dosing, at least one of the alternative dosing regimens resulted in 
adequate PTA for the full LBW range up to a MIC value of 2 mg/L and 1 mg/L for plasma and 
plasma & ISF, respectively. Of note, for a MIC value of 4 mg/L, none of the eight investigated 
dosing regimens reached adequate PTA.  
Similar results were observed for the investigated typical patients (PTA: Table S11, Table S15; 
deterministic simulations of linezolid concentration-time profiles: Appendix Figure S23).  
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 Project III: Development of a risk assessment tool to evaluate 
standard meropenem dosing in critically ill patients with respect 
to ineffective meropenem exposure 
Risk assessment too l for standard meropenem dosing in critically  il l patie nts  
3.3.1 Exploratory data analysis  
3.3.1.1 Patient characteristics 
A total of 48 patients (27 male, 21 female) were included in the study (Table 3.5). 83% of the 
patients suffered from sepsis, which was most frequently caused by pneumonia or peritonitis (75% 
or 20% of the sepsis patients, respectively). Pathogens detected in the patients comprised bacteria 
such as Enterobactericeae, non-fermenters (e.g. Pseudomonas spp.), Staphylococcus spp., 
Streptococcus spp., Enterococcus spp., Bacillus spp., Clostridium spp., Bacteroides spp., 
Mycoplasma spp. and fungi (Candida spp. and Aspergillus spp.). The patient group covered a 
broad range of age (24-84 years), BMI (16-49 kg/m2) and severity of illness (APACHE II score:
 
11-42). Renal function determined by CLCRCG was highly variable, ranging from severely 
impaired up to augmented renal function (e.g. first study day: 24.8-191 mL/min). Seven patients 
received CRRT and six patients underwent extracorporeal membrane oxygenation (ECMO). 28 
patients were post-lung- or post-liver-transplant recipients. 
3.3.1.2 Meropenem dosing and sampling 
Meropenem treatment was initiated in median 22.0 h before start of the study (i.e. drawing of first 
PK serum sample; Appendix Figure S24). During the study period, patients were treated with 
1000 mg (npatients=47) or 2000 mg (npatients=1) of meropenem administered as 30-min infusions 
approximately every 8 h (median 8 h, P0.025-P0.975: 6.94-9.19 h). A total of 1376 blood samples 
(median per patient: 31) were taken during 349 dosing intervals (per patient: median 8, range 4-8). 
23.5% (n=324) of the measurements were Cmin samples, which were collected 7.92 h (median) after 
infusion start (P0.025-P0.975: 6.85-9.08 h). Very few serum concentrations (0.36% of data) revealed 
an implausible increase in the terminal part of the concentration-time profiles and were therefore 
excluded from the data analyses (Appendix Figure S25: red data points). 
3.3.1.3 Meropenem concentrations 
Large interindividual variability was observed for both the observed Cmin values (Figure 3.13) and 
the calculated concentrations C8h and C4h (Table 3.6). While interindividual variability in Cmin and 
C8h was particularly large, varying in both concentrations by up to a factor of approximately 1000 
between the patients, C4h values were slightly less variable (Cmin: range 0.03-30.0 mg/L, 104 %CV; 
C8h: range 0.0426-30.0 mg/L, 110 %CV; C4h: range 0.933-43.3 mg/L, 69.9 %CV). 
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Table 3.5: Patient characteristics of critically ill population at first study day (modified from [233]). 
Diagnosis (multiple possible) Number of patients Percentage of 
patients, % 
Sepsis 40 83.3 
• Origin: Pneumonia 30 75.01 
- Hospital-acquired pneumonia 18 60.02 
- Community-acquired pneumonia 12 40.02 
• Origin: Peritonitis 8 20.01 
• Origin: Urosepsis 1 2.501 
• Origin: Soft tissue infection 13 2.501 
ARDS 7 14.6 
Others 6 12.5 
Continuous patient characteristics [unit] Median P0.05-P0.95 
APACHE II score [-] 27 13-38 
SOFA score [-] 12 4-18 
IL-6 serum concentration [pg/mL] 94.2 24.5-7330 
CRP serum concentration [mg/dL] 9.75 2.10-31.8 
Albumin serum concentration [g/dL] 2.80 2.20-3.56 
CLCRCG [mL/min] 70.8 34.8-160 
• CLCRCG of patients without CRRT [mL/min] 80.8 24.8-191 
• CLCRCG of patients with CRRT [mL/min] 54.1 26.5-72.9 
Age [years] 55.5 32.0-69.9 
Total body weight [kg] 70.5 47.4-121 
BMI [kg/m2] 24.0 18.4-39.6 
Categorical patient characteristics Number of patients Percentage of 
patients, % 
Sex (male) 27 56.3 
CRRT 7 14.6 
• CVVH 1 14.34 
• CVVHD 3 42.94 
• CVVHDF 3 42.94 
Lung transplantation5 19 39.6 
Liver transplantation5 9 18.8 
ECMO 6 12.5 
1In relation to total number of sepsis patients; 2In relation to total number of pneumonia patients; 3Abdominal wall abscess; 4In 
relation to total number of CRRT patients; 5Transplantation within last 28 days.   
Abbreviations: APACHE II: Acute Physiology And Chronic Health Evaluation II [1]; ARDS: Acute respiratory distress 
syndrome; BMI: Body mass index; CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]; CRP: C-
reactive protein; CRRT: Continuous renal replacement therapy; CVVH: Continuous venovenous haemofiltration; CVVHD: 
Continuous venovenous haemodialysis; CVVHDF: Continuous venovenous haemodiafiltration; ECMO: Extracorporeal 





Figure 3.13: Meropenem serum concentrations versus time after last meropenem dose (n=48 patients; 
modified from [233]).   
Dark blue/red circles: Concentrations of patients treated with 1000 mg/2000 mg meropenem; Light blue/orange circles: Cmin 
values of patients treated with 1000 mg/2000 mg meropenem at the end of the actual dosing interval.  
Abbreviations: Cmin: Minimum concentration. 
Apart from interindividual variability, large intraindividual variability was identified (Table 3.6). 
Particularly Cmin (Appendix Figure S25) and calculated C8h values showed large variability, with 
concentrations varying in median 2-fold, up to more than 10-fold within a patient (range of ratio 𝐶𝑚𝑖𝑛_𝑚𝑎𝑥𝐶𝑚𝑖𝑛_𝑚𝑖𝑛 : 1.3-10.9, range of ratio 𝐶8ℎ_𝑚𝑎𝑥𝐶8ℎ_𝑚𝑖𝑛 : 1.22-11.4). Intraindividual variability in C4h values was 
slightly lower but the C4h values within a patient still varied up to more than 5-fold (range of ratio 𝐶4ℎ_𝑚𝑎𝑥𝐶4ℎ_𝑚𝑖𝑛  : 1.10-5.47).  
Table 3.6: Inter- and intraindividual variability of meropenem concentrations at specific time points (CX) 
(modified from [233]). 
Variability level CX (N) Median P0.025-P0.975  
Inter-individual  N=Number of CX values Meropenem concentration (CX) [mg/L] 
Cmin (320) 3.74 0.348-25.0 
C8h (265) 3.41 0.133-24.1 
C4h (265) 11.1 2.08- 39.3 
Intra-individual 
N=Number of CX ratios Meropenem (CX_maxCX_min) ratio in individual patient 
Cmin (48) 2.00 1.35-7.87 
C8h (48) 2.17 1.29-7.22 
C4h (48) 1.60 1.17 -3.70 
Abbreviations: Cmin: Minimum concentrations (here: measured meropenem serum concentration at end of actual dosing 
interval); CX: Concentration at specific time point X of concentration-time profile (here: calculated meropenem serum 
concentrations); P0.025: 2.5th percentile; P0.975: 97.5th percentile. 
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3.3.2 Pharmacokinetic/Pharmacodynamic analysis  
3.3.2.1 Regression model: Impact of renal function on meropenem exposure 
In addition to the large inter- and intrapatient variability in meropenem exposure, i.e. C4h values 
(Figure 3.14 A, y-axis) and C8h values (Figure 3.14 B, y-axis), large variability was also observed 
for renal function, with representatives in all renal function classes from severe renal impairment 
up to augmented renal function (Figure 3.14, x-axes). In addition to the 41 non-CRRT patients, 
7 CRRT patients were investigated. Whereas within the monitored study period for half of the 
patients (n=24), renal function was stable (i.e. constant renal function class), renal function of the 
other half changed between two (npatients=21) or even three (npatients=3) classes of renal function.   
Already at the patient level, a strong dependency between median individual CLCRCG and C4h 
(Figure 3.14 A1) and C8h (Figure 3.14 B1) of the patients was found, interestingly also for the 
CRRT patients (Figure 3.14 A2, B2). Also of note, in patients undergoing ECMO, meropenem 
concentrations were comparable to the meropenem concentrations in non-ECMO patients with 
similar median individual CLCRCG values (bold x-axis tick mark label Figure 3.14 A, B). 
Moreover, within most of the individuals with changing renal function, the same tendency of higher 
meropenem concentrations for decreased renal function was observed: E.g. patient 34 revealed 
worsening of renal function and at the same time increasing meropenem exposure across the four 
study days (grey tick mark label Figure 3.14 A1, B1).   
At the sample level, i.e. when relating all single CLCRCG values as a continuous variable to 
meropenem exposure (C8h), a distinct relation was found, which was described by the hyperbolic 
function 𝐶8ℎ =  40363 · 1(𝐶𝐿𝐶𝑅𝐶𝐺)  2.27 (Figure 3.14 C) and quantified using a regression model in 
logarithmic scale (Figure 3.14 C; Appendix Figure S26). In this model, four C8h values of one 
patient (ID 36) were excluded from the regression since being considerably larger than those of the 
remaining patients with similar renal function; when including the four values of this patient, the 
predicted C8h values in the investigated CLCRCG range changed only negligibly for all metrics: 
Quantified CLCRCG-meropenem exposure relationship, 95% confidence interval, 95% prediction 
interval (Appendix Figure S27).  
3.3.2.2 PK/PD target attainment analysis: Evaluation of standard meropenem dosing 
For infections in non-CRRT patients with pathogens of MIC=2 mg/L, both investigated targets 
were attained in approximately half of the dosing intervals monitored, with slightly higher 
attainment for the 50%T>4xMIC (56%) than the 100%T>MIC target (48%; Table 3.7). Given a MIC of 
8 mg/L, the target 100%T>MIC was attained only in about one fifth of the monitored meropenem 
dosing intervals; attainment of the target 50%T>4xMIC was very low (7%; Table 3.7). Target 




Figure 3.14: Relationship between meropenem serum concentration and creatinine clearance (modified from 
[233]).  
Meropenem serum concentrations at 4 h, C4h (A1, A2), and at 8 h, C8h (B1, B2, C) after start of infusion in non-CRRT 
(A1, B1, C) and CRRT (A2, B2) patients vs. median individual CLCRCG (‘patient level’: A, B) or vs. all single CLCRCG 
(‘sample level’: C) of the patients.   
Tick mark of x-axis (A, B): Median individual CLCRCG at time of determined meropenem C4h or C8h value; Bold tick mark labels 
(A, B): ECMO patients; Grey tick mark labels (A1, B1): Patient example mentioned in the text of section 3.3.2.1; Colour of 
symbols (A-C): Renal function class of a patient at time of determined meropenem C4h or C8h value; Shape of symbol (A, B): 
Study day on which meropenem C4h or C8h value was determined; Dashed vertical lines/horizontal arrows (A-C): Separation 
of renal function classes; Dashed horizontal lines (A-C): EUCAST MIC breakpoints for Enterobacteriaceae, Pseudomonas spp. 
or Acinetobacter spp. (S breakpoint: 2 mg/L, R breakpoint: 8 mg/L [5]); Data points labelled with 36 (C): Four meropenem C8h 
values of patient 36; Black curve (C): Quantified hyperbolic relationship between CLCRCG and meropenem C8h values, 
excluding data of patient 36.  
Abbreviations: CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]; CRRT: Continuous renal 
replacement therapy; C4h: Concentration at 4 h after start of infusion; C8h: Concentration at 8 h after start of infusion; ECMO: 
Extracorporeal membrane oxygenation; EUCAST: European Committee on Antimicrobial Susceptibility Testing; ID: Patient 
identifier; MIC: Minimum inhibitory concentration; RF: Renal function; R: R breakpoint; S: S breakpoint. 
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Stratification of target attainment by the renal function classes in non-CRRT patients, identified 
augmented renal function to mild renal impairment (CLCRCG >130-60 mL/min) as a risk factor for 
non-attainment of both targets (target attainment: 0-46.2% for 100%T>MIC, 0-59.7% for 
50%T>4xMIC; Table 3.7) for infections with pathogens of MIC=2 mg/L. Given a MIC of 8 mg/L, 
meropenem treatment reliable target attainment was only achieved in presence of severe renal 
impairment (CLCRCG: 15-29 mL/min); thus, already moderate renal impairment (CLCRCG: 30-
59 mL/min) was identified as a risk factor for target non-attainment (target attainment for moderate 
renal impairment: 51.4% for 100%T>MIC, 12.5% for 50%T>4xMIC; Table 3.7).  
Table 3.7: Pharmacokinetic/pharmacodynamic (PK/PD) target attainment for all non-CRRT patients and 





NPatients1   x   m l   PK/PD target attainment for 




CX=C4h C4h ≥ 4x2 mg/L, %  
(NC4h samples) 
C4h ≥ 4x8 mg/L, %  
(NC4h samples) 
 All 41 223 56.1 (125) 7.17 (16) 
Severely impaired 1 5 100 (5) 100 (5) 
Moderately impaired 12 72 93.1 (67) 12.5 (9) 
Mildly impaired 11 62 59.7 (37) 1.61 (1) 
Normal 13 60 26.7 (16) 1.67 (1) 





C8h ≥ 2 mg/L, % 
(NC8h samples) 




All 41 223 48.4 (108) 20.6 (46) 
Severely impaired 1 4 100 (4) 100 (4) 
Moderately impaired 12 72 91.7 (66) 51.4 (37) 
Mildly impaired 12 65 46.2 (30) 4.62 (3) 
Normal 11 57 14 (8) 3.51 (2) 
Augmented  5 25 0 (0) 0 (0) 
1Patients were assigned to a renal function class based on their median individual CLCRCG at the time of C4h or C8h 
determination.   
Abbreviations: CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]; CRRT: Continuous renal 
replacement therapy; CX: Concentration at specific time point X of concentration-time profile (here: calculated meropenem 
serum concentrations); PK/PD: Pharmacokinetic/pharmacodynamic; RF: Renal function; T>MIC: Time period that total drug 




3.3.3 Risk assessment tool 
Based on the quantified relationship between CLCRCG and meropenem exposure (Section 3.3.2.1), 
the tool ‘MeroRisk Calculator’ (short: MRC) was developed. The MeroRisk Calculator is an easy-
to-use, 3-step Excel® spreadsheet (graphical user interface) which can be utilised to assess the risk 
of target non-attainment of the PK/PD index 100%T>MIC for non-CRRT patients after standard 
meropenem dosing (Figure 3.15 A). In ‘Step 1’, the user provides either the CLCRCG of a patient 
or its determinants (sex, age, total body weight, serum creatinine concentration), which will then 
be used to calculate CLCRCG. In ‘Step 2’, the user provides the MIC value of a determined or 
suspected infecting pathogen, which is used as the target meropenem concentration. In cases in 
which the MIC value is not available, no MIC value needs to be provided (for handling of blank 
MIC entry see next step). In ‘Step 3’, the MeroRisk Calculator computes the probability (‘risk’) of 
target non-attainment for the given CLCRCG and MIC value; if the MIC entry was left blank, the 
user has now the option to select a EUCAST MIC breakpoint for relevant bacteria [5]. The 
calculated risk (rounded to integer) of target non-attainment is displayed with the following 3-
colour coding system: green (≤10%), orange (>10%-<50%), red (≥50%) (Figure 3.15 B). In 
addition, the tool provides a graphical illustration of the quantified CLCRCG - C8h relationship 
including the 95% prediction interval. Moreover, the tool predicts, based on the 
provided/calculated CLCRCG, the most likely concentration to which meropenem concentrations 
after multiple dosing will decline before the next dosing (C8h), which is graphically highlighted in 
the CLCRCG - C8h relationship (Figure 3.15 B).  
The developed risk assessment tool MeroRisk Calculator (beta version) is publicly available as 
additional file in the article Ehmann et al. Critical Care (2017) [233]. The tool is compatible with 
Windows operating systems and Excel® version 2010 and onwards. When opening the tool, the 
user might be asked to enable macros, enable content, and add to trusted documents. 
 Project IV: Development of a dosing algorithm to identify 
effective meropenem dosing for critically ill patients 
Dosing algorit hm to identify effective meropenem dos ing for critically il l patients  
3.4.1 Exploratory data analysis  
For the results of the exploratory data analysis of patient-specific characteristics and meropenem 
dosing, sampling and concentrations refer to section 3.3.1. Further detailed information on patient-
specific characteristics are summarised in Appendix Table S17.   
With respect to suggestions for a potential NLME PK model, the biphasic meropenem 
concentration-time profile on a semilogarithmic scale, indicated a two-CMT characteristic 
disposition (Appendix Figure S28).  
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Figure 3.15: Graphical user interface of the MeroRisk Calculator (modified from [233]).   
A: Display when opening the tool, i.e. without any entries; B: Display after risk calculation for exemplary patient: female, 60 
years, 65 kg body weight, 0.6 mg/dL serum creatinine, infected with pathogen of MIC=2 mg/L.  
Abbreviations: CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]; CRRT: Continuous renal 
replacement therapy; C8h: Concentration 8 h after start of infusion; MIC: Minimum inhibitory concentration. 
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3.4.2 Nonlinear mixed-effects pharmacokinetic model 
In the following, the results of the PK model development are presented, with a focus on covariate 
analysis (Section 3.4.2.1), the final NLME PK model (Section 3.4.2.3) and the evaluation 
(Section 3.4.2.4).  
3.4.2.1 Base model development 
Pursuant to the results of the exploratory data analysis a two-compartment PK disposition model 
with first-order elimination, parameterised in terms of CL, V1, V2 and Q was selected as structural 
submodel over a one- and three-compartment model, considering the misspecification in the 
goodness-of-fit plots (Appendix Figure S29) and the imprecisely estimated volume of distribution 
parameter of the third compartment (RSE=66.1%) for the one- and three-compartment models, 
respectively. In the stepwise inclusion procedure, IIV was implemented on CL, followed by V1 and 
V2. IIV on Q showed poor precision (RSE=173%) and high η-shrinkage (75%) and was hence not 
included in the model. The fan-shape pattern of the residuals over population predictions 
(Appendix Figure S29) clearly indicated the need of a proportional or combined RUV model, 
which was supported by the considerably higher OFV value when implementing the additive RUV 
model (ΔOFV≥918). The combined RUV model was selected over the proportional model, as the 
additive part (i) was found to be important for the low concentrations, (ii) was estimated with 
adequate precision (RSE=34%), and (iii) led to an improved model performance (ΔOFV=-87.8 
compared to proportional RUV). The investigation of IOV demonstrated superiority of approach 
(ii), i.e. defining as occasion each intensively monitored dosing interval (Section 2.9.3.1, Appendix 
Table S18). IOV was identifiable on CL and V1, however, was at this stage not yet included in the 
model, considering also the high computational demand for the subsequent forward inclusion (e.g. 
execution of 147 models for forward selection step 1 only).  
3.4.2.2 Covariate model development  
The pre-analysis of the two imputation/interpolation strategies using CLCRCG on CL as case 
covariate, revealed clear superiority of the linear interpolation strategy (i.e. strategy B), both in 
terms of OFV (ΔOFV compared to the base model: strategy A=-234, strategy B=-401) but also 
reduction of the unexplained IIV compared to base model (IIVVar CL: strategy A=-65%, strategy 
B=-75%; Appendix Table S19 Subtable A). Hence, the linear interpolation strategy was utilised 
for time-varying covariates in the subsequent covariate model development, which is illustrated in 
Figure 3.16.   
In step 1, the re-estimation of the base model parameters for the non-CRRT patients, revealed 
similar parameter estimates as for all patients, with slightly higher meropenem clearance (~6%; 
Appendix Table S19 Subtable B). In step 2, of the 58 patient-specific characteristics (Appendix 
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Table S2), 27 covariate candidates were selected for further analysis (Figure 3.16). Of these, in the 
forward selection step (step 3), 17 covariate-parameter relationships were selected on CL, V1 and 
V2 (Figure 3.16; information on respective covariate-relationships: Appendix Table S17). In the 
model refinement step (step 4), alternatively investigated covariates and covariate classifications 
did not improve the model; hence, a corresponding adjustment of the full covariate model was not 
made. Additional IOV was implemented on the CL and V1 parameters using exponential models 
and defining each intensively sampled dosing interval as occasion (Section 2.9.3.1), leading to the 
refined full covariate model. In the first part of the backward deletion step (step 5), 9 covariates 
(Figure 3.16) did not reduce the unexplained population parameter variability by more than 5% 
and were hence excluded. In the second part of the backward deletion 5 more covariates were 
excluded successively (in the following order: pH, C-reactive protein, bilirubin, sex, age), based 
on the exclusion criteria precision and statistical significance (Figure 3.16). The last removed 
covariate ‘age’, which showed a negative linear relationship with V1 (per 10 years increase in age: 
8% decrease in V1), was borderline in terms of precision (RSE=51.9%) and statistical significance 
(ΔOFV=5.73). The resulting final covariate model included the three covariates CLCRCG on CL 
(linear model), body weight on V1 (power model), serum albumin concentration on V2 (power 
model) and was undertaken an additional refinement step (step 6, Figure 3.16): First, the automatic 
centring of the covariate relationship, which was implemented by scm was updated to the median 
of the respective covariate values of the non-CRRT patients on the first study day (i.e. CLCRCG: 
80.8 mL/min, body weight: 70 kg, serum albumin concentration: 2.8 g/dL). Second, the 
reassessment of the interpolation of the continuous covariates, again confirmed the superiority of 
the linear interpolation strategy (stepwise compared to linear: ΔOFV=123, up to 67.1% more 
unexplained variability). An additional linear interpolation between the observations of covariates 
also within the NONMEM® script, did not further improve the model and was hence not included. 
Third, a linear covariate model was selected to describe the relationship between serum albumin 
concentration and V2, given the highly comparable results for the power model and linear model 
(ΔOFV=0.498, 1.86% difference in IIVVar on V2). For CLCRCG a piecewise linear relationship was 
selected over the linear relationship (Figure S30) as it was found to significantly improve the model 
prediction (ΔOFV=-10.7, df=1) and reduced the unexplained variability further (e.g. IIVVar on CL: 
8% relative deviation between linear and piecewise linear relationship). Fourth, the implementation 
of the ‘extended Wählby model 1’, which separated within and between-individual covariate 
effects, did not significantly improve the model (ΔOFV=-1.47, df=1) and was hence not included. 
Fifth, the reassessment of the statistical submodel confirmed the need of a combined RUV model 
(ΔOFV=35.9 for sole proportional model) and resulted in an exclusion of the IOV on V2, 
considering the precision of the IOV estimate (RSEVar>50%) and the - with respect to allometric 
principles [204] - less plausible exponent in the power covariate model (model with IOV: 0.78, 
model without IOV: 0.95). The final subgroup analysis (step 7), demonstrated similar PK model 
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parameter estimates for CRRT and non-CRRT patients: For instance, meropenem clearance values 
were highly similar (9.82 and 9.25 L/h, respectively), indicating a similar magnitude of meropenem 
excretion via the CRRT process as for the typical non-CRRT patient via the kidney.  
Figure 3.16: Results of covariate model development: preanalysis and steps 1-5 (based on covariate model 
development strategy, section 2.9.3.2) [continued on next page].  
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Figure 3.16 [continued]: Results of covariate model development: steps 6-7 and final NLME PK model. 
Abbreviations: CL: Clearance; CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]; CLCRUC: 
Creatinine clearance measured using urine collection; CMT: Compartment; CRRT: Continuous renal replacement therapy; 
ECMO: Extracorporeal membrane oxygenation; IIV: Interindividual variability; IOV: Interoccasion variability; i.v.: 
Intravenous; LBW: Lean body weight; MAP: Mean arterial pressure; n: Number; NLME: Nonlinear mixed-effects; PPV: 
Population parameter variability; Q: Intercompartmental clearance; RSE: Relative standard error; RUV: Residual unexplained 
variability; V1, V2: Volume of distribution parameters of central and peripheral CMT. 
Interestingly. also the parameter describing the relationship between CLCRCG and meropenem CL 
(i.e. CLCRCG_CL) was similar between CRRT and non-CRRT patients (per 1 mL/min change in 
CLCR: CL change of 1.29%  and 0.977%, respectively; Appendix Table S20), supporting the 
results of Project III (Section 3.3.2.1). Given the limited number of CCRT patients, overall not all 
parameters could be reliably estimated and hence the CRRT patients were not included in the final 
developed NLME PK model. 
3.4.2.3 Final nonlinear mixed-effects PK model 
The final NLME PK model for meropenem in the critically ill population was a two-compartment 
PK disposition model (typical CL and V: 9.25 L/h and 24 L, respectively) which included 
interindividual variability on CL, V1 and V2, interoccasion variability on CL, a combined residual 
variability model and three covariates: total body weight on V1, serum albumin concentration on 
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V2 and CLCRCG on CL. The NONMEM® model script of the final NLME PK model is provided in 
Appendix 7.4.3, a model sketch can be found in the bottom part of Figure 3.16, and the respective 
PK parameters are summarised in Table 3.8. 
Table 3.8: Parameter estimates including bootstrap results of the final NLME PK model of meropenem in 
critically ill patients (modified from [243]). 
Parameter [unit] 
Final model  Bootstrap3 
Estimate 
(RSE1, %) 
95% CI2 Median 95% CI 
Fixed-effects parameters  
θ CL4 [L/h] 9.25 (4.60) [8.42, 10.1] 9.28 [8.38, 10.1] 
θ V15 [L] 7.89 (11.9) [6.05, 9.73] 7.92 [6.11, 11.5] 
θ Q [L/h] 28.4 (16.1) [19.4, 37.4] 28.4 [11.1, 38.2] 
θ V26 [L] 16.1 (7.40) [13.8, 18.4] 16.1 [11.9, 18.4] 
θ CLCRCG_CL7, % 0.977 (9.20) [0.800, 1.15] 0.987 [0.800, 1.15] 
θ CLCRCG_INF [mL/min] 154 (6.90) [133, 175] 155 [111, 178] 
θ WT_V18 0.945 (16.6) [0.637, 1.25] 0.936 [0.531, 1.32] 
θ ALB_V29, % -20.2 (36.6) [-34.7, -5.72] -20.3 [-40.3, -5.21] 
Interindividual variability parameters, %CV 
ω  L 27.1 (19.3) [13.2, 36.5] 26.3 [17.1, 36.7] 
ω V1 31.5 (14.3) [20.6, 39.8] 30.5 [20.0, 40.2] 
ω V2 16.9 (18.1) [9.02, 22.2] 16.3 [8.07, 23.2] 
Interoccasion variability parameters10, %CV 
К CL 12.5 (12.0) [9.11, 15.2] 12.4 [9.61, 15.5] 
Residual variability parameters  
prop, %CV 16.6 (6.60) [14.5, 18.7] 16.5 [14.5, 18.9] 
add, SD [mg/L] 0.246 (29.0) [0.106, 0.386] 0.234 [0.0932, 0.337] 
1RSE of random-effects parameter estimates ω and  are reported on approximate standard deviation scale; 2Limits of 95% 
confidence intervals are computed as: parameter estimate ± 1.96∙SE; 3Non-parametric bootstrap (n=1000): convergence rate of 
89.7%; 4CL given for median CLCRCG of non-CRRT patients on first study day (80.8 mL/min); 5V1 given for median WT of 
non-CRRT patients (70 kg); 6V2 given for median ALB of non-CRRT patients at first study day (2.8 g/dL); 7Change of clearance 
per mL/min deviation of CLCRCG from 80.8 mL/min (linear CLCRCG-CL relationship); 8Estimated exponent in power WT-V1 
relationship, centred to median in overall population (70 kg); 9Change of V2 per g/dL deviation of ALB from 2.79 g/dL (linear 
ALB-V2 relationship); 10Occasion was defined as intensively monitored dosing interval.  
Abbreviations: ALB: Serum albumin concentration; ALB_V2: ALB effect on V2; CI: Confidence interval; CL: Clearance; 
CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]; CLCRCG_CL: CLCRCG effect on CL; 
CLCRCG_INF: CLCRCG value serving as inflection point for meropenem CL in CLCRCG-CL relationship; CMT: Compartment; 
CRRT: Continuous renal replacement therapy, CV: Coefficient of variation (calculated for random-effects parameters according 
to Eq. 2.6); IIV: Interindividual variability; IOV: Interoccasion variability; Q: Intercompartmental clearance; RSE: Relative 
standard error; SD: Standard deviation; V1, V2: Volume of distribution parameters of central and peripheral CMTs; WT: Body 
weight; WT_V1: WT effect on V1; θ: Fixed-effects parameter; 𝜔: Random-effects parameter: Interindividual variability; К: 
Random-effects parameter: Interoccasion variability; 𝜎: Random-effects parameter: Residual unexplained variability. 
Body weight was implemented on V1 using a power model with an estimated exponent of ~1, i.e. 
doubling the body weight (e.g. 50 kg vs. 100 kg) approximately doubled V1 of meropenem (e.g. 
5.74 L vs. 11.1 L). Between serum albumin concentration and V2, a negative linear relationship 
was implemented which indicated a 20%-change of V2 per 1 g/dL deviation of the serum albumin 
concentration from the median serum albumin concentration (2.8 g/dL). A piecewise linear 
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relationship was implemented and 
quantified between CLCRCG and 
meropenem CL: Per 10 mL/min CLCRCG 
deviation from the median CLCRCG 
(80.8 mL/min), meropenem CL changed 
by ~10% and increased up to a maximum 
meropenem CL of 15.9 L/h at the 
precisely estimated CLCRCG inflection 
point (154 mL/min, RSE=7%; Table 3.8; 
graphical illustration: Appendix 
Figure S30 A). The impact of these 
covariates on the PK parameters is 
graphically illustrated as forest plot in 
Appendix Figure S31: Considering the 
covariate ranges covered in the critically 
ill study population the impact of extreme 
CLCRCG values and high body weight 
was particularly pronounced (e.g. min. CLCRCG (24.8 mL/min): ~0.45 ∙ reference CL; max. WT 
(140 kg): ~1.93 ∙ reference V1). The inclusion of the three covariates considerably reduced the 
unexplained variability on the PK parameters: CLCRCG reduced PPVVar on CL by ~70%, body 
weight reduced IIVVar on V1 by ~40%, and serum albumin concentration IIVVar on V2 by ~30% 
(Figure 3.17). In the final model, the unexplained variability was ≤31.5%CV, with the variability 
within a patient (i.e. IOV) being considerably lower than between the patients (i.e. IIV; e.g. on CL: 
IOV=12.5 %CV vs. IIV=27.1 %CV). 
3.4.2.4 Model evaluation  
Standard goodness-of-fit plots indicated adequate model predictions (Figure 3.18 B-E). The VPC 
demonstrated good predictive performance both for the typical trend and the variability of the 
meropenem concentration-time profiles (Figure 3.18 A) as well as across the full CLCRCG range 
(Appendix Figure S32). A non-parametric bootstrap for the final model (Table 3.8) confirmed 
model robustness (indicated by convergence rate of ~90%), precision (indicated by the narrow 95% 
confidence intervals of the bootstrap parameter estimates) and accuracy of the parameter estimates 
(indicated by low relative bias: Median (min; max) for fixed-effects parameters=-0.358% 
(-0.945%; 0.928%); random-effects parameters=5.36% (0.658%; 6.25%)). 
 
Figure 3.17: Reduction of unexplained variability by 
covariates in the final NLME model for meropenem.  
Absolute variability on variance scale shown. Reduction of 
unexplained variability was derived by univariate exclusion of 
covariates from final model, re-estimation of parameters and 
evaluation of the relative increase in respective variability 
parameters on variance scale, which was considered “explained 
variability”.  
Abbreviations: ALB: Serum albumin concentration; CL: Clearance; 
CLCRCG: Creatinine clearance according to Cockcroft and Gault; 
IIV: Interindividual variability; IOV: Interoccasion variability; 
PPV: Population parameter variability (computed as sum of 
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Figure 3.18: Visual predictive check (A, n=1000 simulations) and goodness-of-fit plots (B-E) for the final 
NLME PK model of meropenem in critically ill patients (modified from [243]).   
A: Circles: Observed meropenem concentrations; Lines: 5th, 95th percentile (dashed), 50th percentile (solid) of the observed 
data; Shaded areas: 95% confidence interval around 5th, 50th and 95th percentile of simulated data.  
B, C: Circles: Observed vs. population predicted (B) and individual predicted meropenem concentrations (C); Lines: Line of 
unity.   
D, E: Circles: Conditional weighted residuals vs. population predicted meropenem concentrations (D) and time after last dose 
(E); Horizontal lines: Reference lines at y=0. 
As expected, during case deletion diagnostics, single patients with high CLCRCG values were found 
to be essential for the estimation of the inflection point of CLCRCG (Appendix Figure S33). Yet, 
their impact on the estimate of the inflection point was only moderate, with a change of the 
parameter by ≤17.9% from the original estimate of 154 mL/min. 
3.4.3 Simulations: Evaluation and optimisation of meropenem exposure and 
dosing regimens 
3.4.3.1 Evaluation of meropenem exposure 
The impact of the three covariates identified in the final NLME PK model (Section 3.4.2.3) on the 
meropenem concentration-time profiles is illustrated in Figure 3.19 by means of deterministic 
exposure simulations. CLCRCG, which was implemented as a covariate on the meropenem 
clearance parameter, mainly affected the terminal phase of the concentration-time profile and was 
hence a strong determinant of meropenem concentrations at the end of the dosing interval, both 
after first and multiple dosing (Figure 3.19: A.1, A.2). In contrast, body weight (implemented on 
V1, Figure 3.19: B.1, B.2) and serum albumin concentration (implemented on V2, 
Figure 3.19: C.1, C.2), only showed a minor impact on the terminal concentration-time profile, but 
as expected rather on maximum concentrations and concentrations in the early declining part of 
the meropenem concentration-time profile. 
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Figure 3.19: Impact of CLCRCG (A), body weight (B) and serum albumin concentrations (C) on the typical 
simulated meropenem concentration-time profiles (modified from [243]).  
For each patient characteristic deterministic simulations were performed for varying covariate values (minimum and maximum 
value of study period and median value of first study day), resulting from standard meropenem dosing (1000 mg, 30- min i.v. 
infusion, q8h).   
A: Varied CLCRCG (inflection point of CLCRCG-CL relationship (=154 mL/min) is displayed instead of maximum CLCRCG, 
given the constant meropenem CL for higher CLCRCG values), body weight and serum albumin set to median of first study day 
(i.e. 70 kg and 2.8 g/dL).   
B: Varied body weight, CLCRCG and albumin set to median of first study day (i.e. 80.8 mL/min and 2.8 g/dL).   
C: Varied albumin, CLCRCG and body weight set to median of first study day (i.e. 80.8 mL/min and 70 kg).  
Left panel (A.1, B.1, C.1): First dosing interval; Right panel (A.2, B.2, C2): First 4 treatment days.  
Abbreviations: CL: Clearance; CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]. 
3.4.3.2 Evaluation and optimisation of meropenem dosing regimens  
This section summarises the results of the PTA and CFR analyses performed for (i) standard 
meropenem dosing to identify impact factors and to evaluate the standard dosing, and (ii) 
alternative meropenem dosing regimens in order to identify optimised meropenem dosing 
regimens.  
Evaluation of standard meropenem dosing  
PTA analysis based on the standard meropenem dosing regimen SI38 (nsimulated patients: 52,500,000 = 
Results 
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105 covariate combinations ∙ 500 patients ∙ 1000 uncertainty simulations) indicated a decreasing 
PTA (i.e. increasing risk of target non-attainment) for patients with increasing CLCRCG 
(Figure 3.20 A.1, Table 3.9 Subtable A), decreasing body weight (Figure 3.20 B.1, Appendix 
Table S21) and increasing serum albumin concentration (Figure 3.20 C.1, Appendix Table S21). 
Of the three covariates, CLCRCG revealed by far the strongest impact on PTA, given the strong 
impact of CLCRCG on the meropenem concentrations in the terminal phase of the concentration-
time profile (Figure 3.20 A). For a MIC value of 2 mg/L, for example, the PTA ranged from 6% to 
100% (∆ ~94%) given the investigated range of CLCRCG. For body weight and serum albumin 
concentration, however, the PTA covered a markedly smaller range (43%-77.8% and 39.8%-
73.0%, i.e. ∆ ~35% and ∆ ~33%, respectively) and PTA values were mainly determined by the 
CLCRCG value (fixed to 80.8 mL/min; Appendix Table S21). The vast importance of creatinine 
clearance as a determinant of PTA was also illustrated by the PTA analyses for ‘best’, ‘typical’ and 
‘worst’ case scenarios (Appendix Figure S35 A): The PTA values regarding creatinine clearance 
(i.e. low, medium and high creatinine clearance), were similar to PTA values investigating ‘best’, 
‘typical’ and ‘worst’ case scenarios considering all three covariates (e.g. ‘best’ case: low creatinine 
clearance, high body weight, low serum albumin concentration; Figure B.4 A). Further evidence 
for creatinine clearance as main determinant of PTA was provided by the PTA analyses for a broad 
range of varying body weight (Appendix Figure S35 B) or serum albumin concentration (Appendix 
Figure S35 C) values given three creatinine clearance values (minimum, median and inflection 
point of CLCRCG-CL relationship). To summarise, the analyses clearly identified creatinine 
clearance as main determinant of PTA and hence as key factor for the risk assessment of potential 
therapy failure.  
Furthermore, as expected, PTA was dependent on the susceptibility of the pathogen, or more 
precisely, increased with decreasing susceptibility of the pathogen, i.e. increasing MIC 
(Figure 3.20 A.1, B.2, C.2). For instance, for a normal renal function (CLCRCG: 90 mL/min), 
standard meropenem dosing reliably resulted in effective meropenem exposure (i.e. 5th percentile 
of PTA≥90%) for MIC≤0.25 mg/L and declined to 29.2% and even to 0% for MIC=2 mg/L and 
8 mg/L, respectively (Table 3.9 Subtable A). Overall, standard meropenem dosing reliably reached 
effective exposure in highly susceptible pathogens (i.e. MIC≤0.06 mg/L) for the full renal function 
range. However, already for the upper level of the isolates belonging to the S category (i.e. 
MIC=2 mg/L) only renal functions ≤40 mL/min reliably attained effective exposure; for the upper 
level of the isolates belonging to the I category (i.e. MIC=8 mg/L) none of the investigated renal 
functions did. Of note, when comparing the PTA results between treatment days 1 and 4, the 
differences were found to be marginal (Appendix Figure S34, Figure S36).  
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Figure 3.20: Probability of target (98%T>MIC) attainment vs. covariates (A.1, B.1, C,1) and vs. MIC (A.2, 
B.2, C.2) on the first day of standard meropenem treatment (1000 mg, 30-min i.v. infusion, q8h) (modified 
from [243]).  
A: Varied CLCRCG, body weight and serum albumin concentration set to median of first study day (i.e. 70 kg, 2.8 g/dL); 
B: Varied body weight, CLCRCG and serum albumin concentration set to median of first study day (i.e. 80.8 mL/min, 2.8 g/dL); 
C: Varied serum albumin concentration, CLCRCG and body weight set to median of first study day (i.e. 80.8 mL/min, 70 kg). 
Dashed horizontal line: PTA of 90%; Coloured circles and lines + shaded areas: Median + 90% CI of the 1000 PTA values 
derived from the 1000 Monte Carlo simulations considering PK parameter uncertainty; Note: Dosing selection was based on 
5th percentile (i.e. lower end of coloured shaded area) for dosing algorithm (Table 3.10); Grey shaded areas: Extrapolated 
covariate range not covered by the study population or CLCRCG ≥154 mL/min (=inflection point of CLCRCG-CL relationship). 
Abbreviations: MIC: Minimum inhibitory concentration; CI: Confidence interval; CLCRCG: Creatinine clearance estimated 
according to Cockcroft and Gault [2]; PTA: Probability of target attainment; T>MIC: Time period that total drug concentration 






Table 3.9: Probability of target attainment (PTA, A) and cumulative fraction of response (CFR, B) for the first day of standard meropenem treatment (1000 mg, 30-
min i.v. infusion, q8h) evaluated for the PK/PD target 98%T>MIC (modified from [243]).   
PTA and CFR are given for varied values of creatinine clearance as well as for selected MIC values and are presented as the median (P0.5), 5th (P0.05) and 95th percentile (P0.95) of the 1000 PTA 
values derived from the 1000 Monte Carlo simulations considering PK parameter uncertainty.  
 








0.06 0.12 0.25 0.5 1 2 4 8 16 32 
P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 
10 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.6 100 100 96.8 100 100 78.2 98 100 16 54.6 93.6 0 0 0.8 
20 100 100 100 100 100 100 100 100 100 100 100 100 99.6 100 100 98.4 100 100 90.6 99 100 59.2 86.2 98.6 4.6 19.4 44.4 0 0 0 
30 100 100 100 100 100 100 100 100 100 99.8 100 100 99 100 100 95.6 99.4 100 81.2 94.2 99.4 39 62.8 81.2 0.6 4.8 13.4 0 0 0 
40 100 100 100 100 100 100 99.8 100 100 99.4 100 100 97.6 99.6 100 90.2 97 99.6 68.8 82.6 93.2 21.6 37.4 51 0 1 4.6 0 0 0 
50 100 100 100 99.8 100 100 99.6 100 100 98.4 99.8 100 94.6 98.4 99.8 82.8 91.2 97.2 52.4 65.6 77 8.39 18.7 30.2 0 0.2 1.8 0 0 0 
60 99.8 100 100 99.6 100 100 98.8 99.8 100 96.8 99.2 100 90 95.6 98.8 73 81.8 89.8 34.8 47.2 57.8 2.2 8.8 18.2 0 0 0.8 0 0 0 
70 99.8 100 100 99.4 100 100 98 99.6 100 94.2 97.8 99.6 84.2 90.6 96 59.6 69.2 78.2 19.4 31.8 43.4 0.4 4 11.2 0 0 0.4 0 0 0 
80 99.6 100 100 98.8 99.8 100 96.4 98.8 100 90.2 95 98.4 75.4 83 90 43.8 55.6 66.2 8.19 19.9 32.2 0 1.6 6.8 0 0 0.2 0 0 0 
90 99.2 99.8 100 97.8 99.4 100 94 97.4 99.4 84.4 90.8 95.6 64 73.6 81.8 29.2 42.8 54.8 3 12.2 23.6 0 0.6 4.2 0 0 0 0 0 0 
100 98.6 99.8 100 96.2 98.8 100 90 95.2 98.4 77.4 85.2 91.4 51.4 63.2 73.4 16.8 31.6 44.8 1 7 17.2 0 0.2 2.4 0 0 0 0 0 0 
110 97.8 99.4 100 94.4 97.6 99.4 85.8 92 96.6 68.8 78.2 86.2 39.4 53 65.2 9.2 22.7 37 0.39 4.1 12.6 0 0 1.6 0 0 0 0 0 0 
120 96.6 98.8 100 92 96.2 98.8 81 87.6 94 59.6 71.2 81 28.4 44.1 58.2 5.2 16.4 30.8 0 2.4 9.6 0 0 1 0 0 0 0 0 0 
130 95 98 99.8 88.6 94 98 74.2 83.4 91.8 50.4 63.6 76.8 19.4 36 52 2.6 11.8 25.8 0 1.4 7.2 0 0 0.6 0 0 0 0 0 0 
140 93 97.2 99.6 85 91.8 97.6 67.8 78.8 90.4 41 56.8 74.2 14 29.8 49.2 1.4 8.8 23 0 0.8 6.2 0 0 0.6 0 0 0 0 0 0 
150 90.6 96 99.4 80.2 89.4 97.2 60 74.4 89.4 32.8 51 73.4 9.99 24.5 46.6 0.8 6.4 20.6 0 0.6 5 0 0 0.4 0 0 0 0 0 0 





















Table 3.9 [continued].  
 




Cumulative fraction of response, % 
 
Full MIC distribution2 
 
MIC distribution of isolates belonging to 
the S category2 
MIC distribution of isolates belonging to 
the I category2 




aeruginosa Acinetobacter spp. 
Pseudomonas 
aeruginosa Acinetobacter spp. 
Pseudomonas 
aeruginosa Acinetobacter spp. 
P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 
10 100 100 100 99.8 99.9 100 99.8 99.9 100 91.2 95.2 98 88.2 94 99.1 100 100 100 99.9 100 100 88.2 99.1 100 89.5 99.2 100 
20 100 100 100 99.8 99.8 99.9 99.7 99.8 99.9 88.8 92.1 94.6 85.4 89.1 92.8 99.7 100 100 99.6 100 100 76.1 93.1 99.4 78.3 94 99.5 
30 100 100 100 99.7 99.8 99.8 99.6 99.7 99.8 86.4 89.4 91.4 83 86 88.2 99.3 99.9 100 98.8 99.9 100 61.7 79.7 91 64.7 81.9 92.3 
40 100 100 100 99.6 99.7 99.8 99.5 99.6 99.7 83.7 86.6 88.7 80.4 83.5 85.5 98.2 99.6 100 97.1 99.2 99.9 47 61.7 73.7 50.4 65 76.7 
50 100 100 100 99.5 99.6 99.7 99.4 99.5 99.6 80.5 83.7 86 77 80.6 83.1 96.5 98.6 99.6 94.5 97.7 99.3 32 43.9 55.3 35.2 47.3 58.7 
60 99.9 100 100 99.2 99.5 99.6 99.1 99.4 99.5 76.9 80.4 83.1 72.9 76.9 80 93.8 96.8 98.6 90.8 94.8 97.5 19.7 29.4 39.5 22.1 32.2 42.3 
70 99.9 99.9 100 99.1 99.4 99.5 98.8 99.3 99.4 72.9 76.9 80.2 68 72.5 76.4 90.3 94 96.6 85.7 90.5 94.2 10.6 18.9 28.5 12 20.9 30.8 
80 99.8 99.9 100 98.8 99.3 99.4 98.3 99 99.3 68.2 72.9 77 62.1 67.5 72.2 85.3 90.1 93.8 79 85 89.9 4.4 11.4 20.5 4.99 12.8 22.3 
90 99.6 99.9 99.9 98.2 99 99.3 97.6 98.6 99.1 63 68.5 73.3 55.8 62.2 67.6 79.2 85.3 90.1 71.3 78.7 84.8 1.61 6.83 14.6 1.83 7.67 16 
100 99.4 99.9 99.9 97.5 98.8 99.1 96.6 98.2 98.8 57.4 63.9 69.5 49.4 56.7 63.1 72.3 79.9 86 63.2 72.2 79.5 0.537 3.85 10.4 0.61 4.35 11.4 
110 99.2 99.7 99.9 96.6 98.2 99 95.5 97.4 98.5 52.1 59.1 65.7 43.6 51.4 58.8 65.6 74.2 81.6 55.9 65.6 74.4 0.21 2.2 7.51 0.238 2.5 8.31 
120 98.8 99.6 99.8 95.4 97.6 98.8 94 96.5 98.1 46.9 54.6 62.2 38.4 46.7 55 59.1 68.7 77.5 49.2 59.6 69.7 0 1.29 5.62 0 1.46 6.24 
130 98.2 99.3 99.8 93.9 96.7 98.6 92.1 95.4 97.7 41.6 50.3 59.2 33.5 42.3 51.7 52.5 63.2 74 42.9 54 65.7 0 0.752 4.15 0 0.853 4.62 
140 97.5 99.1 99.8 92.1 95.9 98.3 90 94.3 97.4 37.1 46.5 57.6 29.5 38.6 50 46.7 58.5 72.1 37.7 49.4 63.6 0 0.43 3.61 0 0.488 4.01 
150 96.7 98.8 99.8 89.9 94.8 98.2 87.5 93 97.1 32.6 43.1 56.5 25.7 35.3 48.7 41.1 54.2 70.8 32.9 45.2 62.1 0 0.322 2.87 0 0.366 3.2 
≥154 96.2 98.7 99.8 89.2 94.3 98.2 86.7 92.3 97.2 31.3 41.8 56.7 24.6 34.2 48.9 39.4 52.6 71 31.5 43.8 62.2 0 0.215 2.66 0 0.244 2.96 
1Body weight and serum albumin concentration set to median value of first study day (i.e. 70 kg and 2.8 g/dL); 2According to EUCAST [132].  
Colour coding: Green: CFR or PTA≥90%, Yellow: CFR or PTA 80-<90%, Orange: CFR or PTA>50-<80%, Red: CFR or PTA≤50%; Grey shaded values: Extrapolated CLCRCG range not covered 
by the study population or CLCRCG≥154 mL/min (=inflection point of CLCRCG-CL relationship). Bold values: 5th percentile of the 1000 PTA values (derived from the 1000 Monte Carlo simulations 
considering PK parameter uncertainty), which was used for dosing selection in the dosing algorithm (Table 3.10).  
Abbreviations: CL: Clearance; CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]; CFR: Cumulative fraction of response; fT>MIC: Time period that unbound drug 
concentration exceeds the MIC; I category: Category ‘susceptible at increased exposure’ [4]; MIC: Minimum inhibitory concentration; P0.05: 5th percentile; P0.5: 50th percentile = median; P0.95: 95th 
percentile; q8h: administered every 8 h, PK: Pharmacokinetic, PD: Pharmacodynamics; S category: Category ‘susceptible at normal dosing’ [4]; T>MIC: Time period that total drug concentration 




For the CFR, similar impact factors and trends were identified as for PTA for meropenem standard 
dosing (CLCRCG: Table 3.9 Subtable B, body weight and serum albumin concentrations: Appendix 
Table S22). For a normal renal function (CLCRCG: 90 mL/min), effective meropenem exposure 
was reliably attained (i.e. 5th percentile of CFR≥90%) for E. coli, E. cloacae and K. pneumonia 
(Table 3.9 Subtable B). For the two least susceptible pathogens P. aeruginosa and Acinetobacter 
spp., however, effective exposure was not reliably reached when evaluating the full MIC 
distribution (68.5% and 62.2%, respectively). Separate evaluation of the MIC distributions based 
on the isolates belonging to the S and I categories, showed considerably higher CFR values for 
isolates of the S category (5th percentile of CFR: P. aeruginosa: 85.3% vs. 6.83%; Acinetobacter 
spp.: 78.7% vs. 7.67%). 
Evaluation of alternative meropenem dosing regimens 
Given the importance of CLCRCG and the similar results for treatment day 1 and 4 (previous 
section), for alternative dosing regimens (Table 2.7) PTA and CFR analyses were performed for 
varying CLCRCG values for treatment day 1 (nsimulated patients: 72,000,000 = 18 covariate 
combinations∙ 8 dosing regimens ∙ 500 patients ∙ 1000 uncertainty simulations). All results are 
summarised in tabular format in the Appendix chapter: Table S23 (PTA, short-term infusions), 
Table S24 (PTA, prolonged infusions), Table S25 (PTA, continuous infusions), Table S26 (CFR, 
short-term infusions), Table S27 (CFR, prolonged infusions), Table S28 (CFR, continuous 
infusions). Typical meropenem concentration-time profiles following all investigated dosing 
regimens are illustrated for varying CLCRCG in Appendix Figure S37.  
Overall, the analyses demonstrated that for bacteria of the S category (MIC≤2 mg/L) effective 
meropenem exposure was reliably attained (i.e. 5th percentile of PTA≥90%) in all investigated 
patients, with at least one of the 8 investigated dosing regimens: Whereas in patients with 
augmented renal function (≥130 mL/min) only the most intensified dosing regimen (CI6) reliably 
resulted in effective exposure: for patients with moderate renal insufficiency (CLCRCG=30-
<60 mL/min), dosing regimens with a standard daily dose did (SI38/PI38/CI3). Bacteria belonging 
to the I category (MIC≥4 mg/L), however, seemed to only be effectively covered in patients with 
renal insufficiency (MIC=4 mg/L: CLCRCG≤80 mL/min, MIC=8 mg/L: CLCRCG≤30 mL/min) 
using intensified dosing regimens (SI68/PI68/CI6). Conversely, for highly susceptible pathogens 
(e.g. MIC<0.12 mg/L for CLCRCG=90 mL/min), even lower than standard dosing reliably resulted 
in effective meropenem exposure (SI212/PI212).   
The analyses demonstrated the following important trends, for MIC≤4 mg/L and day 1 of 
treatment: Firstly, for a given daily dose, continuous-infusion regimens (Appendix Table S25) 
were superior to prolonged (Appendix Table S24) and prolonged to short-term dosing regimens 
(Appendix Table S23). The superiority of continuous over prolonged infusion was more 
pronounced than of prolonged over short-term infusion. Secondly, the type of infusion (e.g. 
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continuous vs. prolonged) on the achievement of effective exposure was more relevant than the 
administered total daily dose (e.g. 3000/3412.5 vs. 6000/6875 mg). For MIC>4 mg/L and 
P. aeruginosa or Acinetobacter spp. isolates of the I category, prolonged infusion rather than 
continuous-infusion regimens was superior.  
3.4.4 Dosing algorithm  
The developed 3-level dosing algorithm is provided in Table 3.10 and shall be illustrated for 
different levels of knowledge about the pathogen by the following example: If at start of treatment 
an infecting pathogen of the S category (L1; non-species-related S breakpoint=2 mg/L) is 
suspected in patients with CLCRCG=50 mL/min, the short-term infusion regimen with an increased 
daily dose of 6000 mg (SI68) would be needed to reliably reach effective exposure (i.e. 5th 
percentile of PTA≥90%); for the prolonged and continuous-infusion regimens lower daily doses 
(PI38/CI3, i.e. 3000/3412.5 mg) would be sufficient. For patients with normal renal function, only 
the highest investigated continuous-infusion regimen (CI6) would reliably reach effective 
exposure. When for the latter patient information on the type of pathogen becomes available (L2), 
a regimen with a reduced daily dose (SI212/SI38/PI212/CI3) could be selected in case of different 
Enterobacteriaceae, whereas for P. aeruginosa or Acinetobacter spp., no regimen seemed effective. 
If additional knowledge of the susceptibility of the pathogen (L3(-MIC)) becomes available, e.g. for 
P. aeruginosa of the S category, apart from the intensified short-term infusion (SI68) an even lower 
daily dose administered as prolonged infusion (PI38) or continuous-infusion (CI3) regimen was 
found to reliably result in adequate PK/PD target attainment; for Acinetobacter spp. of the S 
category: Short-term (SI68), prolonged (PI68) or continuous (CI3) infusion regimens. If the actual 
MIC value is also provided (L3(+MIC)) and is ≤0.12 mg/L, irrespective of the pathogen but 








Table 3.10: Three-level dosing algorithm1 for the first day of meropenem treatment in critically ill patients (modified from [243]). The proposed eight dosing regimens2 
cover three different durations of infusion: short-term infusion (SI: SI212, SI38, SI68), prolonged infusion (PI: PI212, PI38, PI68), continuous infusion (CI: CI3, CI6d); and 
cover three different daily doses: 2000 mg (light blue: SI212, PI212), 30003 mg (blue: SI38, PI38, CI3) and 60004 mg (pink: SI68, PI68, CI6). For detailed description of 
the eight dosing regimens refer to footnote of the table.  
 
Level 1: Pathogen unknown Level 2: Pathogen known Level 3(-MIC): Pathogen and susceptibility known 
CLCRCG5 
[mL/min] 
Non-species related EUCAST PK/PD 
breakpoint [5] 
S breakpoint  
(MIC=2 mg/L) 
R breakpoint  
(MIC=8 mg/L) 
SI PI CI SI PI CI 
10 SI212 PI212 CI3 SI68 PI68 CI6 
20 SI38 PI38 CI3 SI68 PI68 - 
30 SI38 PI38 CI3 - PI68 - 
40 SI38 PI38 CI3 - - - 
50 SI68 PI38 CI3 - - - 
60 SI68 PI68 CI3 - - - 
70 - PI68 CI3 - - - 
80 - PI68 CI3 - - - 
90 - - CI6 - - - 
100 - - CI6 - - - 
110 - - CI6 - - - 
120 - - CI6 - - - 
130 - - CI6 - - - 
140 - - CI6 - - - 
150 - - CI6 - - - 












aeruginosa Acinetobacter spp. 
SI PI CI SI PI CI SI PI CI SI PI CI SI PI CI 
10 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI38 PI38 CI6 SI68 PI68 - 
20 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI68 PI68 CI6 SI68 PI68 - 
30 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI68 PI68 CI6 SI68 PI68 - 
40 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI68 PI68 - - PI68 - 
50 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 - PI68 - - - - 
60 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 - - - - - - 
70 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 - - - - - - 
80 SI212 PI212 CI3 SI212 PI212 CI3 SI38 PI212 CI3 - - - - - - 
90 SI212 PI212 CI3 SI38 PI212 CI3 SI38 PI212 CI3 - - - - - - 
100 SI212 PI212 CI3 SI38 PI38 CI3 SI38 PI38 CI3 - - - - - - 
110 SI38 PI212 CI3 SI38 PI38 CI3 SI38 PI38 CI3 - - - - - - 
120 SI38 PI212 CI3 SI38 PI38 CI3 SI38 PI38 CI3 - - - - - - 
130 SI38 PI38 CI3 SI38 PI38 CI3 SI38 PI38 CI3 - - - - - - 
140 SI38 PI38 CI3 SI38 PI38 CI3 SI38 PI38 CI3 - - - - - - 
150 SI38 PI38 CI3 SI68 PI38 CI3 SI68 PI38 CI3 - - - - - - 




MIC distribution of isolates 
belonging to S category6 
MIC distribution of isolates 









SI PI CI SI PI CI SI PI CI SI PI CI 
10 SI212 PI212 CI3 SI212 PI212 CI3 SI68 PI38 CI6 SI68 PI38 CI6 
20 SI212 PI212 CI3 SI212 PI212 CI3 SI68 PI68 CI6 SI68 PI68 CI6 
30 SI212 PI212 CI3 SI38 PI212 CI3 - PI68 CI6 SI68 PI68 CI6 
40 SI38 PI212 CI3 SI38 PI38 CI3 - PI68 - - PI68 - 
50 SI38 PI38 CI3 SI38 PI38 CI3 - - - - - - 
60 SI38 PI38 CI3 SI38 PI38 CI3 - - - - - - 
70 SI38 PI38 CI3 SI68 PI38 CI3 - - - - - - 
80 SI68 PI38 CI3 SI68 PI38 CI3 - - - - - - 
90 SI68 PI38 CI3 - PI68 CI3 - - - - - - 
100 - PI68 CI3 - PI68 CI3 - - - - - - 
110 - PI68 CI3 - PI68 CI3 - - - - - - 
120 - PI68 CI3 - - CI3 - - - - - - 
130 - - CI3 - - CI3 - - - - - - 
140 - - CI3 - - CI6 - - - - - - 
150 - - CI3 - - CI6 - - - - - - 






















Table 3.10 [continued].  
 




0.004 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 
SI PI CI SI PI CI SI PI CI SI PI CI SI PI CI SI PI CI SI PI CI SI PI CI SI PI CI SI PI CI SI PI CI SI PI CI 
10 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI38 PI38 CI3 SI68 PI68 CI6 
20 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI38 PI38 CI3 SI38 PI38 CI6 SI68 PI68 - 
30 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI38 PI212 CI3 SI38 PI38 CI3 SI68 PI38 CI6 - PI68 - 
40 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI38 PI38 CI3 SI38 PI38 CI3 SI68 PI68 CI6 - - - 
50 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI38 PI212 CI3 SI38 PI38 CI3 SI68 PI38 CI3 - PI68 CI6 - - - 
60 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI38 PI212 CI3 SI38 PI38 CI3 SI38 PI38 CI3 SI68 PI68 CI3 - - CI6 - - - 
70 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI38 PI212 CI3 SI38 PI38 CI3 SI38 PI38 CI3 SI68 PI38 CI3 - PI68 CI3 - - CI6 - - - 
80 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI38 PI212 CI3 SI38 PI38 CI3 SI38 PI38 CI3 SI68 PI38 CI3 - PI68 CI3 - - CI6 - - - 
90 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI38 PI212 CI3 SI38 PI38 CI3 SI38 PI38 CI3 SI68 PI38 CI3 - PI68 CI3 - - CI6 - - - - - - 
100 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI38 PI212 CI3 SI38 PI212 CI3 SI38 PI38 CI3 SI38 PI38 CI3 SI68 PI38 CI3 - PI68 CI3 - - CI6 - - - - - - 
110 SI212 PI212 CI3 SI212 PI212 CI3 SI212 PI212 CI3 SI38 PI212 CI3 SI38 PI38 CI3 SI38 PI38 CI3 SI68 PI38 CI3 - PI68 CI3 - - CI3 - - CI6 - - - - - - 
120 SI212 PI212 CI3 SI212 PI212 CI3 SI38 PI212 CI3 SI38 PI38 CI3 SI38 PI38 CI3 SI38 PI38 CI3 SI68 PI38 CI3 - PI68 CI3 - - CI3 - - CI6 - - - - - - 
130 SI212 PI212 CI3 SI38 PI212 CI3 SI38 PI212 CI3 SI38 PI38 CI3 SI38 PI38 CI3 SI68 PI38 CI3 - PI38 CI3 - PI68 CI3 - - CI3 - - CI6 - - - - - - 
140 SI212 PI212 CI3 SI38 PI212 CI3 SI38 PI212 CI3 SI38 PI38 CI3 SI38 PI38 CI3 SI68 PI38 CI3 - PI38 CI3 - PI68 CI3 - - CI3 - - CI6 - - - - - - 
150 SI38 PI212 CI3 SI38 PI212 CI3 SI38 PI38 CI3 SI38 PI38 CI3 SI38 PI38 CI3 SI68 PI38 CI3 - PI68 CI3 - - CI3 - - CI3 - - CI6 - - - - - - 
≥154 SI38 PI212 CI3 SI38 PI212 CI3 SI38 PI38 CI3 SI38 PI38 CI3 SI38 PI38 CI3 - PI38 CI3 - PI68 CI3 - - CI3 - - CI3 - - CI6 - - - - - - 
 
1The algorithm is currently intended for clinical research and needs further validation in future clinical studies. 2Lowest possible dosing regimen for which the 5th percentile of the 1000 Monte 
Carlo simulations considering PK parameter uncertainty, achieved CFR≥90% (for Level 2, Level 3(-MIC)) or PTA≥90% (for Level 1, Level 3(+MIC)). For SI and PI the PK/PD target 98%T>MIC 
was evaluated, for CI 98%T>4xMIC. 3For first day of treatment: Daily dose of 3412.5 mg incl. loading dose. 4For first day of treatment: Daily dose of 6875 mg incl. loading dose. 5Body weight 
and serum albumin concentration fixed to median of first study day (i.e. 70 kg and 2.8 g/dL). 6EUCAST MIC distribution [132].  
Dosing regimens: SI212: 1000 mg, 30-min i.v. infusion, q12h; SI38: 1000 mg, 30-min i.v. infusion, q8h (=standard dosing; highlighted in bold); SI68: 2000 mg, 30-min i.v. infusion, q8h; PI212: 
1000 mg, 3-h i.v. infusion, q12h; PI38: 1000 mg, 3-h i.v. infusion, q8h; PI68: 2000 mg, 3-h i.v. infusion, q8h; CI3: 3000 mg, CI, q24h following 500 mg, 30-min loading dose; CI6: 6000 mg, 
CI, q24h following 1000 mg, 30-min loading dose. For CI regimens (CI3, CI6) consider to renew the infusion solution dependent on the drug concentration twice or thrice daily (see supplement 
of [380]) to ensure the stability of meropenem.   
Abbreviations: CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]; CFR: Cumulative fraction of response; CI: Continuous infusion; EUCAST: European Committee 
on Antimicrobial Susceptibility Testing; h: Hours; I category: Category ‘susceptible at increased exposure [4]; MIC: Minimum inhibitory concentration; min: Minutes; PI: Prolonged infusion; 
PTA: Probability of target attainment; S category: Category ‘susceptible at normal dosing’ [4]; SI: Short-term infusion; q8h: Every 8 hours; q12h: Every 12 hours; q24h: Every 24 hours; T>MIC: 





By employing pharmacometric modelling and simulation approaches, the present thesis provided 
an enhanced quantitative understanding of the PK of selected antibiotic drugs (linezolid, 
meropenem) in special patient populations (obese surgical, critically ill). The identification of 
patient-specific characteristics, influencing the PK and subsequently the attainment of effective 
drug exposure, enabled the identification of patients at risk for therapy failure with the standard 
antibiotic dosing regimen and allowed suggestions of optimised dosing regimens for the ‘patients 
at risk’. Translating the results gained from the pharmacometric analyses into easy-to-use tools, 
this thesis provided a strategy to make the research results applicable in the clinics which shall 
ultimately support future therapeutic decisions. In addition, the thesis contributed to a better 
characterisation of the variability in the microdialysis sampling technique, as the method of choice 
to determine unbound (i.e. pharmacologically active) drug concentrations directly at the target site. 
Research questions, research categories and key results of the present thesis are graphically 
summarised in Figure 4.1 and will be further discussed in the following sections, also in the light 
of currently available knowledge from scientific literature.  
 Leveraging pharmacometric approaches to characterise linezolid 
plasma and target site exposure in obese and nonobese surgical 
patients and to evaluate and optimise dosing (Project I, II)  
Linezolid plasma/target site exposure and dos ing regime ns in obese and nonobese surgical patie nts  
Employing pharmacometric approaches, Project I and II assessed linezolid therapy in obese and 
nonobese surgical patients. While Project I focused on the characterisation of linezolid PK in 
plasma (total and unbound) as well as at the target site (unbound) by means of the development of 
a NLME PK model and the performance of deterministic exposure simulations (research category: 
basic research; Figure 4.1), Project II utilised probability of target attainment analyses to evaluate, 




Figure 4.1: Graphical overview of key results, central objectives and research categories of the present thesis.  
The key results of the four research projects are illustrated in form of the key figures/tables around the illustration of the 
objectives and research categories (Figure 1.5). Each figure/table is assigned by the colour of the project header, to one of the 
research categories (green: basic research; light blue: applied research; dark blue: translational research). For each figure/table, 
the section is provided in which the key results are presented and discussed.  
4.1.1 Characterisation of linezolid plasma and target site exposure in obese and 
nonobese surgical patients (Project I) 
Database. The pharmacometric analysis in Project I was based on a solid and unique PK database 
which allowed to, for the first time, characterise not only plasma PK of total (i.e. bound + unbound) 
and unbound linezolid but also target site PK of unbound linezolid, both in obese and nonobese 
patients undergoing abdominal surgery. In contrast to other microdialysis studies that typically 
included around 10 patients [46,48,50,51,252–254], the present study investigated a relatively 
large number of patients (n=30). Furthermore, a rich PK database was available (nsamples>1000), 
collected in plasma and in the ISF of the s.c. adipose tissue using the microdialysis technique. This 
enabled the comparison of linezolid exposure in plasma and s.c. adipose tissue and the 
identification of patient- and surgery-specific clinical determinants. A special characteristic of the 
dataset was the availability of target site PK data that had been collected via two microdialysis 
catheters per patient which were identical in construction and inserted in the s.c. adipose tissue. 
Linezolid plasma/target site exposure and dosing regimens in obese and nonobese surgical patients 
122 
Since additionally calibration was performed twice per catheter, the quantification of different 
variability levels in the microdialysis technique was possible, leading to an improved 
characterisation of the microdialysis sampling technique. The methodology-related aspects will be 
discussed in section 4.2, while the present section (4.1.1) will mainly focus on PK-related aspects. 
NLME modelling approach. In order to provide a better understanding of the results in the 
following, the underlying NLME modelling approach will be shortly discussed, before focusing on 
the PK-related findings of the project. In a systematic stepwise manner, a NLME PK model was 
developed integrating all available PK data, i.e. total plasma concentrations, unbound plasma 
concentrations as well as microdialysate and retroperfusate/-dialysate concentrations collected 
with both microdialysis catheters. By jointly assessing all available PK data, separation and 
quantification of the RUV by sampling matrix and sampling technique was possible, which enabled 
a comparison of the magnitudes of RUV. Overall, RUV was relatively low, with microdialysate 
concentrations (13.3%CV) showing higher RUV than total and unbound plasma concentrations 
(<4.76%CV). This is likely to be related to the complexity in the microdialysis sampling technique 
(for further discussion on variability in technique see section 4.2). However, in contrast to previous 
clinical microdialysis studies, the observed magnitude of RUV related to microdialysate 
concentrations was comparably low (e.g. RUV, %CV: 33.9 [45], 27.0 [45], 20.7 [255], 17.0 [46]). 
To jointly analyse all available PK data (i.e. plasma, micro- and retrodialysis), the advanced 
integrated dialysate-based modelling approach (Section 2.6.4.1) was applied, which was originally 
developed by Tunblad et al. [229], based on animal data and afterwards successfully applied by 
Minichmayr and Schaeftlein et al. at our department for the analysis of clinical microdialysis PK 
data [45,230]. This modelling approach – although more complex (also with respect to the required 
dataset structure; Section 2.6.3.1) and computationally more intensive – was proven superior to the 
often-used basic mid-time approach in terms of the underlying assumptions, being less biased, and 
more informative. The use of this modelling approach further facilitated the assessment of 
variability in the microdialysis technique, as the RR value was estimated within the model and 
different variability levels were assessable and quantifiable by the inclusion of random-effects 
parameters. Also, the microdialysate and retroperfusate/-dialysate data were included into the 
model in a stepwise manner (i.e. in a first step only the data of one catheter per patient were 
implemented, in a second step data of second catheter were added; Figure 3.3). This enabled to 
focus on the development of a suitable structural PK model describing linezolid distribution and 
elimination in the first place, before assessing variability linked to the measurement technique 
itself, i.e. different levels of variability based on the data of both catheters. Of note, dissecting the 
variability in the microdialysis methodology-related parameters (i.e. RR) from the variability in 
the PK parameters (e.g. CL, V2, TF), allowed to consider only the relevant PK variability in 
stochastic exposure simulations which served as basis for the dosing evaluation and optimisation 
in Project II.   
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Protein binding of linezolid. The availability of both total and unbound plasma concentrations 
enabled the assessment of the protein binding of linezolid. In contrast to the protein binding 
reported by the manufacturer (~31% [139]), the protein binding observed in the present clinical 
study was considerably lower (fu=85.6%, i.e. protein binding 14.4%; Section 3.1.2.2). This finding 
supported prior clinical investigations that showed fu values of similar magnitude (fu=88.2% 
[45,256], fu=85% [253], fu=83.1% [257], fu=87.6% [258]). Of note, in all clinical investigations, 
ultrafiltration was used to determine the unbound concentrations; yet, it remains unclear which 
method was used by the manufacturer. Future clinical studies are warranted, investigating and 
substantiating the magnitude of linezolid protein binding, potentially also by comparing different 
methodologies [259,260]. Reliable knowledge on protein binding is crucial, considering that 
published fu values are used to derive unbound linezolid concentrations, in situations in which only 
total concentrations are available [261]. Using the computed unbound linezolid concentrations for 
instance for the assessment of PTA might severely impact or bias the resulting clinical implications. 
The analysis of the unbound linezolid plasma concentrations for low, medium and high drug 
concentrations, revealed no concentration-dependency of the protein binding, which was in 
concordance with the manufacturer’s information [139]. Moreover, the present analysis 
demonstrated similar fu values between obese and nonobese patients, indicating that body size did 
not impact fu, which has been reported for other drugs in obese patients as well [262,263]. Note 
that also on the individual level (i.e. between the 30 investigated patients), the fu values were 
consistent as demonstrated by the negligibly small interindividual variability (0.3%CV).  
In light of the increasing evidence that the plasma protein binding of linezolid in the clinics is 
approximately 14% as well as the low interindividual variability in protein binding, this work 
suggests using a fu value of 86% for future studies in which protein binding has not been 
determined.  
Plasma versus target site: Tissue fluid distribution of linezolid. NLME modelling has been 
proven to be an adequate approach to analyse microdialysis data ([229], Section 2.6.4.1). In 
contrast to exploratory data analyses, NLME modelling facilitates an integration of the 
microdialysate concentration-time profile over the collection interval and thus allows to analyse 
the data without making any assumptions regarding the allocation of the measured microdialysate 
concentration. Accordingly, NLME modelling is a valuable methodology to adequately 
characterise the kinetic behaviour of the drug at the target site. Of the different distribution kinetics 
models assessed for linezolid in the present work (assuming a rapid or delayed distribution; 
Figure 3.3: Target site model), the delayed distribution model was selected, that assigned the s.c. 
adipose tissue ISF to the peripheral compartment of the plasma model. The model included an 
additional parameter, the tissue factor TF, scaling the concentration-time profile in the peripheral 
compartment to the concentration-time profile in the ISF of the s.c. adipose tissue. This model 
structure is supported from a physiological point of view: As also the central compartment, the 
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peripheral compartment can be understood as a ‘lumped compartment’ in which tissues showing 
similar delayed distribution kinetics (i.e. concentration-time profiles in the tissues show similar 
‘shapes’) are lumped together [210,264]. Huisinga and colleagues, for instance, reduced 
physiologically based pharmacokinetic (PBPK) models to low-dimensional compartment models 
by lumping highly perfused tissues such as lung, kidney, liver, spleen to the central compartment 
and by assigning less perfused adipose, bone, skin, or muscle tissues to peripheral compartment(s) 
[210,264]. Thus, the concentration-time profile in the peripheral compartment represents the 
volume-normalised profile of all lumped tissues and the estimated tissue-specific parameter TF 
scales this concentration-time profile to the actual profile in the ISF of the s.c. adipose tissue. 
Moreover, taking into consideration that the ISF concentrations of the s.c. adipose tissue 
determined using the microdialysis method, represent unbound drug concentrations, the remaining 
structural model was defined on the unbound scale as well. This resulted in an even more 
physiologically plausible model, considering that only the unbound concentrations can distribute 
from plasma into tissue [54,265].   
For the studied patient population of obese and nonobese patients undergoing an abdominal 
surgery, the typical TF without stratification was estimated to be 55.6% (Table S4), indicating that 
the typical unbound linezolid concentrations in the ISF of the s.c. adipose tissue were 
approximately half of the typical unbound linezolid concentrations in the lumped peripheral 
compartment. Consequently, interpreting the peripheral compartment as the lumped compartment 
comprising different tissues with similar kinetic behaviour, other tissues may show comparably 
higher linezolid concentrations. For muscle tissue, for instance, previous investigations 
demonstrated a good penetration of linezolid. Schwameis et al. determined an AUC ratio of 0.98 
for unbound linezolid concentrations in muscle tissue (determined using microdialysis) to unbound 
concentrations in plasma, in patients who underwent an elective knee arthroscopy [266]. Similarly, 
Minichmayr et al. demonstrated high distribution of linezolid into muscle tissue in healthy 
volunteers and septic patients (TFplasma → ISF muscle: 98.0%; [256]). While this study revealed high 
tissue penetration also for adipose tissue in the two subpopulations (TFplasma → ISF adipose: 102%), 
diminished linezolid penetration into adipose tissue for an overweight diabetic population was 
indicated (TFplasma → ISF adipose: 74.0%). The high proportion of morbidly obese patients in the present 
study population might explain the reduced linezolid distribution into ISF of s.c. adipose tissue 
observed in the present study. This is also supported by an investigation by Stein et al., that 
identified an even lower mean ratio of 51% between linezolid concentrations in plasma and in the 
s.c. adipose tissue for a diabetic population (mean body weight: 98 kg; [267]). Yet, in that study 
tissue concentrations were determined in homogenised tissue biopsy samples (i.e. homogenised 
ISF, adipocytes, blood vessels), which might have lowered the observed linezolid concentrations, 
given the low accumulation of linezolid in cells [268] i.e. adipocytes.   
Overall, in contrast to other antiinfective drugs for which target site exposure has been shown to 
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be similar to plasma exposure [269,270], linezolid target site exposure in obese and nonobese 
patients was found to be considerably lower than linezolid exposure in plasma and the distribution 
of linezolid from plasma to target site was delayed.  
Obese versus nonobese: Impact of body size on linezolid PK. The covariate analysis revealed 
that linezolid tissue fluid distribution was impaired by the obesity status of the patient, with obese 
patients tending to show lower magnitudes of linezolid concentrations in the ISF of the s.c. adipose 
tissue than nonobese patients. In the NLME model this was captured by a considerably lower TF 
for obese patients (~54% vs. 69% for nonobese patients; Table 3.2). This appears plausible, 
considering that obese patients typically show a reduced peripheral perfusion of the s.c. adipose 
tissue, as the density of capillary vessels decreases with increasing mass of adipose tissue [90,271]. 
In line with the findings of previous investigations of linezolid PK in obese patients [257,272], the 
comprehensive stepwise covariate analysis further demonstrated an impact of body size on both 
volume of distribution parameters (i.e. V1 and V2) as well as on the intercompartmental exchange 
between the central and the peripheral compartment (i.e. Q). More concretely, LBW was identified 
as most appropriate predictor, implemented according to the principle of allometry [204]. The 
adequacy of LBW as size descriptor was verified by a mechanistic implementation of body size 
into the NLME model proposed by Huisinga et al. [210] and Holford et al. [204] (Eq. 2.37, 
Eq. 2.38, respectively). This approach aims to define appropriate body size descriptors based on 
the available information on drug PK and body size of the patient. Concretely, within the NLME 
model, the body size descriptor impacting a specific PK parameter is defined as a composition of 
LBW and FM and the proportions of the two measures are estimated. This body size descriptor is 
drug-specific and also PK parameter-specific, i.e. the physicochemical properties of the drug 
impact the proportions as well as the type of PK parameter (biological structure parameter (e.g. V) 
or function parameter (e.g. CL) [204]). In the present analyses, for none of the investigated 
linezolid PK parameters this estimated body size descriptor was superior to LBW alone, suggesting 
LBW as an appropriate body size descriptor to scale the PK parameters of linezolid. This was 
supported by the marked reduction in the interindividual variability of the respective PK 
parameters, e.g. in the final NLME model interindividual variability in V2 was reduced by ~70% 
compared to the base model (Section 3.1.2.2). The magnitude of the volume of distribution (when 
transformed from the unbound to the total linezolid concentration scale) of 45.7 L (for a typical 
male subject: WT=70 kg, LBW=55 kg, HT=1.75 m [273]) was in line with prior clinical 
investigations (e.g. V=46 L/45.4 L after single/multiple i.v. dosing of 625 mg linezolid in healthy 
adults [274], V=42.6 L after multiple p.o. and i.v. dosing of 600 mg q12h, for WT=69.5 kg [256]). 
Given the identified LBW-PK parameter relationships, on the exposure level, LBW mainly 
impacted the maximum linezolid concentrations and the concentrations in the early declining phase 
of the concentration-time profile in such a way, that higher LBW resulted in lower linezolid 
concentrations and a steeper initial decline (Figure 3.6). Yet, the impact of LBW on the terminal 
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concentrations was less pronounced and the relationship inverse, i.e. higher LBW resulted in higher 
terminal linezolid concentrations. This observation can be explained by the increase in half-life of 
linezolid resulting from the increase in both volumes of distribution as consequence of the increase 
in LBW.   
Of note, for linezolid clearance no impact of body size was detectable, but rather the opposite was 
observed: The inclusion of any body size descriptor reduced the model predictivity and increased 
the variability in linezolid clearance (Appendix Table S6). From the perspective of allometry, an 
increase in clearance would have been expected for obese patients, when assuming an increase in 
the size of eliminating organs and an increased renal blood flow associated with obesity [90]. 
However, comorbidities in the obese patients (e.g. diabetic nephropathy) might have also led to an 
opposite impact, i.e. resulting in a reduced excretion of linezolid in obese patients [90], which has 
already been indicated by Minichmayr et al. who detected a lower linezolid clearance in a diabetic 
subpopulation compared to healthy volunteers and other patient groups (septic patients, cystic 
fibrosis patients [256]). On the basis of the present dataset, a first analysis assessed a combined 
impact of LBW according to allometric principles with an empirical counteractive impact of FM 
on linezolid clearance – an approach which has been suggested by Holford et al. [204,275] 
(Appendix Table S5: Steps 4I and 4J). This approach assumed a decrease in linezolid clearance 
with increasing FM; yet, did not improve model predictivity. It needs to be kept in mind that this 
approach is limited in such a way that it assumes a direct link between FM and the occurrence of 
comorbidities reducing the excretion of linezolid, which may not necessarily hold true. Future 
investigations, focusing on the evaluation of comorbidities of the patients, might allow to 
adequately capture both impact factors and relationships and might help to better understand the 
impact of obesity on linezolid clearance.  
Linezolid clearance. On the basis of clinical linezolid PK data, different empirical clearance 
models have been described before. The clearance models published, cover linear [261,276–
284,266,285,286,257,287–289] and nonlinear clearance models, the latter depending on linezolid 
concentrations (Michaelis Menten [290,248,291–293]) or on linezolid concentration and 
additionally on time of treatment (empirical inhibition compartment [45,146,272,294]). The variety 
of detected clearance models is likely to be explained by the differences in the underlying datasets 
which might (not) have supported the identification of nonlinearity models (e.g. due to richness of 
data in terminal phase of the concentration-time profile, data on single/multiple dosing). 
Additionally, not all authors even investigated nonlinear clearance models and might thus have 
missed to detect a potential nonlinearity in linezolid elimination. In the present work, the 
exploratory graphical data analysis already demonstrated an increase in the steepness of the decline 
in the terminal phase of the linezolid plasma concentration-time profile (Figure 3.2 B), which 
provided strong evidence for a nonlinearity in linezolid clearance. Considering that this observed 
nonlinearity tended to occur at similar concentrations in the individual concentration-time profiles 
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but, at the same time, at the end of the anaesthesia, two possibly adequate clearance models were 
identified. In line with previously published models for linezolid [290,248,291,292], one of the two 
models comprised a parallel linear and nonlinear Michaelis Menten implementation of clearance, 
i.e. one proportion of the clearance was considered constant, the other proportion changed 
depending on the linezolid concentration. In the second model, linezolid clearance was independent 
of linezolid concentrations but was impacted by the anaesthesia status of the patient: While a 
reduced and constant clearance was assumed in the intra-anaesthetic period, an increase of 
clearance according to an Emax model was identified after the end of anaesthesia. Of note, also 
additional described nonlinearity models for linezolid clearance were assessed based on the plasma 
data, however, were found to be clearly inferior (Michaelis Menten model) to the two favourite 
clearance models described above or not supported by the available single dose data (empirical 
inhibition compartment, Appendix Figure S14, which should be considered for long-term 
microdialysis data).  
Anaesthesia has previously been discussed to impact drug metabolism and excretion by altering 
the drug transport to eliminating organs or by impacting enzymes involved in drug metabolism 
[97,98]. More precisely, anaesthesia-related haemodynamic changes such as decrease in cardiac 
output, heart rate and blood pressure, might lead to a reduced blood flow into the periphery and to 
vital organs, which again results in a reduced transport of drugs to the eliminating organs (e.g. liver 
and kidney) and thus a reduced elimination [98]. Furthermore, during anaesthesia the delivery of 
oxygen to the organs may be reduced, considering the impaired organ blood flow and impaired 
capacity of the blood to carry oxygen [98,295]. As Phase I enzymes, especially the ones involved 
in oxidative metabolic processes are susceptible to small changes in oxygen tensions, reduced 
hepatic oxygen delivery might also hamper drug metabolism [295]. Also, mitochondrial function 
has been described as susceptible to mild hypoxic changes. Considering these discussions about 
the impact of anaesthesia on drug metabolism and excretion, and given the improved model 
predictivity after implementing its impact on model parameters, it seems likely that linezolid 
elimination was altered by anaesthesia in the present study. Firstly, as linezolid is partly excreted 
as parent substance via the urine, the relatively low median MAP observed in the present patient 
population during anaesthesia might have led to a reduced intra-anaesthetic renal excretion of 
linezolid (median MAP intra-anaesthetic 72.7 mmHg; Table 3.1), [144]. As an example, for 
cefazolin, an antibiotic drug which is largely excreted via the kidneys, a reduction in clearance by 
nearly 50% during surgery was demonstrated when compared with pre- and post-surgery clearance 
[296]. Secondly, it also appears likely that the nonrenal clearance of linezolid via oxidation was 
reduced by anaesthesia-related changes in metabolism and excretion. Nevertheless, to formulate 
hypotheses on the potential impact of anaesthesia on the nonrenal pathway of linezolid, future in 
vitro studies are needed to better understand and characterise the metabolism pathways of linezolid. 
Integrating all available information in the assessment of an adequate nonlinearity model for 
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linezolid elimination in the present surgical patient population, a combination of the previously 
described parallel linear and nonlinear Michaelis Menten model including an additional impact of 
anaesthesia was most suitable. In order to achieve this, the parallel linear and nonlinear Michalis 
Menten model was implemented in the structural base model and a subsequent covariate analysis 
in the NLME model allowed to describe and quantify the additional impact of anaesthesia. Besides 
the anaesthesia status also haemodynamic markers (e.g. heart rate, MAP, estimated CO) were 
assessed as potential impact factors on linezolid clearance. The final NLME model included in 
addition to the parallel linear and nonlinear Michaelis Menten clearance, the longitudinally 
monitored marker MAP as determinant of total linezolid clearance, which – in comparison to the 
binary marker anaesthesia status – contained time-varying information on the haemodynamic 
changes. The implementation of MAP on the total linezolid clearance indicated that both the linear 
and the nonlinear clearance of linezolid were impacted by hamedoynamic changes. Unexplained 
interindividual variability in the clearance-related parameter (i.e. CL and Km), considerably 
reduced in the final NLME model including the covariates compared to the base NLME model 
(IIVVar: CL -50.5%, Km: -39.9%; Section 3.1.2.2).   
As discussed in the section above, the impact of different body size descriptors on linezolid 
clearance was comprehensively investigated during covariate model development as well; yet, no 
relationship was identifiable. Nevertheless, given the MAP-linezolid CL relationship, obese 
patients tended to show slightly higher CL values, due to their higher MAP values (median MAP: 
76.7 vs. 72.5 mmHg for obese and nonobese patient, respectively; Table 3.1). Altered 
haemodynamics have been described for obese patients in literature before [91]: For instance, a 
recent study that compared haemodynamic patterns in obese and nonobese patients, demonstrated 
increased magnitudes of haemodynamic markers in the obese population (normal weight/obesity: 
mean systolic arterial pressure 133/142 mmHg, mean CO 5.2/6.7 L/min; [93]). Furthermore, in the 
present analysis no relationship between CLCRCG and linezolid CL was detected, although 
previous clinical PK studies suggested the renal function marker as determinant of linezolid CL 
[45,276,278,279,281,248,297]. In this context Minichmayr et al. pointed out, that the clinical PK 
studies which identified a significant relationship between CLCRCG and linezolid clearance, were 
almost exclusively based on multiple dosing data [256]. The availability of solely single dose data 
– as it was the case in the present study - might hinder the detection of the relationship [256]. 
Moreover, the observed distribution of CLCRCG in the present population (covering moderately 
impaired up to normal renal function; 90%CI: 38.0-105 mL/min) might have additionally hindered 
the detection of a significant impact of CLCRCG on clearance.   
In the final NLME PK model the unexplained variability in the clearance parameters was 
considerably reduced compared to the base model (IIVVar CL and Km: -50.5% and -38.9%, 
respectively). Despite the relatively high degree of complexity in the linezolid clearance model, 
jointly describing the concentration dependency in clearance and the impact of the haemodynamic 
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changes, the respective parameters were still precisely estimated. Only for the random-effects 
parameter IIV on the Michaelis Menten constant Km, the bootstrap indicated a high upper limit of 
the confidence interval. This indicated that in some bootstrap samples, mainly patients with 
extreme Km values were sampled, i.e. patients in whom nonlinear clearance was less relevant at 
clinically observed linezolid concentrations (i.e. patients that showed only two phases in declining 
phase of the concentration-time profile; Figure 3.2 B2) or patients in whom nonlinear clearance 
became already relevant at very low linezolid concentrations (i.e. patients with an additional third 
steeper phase; Figure 3.2 B2). Moreover, this finding is not surprising considering the limited 
number of patients (i.e. sample size) underlying the non-parametric bootstrap and keeping in mind 
that the estimation of a Michaelis Menten model purely based on clinical PK data can oftentimes 
be challenging [298–300]. The inclusion of a higher number of patients would allow to further 
inform and thus more precisely estimate the variability in the Km parameter [299].  
The average total clearance of linezolid (7.80 L/h) which was derived based on integration of the 
observed linezolid clearance-time profiles and transformation from the unbound to the total 
concentration scale, was of similar magnitude as total clearance values previously described for 
linezolid in overweight/obese populations (e.g. 7.80 L/h [257], 6.11-8.24 L/h [290], 9.98 L/h 
[285]). In the developed model, the linear linezolid clearance (2.84 L/h on total scale, Table 3.2) 
accounted for approximately 36% of the total linezolid clearance. It is notable that this percentage 
corresponds to what is described for renal clearance (35%). This suggests that the linear clearance 
might reflect the renal clearance pathway of linezolid. Under this assumption, the nonlinear 
clearance would consequently reflect the nonrenal elimination of linezolid, i.e. the metabolism via 
oxidation mechanisms. Yet, future in vitro investigations should be performed to better characterise 
the metabolic pathways, to interpret and verify the plausibility of the nonlinear clearance according 
to the Michaelis Menten, which suggests a saturable process involved in the linezolid elimination. 
Intra- versus post-anaesthetic: Impact of anaesthesia on linezolid PK. In addition to the impact 
of MAP as a marker for anaesthesia-related haemodynamic changes (see section above), the 
present analysis revealed an influence of anaesthesia on the tissue fluid distribution of linezolid. 
This was already indicated by the base model including plasma and micro-/retrodialysis data, 
which tended to overestimate the microdialysate concentrations in the intra-anaesthetic period and 
to underestimate the microdialysate concentrations in the post-anaesthetic period as depicted by 
the undulating pattern in the CWRES versus time plot (Appendix Figure S19 A.1). The inclusion 
of the anaesthesia status as a covariate on the TF parameter considerably improved the model 
predictivity (Appendix Figure S19 A.1) and reduced the interindividual variability in the TF by 
more than half. The TF was 13.6% lower in the intra-anaesthetic period compared to the post-
anaesthetic period, which indicated a reduced distribution of linezolid into the ISF of the s.c. 
adipose tissue during anaesthesia. From a physiological point of view this appears plausible, 
considering the reduced blood flow to the periphery caused by anaesthesia, which was already 
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discussed in more detail above. Keeping in mind that the tissue distribution has been quantified 
based on intra- and post-anaesthetic linezolid PK data, future clinical studies are warranted that in 
addition to the intra- and post-anaesthetic data also determine pre-anaesthetic linezolid PK data in 
obese and non-obese patients. Similar tissue distribution in the pre- and post-anaesthetic period 
would even broaden the applicability of the developed NLME model towards translation of the PK 
to the non-surgical setting.   
Conclusion and perspectives. Based on the unique dataset comprising total and unbound plasma 
linezolid concentration and target site concentration data of linezolid originating from obese and 
nonobese surgical patients, for the first time a joint NLME model was developed simultaneously 
describing PK- and microdialysis methodology-related aspects, plasma (total and unbound 
linezolid concentration) and target site PK as well as the impact of body size and anaesthesia on 
the PK of linezolid. This novel model improves the understanding of the PK of linezolid in obese 
and nonobese surgical patients:  
• Firstly, target site exposure of linezolid was found to be considerably lower than in plasma 
and the distribution of linezolid from plasma to target site delayed.  
• Secondly, LBW, which was generally higher for obese patients, was identified as a vital 
determinant for the PK of linezolid. On top of that, an additional effect of obesity on tissue 
fluid distribution was observed, i.e. an effect not directly linked to body mass, but likely to 
be a surrogate for other not available covariates. Both impacts resulted in a lower linezolid 
exposure in obese patients compared to nonobese patients, which was particularly 
pronounced at the target site.  
• Thirdly, an impact of anaesthesia and the related haemodynamic changes on linezolid 
clearance and tissue fluid distribution was detected and quantified, with reduced linezolid 
clearance and tissue fluid distribution during the intra-anaesthetic period.  
Future studies are warranted that assess whether the observed PK characteristics and influential 
factors determined in the present non-ICU population also hold true for special patient populations 
such as critically ill patients, for which linezolid plays a vital role in the treatment of severe 
infections. In light of the known haemodynamic variations in ICU patients, for instance due to 
pathophysiological causes (e.g. sepsis [103]), sedation therapy [301]), a reassessment of the finding 
of the present work may also be of value for the ICU population. Furthermore, the development of 
similar types of NLME models and/or even combined NLME models based on the PK data 
available for the additional drugs investigated in the clinical study [226] might help to further 
characterise the impact of obesity and anaesthesia on the drug PK and to identify drug-specific 
differences. For this purpose, the proposed NLME model development strategy (Section 2.6.4.2; 
including the implementation of different levels of microdialysis methodology-related variability, 
the mechanistic implementation of body size as covariate etc.) forms a versatile basis. 
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4.1.2 Evaluation and optimisation of linezolid dosing in obese and nonobese 
surgical patients (Project II) 
The NLME PK model of linezolid developed in Project I enabled the evaluation and optimisation 
of linezolid dosing in obese and nonobese surgical patients by the use of PTA analyses (Project II). 
A first application of the model focused on the evaluation of the adequacy of standard linezolid 
dosing for perioperative infection prophylaxis in abdominal surgery, which corresponds to the 
study design on which the developed NLME PK model was based. In a second step, the model was 
used to extrapolate to the treatment of an acute infection, i.e. a clinically more frequently observed 
setting.  
Selection of PK/PD target for infection prophylaxis. PK/PD target values for linezolid have been 
derived based on acute infection therapy [149–152], but no targets exist for infection prophylaxis. 
Yet, different national and international guidelines on perioperative antibiotic prophylaxis 
highlight the importance of adequate antibiotic exposure in the surgical area (i.e. the target site) 
during the period of potential contamination, i.e. from the time of incision until the time of suture 
[302–304]. The ‘Clinical practice guidelines for antimicrobial prophylaxis in surgery’ from the 
American Society of Health-System Pharmacists (ASHP) further specifies that the drug 
concentrations in serum and tissue should exceed the MIC of a probable pathogen associated with 
the surgery during the duration of the surgical intervention [303]. According to these 
recommendations, a strict PK/PD target of 100%fT>MIC for evaluation of antibiotic target site 
exposure is deemed reasonable in order to assess the adequacy of antibiotic dosing in the setting of 
perioperative infection prophylaxis. This was deemed reasonable considering that even the 
available T>MIC targets for linezolid treatment of acute infections, which were notably determined 
based on plasma PK data, were of similar magnitude (e.g. fT>MIC 100% [149]; Section 1.4.2.1 
PK/PD targets). Considering the observed delayed distribution of linezolid to target site (i.e. ISF 
of the s.c. adipose tissue; Section 3.1.3), the target 95%fT>MIC was selected, in order to allow 
classifying patients that achieved the target MIC during nearly the full incision-suture duration 
(e.g. 99.0%) as ‘effectively treated’ rather than ‘ineffectively treated’. Three different incision-
suture durations of 2 h, 4 h, and 6 h were selected for PTA evaluation, capturing the time periods 
observed in the present study (P0.05-P0.95: 2.38-3.57) as well as typical time periods of bariatric 
surgery, generally not exceeding 4 h [255,305]. As mentioned above, adequate antibiotic exposure 
is recommended with respect to MIC values of pathogens which are likely to be associated with 
the surgery type [303]. The pathogens that are reported to most frequently cause postoperative 
wound infections in bariatric surgeries are S. aureus, Enterococcus spp. and α-haemolytic 
Streptococcus spp. [306,307]. Based on the information on the MIC distributions of these 
pathogens, the MIC values of 4 mg/L and 2 mg/L were selected, representing EUCAST MIC R 
and S breakpoints of the respective pathogens (R/S [mg/L]: S. aureus 4/4, Enterococcus spp. 4/4, 
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Streptococcus spp. 2/4 [5]). For comparison also two more susceptible MIC values were selected 
(1 mg/L and 0.5 mg/L).  
PTA analysis for infection prophylaxis. Although linezolid is not frequently used for infection 
prophylaxis in clinical routine, the PTA analysis in obese surgical patients was deemed valuable 
considering the following aspects which are also emphasised in current guidelines on perioperative 
infection prophylaxis [303]: First, in the setting of preoperative infection prophylaxis, the obese 
patient population is regarded as a highly vulnerable patient group, considering the increased 
incidence of postoperative wound infections and at the same time the associated severity of these 
complications. Secondly, PK information on antibiotic target site exposure is limited for the obese 
surgical population and the suitability of standard antibiotic dosing remains unclear. The NLME 
PK model for plasma and target site (Section 3.1.2.2), together with the PK/PD targets elucidated 
above, enabled the assessment of linezolid exposure directly at the surgical site at risk of potential 
contamination (i.e. target site) in obese and nonobese patients undergoing abdominal surgery. For 
the typical obese and nonobese patient of the present patient population, the PTA analysis 
suggested that a single standard linezolid dose is likely to result in effective target site exposure 
(i.e. PTA≥90%) for pathogens with MIC up to 1 mg/L for incision-suture durations up to 6 h. 
However, for pathogens with a MIC value of 2 mg/L only in case of short incision-suture durations 
(up 2 h and 4 h for typical obese and nonobese typical patient) effective exposure was reached; for 
a MIC value of 4 mg/L, for none of the incision-suture durations standard linezolid dosing seemed 
effective (Table 3.3). Given that bariatric surgeries are typically of rather short duration (<4 h 
[255,305]), for MIC values up to 2 mg/L standard linezolid dosing for infection prophylaxis is 
relatively likely to result in a sufficient prophylactic effect in a typical obese patient undergoing 
bariatric surgery. Thus, for S. aureus which is reportedly the most frequent pathogen for surgical 
site infections in bariatric surgeries [303,307], the methicillin-sensitive isolates (MSSA) are likely 
to be covered, but not the methicillin-resistant isolates (MRSA) (MIC90: 2 mg/L and 4 mg/L, 
respectively; derived based on EUCAST MIC distributions [132]).  
Comparing the PTA for obese and nonobese patients, the typical obese patient was found to show 
lower PTA values than the typical nonobese patients. It needs to be kept in mind that the 
simulations focused on the two typical study patients who did not solely differ in body size, but 
also in their haemodynamic patterns, with the typical obese patient showing slightly higher MAP 
values than the typical nonobese patient (median MAPintra-anaesthetic: 71.7 vs. 66.7 mmHg, 
respectively; Table 2.4). Despite the positive relation between MAP and the total clearance of 
linezolid, the impact of the MAP on the PTA at the target site, however, is likely to be low, 
considering that the exposure simulations for different MAP values showed only little impact on 
the declining phase of concentration-time profile at the target site (Figure 3.5 C).  
To better characterise the sole impact of body size on the attainment of effective linezolid exposure 
at the target site, PTA analyses were performed for varying body size (i.e. varying values of the 
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identified covariate LBW), but constant MAP. The analysis indicated a decline in the PTA with 
increasing body size of the patient. This can be explained by the implementation of LBW and 
obesity in the NLME model (Section 3.1.2.2): (i) an increase in LBW resulted in an increase in the 
volume of distribution which led to decline in linezolid concentrations especially in the maximum 
and the early declining phase of the linezolid concentration-time; (ii) the presence of obesity further 
reduced the exposure at the target site by its impact on the TF profile (Figure 3.6 B). Consequently, 
linezolid target site exposure was lower in obese than in nonobese patients at the time points of 
interest (2/4/6 h after start of incision, i.e. 2.5/4.5/6.5 h after start of linezolid infusion; Figure 3.7). 
The overall conclusions with respect to adequacy of standard linezolid dosing in the setting of 
infection prophylaxis were similar as for the typical obese and nonobese patients: While for 
susceptible MIC values up to 1 mg/L dosing seemed effective, for a MIC value of 4 mg/L dosing 
seemed ineffective across the full LBW range. For the MIC value of 2 mg/L, only for the short 
incision-suture durations and low LBW values, standard dosing was likely to show effective 
antibiotic exposure.  
Conclusion and perspectives for infection prophylaxis. For the study drug linezolid, the present 
analysis indicated that single standard linezolid dosing for perioperative infection prophylaxis is 
likely to show effective antibiotic exposure for a prophylactic effect in obese patients undergoing 
bariatric surgery, in case of infecting susceptible pathogens. Yet, if aiming at prophylactically 
covering pathogens with reduced susceptibility, intensified dosing might be required to reliably 
attain effective exposure at the target site.   
In line with the recommendations by different national and international guidelines on 
perioperative antibiotic prophylaxis, the present PTA analysis was based on the PK/PD index T>MIC 
(target 95%fT>MIC). The PK/PD index AUC/MIC, which has been suggested for linezolid before 
based on data of acute infection therapy, was not deemed adequate for the setting of infection 
prophylaxis. Future research on target site specific PK/PD targets for infection prophylaxis is 
highly warranted. In this regard, complementary to clinical investigations, in silico investigations 
– as has been proposed for acute infection therapy by Minichmayr et al [256] – could provide a 
valuable approach: The developed NLME PK model could be linked to a semi-mechanistic PD 
model describing the bacterial growth/death of a relevant pathogen (e.g. S. aureus) resulting from 
linezolid target site exposure, which could ultimately be used to simulate dose fractionating studies 
in order to derive target site specific PK/PD targets [256].  
Furthermore, based on the developed NLME PK model a next simulation study could focus on 
assessing the impact of haemodynamic changes during surgery on the linezolid PK and the 
respective impact on the PTA at the target site. Additional simulation studies could assess and 
further optimise the timing of linezolid infusion with respect to the incision time. Deterministic 
exposure simulations already indicated that linezolid target site concentrations – even though 
showing a relatively steep initial increase (Figure 3.6 B) – were only reaching the MIC values of 
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interest after 30 min, i.e. the typical time observed between start of antibiotic infusion and surgical 
cut in the present study. Considering the PK variability between the patients (Figure 3.7), an earlier 
initiation of linezolid treatment with respect to incision time might further improve the attainment 
of the PK/PD target in some patients and thus enhance the PTA. Overall, similar PTA analyses are 
warranted for the additional antibiotic drugs which were assessed in the clinical study, especially 
the antibiotics that are more frequently used for perioperative infection prophylaxis (e.g. cefazolin). 
PTA analysis for acute therapy. Keeping in mind that linezolid is rarely used for perioperative 
infection prophylaxis, a second application of the NLME PK model focused on the evaluation of 
linezolid dosing for the clinically highly relevant treatment of acute infection. For this purpose, the 
model was used to predict linezolid concentrations in plasma and at the target site following 
multiple standard linezolid dosing in the initial phase of treatment, i.e. the first 24 h. Because a 
large amount of PK data underlying the model development was collected during intra-anaesthetic 
period, all PTA analyses for the acute therapy were performed for intra-anaesthetic patients, which 
could represent patients in medically induced coma as frequently encountered at the ICU [308]. As 
for infection prophylaxis, the PK/PD target 95%fT>MIC was selected, which is in line with 
previously derived T>MIC targets for linezolid treatment (e.g. fT>MIC 100% [149]; Section 1.4.2.1 
PK/PD targets). Again, the PTA was assessed for linezolid exposure in the ISF of the s.c. adipose 
tissue, representing a potential target site of a skin and soft tissue infection [132]. In addition to 
target site assessment, the PTA was analysed for plasma in order to evaluate the adequacy of 
linezolid standard dosing to prevent a spread of the pathogen from the site of infection via the blood 
circulation. Note that in contrast to the infection prophylaxis, in which the attainment of the PK/PD 
target was assessed for a short time period (i.e. incision-suture duration), in acute infection therapy, 
target attainment was evaluated over the full 24 h.  
Overall, the results of the PTA analysis suggested that standard linezolid dosing is likely to result 
in ineffective exposure (i.e. PTA<90%) at the target site and even also in plasma for most of the 
investigated pathogen-patient combinations (Figure 3.9). In plasma, standard linezolid dosing 
achieved effective exposure (i.e. PTA≥90%) only for the lowest investigated MIC value (0.5 mg/L) 
in combination with a higher LBW value (>35 kg). Similar results were obtained by Minichmayr 
et al., who investigated the PTA for standard linezolid dosing in plasma and in the ISF of s.c. 
adipose tissue for a septic population with varying renal function, yet for the AUC/MIC index in 
plasma [45,256]: For a CLCRCG value of 63.8 mL/min, which is in line with the median renal 
function in the present population (Table 3.1), Minichmayr et al. demonstrated adequate PTA only 
for MIC values ≤0.25 mg/L and ≤1 mg/L in ISF and plasma, respectively. Furthermore, a recent 
clinical investigation by Cojutti et al. focused on the assessment of linezolid dosing in an 
overweight/obese population, however, based on plasma PK data only and using the AUC/MIC 
index [290]: For standard linezolid dosing all investigated patient groups reliably attained the 
PK/PD target only for a MIC of 0.5 mg/L. Taken together, the findings of the previous 
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investigations and the present work suggest that standard linezolid dosing is only effective in highly 
susceptible pathogens, especially when aiming to target pathogens located in the ISF of the s.c. 
adipose tissue.   
In view of these findings, seven alternative dosing regimens with intensified doses and/or 
prolonged infusion duration and/or shortened dosing interval were assessed (Table 2.5). In 
particular the increase of the linezolid daily dose by 1.5- to 2-fold was found to enhance the PTA 
(Section 3.2.2.1). Although assessing intensified linezolid doses which were up to twice as high as 
the approved linezolid dose (e.g. 2400 mg per day), effective exposure (i.e. PTA≥90%) for the full 
LBW range was only attained for MIC values up to 2 mg/L or 1 mg/L for plasma and ISF, 
respectively. It is worth noting that none of the regimens led to effective exposure for MIC=4 mg/L 
and MIC≥2 mg/L in plasma and ISF, respectively. Minichmayr et al., who assessed two additional 
alternative dosing regimens (front loading with 1200 mg before standard dosing; 1200 mg q24h 
following a single dose of 600 mg; [45,256]), similarly described that even for the alternative 
dosing regimens an achievement of adequate PTA was unlikely for both matrices for MIC>4 mg/L. 
In general, also the prolongation of the infusion duration from 30 min to 4 h improved the PTA 
(Section 3.2.2.2) In some scenarios, however, PTA was lower for the prolonged than for the 
corresponding short-term infusion regimen (e.g. for scenarios with higher MIC values and/or high 
LBW values and particularly in ISF). In these scenarios the prolongation of the infusion duration 
resulted in relevant time periods in which linezolid concentrations were lower than the respective 
MIC value in the initial phase of the concentration-time profile (Appendix Figure S22), which in 
turn resulted in linezolid concentrations not exceeding the MIC value for the targeted 95% of the 
24 h. The findings suggest that a frontloading prior to start of prolonged linezolid dosing, either 
with an intensified loading dose and/or with a short-term infusion regimen may be beneficial. A 
future simulation study based on the developed NLME PK model, could assess the impact of 
different types of frontloading on the PTA for varying MIC values and varying body size. The 
impact of shorting the dosing interval on the PTA was investigated for the daily dose of 1800 mg, 
by administering either every 12 h a linezolid dose of 900 mg or every 8 h a linezolid dose of 
600 mg. In general, shortening of the dosing interval improved the PTA (Section 3.2.2.3). 
However, in some scenarios (e.g. for higher MIC values and/or high LBW values and particularly 
in ISF), the reduced linezolid dose which was administered every 8 h, resulted in relevant time 
periods in which linezolid concentrations were lower than the respective MIC value. This explains 
why in some of the investigated scenarios, lower PTA was observed for the q8h regimen than for 
the corresponding q12h regimen.   
Overall, of the three investigated dosing alterations (intensification of daily dose, prolongation of 
infusion duration and shortening of dosing interval), the increase of the daily dose showed the 
strongest impact on the attainment of adequate PTA. Furthermore, the increase in daily dose 
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consistently resulted in an improvement in PTA, while for the prolongation of the infusion duration 
or the shortening of the dosing interval, in a few investigated scenarios (especially for higher MIC 
values and/or high LBW values and/or in ISF) the alterations of the dosing resulted in a reduction 
of the PTA.   
The impact of LBW on the PTA (Section 3.2.2.4) was highly dependent on the MIC value and 
various determinants of linezolid exposure, namely, the LBW value, the matrix of interest (i.e. 
plasma, ISF) and the type of dosing regimen (daily dose, infusion duration, dosing interval). As 
discussed above, an increase in LBW led to reduced linezolid concentrations in the maximum and 
early declining part of the concentration-time profile. At the same time, however, the increase in 
LBW resulted in a slower decline of the linezolid concentrations at the end of the dosing interval, 
due the higher volume of distribution and thus the increase in half-life. As a result, in various 
investigated scenarios, the linezolid concentrations for a high LBW value exceeded the linezolid 
concentrations for a low LBW value after the intersection of the respective concentration-time 
profiles (point of intersection) in the terminal phase of the concentration-time profiles (Appendix 
Figure S22). Depending on the magnitude of the MIC value relative to linezolid concentration at 
the point of intersection (CInt), the time that linezolid concentrations exceeded the MIC value was 
higher for a low LBW value (if MIC>CInt) or for a high LBW value (if MIC<CInt). This explains 
why overall for lower MIC values and/or lower LBW values a positive LBW-PTA relationship 
was detected (i.e. an increase in LBW improved the PTA), while for higher MIC values and/or 
higher LBW values a negative LBW-PTA relationship was observed (i.e. an increase in LBW 
reduced the PTA).  
Assumptions, conclusion and perspectives. Some assumptions and limitations have to be 
acknowledged with respect to the PTA analyses performed for acute infection therapy. Firstly, the 
NLME PK model which was developed based on the single dose PK data over 8 h, was used to 
extrapolate to multiple linezolid dosing over 24 h, i.e. the underlying PK of linezolid was assumed 
to be the same for single and multiple dosing. This assumption seems justified as a previous 
analysis showed a relevant change of linezolid CL over time only after several days of treatment, 
while in the present analysis only a short time frame of 24 h was assessed [146,230]. Further PK 
data originating from similar patients (i.e. obese/nonobese surgical patients) treated with multiple 
linezolid dosing over a longer time period could confirm this assumption. Secondly, extrapolating 
to higher doses might be compromised by the fact that a partly nonlinear concentration-dependent 
CL was observed. The CL model should be confirmed by assessing the predictivity for high-
exposure data originating from intensified linezolid dosing regimens. Thirdly, PTA analyses were 
based on the PK/PD target 95%fT>MIC which has previously been shown to correlate with the 
efficacy of linezolid in animal models and in clinical investigations [149,153]. Yet, also the PK/PD 
index AUC/MIC has been identified for linezolid before [150,151,153]. Future PTA analysis 
should be performed using the developed model for the fAUC/MIC target in order to assess whether 
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similar results are obtained as for the fT>MIC target. Considering that overall similar results were 
obtained by others [45,290,256] who used AUC/MIC targets for plasma PK data, the general 
conclusion is expected to stay the same. Nevertheless, the relationship between LBW on the PTA 
might differ, as a different PK measure (AUC) is evaluated. Fourthly, the PTA analyses for acute 
infection therapy were performed for intra-anaesthetic patients, i.e. the results are not directly 
transferable to patients not receiving anaesthesia. The NLME model which is based on intra- and 
post-anaesthetic linezolid PK data could be expanded by PK data originating from patients without 
anaesthesia. This would not only allow to perform PTA analysis also for non-anaesthetic patients, 
but additionally provide further information on the PK differences between a non-anaesthetic and 
a post-anaesthetic patient, as well as on the impact of anaesthesia on the PK.   
Despite the aforementioned assumptions and limitations, the PTA analysis based on the NLME PK 
model for plasma and target site in obese and nonobese surgical patients, allowed to draw 
conclusions for the adequacy of linezolid dosing in acute infection treatment. Overall, the results 
of the analysis suggested that already for susceptible pathogens, standard linezolid dosing is 
unlikely to result in effective exposure for infections located in the s.c. adipose tissue and also to 
prevent the spread of pathogens via blood circulation. Dosing intensification might be beneficial; 
however, for pathogens with reduced susceptibility (e.g. MRSA) very high doses seem to be 
required, which bare the risk of increased toxicity. As outlined above, future PTA analyses for 
dosing regimens combining frontloading followed by prolonged infusion, would allow to detect 
and quantify the impact and added value of the frontloading on the PTA and to potentially suggest 
appropriate frontloading schemes. Future clinical studies are warranted to simultaneously assess 
the efficacy and toxicity of intensified linezolid dosing regimens. Given the complex relationships 
discussed above between PTA and the body size of the patient, which are determined by various 
influencing factors (MIC, LBW, dosing regimen and matrix of interest), the use of the NLME PK 
model – after successful clinical evaluation – would be beneficial to determine an appropriate 
dosing regimen for a given patient. In order to facilitate the application in a clinical setting, the 
model could be implemented in a dosing software (e.g. TDMx [309]), which could ultimately 
support therapeutic decisions by health-care professionals. 
 Leveraging pharmacometric approaches to characterise 
variability in the microdialysis sampling technique (Project I) 
Variability in microdialy sis sampling technique  
The present thesis illustrated that pharmacometric modelling and simulation approaches do not 
only provide a powerful tool to enhance the knowledge on the pharmacokinetics of antibiotic drugs 
in special patient populations, but can also be successfully employed to evaluate and quantify 
different types of variability in the microdialysis sampling method based on clinical data collected 
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using this technique (Project I; research category: basic research; Figure 4.1).   
In the last three decades microdialysis has become an important technique to gain a better 
understanding of unbound drug concentrations in ISF of the target tissue, which represent the actual 
drivers of the drug effect and thus provide highly valuable information. [60]. To reliably quantify 
the drug concentrations in the target tissue, in vivo calibration of each microdialysis catheter is 
crucial [65,310]. Today retrodialysis is the most frequently used calibration technique in the 
clinical setting and was also applied in the clinical study underlying Project I. The retrodialysis 
calibration provides a RR value, which can be used to convert the drug concentrations quantified 
using the microdialysis technique, into the ISF concentrations of the target tissue [65,310]. 
Previous studies have identified multiple factors influencing the RR value (flow rate, 
semipermeable membrane of catheter, drug characteristics, catheter-surrounding tissue etc. 
[65,66]); however a model-based systematic in vivo investigation of different levels of variability 
in the RR value is still lacking. To provide a better understanding of the variability in the 
microdialysis technique an informative unique dataset had been collected in the study underlying 
Project I, containing information on various levels of variability (Figure 4.2): (i) data originating 
from the retrodialysis, which was performed twice for a large portion of the catheters, containing 
information on the variability within one catheter between two consecutive retrodialysis samplings 
(in the thesis referred to as ‘intracatheter variability’; illustrated in Figure 4.2 by two vials), (ii) 
data originating from two catheters that were identical in construction and were inserted in the 
same type of tissue of the same patient, containing information on the variability between two 
inserted catheters (in the thesis referred to as ‘intercatheter variability’; illustrated in Figure 4.2 by 
two microdialysis systems), and (iii) data originating from microdialysis experiments performed 
in a variety of patients, containing information on the variability between the patients (in the thesis 
referred to as ‘interindividual variability’; illustrated in Figure 4.2 by 30 patients). The NLME 
modelling approach allowed to dissect and quantify different hierarchical levels of variability by 
including additional random-effects parameters on the fixed-effects parameter RR, which were 
estimated within the integrated dialysate-based modelling approach (Figure 4.3).   
Intercatheter variability. The analysis revealed moderate intercatheter variability in the RR value 
(26.1%CV, Figure 4.3). This was expected, considering that firstly, each single catheter – although 
identical in construction – might show slight variations in membrane surface due to the handmade 
production process, which might impact the RR value. Secondly, the exact location of the catheter 
in s.c. adipose tissue might show an additional impact on the resulting RR value. Here, for instance, 
it might be of relevance whether the semipermeable membrane is inserted close to a capillary 
vessel, as this might result in a shorter diffusion path of the drug to reach the semipermeable 
membrane of the microdialysis catheter. In vivo, ultrasound can assist positioning the catheter into 
the tissue of interest [311]. A recent investigation by Burau et al. [249] revealed intercatheter 
variability in linezolid RR values, although investigated in vitro using a standardised microdialysis 
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system (difference between max. and 
min. RR values: ≤18.1% RR). Similar 
findings were also described by other 
research groups [312,313]. Considering 
the highly standardised conditions of the 
in vitro experiments, which reduce 
variability caused by the surrounding 
medium, the findings from the in vitro 
investigations illustrated that the 
catheters themselves are already variable 
in their determined RR values. Yet, it 
needs to be kept in mind that the 
interindividual variability in RR value is 
not a concern for the resulting ISF drug 
concentrations, as long as the RR value 
per catheter is the same during the drug delivery (i.e. retrodialysis setting) and the drug recovery 
(i.e. microdialysis setting). In other words, variability observed on the level of the RR values might 
cancel out on the level of ISF drug concentrations, as the ratio of microdialysate concentrations 
and the RR value of a catheter, determines the resulting ISF exposure. However, this requires an 
in vivo calibration of each single catheter. Nevertheless, dissecting and quantifying the intercatheter 
variability within the NLME model is crucial, as otherwise the variability will show up on other 
random-effects parameters and lead to inflated magnitudes of the corresponding variabilities. To 
further dissect the observed intercatheter variability into variability caused by the catheter itself 
and variability caused by the exact location of the catheter in the tissue, future in vitro 
investigations could aim at systematically investigating variabilities between the catheters. The 
results could ultimately inform the NLME model about the magnitude of variability caused by the 
catheter.  
Intracatheter variability. On the basis of the two successively performed retrodialysis samplings 
within one catheter (i.e. retroperfusate/retrodialysate concentrations), intracatheter variability in 
the RR value was quantified, which was found to be of moderate magnitude (27.2%CV; 
Figure 4.3). Similar findings were observed by others: For instance Bouw et al. [314] reported 
already for rats a fluctuation of the RR value over time within each probe. Potential impact factors 
of the retrodialysis setting on the RR value (e.g. flow rate changes, air in the microdialysis system) 
were recently investigated for linezolid and other antibiotics by Burau et al. at our department. The 
analysis revealed that flushing of the microdialysis catheter (i.e. using an increased flow rate) 
before the performance of retrodialysis might lead to erroneously low RR values. In the present 
study the catheter was flushed only before the first retrodialysis, but not prior to the second one. 
Figure 4.2: Schematic representation of database of the 
present clinical microdialysis study informing different 
levels of variability in the microdialysis technique 
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As the observed variability in RR values was random and not due to lower RR values observed 
during the first retrodialysis, this was not considered as explanation for the present finding. 
Moreover, the analysis demonstrated that air in the microdialysis system increased the variability 
in the RR value [249]. Since the perfusate was changed before performance of retrodialysis, an 
unintended inclusion of air in the microdialysis system might have occurred, potentially causing 
the observed intracatheter variability. This hypothesis was also supported by the fact that the 
measured microdialysate concentrations showed a relatively ‘smooth’ profile over time (i.e. 
without greater fluctuations), which indicated a low variability in the RR value during 
microdialysis sampling. In the present analysis, all available retrodialysis data were included in the 
analysis, to minimise a potential impact of the variable RR values on the converted ISF 
concentrations. It also needs to be kept in mind that a separation of RUV and intracatheter 
variability is not possible based on the retrodialysate data , since on the basis of the catheter input 
(i.e. retroperfusate concentration) and the output of the two catheters (i.e. retrodialysate 
concentrations) only one level of variability is supported. Thus, in the NLME model the RUV was 
assumed to be as high as the reported assay imprecision (1.9%CV [249]). This was deemed 
reasonable as most of the typically discussed sources of RUV for in vivo PK data (e.g. erroneous 
documentation of sampling time point or model misspecification; section 2.3.1.2), are of little 
relevance in the setting of retrodialysis.   
 
Figure 4.3: Hierarchical structure of three different levels of unexplained variability on the relative recovery 
parameter. 
Level 1: Interpatient variability; Level 2: ‘Intercatheter’ variability; Level 3: ‘Intracatheter’ variability.  
Abbreviations: CAT: Catheter; CV: Coefficient of variation; IDX: Individual identifier X (e.g. ID1: Individual identifier 1); RR: 
Relative recovery; RRIDX: RR for IDX; RRIDX_CAT1: RRIDX for catheter 1; RRIDX_CAT1_RD1: RRIDX_CAT1 determined during first 
retrodialysis; RRIDX_CAT1_RD2: RRIDX_CAT1 determined during second retrodialysis; RRIDX_CAT2: RRIDX for catheter 2; 
RRIDX_CAT2_RD1: RRIDX_CAT2 determined during first retrodialysis; RRIDX_CAT2_RD2: RRIDX_CAT2 determined during second 
retrodialysis; RRpop: Typical RR (‘population RR’). 
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In light of the previously discussed hypothesis of air inclusion into the microdialysate system when 
changing the perfusate, alternative catheter calibration techniques might be assessed. For instance, 
the so-called ‘retrodialysis by calibrator’ [60,65,66] - a modified retrodialysis strategy - would not 
require a change of the perfusate for catheter calibration. Here, a calibrator, ideally the modified 
study drug (e.g. deuterated drug [315]), is added to the perfusate during the course of the 
investigations allowing to continuously monitor the RR, which in turn could be implemented in 
the NLME model. In addition, future analyses shall aim at investigating the variability levels also 
for the additional drugs measured in this study – considering that for some of the drugs the 
retrodialysis sampling per catheter was even performed thrice.  
Interindividual variability. The use of the NLME approach also allowed to separate and quantify 
an additional impact of the individual patient on the RR values of the two catheters inserted in the 
patient which was captured in the interindividual variability parameter and was estimated to be 
~14%CV (Figure 4.3) which is relatively low compared to interindividual variability of PK 
parameters (Table 3.2). Interestingly, when investigating potential factors that explain the observed 
variability between the patients, the obesity status of the patients was identified as strong impact 
factor and was found to be superior to continuous body size descriptors such as body weight. The 
inclusion of the obesity status as dichotomous covariate on the RR parameter almost completely 
explained the interindividual variability in RR (IIV RR after inclusion of obesity status: 0.3%CV). 
In obese patients, the typical RR value was considerably lower than in the nonobese population 
(RR obese vs. nonobese: 37.5% vs. 57.5%). Related supporting findings were described by Lutgers 
et al. [316] who observed a negative relationship between skinfold thickness of diabetic patients 
and the RR value of glucose when performing microdialysis in the abdominal adipose tissue. 
Knowing that the tortuosity of the sampling matrix surrounding the microdialysis catheter 
influences the RR value [60,65,66], the observed differences in the RR value of obese and nonobese 
patients might be explained by differences in the structure and/or composition of the s.c. adipose 
tissue. It is known that the adipocytes in obese patients tend to be hyperplastic (i.e. increased 
number of cells) and/or hypertrophic (i.e. increased size of the cells) [317]. Moreover, the density 
of capillary vessels decreases with increasing mass of adipose tissue, which results in a reduced 
perfusion of the adipose tissue in the obese population [90]. In addition to that, obesity has been 
found to impair the lymphatic function, more concretely to reduce the interstitial fluid transport as 
well as the pumping of lymphatic collecting vessels [318–320]. The aforementioned points, 
together with the ‘tighter packed’ adipocytes, might cause the reduced RR value in the obese 
population. Furthermore, differences in the volume and/or composition (e.g. lipids, proteins, 
electrolytes, pH [321,322]) of the ISF of the s.c. adipose tissue between obese and nonobese 
patients might be a reason for the observed differences in the RR values, yet, further research is 
needed. This hypothesis could be addressed by additionally analysing the remaining study drugs 
[226] with respect to differences in RR between obese and nonobese patients. Beyond that, future 
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systematic microdialysis in vitro investigations in artificial ISF and/or s.c. adipose tissue using a 
standardised in vitro microdialysis system [228,323] could provide valuable knowledge to better 
understand the clinical finding.  
Conclusion and perspectives. Microdialysis is a powerful technique to enhance the understanding 
of unbound drug concentration-time profiles at the site of therapeutic action; yet, knowledge on 
variability in the technique in vivo has been lacking. The present work systematically investigated 
and quantified different levels of variability in the RR value based on clinical data using the NLME 
approach. The quantified inter- and intracatheter variabilities emphasise the importance of 
individually calibrating every single catheter in vivo and the need of special care in placement of 
the microdialysis catheter (e.g. using ultrasound) and the performance of the micro- and 
retrodialysis. As a next step, a systematic simulation study, successively including the quantified 
variability levels in the microdialysis technique, would help to assess their impact on the predicted 
target site exposure. Furthermore, the proposed approach to dissect and quantify the variability 
levels using NLME software (e.g. NONMEM®) can be applied for the additional study drugs [226]. 
This would allow to further evaluate and substantiate the findings for linezolid.  
The investigations did not only enhance the understanding of the variabilities in the microdialysis 
technique but also generated new hypotheses which require future research: For instance, the 
obesity status of the patient seemed to impact the RR value. To date, differences in adipose tissue, 
blood flow and lymph function have been described in obese compared to nonobese patients; yet, 
little is known about the differences in the composition of the ISF in the s.c. adipose tissue. Future 
in vitro investigations should focus on the assessment of these pathophysiological differences and 
their impact on the RR value to explain the observed impact of obesity on the RR value and/or to 
derive an even better marker than obesity.  
 Leveraging pharmacometric approaches to characterise the 
pharmacokinetics of meropenem in critically ill patients and to 
evaluate and optimise dosing (Project III, IV)  
Meropenem pharmacokinetics and dos ing regime ns in critically ill  patie nts  
By means of pharmacometric approaches, this thesis contributed to a better characterisation of the 
pharmacokinetics of the betalactam antibiotic meropenem in the vulnerable population of critically 
ill patients (Project III and IV; research category: basic research; Figure 4.1), identified the patient 
subgroups at risk for therapy failure when administering standard meropenem dosing (Project III, 
IV; research category: applied research; Figure 4.1) and suggested optimised dosing regimens 
(Project IV; research category: applied research; Figure 4.1). The respective results and technical 
considerations of the modelling and simulation analyses in Project III and IV will jointly be 
discussed in the following sections. 
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4.3.1 Characterisation of meropenem pharmacokinetics in critically ill patients 
(Project III, IV) 
The pharmacometric analyses in both projects (Project III: non-compartmental approach; 
Project IV: compartmental NLME approach) were based on extensively sampled data from a 
prospective observational study. A large number of patients with highly heterogeneous patient-
specific characteristics from different ICUs was included to best represent the diversity in ICU 
patients [324], though at one single study centre. This clinical study focused on evaluating the PK 
of the approved and still most frequently used standard meropenem dosing regimens in ICUs 
(1000 mg administered as 30-min i.v. infusion every 8 h; [325,326]).  
Variability in meropenem PK. The analyses demonstrated large interindividual variability in 
meropenem exposure, in accordance with previous studies in critically ill patients [327,328]. The 
exploratory analysis in Project III revealed larger variability in concentrations of the late phase 
compared with the earlier phase of the concentration-time profile (variability in Cmin and C8h > 
variability in C4h, Section 3.3.1.3), which suggested that PK variability was due to variability in 
drug elimination processes rather than in drug distribution. This finding was supported by the 
NLME PK base model developed in Project IV (Appendix Table S18) as well as previously 
performed NLME analyses [329,330], that identified larger interindividual variability on the PK 
parameter clearance compared to variability on volume of distribution. The relatively long 
observation period of 4 days and the large number of samples collected per patient, additionally 
enabled the quantification of intraindividual variability in meropenem exposure. Its relatively large 
value led to the hypothesis that meropenem exposure is influenced by certain time-varying patient-
specific factors which was confirmed in the systematic covariate analysis performed in Project IV. 
Patient characteristics impacting meropenem PK. To provide further knowledge about patient 
characteristics (not) impacting the PK of meropenem, in Project IV, a systematic covariate analysis 
was performed on the basis of 58 available patient characteristics (categorical and continuous, 
many of them determined longitudinally during study period). In contrast to previous PK studies 
of meropenem, which typically investigated around 8 covariates (=median, range: 4-15 [327–343]), 
a high number of pre-selected covariate candidates (n=27) was assessed within the NLME 
modelling framework. For this purpose, a comprehensive systematic stepwise covariate analysis 
strategy was set up and applied (Sections 2.9.3.2 and 3.4.2.1). The strategy did not solely base the 
selection of the covariates on statistically significant improvement of the model (i.e. significant 
reduction in OFV) but considered additional crucial criteria: Reduction of unexplained variability, 
precision of the estimate quantifying the covariate effect, clinical relevance and biological 
plausibility of the covariate effect. Although of importance for reliable covariate selection, today, 
additional selection criteria are still widely neglected or ignored completely in NLME covariate 
analyses [207,340,342,344–347]. This is likely to be due to the higher complexity and expenditure 
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of time for the multi-criteria-based covariate analysis strategy, compared to the OFV-based 
covariate analysis strategy for which rapid, automated methodologies exist (e.g. scm in PsN [209]). 
The covariate analysis strategy proposed in Project IV may serve as starting point for further 
NLME analyses; but naturally, requires adjustments depending on the data situation.   
Of the 27 preselected patient characteristics, approximately 37% were not selected during forward 
inclusion of the covariate model building, (e.g. ECMO, lung transplantation, sodium serum 
concentration etc.; Table S17, Figure 3.16) and were thus considered unlikely to influence the PK 
of meropenem. At the final step of the analysis, three physiologically plausible covariate-PK 
parameter relationships fulfilled all covariate selection criteria and were kept in the final NLME 
PK model (CLCRCG on CL, body weight on V1, serum albumin concentration on V2). For the 
remaining covariates that were included in the NLME PK model during forward inclusion, but 
excluded during the backward deletion, especially the ‘borderline covariates’ which were excluded 
late during the backward deletion (e.g. age, sex, bilirubin, C-reactive protein, pH value of the blood; 
Table S17, Figure 3.16), a reassessment is recommended when additional clinical data will be 
available.   
Impact of CLCRCG on meropenem CL. As expected from the predominantly renal excretion of 
meropenem [161] and as described previously [235,329–332,334,335,337,338,341,342,346], 
CLCRCG was identified as important factor, influencing the CL of meropenem. For instance, for a 
CLCRCG of 80.8 mL/min (i.e. 4.85 L/h) the typical meropenem CL was 9.25 L/h, indicating both 
glomerular filtration and active secretion of meropenem in the kidneys. This is in line with the 
results of interaction studies with probenecid - a drug which blocks active secretion transporters in 
the proximal tubule of the kidney [160,348]: The studies observed an increase in AUC of 
meropenem (by 55% [348] and 43% [160]) when administering meropenem concomitantly with 
probenecid, thus demonstrating that meropenem is partly cleared via active secretion. The 
magnitude of meropenem CL was in good agreement with previous studies investigating 
meropenem PK in critically ill patients with similar renal function (e.g. 9.2 L/h for 
CLCRCG=80 mL/min [256]; 7.34 L/h for CLCR=67 mL/min [349]). The broad range of CLCRCG 
values
 
(25-255 mL/min; i.e. covering the full spectrum of five renal function classes) allowed the 
identification of a piecewise linear CLCRCG-CL relationship, which indicated a linear increase of 
meropenem CL with increasing CLCRCG up to a maximum constant CL of approximately 16 L/h 
at a CLCRCG inflection point of 154 mL/min, i.e. for highly augmented renal function, meropenem 
CL was not further increasing. Comparing the piecewise linear relationship with the a sole linear 
CLCRCG-CL relationship, it was noticeable that the two models were nearly congruent up to the 
inflection point and differed mainly for augmented renal function (Figure S30). Most previous 
analyses for meropenem in ICU patients described the CLCRCG-CL relationship by using a linear 
function [271,328–332,334,336,340,350] or power function [337]. Yet, in many of the studies, the 
range of CLCRCG values covered in the study population was narrower and/or it remained unclear 
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whether a piecewise linear relationship was investigated. An analysis by Roehr et al., however, 
demonstrated a similar piecewise linear CLCRCG-CL relationship when investigating meropenem 
PK in patients covering a CLCRCG range similar to the present study [351]. Beyond that, a very 
recent analysis by Dhaese et al. [344] evaluated the predictive performance of eight published PK 
models of meropenem in critically ill patients that included mainly linear [327–
329,335,336,342,344] or power relationship [343] between renal function and meropenem CL, for 
an evaluation dataset with a broad range of CLCRCG (13.6-346 mL/min). Five of the models 
showed an underprediction of meropenem concentrations in the evaluation dataset which might 
suggest a misspecification of the included relationship between renal function and meropenem 
clearance: The extrapolation of the linear/power relationships to patients with augmented renal 
function is likely to have resulted in the extremely high meropenem CL values, which again has 
caused the observed underprediction in meropenem exposure. Yet, in the article the model 
predictivity was not stratified by renal function. In light of the findings of the present thesis as well 
as by Roehr et al. [351] and Dhaese et al. [344], a future evaluation of the functional CLCRCG-CL 
relationship is warranted, as the identified relationship might impact model predictions – especially 
for augmented renal function - and hence also model-based clinical implication: An external 
evaluation of the developed NLME PK model based on a rich PK dataset originating from patients 
with augmented renal function (e.g. the evaluation dataset by Dhaese et al.) would allow to assess 
and confirm the identified piecewise linear relationship. Future analyses could focus on further 
refining the meropenem clearance model by assessing alternative CLCRCG-CL relationship which 
allow a less abrupt but more smooth change in CL. Beyond that, even more physiological 
approaches could be applied which dissect and quantify the two parallel clearance processes, 
glomerular filtration and active secretion.   
Impact of body weight and serum albumin concentration on the volume of distribution of 
meropenem. In addition, total body weight was identified as predictor for the central volume of 
distribution of meropenem (Table 3.8), which is in line with others, who already identified body 
size descriptors to influence the volume of distribution of meropenem [90,336,341,347,352,353]. 
Within the model, the relationship was quantified using a power model, with an estimated exponent 
of approximately 1, which is in line with the principle of allometry [204,354]. Thus, the model 
described a plausible, approximately linear relationship between body weight and V1: An increase 
in body weight (e.g. doubling the body weight from 50 kg to 100 kg) resulted in an increase in V1 
(e.g. from 5.4 L to 11.1 L, respectively)
.
 
As already indicated by Mattioli et al. [327] and Ramon-Lopez et al. [333], the covariate analysis 
identified serum albumin concentration to be negatively related with the peripheral volume of 
distribution of meropenem: A decrease in albumin concentrations by 0.5 g/dL, resulted in 10% 
increase in V2. Such a decrease in albumin concentrations is not unusual for the critically ill 
population, considering the high incidence of hypoalbuminaemia (40-50% [355]). This relation can 
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potentially be explained by an increased capillary leakage and the resulting fluid shifts from the 
intravascular space to the interstitial space in tissue which is related to the reduced serum albumin 
concentrations [110,111]. Contrary to highly protein-bound drugs, for meropenem, an impact of 
albumin concentration on the protein binding is not expected, considering the low magnitude of 
protein binding (2% [63,160]). The total volume of distribution of 24 L, for the typical study patient 
(body weight=70 kg, serum albumin=2.8 g/dL), was in line with previous investigations for 
meropenem in this special patient group (e.g. 23.7 L [329], 20.6 L [343], 22.7 L [350]).  
Reduction in unexplained variability. The inclusion of the three covariates into the population 
PK model led to a distinct reduction in both inter- and intraindividual unexplained PK variabilities 
(with CLCRCG causing the strongest reduction of PPVVar on CL by ~70%; Figure 3.17), resulting 
in – for the special critically ill population – low unexplained variabilities of ≤31.5%CV (Table 3.8; 
compared with e.g. ≤66.5%CV [327]; ≤48.0%CV [329]; ≤44.7%CV [350]). Yet, the remaining 
unexplained PK parameter variability of 12.5%CV to 31.5%CV (for IOV on CL and IIV on V1, 
respectively; Table 3.8) indicates that further factors, not identified in the NLME PK modelling in 
Project IV, impact the PK of meropenem. Similarly, Project III identified patients (e.g. ID 36: 
higher C8h values, Figure 3.14) for whom the CLCRCG-meropenem C8h relationship deviated from 
the remaining patients, suggesting additional impact factors, which have not yet been identified. In 
light of the high average numbers of administered drugs per critically ill patient (~13 [356–358]), 
future investigations of PK drug-drug interactions are warranted. Considering the renal active 
tubular secretion of meropenem via organic anion transporters (OAT) (namely OAT1 and OAT3 
[161,162]), comedication impacting the OAT system (e.g. OAT inhibitors such as probenecid but 
also NSAIDs [359]) should be documented and analysed as potential impact factor for meropenem 
PK in future NLME analyses. In addition, investigation of comedication influencing the pH of the 
urine is desirable, as the distribution of microspecies of meropenem and hence the urinary excretion 
processes might differ at altered pH [360,361], which in turn might have an impact on the renal 
excretion of meropenem.  
Of note, the observed lower magnitude of intraindividual PK variability compared to 
interindividual variability, provides an essential prerequisite for therapeutic drug monitoring 
(TDM) of meropenem, if e.g. aiming to individualise the dosing for an individual patient based on 
the measured meropenem concentration [362,363].   
Impact of patient characteristics on meropenem concentration-time profile. The application 
of the NLME PK model by exposure simulations in Project IV allowed to characterise the phases 
of the concentration-time profile in which the covariates were most influential. Body weight and 
serum albumin concentrations were implemented on volume parameters (i.e. V1, V2, respectively) 
and therefore affected the maximum meropenem concentrations and the early declining part, while 
CLCRCG was implemented on the CL parameter and consequently had a strong impact on the 
terminal phase. The strong impact of CLCRCG on the terminal concentrations, also explained why 
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CLCRCG was identified as key determinant during PTA analyses (further discussed in 
section 4.3.2). The hyperbolic relationship between CLCRCG and meropenem C8h values quantified 
in Project III, is another consequence of the impact of CLCRCG on the terminal phase of the 
meropenem concentration-time profile.   
Special patient subgroups. The present study also included special patient subgroups such as 
CRRT and ECMO patients. For CRRT patients, authors of other publications identified measured 
CLCR determined via 24-h urine collection [330] or residual diuresis [345,353] as influencing 
factors on meropenem exposure, both requiring time-consuming urine collection. Although the 
present analysis included a rather small number of CRRT patients, it revealed CLCRCG as a 
potential determinant of meropenem exposure (Project III: Figure 3.14 A.1, B2; Project IV: 
Appendix Table S20) which can be assessed more easily and quickly in clinical practise than renal 
function markers determined via 24-h urine collection. This finding requires further investigation 
with a larger number of patients under a well-designed study protocol. For the six ECMO patients, 
the relationship between CLCRCG and meropenem concentrations, quantified in Project III, did not 
seem different from that of the remaining patients, suggesting that ECMO therapy did not have a 
strong impact on meropenem serum exposure (Figure 3.14). This was confirmed in Project IV, in 
which ECMO was not identified as covariate on the PK parameters of meropenem and is in line 
with findings reported by Donadello et al. showing no significant difference between the PK 
parameters of ECMO and control non-ECMO ICU patients [364]. Further scientific evidence was 
provided by a very recent study by Hanberg et al. [346] that investigated meropenem dosing in 
patients undergoing both ECMO and CRRT and demonstrated comparable PK for the ECMO-
CRRT patients, as characterised before for CRRT patients not undergoing ECMO [365]. Note that 
in these analyses only a limited number of patients was investigated. However, a large clinical 
study is currently ongoing which may shed more light on the impact of ECMO on the PK of 
meropenem [122].  
Conclusions and perspectives. The PK analyses demonstrated large variability in meropenem 
pharmacokinetics between the individuals but also within one patient between different occasions. 
The systematic covariate analysis identified three vital clinical determinants for meropenem PK 
which reduced the unexplained PK variability considerably: Renal function estimated according to 
Cockcroft and Gault [2], total body weight and serum albumin concentration. Yet, future analyses 
are warranted that evaluate and refine the developed models (regression model: Project III, NLME 
model: Project IV) based on clinical PK data of meropenem in the critically ill population. The 
inclusion of more patients with heterogeneous patient characteristics and information on 
administered comedication would allow to even better capture the real-life variability in the PK, to 
confirm the identified covariate-parameter relationships and to potentially identify further clinical 
determinants.  
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4.3.2 Evaluation and optimisation of meropenem dosing in critically ill patients 
(Project III, IV) 
Project III and IV both contributed to the evaluation and optimisation of meropenem dosing in the 
critically ill population by the performance of PTA analyses which are summarised in Table 4.1 
and will be jointly discussed in more detail below.   
Evaluation of standard dosing in the study population. The PK/PD analysis in Project III 
(Table 4.1, Analysis A) demonstrated that standard meropenem dosing did not achieve the desired 
meropenem PK/PD targets 100%T>MIC and 50%T>4×MIC in a considerable fraction of patients in the 
study population (Table 3.7): For pathogens with a MIC of 2 mg/L, which represents the upper 
MIC limit of the S category for many important bacteria (EUCAST MIC S breakpoint [5]), 
meropenem exposure was inadequate in every second dosing interval monitored. In line with the 
present work, Carlier et al. found similar results for the target 100%T>MIC given the same MIC 
value (target attainment 55% [366]). For infections with less susceptible bacteria of MIC 8 mg/L 
(EUCAST MIC R breakpoint [5]), which have been shown to commonly occur in ICUs [102,367], 
target non-attainment was high, with even four out of five dosing intervals resulting in 
subtherapeutic concentrations (target 100%T>MIC).   
PK/PD target. The PK/PD target 100%T>MIC (i.e. meropenem concentrations exceeding 1x the 
MIC for the entire dosing interval) was selected for target attainment analysis, as it has previously 
been shown to improve clinical cure and bacteriological eradication in patients with serious 
bacterial infections treated with betalactam antibiotics [235,236]. In Project III, a second target 
50%T>4×MIC (i.e. meropenem concentration exceeding 4xMIC for half of the dosing interval) was 
evaluated and the results compared to the results for the target 100%T>MIC. For this second target 
clinical evidence is currently lacking, yet it has been selected for PTA analysis in previous clinical 
studies [237–239]. The target attainment analysis, performed in the present thesis, revealed similar 
results for the two selected PK/PD targets (Table 3.7), thus providing some first evidence for the 
use of this PK/PD target. However, future studies are warranted that confirm the validity of the 
PK/PD target 50%T>4×MIC in the clinics. Moreover, it needs to be considered that current knowledge 
on PK/PD targets for meropenem in heterogeneous ICU populations is limited and a PK/PD target 
for this special patient population has not been derived. In relation to other PK/PD targets 
determined for meropenem in diverse clinical studies (e.g., 19.2%T>MIC and 47.9%T>MIC [166], 
54%T>MIC [167] and 76-100%T>MIC [235]), the two PK/PD targets selected for the present analysis 
were at the upper end (i.e., stricter). The selection of the higher targets seemed reasonable, given 
(i) limited knowledge on an adequate PK/PD target for heterogeneous ICU populations and (ii) the 
high mortality rates in ICU patients and high severity of illness (median APACHE II first study 
day: 27), (iii) the high proportion of patients with transplants (~58%) in the evaluated population 
and (iv) given the relatively good safety profile of meropenem [171]. 
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SI212: 1000 mg, 30-min i.v. infusion, q12h; SI38: 1000 mg, 30-min i.v. infusion, q8h (=standard dosing; highlighted in bold); 
SI68: 2000 mg, 30-min i.v. infusion, q8h; PI212: 1000 mg, 3-h i.v. infusion, q12h; PI38: 1000 mg, 3-h i.v. infusion, q8h; PI68: 
2000 mg, 3-h i.v. infusion, q8h; CI3: 3000 mg, CI, q24h following 500 mg, 30-min loading dose; CI6: 6000 mg, CI, q24h 
following 1000 mg, 30-min loading dose.  
Abbreviations: CI: Continuous infusion; CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]; i.v.: 
Intravenous; PK/PD: Pharmacokinetic/pharmacodynamic; PTA: Probability of target attainment; qXh: Every X hours (e.g. q8h: 
every 8 h); %T>MIC: Percentage of time period that total drug concentration exceeds the MIC; %T>4xMIC: Percentage of time 
period that total drug concentration exceeds four times the MIC. 
Indeed, the two selected targets have been reported to be commonly used in clinical practise for 
ICU patients [131] and a recent guideline on the ‘Optimisation of the treatment with betalactam 
antibiotics in critically ill patients’ recommends to use strict PK/PD targets in the ICU setting [368]. 
However, owing to the limited knowledge of PK/PD targets in ICU patients, there is a crucial need 
to explore which PK/PD target is best related to clinical outcome of critically ill patients in a 
prospective clinical trial. Further analyses should also be aimed at investigating differences in 
PK/PD targets between, for example, different patient subgroups (e.g., with vs. without 
transplants), different states of severity of illness or different types of infecting bacteria (gram-
positive vs. gram-negative) in a sufficiently large number.   
In the context of the MIC-based PK/PD targets, it needs to be kept in mind that the MIC value is 
associated with a certain inaccuracy: The susceptibility of the pathogen is provided on a 
discontinuous scale (usually 2-fold dilution scale), which categorises all values across the 2-fold 
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intervals (e.g. although a MIC is determined as 2 mg/L, the MIC of the bacterial strain might lie 
between >1 mg/L and 2 mg/L). Furthermore, MIC values might differ between/within laboratories 
due to differences in experimental settings (e.g. media, incubation temperature/time) or differences 
in technical skills and degree of training of the technician [129]. Nonetheless, the MIC value has 
proven as practical standard susceptibility measure and the assessment of MIC-based PK/PD 
targets is suggested by regulatory authorities to assess the adequacy of antibiotic dosing [63].  
Evaluation of standard dosing dependent on the renal function class. The stratification of the 
PTA by the renal function class in Project III (Table 4.1, Analysis B), demonstrated a strong impact 
of renal function on the target attainment (Table 3.7), which was overall in accordance with the 
results of a recent publication by Isla et al. [369], in which the probability of attaining the target 
100%T>MIC was analysed for three specific CLCRCG values: Target attainment was 51% for 
CLCRCG 35 mL/min (vs. 51% in the present study for CLCRCG range 30–59 mL/min), 3% for 
CLCRCG 71 mL/min (vs. 4.6%, 60–89 mL/min) and 0% for CLCRCG 100 mL/min (vs. 3.5%, 90–
129 mL/min) for a MIC value of 8 mg/L. Because the present study included patients covering the 
full spectrum of five renal function classes, additional investigation of target attainment in extreme 
renal function classes (severely impaired, augmented renal function) was possible. For infections 
caused by bacteria of MIC 2 mg/L, augmented, normal and mildly impaired renal function was 
identified as a risk factor of target non-attainment; given bacteria of MIC 8 mg/L, moderate renal 
impairment was an additional risk factor. These findings imply the need for dosing intensification 
in patients identified to be at risk of target non-attainment, such as by increasing the dose or 
prolonged up to continuous infusion, which was one objective of Project IV. Continuous infusion 
– currently a ‘hot topic’ in antibiotic therapy – is under clinical investigation, owing to the results 
of previous studies that have associated continuous infusion with improved clinical cure rates 
[370,371]. In the study population, the only patient group that reliably reached the PK/PD targets 
was the subgroup with severe renal impairment. It must be kept in mind that these patients also 
received 1000 mg meropenem every 8 h as 30-min infusions and thus received higher doses than 
recommended in the summary of product characteristics (half of indicated dose every 12 h for 
patients with CLCRCG 10–25 mL/min [157]).   
Evaluation of standard dosing dependent on the three covariates. In Project IV, the impact of 
renal function on the PTA following standard meropenem dosing, was further elucidated by 
assessing the impact not of the categorised but of the continuous renal function marker CLCRCG as 
well as the impact of the two other covariates body weight and serum albumin concentration, 
implemented in the NLME PK model
 
(Table 4.1, Analysis C). The PK/PD target 98%T>MIC was 
used, considering the similar PTA results for the two selected PK/PD targets demonstrated in 
Project III (100%T>MIC, 50%T>4×MIC) and the available clinical evidence for this target (attainment 
resulted in improved clinical cure and bacteriological eradication in patients with serious bacterial 
infections treated with betalactam antibiotics [235,236]). Of the three covariates implemented in 
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the NLME PK model, CLCRCG revealed by far the strongest impact on PTA (Figure 3.20). While 
an increase in CLCRCG and serum albumin concentration led to a reduced PTA, an increase in body 
weight improved (i.e. increased) the PTA (Table 3.9). The observed direction of the impact of body 
weight and serum albumin concentration on the PTA – systematically investigated and illustrated 
for meropenem for the first time – can be explained by their impact on the volume of distribution 
and hence on the half-life of meropenem, slightly influencing the terminal concentrations of the 
meropenem concentration-time profile. These relationships will be further illustrated in the 
following using body weight as example: An increase in body weight (e.g. of 50 kg) increases the 
volume of distribution (e.g. by 71%), which in turn prolongs the half-life of meropenem (e.g. 71%). 
Thereby, meropenem concentrations in the terminal phase of the concentration-time profile 
increase and thus also the time that the drug concentration exceeds the MIC value. This explains 
the observed increase in PTA with increasing body weight. Consequently, according to the 
observed covariate-PTA relationships, the ‘high-risk patient’ subpopulation under standard 
meropenem dosing, was the low-weight critically ill patient with augmented renal function and 
high serum albumin concentrations. Yet, the impact of body weight and serum albumin 
concentrations was marginal compared to CLCRCG and consequently CLCRCG was considered as 
key determinant for risk assessment. Overall, the results of the PTA analysis indicated a relevant 
risk of ineffective meropenem exposure in many of the patients (i.e. 5th percentile of PTA<90%). 
Already for susceptible bacteria with a MIC value of 0.5 mg/L for instance, CLCRCG values 
≥90 mL/min were identified as risk factors for ineffective meropenem exposure when 
administering standard meropenem dosing; i.e., only CLCRCG values ≤80 mL/min reliably resulted 
in effective exposure (5th percentile of PTA≥90%). For the S breakpoint for many relevant bacteria 
(MIC=2 mg/L [5]), even CLCRCG values ≥50 mL/min were identified as risk factors. For the R 
breakpoint for many relevant bacteria (MIC=8 mg/L ([5]), even none of the investigated CLCRCG 
values (i.e. ≥10 mL/min) reliably reached effective meropenem exposure (Table 3.9).    
Cumulative fraction of response analysis. In addition to the PTA analysis, which is typically 
performed when information on the MIC values is available, in Project IV, the CFR was 
investigated (Section 2.9.4.2). In contrast to the PTA, the full MIC value distribution of a pathogen 
is considered, i.e. all possible MIC values of the pathogen including their respective frequencies. 
This allows to assess the probability of therapeutic exposure for a given pathogen when the actual 
MIC value is unknown – a situation which is still frequently encountered on ICUs [239]. For this 
purpose, five pathogens, commonly encountered on the ICU, with varying susceptibility against 
meropenem were selected [372–374]: Three more susceptible pathogens E. coli, K. pneumonia, 
E. cloacae and two rather susceptible pathogens P. aeruginosa and Acinetobacter spp. 
(MIC90=0.032, 0.064, 0.125 and 8, 16 mg/L, respectively; derived based on EUCAST MIC 
distributions [375]). Following standard meropenem dosing, effective meropenem exposure was 
reliably reached (i.e., 5th percentile of CFR≥90%) for the three susceptible pathogens across all 
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renal function classes, whereas for P. aeruginosa and Acinetobacter spp. only in some of the 
patients with severely impaired renal function standard meropenem dosing seemed sufficient. By 
considering available knowledge on the MIC distribution of the pathogen, the CFR provides the 
most likely estimate of the probability of target attainment, in situations in which the infecting 
pathogen is known, but information on the susceptibility of the pathogen is lacking. Yet, in case of 
pathogens of the S category, the CFR might overestimate the risk of inadequate exposure, while 
for pathogens of the I or R category the risk might be underestimated. To further refine the CFR 
estimate, the present analysis assessed the CFR of meropenem separately for MIC distributions of 
the pathogens belonging to the S and I category (Section 2.9.4.2). These results provide valuable 
information in situations in which in addition to the pathogen, the susceptibility category is known 
(i.e. S, I, R category). In hospitals, the susceptibility category is still frequently used to report 
pathogen susceptibilities, as alternative to MIC values. This promising novel approach of assessing 
the CFR in dependence of the available knowledge on the susceptibility category of the pathogen 
can also be applied for other antibiotic drugs and/or patient groups.  
Consideration of PK parameter uncertainty in the simulations. Today, PTA analyses are 
frequently applied to assess the adequacy of antibiotic dosing based on NLME PK models. 
However, recently, Colin et al. sounded a note of caution when interpretation the results of PTA 
analyses [245]. The authors emphasised that, at this point, PTA analyses are based on MC 
simulations for the typical individual/population only, i.e. uncertainty which is associated with the 
PK parameters of the NLME PK model is typically ignored completely, not allowing a reliable 
judgement of PTA results in support of therapeutic decision making. This point of view was also 
supported by the recently published EMA guideline on the use of PK and PD in the development 
of antimicrobial medicinal products, which suggested to report a measure of uncertainty (more 
concretely, the 95% confidence intervals) for the PTA [63]. To the best of found knowledge, the 
present work for the first time implemented these recommendations for meropenem in the PTA 
and CFR analyses, by considering PK parameter uncertainty in the underlying MC simulations, 
providing confidence intervals around the typical PTA/CFR and considering the uncertainty in the 
dosing selection (Section 3.4.4). Of note, despite the relatively precisely estimated PK parameters 
in the final population PK model (Table 3.8), a relevant impact on the selection of the dosing 
regimens was observed when considering PK parameter uncertainty (‘novel approach’) compared 
to not considering PK parameter uncertainty (‘traditional approach’). With increasing elimination 
capacity of the kidney (i.e. increasing CLCRCG), an intensified dosing regimen was required earlier 
(i.e. at lower CLCRCG values) when using the novel approach compared to the traditional approach 
(Table S29): While, for instance, for a patient with ‘normal’ renal function (CLCRCG=90 mL/min) 
and a pathogen with a MIC of 2 mg/L, only the most intensified continuous dosing regimen (CI6: 
6000 mg, q24h following a 1000 mg, 30-min loading dose) was selected using the ‘novel 
approach’; for the ‘traditional approach’ a less intensified continuous-infusion dosing regimen 
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(CI3: 3000 mg, q24h following a 500 mg, 30-min loading dose) seemed adequate (Table S29). Of 
note, the differences between the dosing regimens identified based on the novel versus traditional 
approach were particularly relevant in less susceptible pathogens (Table S29).   
To sum up, it can be noted that the inclusion of parameter uncertainty into PTA/CFR analyses 
utilised for dosing selection may have clinical implications, even in case of relatively precisely 
estimated PK parameters. Thus, it is recommended to considered PK parameter uncertainty in 
future analyses, particularly for vulnerable patient populations such as critically ill patients for 
which adequate dosing is of crucial importance.  
Evaluation and optimisation of meropenem dosing dependent on CLCRCG. Due to the 
pronounced impact of CLCRCG on the PTA, caused by its strong influence on the descending part 
of the concentration-time profile, the dosing simulations for alternative dosing regimens in 
Project IV, were performed for varying CLCRCG values (Table 4.1, Analysis D). 
Overall, the analyses suggested that for bacteria of the S category (MIC≤2 mg/L), effective 
concentrations were reliably reached (i.e. 5th percentile of PTA≥90%) in all investigated patients 
with at least one of the eight investigated dosing regimens, even if displaying augmented renal 
function, a characteristic which is frequently observed in the ICU setting (Section 3.4.3.2). Bacteria 
of the I category, however, seemed to only be effectively treated in patients with renal insufficiency 
(MIC=4 mg/L: CLCRCG≤80 mL/min, MIC=8 mg/L: CLCRCG≤30 mL/min) using the most 
intensified dosing regimens (SI68/PI68/CI6). Conversely, for highly susceptible pathogens (e.g. 
MIC<0.12 mg/L for CLCRCG=90 mL/min), even lower than standard dosing seemed to be 
sufficient, however, advantages or disadvantages of such adaptions to lower dosing have to be 
further evaluated in prospective clinical trials. Yet, this finding demonstrated that reporting MIC 
values in the clinics, even within the low susceptible range, might be relevant.  
The systematic PK/PD analysis demonstrated superiority of prolonged over short-term infusion 
regimens and of continuous-infusion over prolonged infusion regimens for MIC≤4 mg/L and day 1 
of treatment – emphasising that even a stricter PK/PD target was evaluated for continuous infusion 
compared to the remaining infusion regimens. Previous investigations for meropenem revealed that 
continuous infusion – despite the reported instability [376–379] – is feasible at 25°C, if renewing 
the solution depending on the drug concentration twice or thrice daily (see Supplement of article 
by Minichmayr et al. [380]). For MIC>4 mg/L and P. aeruginosa or Acinetobacter spp. of the 
I category, prolonged infusion rather than continuous-infusion regimens was superior. 
Furthermore, the type of infusion (e.g. continuous vs. prolonged) on the achievement of effective 
exposure was more relevant than the administered total daily dose (e.g. 3000/3412.5 vs. 
6000/6875 mg). Yet, it needs to be kept in mind, that due to the initial loading dose on day 1, for 
continuous infusion total daily doses were ≤14.6% higher compared to the other regimens. Note, 
that the above-mentioned findings are based on the evaluation of the selected PK/PD targets (for 
SI and PI: 98%T>MIC, for CI: 98%T>4xMIC). The selection of the stricter target of 98%T>4xMIC for 
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continuous-infusion regimens, was deemed reasonable in light of the increasing spread of 
resistance [22] and the raised concerns that plateau-like meropenem concentrations achieved at 
steady state following continuous infusion, may – if close to/below the MIC value – favour the 
selection of resistant strains [42,381,382]. It needs to be noted that even stricter targets have been 
suggested: For instance, Tam et al. [42] suggested an target of Cmin values not only exceeding 4x 
but 6.2x the MIC value to supress in vitro resistance of Pseudomonas aeruginosa. Despite the strict 
target of 98%T>4xMIC the evaluation revealed that continuous-infusion regimens were superior over 
short-term or prolonged infusion regimens with respect to the PTA/CFR for MIC values ≤4 mg/L. 
However, trends might differ when evaluating other targets (e.g. 50%T>MIC or 50%T>4xMIC) or non-
critically ill patient populations.   
Conclusions and perspectives. The PK/PD analyses demonstrated that standard meropenem 
dosing is likely to result in ineffective meropenem exposure in a considerable fraction of critically 
ill patients, especially when assuming infections caused by less susceptible bacteria commonly 
encountered in ICU patients. Of the three covariates identified in the NLME PK model, CLCRCG 
was found to be a vital clinical determinant for PTA and was thus focus of the dosing simulations. 
While patients with higher CLCRCG and lower pathogen susceptibility required mainly intensified 
dosing regimens, even lower than standard doses seemed effective for highly susceptible 
pathogens. Integrating for the first time PK parameter uncertainty in the meropenem dosing 
simulations, allowed to more reliably judge the PTA results and hence dosing selections. 
Considering the available knowledge on the pathogen causing the infection and its susceptibility, 
which varies between hospitals, the comprehensive PK/PD analysis focused on the identification 
of improved dosing regimens based on the available level (L) of knowledge: L1: not knowing the 
infecting pathogens, L2: knowing the infecting pathogen, L3(-MIC): knowing the infecting pathogen 
and susceptibility category and L3(+MIC): knowing the MIC value. The findings of the present work 
indicate that dosing adjustment is needed, depending on a patient’s renal function and the 
susceptibility of the infecting pathogen. In addition to the assessment of effective exposure, which 
is certainly most relevant for the vulnerable patient population of ICU patients, future analyses 
shall aim at investigating dosing regimens with respect to the achievement of exposure linked to 
high risk of adverse drug reactions and/or occurrence of toxicity. In an analysis by Minichmayr et 
al. an upper threshold of steady state meropenem concentrations of 32 mg/L was used in a PK 
analysis of critically ill patients. Nevertheless, as currently available evidence for meropenem 
toxicity thresholds in critically ill patients is limited, future clinical research is warranted in this 
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In contrast to most analyses performed to evaluate and/or optimise meropenem dosing in special 
patient populations [335,345,349,365,384], the present thesis went one step further and translated 
the research results into the clinics. The focus was set on the development of easy-to-use tools 
which convey the clinically relevant aspects of the pharmacometric modelling and simulation 
results and are easily applicable and interpretable by non-pharmacometricians (Project III, IV; 
research category: translational research; Figure 4.1). 
4.4.1 Risk assessment tool: MeroRisk Calculator (Project III) 
To enable the practical applicability of the quantified relationship between renal function and 
meropenem exposure and consequently target attainment, in Project III a risk assessment tool, the 
MeroRisk Calculator, was developed in a commonly available and known software (Microsoft 
Excel®; Section 3.3.3). The beta version of this tool is publicly and freely accessible as additional 
file of the open access article by Ehmann et al. Critical Care (2017) [233] and has been 
accompanied by an dedicated editorial by Abdul-Aziz et al. Critical Care (2017) [385], supporting 
the translational approach taken in this analysis: ‘investigators are certainly heading in the right 
direction with their proposed solution’. This easy-to-use tool allows the assessment of the risk of 
target (100%T>MIC) non-attainment, i.e. ineffective meropenem exposure, for non-CRRT patients 
displaying renal function within a broad range (CLCRCG 25–255 mL/min) and receiving standard 
dosing of meropenem (1000 mg every 8 h as 30-min infusions). The PK/PD target 100%T>MIC was 
selected for the assessment of target attainment as it originates from the results of clinical 
investigations and as the PTA results in the present work were comparable to the results of the 
additionally investigated target 50%T>4xMIC (Section 3.3.2.2). The risk of target non-attainment of 
meropenem was implemented depending on creatinine clearance estimated according to Cockcroft 
and Gault (CLCRCG) rather than creatinine clearance determined by 24-h urine collection 
(CLCRUC), as CLCRCG can be assessed much more easily in clinical practise and as the relationship 
between CLCRUC and meropenem exposure was not more predictive than between CLCRCG and 
meropenem exposure (Figure S38).  
To tool can be easily applied in three steps: In step 1, the user needs to provide only the CLCRCG 
or its determinants (i.e., sex, age, total body weight and the routinely determined laboratory value 
serum creatinine; Figure 3.15). In step 2, the MIC value of a pathogen determined or suspected in 
the patient needs to be provided. Should MIC values not be available, the user has the option to 
select an MIC breakpoint for important pathogens from the EUCAST database [4]. In step 3, the 
tool then calculates the risk of target non-attainment which is displayed with a 3-colour coding 
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system, indicating low-risk patients in green (probability of target non-attainment: ≤10%), 
medium-risk patients in orange (>10%-<50%) and high-risk patients in red (≥50%). Because only 
a limited number of patients with augmented or severely impaired renal function were included in 
this analysis, the uncertainty of the CLCRCG-meropenem exposure relationship implemented in the 
MeroRisk Calculator is higher for the extremes of the renal function spectrum. Furthermore, the 
user of the tool needs to keep in mind that in addition to CLCRCG, other factors might influence 
meropenem C8h values. To visualise the prediction uncertainty (i.e., uncertainty in the CLCRCG-
meropenem C8h relationship combined with the variability in C8h values) of the calculated 
meropenem C8h value for a patient’s CLCRCG, the prediction interval around the CLCRCG-
meropenem exposure relationship is additionally provided in the risk assessment tool. Of particular 
note, using the MeroRisk calculator does not require the measurement of a meropenem serum 
concentration of a patient and can thus be used a priori to meropenem treatment. In case of 
available meropenem concentrations in a patient, use of therapeutic drug monitoring is encouraged 
to aid therapeutic decision making in the course of meropenem treatment.  
Conclusion and perspectives. The MeroRisk Calculator, an easy-to-use tool to assess the risk of 
PK/PD target non-attainment after meropenem standard treatment, has been developed for 
critically ill patients. The current beta version of the MeroRisk Calculator is intended to be used in 
the setting of clinical research and training. As also suggested in the editorial by Abdul-Aziz and 
colleagues [385], as a next step, a comprehensive prospective validation of the risk calculator in 
clinical research setting is warranted. In a first step, the evaluation of the ‘PK-side’ of the tool shall 
be aimed for, i.e. an evaluation of the predictivity for the meropenem C8h values based on the 
CLCRCG of a patient. In addition, in a second step, clinical studies shall further address the ‘PD-
side’ of the tool, i.e. evaluate whether the risk of target non-attainment correlates with clinical PD 
data (e.g. change in inflammation makers). Step 1 has already been initiated in collaboration with 
the University Hospital, LMU Munich, Germany, and PK data collection based on routinely 
monitored TDM samples is currently ongoing (ClinicalTrials.gov Identifier: NCT03985605). In 
future, the newly developed risk assessment tool as a graphical user interface might, if all 
requirements are met, be beneficial in clinical practise for therapeutic decision making. An ICU 
patient’s risk of target non-attainment, given his/her renal function and the MIC value of the 
infecting pathogen, would already be accessible when no meropenem concentration measurement 
is available, such as prior to the start of antibiotic treatment.  
4.4.2 Three-level dosing algorithm (Project IV) 
In the present thesis, a three-level meropenem dosing algorithm (Table 3.10) was generated 
proposing dosing regimens for meropenem in critically ill patients, aiming to reach effective 
meropenem exposure by means of a comprehensive NLME pharmacokinetic/pharmacodynamic 
Discussion 
157 
modelling analysis. In short, the investigated dosing regimens are provided in an intuitive tabular 
overview, which only considers creatinine clearance as the crucial patient-specific factor for 
meropenem target attainment. No additional covariates were needed to be included, as they only 
showed little impact on the achievement of effective antibiotic exposure. Additionally, the dosing 
overview considers different levels of pathogen-specific information (L1: pathogen unknown, L2: 
pathogen known, L3(-MIC): pathogen and susceptibility category known, L3(+MIC): MIC value known) 
as might be encountered in different clinical settings. Moreover, the reliability of the proposed 
dosing regimens is deemed high, as the underlying analysis considered also the uncertainty in the 
estimated PK model parameters.  
For the vulnerable population of critically ill patients, TDM has been recommended for individual 
dose adjustment [327,339,386,387]. However, TDM of antibiotics is still only rarely available in 
clinical routine, e.g. the recent ADMIN-ICU survey indicated only 2% of the investigated ICUs 
implementing TDM for carbapenems [325]. As especially at start, but also during meropenem 
treatment, TDM is mostly not available, reliable dosing recommendations are needed. In contrast 
to previous suggestions, the present work systematically investigated seven alternative dosing 
regimens for meropenem given different levels of information about the pathogen and considered 
PK parameter uncertainty in the underlying simulations [347,350,369,380,388]. To the best of 
found knowledge, this is the first analysis of meropenem which also considered PK parameter 
uncertainty in the MC simulations [245] underlying the selection of dosing regimens for the dosing 
algorithm. Compared to the traditional approach not considering PK parameter uncertainty, the 
dose selection was more conservative (Table S29) and thus, the results were deemed to be more 
reliable, which may be important to ensure effective meropenem exposure especially for critically 
ill patients. The developed three-level dosing algorithm (Table 3.10) summarises improved dosing 
regimens based on a patient’s renal function and the level of knowledge about a pathogen. Hence, 
the algorithm provides information for different stages of treatment (pathogen and/or antibiogram 
available or not (yet)) and for different ways of reporting susceptibility in the patient records (S/R 
classification or MIC value). Choosing the dosing regimen based on the highest level of knowledge 
about a pathogen could allow to achieve effective exposure with the potential advantage of more 
probable or faster eradication of the pathogen [38,40,168] and reduced risk of unnecessary high or 
toxic concentrations and of resistance development and spread.   
To give an example, in ‘Level 1’ (pathogen unknown; based on the non-species related EUCAST 
PK/PD breakpoints, e.g. S=2 mg/L [246]) for patients with normal renal function 
(CRCL≥90 mL/min) a very high dosing regimen is proposed (CI6, Figure 4.4). However, if the 
infecting strain is known (‘Level 2’) in most cases (for all evaluated Enterobacteriaceae) it is 
recommended to reduce the dosing. For the bacteria listed in the algorithm, only for infections with 
P. aeruginosa or Acinetobacter spp. none of the investigated dosing regimens was sufficient, which 
can be explained by the higher proportion of pathogens in the I or R category for meropenem [132]. 
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Figure 4.4: Example illustrating the application of the dosing algorithm, which is also described in the result 
chapter (Section 3.4.4) (modified from [243]). 
Left: Flow chart; Right: Snapshot of parts of the dosing algorithm (s. main text, Table 4) relevant for the example given on the 
left in black font.  
Dosing regimens: SI212: 1000 mg, 30-min i.v. infusion, q12h; SI38: 1000 mg, 30-min i.v. infusion, q8h (=standard dosing; 
highlighted in bold); SI68: 2000 mg, 30-min i.v. infusion, q8h; PI212: 1000 mg, 3-h i.v. infusion, q12h; PI38: 1000 mg, 3-h i.v. 
infusion, q8h; PI68: 2000 mg, 3-h i.v. infusion, q8h; CI3: 3000 mg, CI, q24h following 500 mg, 30-min loading dose; CI6: 6000 
mg, CI, q24h following 1000 mg, 30-min loading dose.  
For CI regimens (CI3, CI6) consider to renew the infusion solution dependent on the drug concentration twice or thrice daily 
(see supplement of article [380]) to ensure the stability of meropenem.  
Abbreviations: CI: Continuous infusion; CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]; i.v.: 
Intravenous; MIC: Minimum inhibitory concentration; qXh: Every X hours (e.g. q8h: every 8 h). 
In such situations, combination therapy might be an option for critically ill patients, which has been 
recommended by the most recent International Guideline for Management of Sepsis and Septic 
Shock [37] for empirical treatment of multidrug-resistant pathogens such as P. aeruginosa or 
Acinetobacter spp. However, no clear evidence is yet established that suggests the use of 
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combination therapies over monotherapy for infections with e.g. P. aeruginosa [389]. Thus, future 
randomised controlled trials, that assess survival and resistance development in large patient 
cohorts, are warranted. When applying the dosing algorithm, the availability of additional 
information on the susceptibility of the pathogen (either as S/I/R categorisation, ‘Level 3(-MIC)’ or 
as MIC value, ‘Level 3(+MIC)’) would allow to adjust and further specify the dosing for the specific 
patient-pathogen combination (Figure 4.4 bottom). Of note, the PTA and CFR analyses of 
treatment day 1 and 4 revealed only little difference, with the results of day 1 being slightly more 
conservative. This is in line with the short elimination half-life of meropenem (study ICU patient: 
median=2.27 h, range=0.946-5.64 h) and the therefore limited accumulation of meropenem over 
time of treatment. In light of the minor difference between the results of days 1 and 4, the dosing 
algorithm – which is provided for the start of treatment – is considered appropriate also during later 
meropenem treatment.  
Conclusion and perspectives. In conclusion, a three-level meropenem dosing algorithm was 
developed, suggesting meropenem dosing regimens for critically ill patients based on their renal 
function as well as different levels of knowledge about the pathogen. Additional independent 
clinical studies will be necessary to validate the dosing algorithm in order to make it applicable in 
clinical practise. Apart from evaluating the proposed dosing regimen with respect to improved 
clinical outcome, the assessment of the occurrence of adverse drug reactions and toxicity and 
resistance development of the pathogens is warranted. A first prospective clinical investigation has 
already been initiated in collaboration with the University Hospital Charité – Universitätsmedizin 
Berlin, Germany.   
The meropenem dosing algorithm is provided for a broad range of CLCRCG values, but fixed body 
weight and albumin concentration, which was deemed reasonable considering the pronounced 
impact of CLCRCG on the PTA (Section 4.3.2). Particular attention should be paid to the extremes 
of the renal function spectrum, considering the limited number of patients with severely impaired 
and augmented renal function that were included in the underlying analyses. If aiming at 
additionally taking body weight and albumin values into account, the use of the full NLME PK 
model by means of a dosing software (e.g. TDMx: tdmx.eu [309], InsightRx: insight-rx.com, 
DoseMeRx: doseme-rx.com, BestDose: lapk.org/bestdose.php) is required, which can ultimately 
allow to determine an improved dosing regimen for individual patients (with individual CLCRCG-
weight-albumin combinations). While, e.g. in TDMx the ‘Probabilistic Dosing’ module would 
facilitate a priori dose suggestion based on the covariates implemented in the model, the ‘Bayesian 
dosing’ module would allow a posterior dose suggestion considering in addition to the covariate 
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Overall conclus ions and perspectives  
The present thesis has taken substantial steps towards therapeutic decision support of antibiotic 
dosing in special patient populations, leveraging pharmacometric modelling and simulation 
approaches in basic, applied and translational research.  
The thesis focused on the two clinically relevant antibiotic drugs, ‘linezolid’ and ‘meropenem’, in 
the selected special patient populations of ‘obese surgical patients’ and ‘critically ill patients’, 
respectively. 
As basic research, the successfully developed pharmacometric models contributed to an advanced 
quantitative understanding of the antibiotic PK in these special patient populations. Integrating 
clinical microdialysis data into the pharmacometric model, as done for linezolid, advanced the 
understanding of the distribution of the antibiotic drug to the potential target site of bacterial 
infection. This provides valuable information on the antibiotic exposure at the target site, which is 
the driving factor for antibacterial efficacy. Furthermore, the pharmacometric models allowed to 
better characterise the PK variabilities between and within patients and importantly also to identify 
factors causing the observed variabilities. For meropenem, high inter- and intrapatient variability 
was observed in the critically ill population which could be explained to a large extent by three 
highly diverse patient-specific characteristics (renal function, body weight and serum albumin 
concentrations). Besides patient-specific characteristics (LBW, obesity status), the modelling 
revealed also surgery-specific characteristics (anaesthesia status and haemodynamic changes) 
influencing the PK of linezolid. The identification of such factors is of crucial importance for 
individual exposure predictions, which serve as basis for model-based dosing suggestions, as 
utilised within the applied research part of present thesis.  
In addition to the PK-related aspects, the present work contributed to a more detailed 
characterisation of the variability in the microdialysis sampling technique, the method of choice 
for determining unbound (i.e. pharmacologically active) drug concentrations directly at the target 
site. Integrating the data originating from a variety of clinical microdialysis samplings into the 
pharmacometric model, enabled to (i) discriminate between PK and microdialysis methodology-
related variabilities and to (ii) further dissect and quantify different levels of variability in the 
microdialysis methodology. This illustrates how pharmacometric modelling approaches can be 
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leveraged to assess data other than PK. Applying the proposed approach to a larger number of 
microdialysis sampling data, would further inform the variability levels and provide valuable 
knowledge on the interpretation/reliability of target site concentrations determined by 
microdialysis. In summary, the present thesis successfully utilised pharmacometric modelling 
approaches to synthesise knowledge on the antibiotic PK in special patient groups, as well as on 
the variability in the microdialysis technique.  
The application of the developed pharmacometric models enabled the evaluation of standard 
antibiotic dosing regimens in special patient groups with respect to the attainment of effective 
antibiotic exposure – crucial for antibacterial efficacy. Overall, the results of the present thesis 
indicate that standard dosing frequently results in ineffective antibiotic exposure in these special 
patient populations, partly even for susceptible pathogens. Utilising the pharmacometric models 
allowed to determine factors associated with ineffective exposure and thus enabled to identify 
patients at potential risk of therapy failure. For meropenem treatment in critically ill patients, the 
risk of ineffective exposure was strongly related to the renal function of the patient. The risk was 
highest for patients with normal or augmented renal function and expectedly for pathogens with 
low susceptibility. Thus, the present work underlined the need of tailoring the dosing regimen to 
patient-specific and pathogen-specific characteristics. The application of pharmacometric models 
to simulate the antibiotic exposure in ‘at risk patients’ for various alternative dosing regimens (e.g. 
intensified dose and/or prolonged infusion duration and/or shortened dosing interval), allowed to 
identify regimens resulting in effective antibiotic exposure. By additionally integrating different 
levels of knowledge about the pathogen (i.e. pathogen unknown / pathogen known / pathogen + 
susceptibility category known / MIC value known) into simulations, the present work did not only 
consider the patient for dosing suggestions, but also the available knowledge about the pathogen.  
The present thesis took one step further and translated the model-based dosing suggestions into 
practical applicability. The focus was set on the critically ill population, a highly vulnerable 
population which exhibits large infection-related mortality rates. To this end, the present thesis 
developed easy-to-use tools that convey the clinically relevant aspects of the pharmacometric 
modelling and simulation results without presenting complex equations or graphics. The risk 
assessment tool ‘MeroRisk Calculator’ is provided in a commonly used software (Microsoft 
Excel®) which is familiar to many health-care professionals. The tool supports the user in 
identifying ‘at-risk patients’ for which standard meropenem dosing is likely to result in ineffective 
exposure and encourages meropenem dosing adjustment in these patients. The newly developed 
‘3-level dosing algorithm’ provides an intuitive tabular overview to support dosing selection for 
individual patients. The algorithm is applicable for different levels of knowledge about the 
suspected or infecting pathogen and therefore offers a wide range of application. This is particularly 
helpful in situations in which the MIC value is not (yet) available. The newly developed tools are 
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easily applicable and interpretable by non-pharmacometricians and therefore have the potential to 
support a rapid selection of an individualised dosing regimen in the clinics – which is of crucial 
importance for the critically ill population in which ‘speed is life’. In the future, after successful 
clinical evaluation, such tools could be used directly by the attending physician and/or by other 
health-care professional (e.g. members of antibiotic steward ship team, clinical pharmacists).   
By translating the modelling and simulation results into the clinics, the present thesis took 
substantial steps towards model-based therapeutic decision support to combat bacterial infections 
with a rational and patient-centred treatment. To make the tools applicable in clinical practise, a 
comprehensive evaluation of the tools in clinical research setting is warranted. First clinical studies 
have already been initiated, e.g. the PK predictivity of the MeroRisk calculator is currently under 
clinical investigation. Additional clinical studies should evaluate the tools with respect to clinical 
response (i.e. efficacy/clinical benefit and safety) and emergence of antimicrobial resistance. 
Collected clinical data could also be used to further refine the underlying pharmacometric models. 
In light of the increasing availability of electronic health record systems in hospitals, a link between 
therapeutic decision supporting tools and patient-specific information in the systems, could provide 
automated warnings for ‘at-risk patients’ or model-based dosing regimen suggestions. This would 
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 Supplementary tables 
Table S1 (Project I) Inclusion and exclusion criteria. 
Inclusion criteria  Exclusion criteria 
Index group: 
•  ge ≥18 ye rs 
• Abdominal surgical intervention with a need 
of an antibiotic prophylaxis 
• Written informed consent  
• B   of ≥35 kg/ ² (= at least class II obesity1) 
 
Control group:  
•  ge ≥18 ye rs 
• Abdominal surgical intervention with a need 
of an antibiotic prophylaxis 
• Written informed consent  
• BMI of <30 kg/m² (= up to max. overweight1)  
 
• Treatment with the study medication within 
72 h before surgery 
• Known allergic reactions, hypersensitivity or 
contraindications against one of the drugs 
• Severe liver insufficiency 
• Bone-marrow function disorders (e.g. after 
cytostatic treatment) or diseases of the 
haematopoietic system 
• Genetically caused Glucose-6-phosphate 
dehydrogenase deficiency  
• Acute hepatic porphyria 
• Hypotension 
• Phenylketonuria or hereditary fructose 
intolerance 
• Treatment with drugs that inhibit monoamine 
oxidases A or B, within the last 2 weeks 
• Pregnancy or breastfeeding 
• Participation of additional interventional 
therapy studies according to the German 
medicines law (AMG) 
1Classification according to WHO.  







Table S2 (Project IV) Overview of patient-specific characteristics recorded during study period. Pre-selected patient-specific characteristics for covariate analysis are 
highlighted in blue. 
Measured once during study period Measured longitudinally during study period 
A: categorical B: continuous A: categorical B: continuous 




• Sepsis  
• 28-day 
mortality 
• Liver transpl. 
• Lung transpl. 
• ARDS 
• Peritonitis4  
• Cause of 
sepsis  
• Age 
• Body height 
• Body weight 
• BMI4 
• Anuria2,4 Disease score items1: 
• Body temperature2 
• Mean arterial pressure2 
• Heart rate2 
• Respiratory rate2 
• Respiratory rate2 
• PaO2/FiO2 ratio2 
• Cardio vascular system2 
• Glasgow coma score2 
• Urine volume2 
• Fluid balance2 
• Urine creatinine2 
• Urine albumin2 
• Serum creatinine2 
• Serum albumin2 













• Bilirubin2  
• Aspartate 
Aminotransferase2 
• Alanine Aminotransferase2 
• Cholinesterase enzyme2 
• Factor V2 
 
• Interleukin-63 
• C-reactive protein3 




• Potassium2  
• Glucose2 
• Inorganic phosphate2 




• APACHE II Score 
• SOFA Score 
1Extracted from APACHE II or SOFA score; 2Determined once every study day; 3Determined once every study day and the two days before and after the study period; 4Derived/Computed from 
determined/measured patient-specific characteristics.  
Abbreviations: APACHE: Acute Physiology And Chronic Health Evaluation [1]; ARDS: Acute respiratory distress syndrome; BMI: Body mass index; CD64: Cluster of Differentiation 64; CLCRCG: 
Creatinine clearance estimated according to Cockcroft and Gault [2]; CLCRUC: Creatinine clearance measured using urine collection; ECMO: Extracorporeal membrane oxygenation; PaO2/FiO2: Ratio 
of partial pressure arterial oxygen and fraction of inspired oxygen; RRT: Renal replacement therapy; transpl: Transplantation; SOFA: Sepsis-related Organ Failure Assessment [6]. 
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Table S3: (Project I) Parameter estimates of plasma NLME base models for linezolid with different clearance 
(CL) models. 
Model A: Linear CL; Model B: Heart rate as covariate on CL; Model C: Time-varying CL according to an Emax model after end 
of anaesthesia; Model D: Concentration-dependent parallel linear and nonlinear Michaelis-Menten clearance. 


















OFV 189.775 64.618 70.173 161.586 
Fixed-effects parameters 
θ CL [L/h] 7.34 (6.20) 5.812 (8.80) 2.063 (22.3) 7.424 (6.20) 
θ CLTime-varying_max [L/h] -- 6.83 (18.0) -- -- 
θ t50 [h] -- 1.53 (25.6) -- -- 
θ Vmax [mg/h] -- -- 45.9 (8.10) -- 
θ Km [mg/L] -- -- 1.82 (21.3) -- 
θ HR_CL, % -- -- -- 1.375 (27.1) 
θ V1 [L] 12.3 (12.6) 15.7 (9.70) 15.5 (10.3) 12.3 (12.0) 
θ Q [L/h] 65.5 (12.0) 47.2 (12.8) 49.9 (12.0) 65.7 (14.1) 
θ V2 [L] 25.2 (7.50) 27.4 (6.10) 28.4 (6.80) 26.2 (7.60) 
θ fu, % 83.6 (0.60) 85.5 (0.70) 85.6 (0.70) 83.9 (0.60) 
Interindividual variability parameters, %CV 
ω  L
 
35.1 (17.3) 49.7 (19.2) 94.4 (18.6) 35.9 (15.5) 
ω V1 60.3 (13.5) 49.1 (14.0) 45.9 (13.9) 57.7 (14.9) 
ω Q
 
57.4 (21.6) 61.5 (18.8) 60.2 (22.3) 61.3 (20.1) 
ω V2 30.1 (17.2) 30.7 (14.5) 28.5 (17.1) 29.0 (16.9) 
ω  LTime-varying_max  41.5 (17.5) -- -- 
Residual variability parameters, %CV 
prop 𝐶𝑃_𝑡𝑜𝑡 6.7 (8.40) 4.21 (13.9) 4.59 (8.10) 6.17 (9.20) 
prop 𝐶𝑃_𝑢 3.4 (17.2) 3.71 (14.3) 3.95 (13.6) 3.53 (19.5) 
1RSE of random-effects parameter estimates ω and  are reported on approximate standard deviation scale; 2Linear clearance 
during anaesthesia; 3Linear clearance of parallel linear/nonlinear clearance model; 4For median heart rate of 71 min-1; 5Change 
in clearance per min-1 deviation from median heart rate of 71 min-1 (i.e. indicates 13.7% change in clearance per 10 min-1 heart 
rate deviation from median; linear HR-CL relationship).  
Abbreviations: CL: Clearance; CLTimevarying_max: Maximum time-varying clearance; 𝐶𝑃_𝑡𝑜𝑡: Total plasma concentrations; 𝐶𝑃_𝑢: 
Unbound plasma concentrations; CV: Coefficient of variation (calculated for random-effects parameters according to Eq. 2.6); 
fu: Fraction unbound; Km: Michaelis-Menten constant; HR_CL: Effect of heart rate on CL; NLME: Nonlinear mixed-effects; Q: 
Intercompartmental clearance; RSE: Relative standard error; t50 : Time to reach half-maximum of time-varying clearance; V1, 
V2: Volume of distribution parameters of central and peripheral CMTs; Vmax: Maximum elimination rate; θ: Fixed-effects 





Table S4: (Project I) Parameter estimates (PK parameters of unbound linezolid and microdialysis 
methodology-related parameters) of the base NLME model of linezolid in obese and nonobese surgical 
patients, already including obesity status as covariate on methodology-related parameter RR. For final joint 
NLME model including all covariates on PK parameters see Table 3.2. 
Parameter [unit] Final model  
‘Unbound’ estimate  
(RSE1, %) 
Computed ‘total’ parameter2  
OFV -50.032 -- 
Fixed-effects parameters 
θ CLu4 [L/h] 1.95 (31.5) 1.68 
θ Vmax,u [mg/h] 45.3 (9.80) 38.9 
θ Km,u [mg/L] 0.977 (35.9) 0.839 
θ V1,u [L]5 17.5 (9.50) 15.0 
θ Qu [L/h]5 56.8 (9.70) 48.8 
θ V2,u [L]5 34.2 (6.30) 29.4 
θ fu, % 85.9 (0.80) -- 
θ TFu, % 55.6 (5.60) -- 
θ RROBE, % 35.7 (7.10) -- 
θ RRNOBE, % 59.5 (5.00) -- 
Interindividual and method variability parameters, %CV 
ω  Lu 105 (25.2) -- 
ω Km,u 102.9 (33.4) -- 
ω V1,u 55.9 (11.4) -- 
ω Qu 53.2 (15.7)  -- 
ω V2,u 30.3 (16.1) -- 
ω  Fu 22.3 (15.7) -- 
ωIntercatheter RR 26.2 (18.7) -- 
ωIntracatheter RR 26.9 (10.6) -- 
Residual variability parameters, %CV 
prop 𝐶𝑃_𝑡𝑜𝑡 5.02 (14.4) -- 
prop 𝐶𝑃_𝑢 4.82 (14.7) -- 
prop 𝐶µ𝐷 15.3 (6.00) -- 
prop 𝐶𝑅𝐷 1.9 FIX3 -- 
1RSE of random-effects parameter estimates ω and  are reported on approximate standard deviation scale; 2’Total’ 
parameter=’Unbound’ parameter estimate∙fu; 3Fixed to interassay variability [228]. 
Abbreviations: CLu: Clearance of unbound linezolid; CLTot,u: Total clearance of unbound linezolid; CMT: Compartment; CP_tot: 
Total plasma concentrations; 𝐶𝑃_𝑢: Unbound plasma concentrations; 𝐶𝑅𝐷: Retrodialysate concentration; 𝐶𝑅𝑃: Retroperfusate 
concentration; 𝐶µD: Microdialysate concentration; CV: Coefficient of variation (calculated for random-effects parameters 
according to Eq. 2.6); fu: Fraction unbound; Km,u: Michaelis-Menten constant of unbound linezolid; NLME: Nonlinear mixed-
effects; Qu: Intercompartmental clearance of unbound linezolid; RSE: Relative standard error; RROBE, RRNOBE: Relative recovery 
for obese and nonobese patients; TFu: Tissue factor of unbound linezolid; V1,u, V2,u: Volume of distribution parameters of central 




Table S5: (Project I) Strategy of the stepwise covariate analysis to identify the impact of body size and renal 
function markers on the PK of linezolid. [continued on next page] 
Step PK parameter Body size descriptor Additional information 
Step 1: Body size on TF 
1 A TF OBE -- 
1 B TF WT -- 
1 C TF LBW -- 
1 D TF FM  -- 
1 E TF NFM -- 
Step 2: Body size on V1 and V2 
2 A V1, V2 WT -- 
2 B V1, V2 LBW -- 
2 C V1, V2 Same NFM -- 
2 D V1, V2 Separate NFM -- 
2 E V1 NFM -- 
2 F V2 NFM -- 
2 G V1, V2 NFM, LBW, respectively -- 
2 H V1, V2 LBW, NFM, respectively -- 
Step 3: Body size on Q 
3 A Q TBW w and w/o allometric scaling 
3 B Q LBW w and w/o allometric scaling 
3 C Q NFM w and w/o allometric scaling 
Step 41: Body size on CL and Vmax 
4 A CL, Vmax TBW w and w/o allometric scaling 
4 B CL, Vmax LBW w and w/o allometric scaling 
4 C CL, Vmax Same NFM w and w/o allometric scaling 
4 D CL, Vmax Separate NFM w and w/o allometric scaling 
4 E CL NFM w and w/o allometric scaling 
4 F Vmax NFM w and w/o allometric scaling 
4 G CL, Vmax NFM, LBW, respectively w and w/o allometric scaling 
4 H CL, Vmax LBW, NFM, respectively w and w/o allometric scaling 
4 I CL, Vmax LBW w allometric scaling 
   + Same FM see table footnote3 
4 J CL, Vmax LBW w allometric scaling 
   + Separate FM see table footnote4 
Step 5: Renal function marker on CL 
5 A CL CREA -- 
5 B CL, Vmax CREA -- 
5 C CL CLCRCG_LBW -- 
5 D CL, Vmax CLCRCG_LBW -- 
Step 6: 1-by-1 backward deletion2 
 
Step 7: Additional impact of OBE  
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Step PK parameter Body size descriptor Additional information 
7 A CL OBE -- 
7 B Vmax OBE -- 
7 C V1 OBE -- 
7 D V2 OBE -- 
7 E Q OBE -- 
Step 8: Reinvestigate OBE on TF 
8 A V2 OBE Instead of OBE on TF 
8 B Q OBE Instead of OBE on TF 
1Based on base model with IIV on Vmax; 2Backward deletion: for df=1 ΔOFV≥6.64 (α=0.01).  
3Step 4I: 𝑇𝑉𝐶𝐿𝐿𝐵𝑊,𝐹𝑀 = 𝜃𝐶𝐿 ∙ ( 𝐿𝐵𝑊𝐿𝐵𝑊𝑟𝑒𝑓)0.75 ∙ 𝑒𝜃𝐹𝑀∙(𝐹𝑀−𝐹𝑀𝑟𝑒𝑓) , 𝑇𝑉𝑉𝑚𝑎𝑥𝐿𝐵𝑊,𝐹𝑀 = 𝜃𝑉𝑚𝑎𝑥 ∙ ( 𝐿𝐵𝑊𝐿𝐵𝑊𝑟𝑒𝑓)0.75 ∙ 𝑒𝜃𝐹𝑀∙(𝐹𝑀−𝐹𝑀𝑟𝑒𝑓)   
4Step 4J: 𝑇𝑉𝐶𝐿𝐿𝐵𝑊,𝐹𝑀 = 𝜃𝐶𝐿 ∙ ( 𝐿𝐵𝑊𝐿𝐵𝑊𝑟𝑒𝑓)0.75 ∙ 𝑒𝜃𝐹𝑀_𝐶𝐿∙(𝐹𝑀−𝐹𝑀𝑟𝑒𝑓) , 𝑇𝑉𝑉𝑚𝑎𝑥𝐿𝐵𝑊,𝐹𝑀 = 𝜃𝑉𝑚𝑎𝑥 ∙ ( 𝐿𝐵𝑊𝐿𝐵𝑊𝑟𝑒𝑓)0.75 ∙ 𝑒𝜃𝐹𝑀_𝑉𝑚𝑎𝑥∙(𝐹𝑀−𝐹𝑀𝑟𝑒𝑓)  
Abbreviations: CL: Clearance; CMT: Compartment; CLCRCG_LBW: Creatinine clearance according to Cockcroft and Gault using 
LBW; CREA: Serum creatinine concentration: FM: Fat mass; FMref: Reference FM value; LBW: Lean body weight; LBWref: 
Reference LBW value; NFM: Normalised fat mass; OBE: Obesity status; PK: Pharmacokinetics; Q: Intercompartmental 
clearance; TF: Tissue factor; TVCLLBW,FM: Typical value of CL for a given LBW and FM value; WT: Total body weight; V1, V2: 
Volume of distribution parameters of central and peripheral CMTs; Vmax: Maximum elimination rate; TVVmaxLBW,FM: Typical 
value of Vmax for a given LBW and FM value; w: With; w/o: Without; 𝜃CL: Typical value of CL for LBWref and FMref; 𝜃𝑉𝑚𝑎𝑥: 
Typical value of Vmax for LBWref and FMref; 𝜃𝐹𝑀: Impact of FM on CL and Vmax; 𝜃𝐹𝑀_𝐶𝐿: Impact of FM on CL; 𝜃𝐹𝑀_𝑉𝑚𝑎𝑥: 
Impact of FM on Vmax.   
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Table S6: (Project I) Parameter estimates of NLME model of linezolid in obese and nonobese surgical 
patients including body size as covariate on linezolid clearance parameters.   
Selected models of step 4 (allometrically scaled: 4 A – 4 D) of the covariate analysis (Table S5) are presented for illustration. 
Reference model: Selected covariate model of step 3 of the covariate analysis (i.e. OBE on TF, LBW on V1 and V2 with 
allometric exponent of 1, LBW on Q with allometric exponent of 0.75). 
Parameter [unit] Estimate (RSE1, %) 
Reference model 
(Step 3) 
Step 4 A: 
TBW on CL, 
Vmax 
Step 4 B: 
LBW on CL, 
Vmax 
Step 4 C: 
Same NFM on 
CL, Vmax 
Step 4 D: 
Separate NFM on 
CL, Vmax 
OFV -82.309 -50.184 -67.508 -68.556 -68.584 
Fixed-effects parameters  
θ CLu [L/h] 2.00 (29.8) 1.49 (49.6) 1.88 (34.8) 2.09 (32.2) 2.03 (36.0) 
θ Vmax,u [mg/h] 44.2 (9.00) 39.4 (28.7) 52.7 (8.40) 55.0 (9.20) 55.5 (7.00) 
θ Km,u [mg/L] 0.89 (37.5) 1.53 (66.0) 1.41 (27.1) 1.31 (26.6) 1.34 (26.7) 
θ V1,u [L] 19.3 (7.80) 19.5 (7.90) 19.4 (7.70) 19.4 (7.70) 19.4 (7.70) 
θ Qu [L/h] 61.0 (8.80) 60.3 (9.00) 60.8 (8.80) 60.8 (8.80) 60.8 (8.80) 
θ V2,u [L] 37.4 (4.30) 36.8 (4.60) 37. (4.40) 37.2 (4.40) 37.2 (4.40) 
θ fu, % 85.8 (0.80) 85.6 (0.80) 85.7 (0.80) 85.7 (0.80) 85.7 (0.80) 
θ TFOBE,u, % 47.4 (8.10) 38.7 (7.60) 38.7 (7.60) 38.7 (7.60) 38.7 (7.60) 
θ TFNOBE,u, % 64.4 (6.50) 64.6 (6.50) 64.5 (6.50) 64.5 (6.50) 64.5 (6.50) 
θ RROBE, % 38.7 (7.60) 38.7 (7.60) 38.7 (7.60) 38.7 (7.60) 38.7 (7.60) 
θ RRNOBE, % 55.5 (7.00) 55.5 (7.00) 55.5 (7.00) 55.5 (7.00) 55.5 (7.00) 
Interindividual and method variability parameters, %CV  
ω  Lu 107 (24.0) 153 (24.9) 130 (23.2) 124 (23.0) 127 (21.1) 
ω Km,u 127 (32.2) 125 (20.9) 113 (17.9) 122 (19.1) 120 (18.5) 
ω V1,u 40.7 (12.1) 40.4 (12.1) 40.4 (12.1) 40.4 (12.0) 40.5 (12.0) 
ω Qu 46.3 (17.3) 46.9 (17.1) 46.7 (17.2) 46.5 (17.3) 46.5 (17.3) 
ω V2,u 15.9 (28.0) 17.0 (26.1) 16.4 (26.6) 16.3 (27.0) 16.3 (27.0) 
ω  Fu 18.2 (25.4) 18.2 (25.5) 18.2 (25.5) 18.2 (25.5) 18.2 (25.5) 
ωIntercatheter RR 27.2 (23.8) 27.2 (23.9) 27.2 (23.8) 27.2 (23.9) 27.2 (23.9) 
Residual variability parameters, %CV  
prop 𝐶𝑃_𝑡𝑜𝑡 5.04 (14.5) 5.14 (14.4) 5.08 (14.7) 5.07 (14.6) 5.06 (14.6) 
prop 𝐶𝑃_𝑢 4.95 (14.6) 4.96 (15.0) 4.97 (14.8) 4.97 (14.7) 4.97 (14.8) 
prop 𝐶µ𝐷 15.3 (6.10) 15.3 (6.30) 15.3 (6.20) 15.3 (6.10) 15.3 (6.20) 
prop 𝐶𝑅𝐷 27.4 (12.0) 27.4 (12.0) 27.4 (12.0) 27.4 (12.0) 27.4 (12.0) 
1RSE of random-effects parameter estimates ω and  are reported on approximate standard deviation scale.  
Abbreviations: CLu: Clearance of unbound linezolid; CMT: Compartment; 𝐶𝑃_𝑡𝑜𝑡: Total plasma concentrations; 𝐶𝑃_𝑢: Unbound 
plasma concentrations; 𝐶𝑅𝐷: Retrodialysate concentration; 𝐶𝑅𝑃: Retroperfusate concentration; 𝐶µD: Microdialysate 
concentration; CV: Coefficient of variation (calculated for random-effects parameters according to Eq. 2.6); fu: Fraction 
unbound; Km,u: Michaelis-Menten constant of unbound linezolid; LBW: Lean body weight; NLME: Nonlinear mixed-effects; 
OBE: Obesity; Qu: Intercompartmental clearance of unbound linezolid; RSE: Relative standard error; RROBE, RRNOBE: Relative 
recovery for obese and nonobese patients; TFOBE,u, TFNOBE,u: Tissue factor of unbound linezolid for obese and nonobese patients; 
V1,u, V2,u: Volume of distribution parameters of central and peripheral CMTs of unbound linezolid; Vmax,u: Maximum elimination 
rate of unbound linezolid; θ: Fixed-effects parameter; 𝜔: Random-effects parameter: Interindividual variability; 𝜎: Random-




Table S7: (Project I) Results of stepwise covariate analysis to identify the impact of body size and renal 
function markers on the PK of linezolid (Table S5). 
Step Identified covariate-parameter relationship 
Covariate PK parameter Functional relationship 
Step 1: Body size on TF OBE TF Fractional change 
Step 2: Body size on V1 and V2 LBW V1 and V2 Power (with fixed allometric 
exponent of 1) 
Step 3: Body size on Q LBW Q Power (with fixed allometric 
exponent of 0.75) 
Step 4: Body size on CL and 
Vmax 
- - - 
Step 5: Renal function marker 
on CL 
- - - 
Step 6: 1-by-1 backward 
deletion2 
Note: No covariate removed during backward deletion 
Step 7: Additional impact of 
OBE 
- - - 
Step 8: Reinvestigate OBE on 
TF 
- - - 
Abbreviations: CL: Clearance; CMT: Compartment; LBW: Lean body weight; OBE: Obesity status; PK: Pharmacokinetics; 
Q: Intercompartmental clearance; TF: Tissue factor; V1, V2: Volume of distribution parameters of central and peripheral CMTs; 




Table S8: (Project I) Parameter estimates of NLME models for linezolid considering the impact of different 
surgery-specific characteristics. [continued on next page] 
Model 0: No surgery-specific characteristics implemented; Model 1: Anaesthesia impact implemented on Vmax and TF; Model 2: 
Cardiac output and MAP implemented on TF and CLTot, respectively; Model 3: Anaesthesia impact and MAP implemented on 
TF and CLTot, respectively. 
Parameter [unit] Estimate (RSE1, %) 
Model 0:  












OFV -82.309 -100.679 -143.318 -194.060 
Fixed-effects parameters 
θ CLu [L/h] 2.00 (29.8) 4.67 (36.4) 2.80 (32.3) 3.47 (27.0) 
θ Vmax,u [mg/h] 44.2 (9.00) 23.32 (82.0) 44.1 (17.8) 42.0 (22.0) 
θ Km,u [mg/L] 0.89 (37.5) 3.14 (114) 2.02 (27.2) 2.53 (28.9) 
θ ANAE_Vmax,u3, % -- 88.8 (59.2) -- -- 
θ MAP_CLTot,u4, % -- -- 0.782 (43.5) 0.836 (41.3) 
θ V1,u5 [L] 19.3 (7.80) 20.0 (16.4) 18.8 (7.90) 18.5 (8.20) 
θ Qu5 [L/h] 61.0 (8.80) 75.2 (25.9) 63.7 (8.80) 66.0 (9.00) 
θ V2,u5 [L] 37.4 (4.30) 36.4 (8.70) 36.9 (4.80) 36.1 (4.70) 
θ fu, % 85.8 (0.800) 85.6 (1.60) 85.7 (0.700) 85.6 (0.700) 
θ TFOBE,u, % 47.4 (8.10) 43.86 (15.3) 45.8 (7.80) 51.68 (7.90) 
θ TFNOBE,u, % 64.4 (6.50) 60.76 (13.3) 63.4 (6.60) 71.38 (5.70) 
θ ANAE_TFu, % -- 17.57 (12.9) -- -15.49 (15.9) 
θ COLZ_TFu10, % -- -- 0.819 (21.2) -- 
θ RROBE, % 38.7 (7.60) 38.7 (19.4) 38.8 (7.70) 38.6 (7.70) 
θ RRNOBE, % 55.5 (7.00) 55.5 (13.3) 55.4 (7.00) 55.6 (6.80) 
Interindividual and method variability parameters, %CV 
ω  Lu 107 (24.0) 56.8 (24.5) 81.3 (31.5) 69.4 (30.0) 
ω Km,u 127 (32.2) 152 (77.1) 106 (46.4) 120 (47.8) 
ω V1,u 40.7 (12.1) 43.6 (28.4) 41.1 (11.9) 41.8 (12.0) 
ω Qu 46.3 (17.3) 59.5 (21.9) 45.9 (16.2) 49.0 (18.4) 
ω V2,u 15.9 (28.0) 15.9 (43.8) 16.4 (25.9) 16.6 (24.5) 
ω  Fu 18.2 (25.4) 17.5 (40.9) 17.6 (25.5) 17.8 (22.5) 
ωIntercatheter RR 27.2 (23.8) 27.4 (19.6) 27.2 (23.5) 27.4 (23.5) 
Residual variability parameters, %CV 
prop 𝐶𝑃_𝑡𝑜𝑡 5.04 (14.5) 6.19 (1.10) 4.82 (13.0) 4.87 (12.8) 
prop 𝐶𝑃_𝑢 4.95 (14.6) 4.82 (16.2) 4.71 (12.6) 4.61 (12.9) 
prop 𝐶µ𝐷 15.3 (6.10) 13.6 (3.20) 14.7 (6.30) 13.8 (6.20) 
prop 𝐶𝑅𝐷 27.4 (12.0) 27.6 (11.7) 27.4 (11.8) 27.5 (11.9) 
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1RSE of random-effects parameter estimates ω and  are reported on approximate standard deviation scale; 2Intra-anaesthetic 
Vmax,u; 3Post-anaesthetic change of Vmax,u; 4Change of clearance per mmHg deviation of MAP from 75 mmHg (linear MAP-CL 
relationship); 5Allometrically scaled with LBW (exponent of 1 and 0.75 for V1/V2 and Q, respectively) and centred to reference 
LBW of 70 kg; 6Intra-anaesthetic TFu; 7Post-anaesthetic change of TFu; 8Post-anaesthetic TFu; 9Intra-anaesthetic change of TFu; 
10Change of TFu per L/min deviation of COLZ from 20 L/min (linear COLZ-TFu relationship).  
Abbreviations: ANAE_TFu: Anaesthesia effect on TFu: ANAE_Vmax,u: Anaesthesia effect on Vmax,u ;CLu: Clearance of unbound 
linezolid; CLTot,u: Total clearance of unbound linezolid; CMT: Compartment; COLZ: Cardiac output estimated according to 
Liljestrand and Zander (unadjusted) [3]; COLZ_TFu: Effect of COLZ on TFu; 𝐶𝑃_𝑡𝑜𝑡: Total plasma concentrations; 𝐶𝑃_𝑢: Unbound 
plasma concentrations; 𝐶𝑅𝐷: Retrodialysate concentration; 𝐶𝑅𝑃: Retroperfusate concentration; 𝐶µD: Microdialysate 
concentration; CV: Coefficient of variation (calculated for random-effects parameters according to Eq. 2.6); fu: Fraction 
unbound; Km,u: Michaelis-Menten constant of unbound linezolid; LBW: Lean body weight; MAP: Mean arterial blood pressure; 
MAP_CLTot,u: Effect of MAP on CLTot,u; NLME: Nonlinear mixed-effects; Qu: Intercompartmental clearance of unbound 
linezolid; RSE: Relative standard error; RROBE, RRNOBE: Relative recovery for obese and nonobese patients; TFOBE,u, TFNOBE,u: 
Tissue factor for obese and nonobese patients of unbound linezolid; V1,u, V2,u: Volume of distribution parameters of central and 
peripheral CMTs of unbound linezolid; Vmax,u: Maximum elimination rate of unbound linezolid; θ: Fixed-effects parameter; 𝜔: 
Random-effects parameter: Interindividual variability; 𝜎: Random-effects parameter: Residual unexplained variability. 
Table S9: (Project II) Scenarios investigated to assess the impact dosing alteration on the frequency of the 
attainment of adequate PTA (i.e. PTA≥90%). Dosing alteration comprised intensification of the daily dose 







Setting of scenarios 
Details on investigated combinations of  
LBW, MIC, dosing regimen and matrix 
LBW (nLBW=10: 35-80 kg in steps of 5 kg) 





Dosing regimens Matrix 
DD A1  
(all)  
nregimen=2 per DD: 
• DD=1200 mg (SI1.212 & PI1.212) 
• DD=1800 mg (SI1.812 & PI1.812) 








nregimen=1 per DD: 
• DD=1200 mg (SI1.212) 
• DD=1800 mg (SI1.812) 




ncomb =80  
per DD 
DD C1  
(INF=4 h) 
nregimen=1 per DD: 
• DD=1200 mg (PI1.212) 
• DD=1800 mg (PI1.812) 






DD D1  
(plasma) 
nregimen=2 per DD: 
• DD=1200 mg (SI1.212 & PI1.212) 
• DD=1800 mg (SI1.812 & PI1.812) 






DD E1  
(ISF) 
nregimen=2 per DD: 
• DD=1200 mg (SI1.212, PI1.212) 
• DD=1800 mg (SI1.812, PI1.812) 





INF A2  
(all)  
nregimen=4 per INF: 
• INF=30 min (SI1.212 & SI1.812 & SI1.88 & SI2.412) 






INF B2  
(DD=1200 mg) 
nregimen=1 per DD: 
• INF=30 min (SI1.212) 














Setting of scenarios 
Details on investigated combinations of  
LBW, MIC, dosing regimen and matrix 
LBW (nLBW=10: 35-80 kg in steps of 5 kg) 





Dosing regimens Matrix 
INF C2  
(DD=1800 mg) 
nregimen=2 per DD: 
• INF=30 min (SI1.812 & SI1.88) 




ncomb =160  
per INF 
INF D2  
(DD=2400 mg) 
nregimen=1 per DD: 
• INF=30 min (SI2.412) 




ncomb =80 per 
INF 
INF E2 
(𝜏=12h) nregimen=3 per INF: • INF=30 min (SI1.212 & SI1.812 & SI2.412) 






INF F2  
(𝜏=8h) nregimen=1 per DD: • INF=30 min (SI1.88) 






INF G2  
(plasma) 
nregimen=4 per INF: 
• INF=30 min (SI1.212 & SI1.812 & SI1.88 & SI2.412) 





INF H2  
(ISF) 
nregimen=4 per INF: 
• INF=30 min (SI1.212 & SI1.812 & SI1.88 & SI2.412) 





𝜏 A3  
(all)  
nregimen=2 per 𝜏: 
• 𝜏=12 h (SI1.812 & PI1.812) 








nregimen=1 per 𝜏: 
• 𝜏=12 h (SI1.812) 






𝜏 C3  
(INF=4 h) 
nregimen=1 per 𝜏: 
• 𝜏=12 h (PI1.812) 








nregimen=2 per 𝜏: 
• 𝜏=12 h (SI1.812 & PI1.812) 








nregimen=2 per 𝜏: 
• 𝜏=12 h (SI1.812 & PI1.812) 





1ncomb= nregimen ∙ nmatrix ∙ nLBW ∙ nMIC.  
Dosing regimens: SI1.212: 600 mg 30-min i.v. infusion, q12h; SI1.812: 900 mg 30-min i.v. infusion, q12h; SI1.88: 600 mg 30-
min i.v. infusion, q8h; SI2.412: 1200 mg 30-min i.v. infusion, q12h; PI1.212: 600 mg 4-h i.v. infusion, q12h; PI1.812: 900 mg 4-
h i.v. infusion, q12h; PI1.88: 600 mg 4-h i.v. infusion, q8h; PI2.412: 1200 mg 4-h i.v. infusion, q12h. . 
Abbreviations: DD: Daily dose; INF: Infusion duration; ISF: Interstitial space fluid; LBW: Lean body weight; ncomb: number of 
investigated combinations of dosing regimen, matrix, LBW and MIC; nLBW: Number of investigated LBW values; nMIC: Number 









Table S10: (Project II) Probability of target (95%fT>MIC) attainment for varying LBW [continued on next page].   





Probability of target attainment, % 
Short-term infusion regimens2 Prolonged infusion regimens2 
SI1.212 SI1.812 SI1.88 SI2.412 PI1.212 PI1.812 PI1.88 PI2.412 
Plasma ISF Plasma ISF Plasma ISF Plasma ISF Plasma ISF Plasma ISF Plasma ISF Plasma ISF 
0.5 
35 68.8 59.2 85.5 81.6 96.1 93.3 91.4 88.9 81.6 73.6 92.5 89.3 99.5 97.6 96.3 94.2 
40 77.3 68.5 91.3 86.9 98.1 96.3 95.6 93 87.6 80.3 97 93.2 99.6 98.4 98.7 97.1 
45 82.8 74 94 90.2 98.7 97 97.2 95.6 91 84.3 97.6 95.6 100 98.6 98.9 98 
50 88 72.6 96.4 91.2 99.2 97.3 98.1 96.7 94.3 80.9 98.4 96.1 99.9 97 99.4 98 
55 89.8 75.6 96.8 93.1 99.3 97 98.1 96.6 95.1 82.8 98.6 95.8 99.9 96.3 99.5 97.9 
60 91.9 77.2 98.3 93.5 99.9 97.9 99.4 97.6 96.5 82.1 99.7 96.6 100 94.7 99.9 98.6 
65 92.5 79.1 97.9 94.3 99.4 98.1 99.1 97.9 97.1 81.2 99.2 96.4 99.8 92.8 99.6 98.6 
70 93.5 82.6 97.7 94.7 99.9 97.5 99.2 97.2 97 82.7 99.7 95.3 100 92.2 100 98.1 
75 95.5 82 99.1 95.7 99.9 97.6 99.4 97.8 98.4 80.2 99.6 96.5 100 89.2 100 98.1 
80 95.7 81.9 98.9 96.1 99.7 98 99.5 98.5 98.2 77.8 99.6 96.7 100 85.5 99.8 98.5 
1 
35 50.3 36.1 76.8 68.7 91 84.5 85.9 81.4 67.8 47.9 87.6 79.9 98 90.3 92.4 88.8 
40 60.9 46.2 83.9 75.5 94.9 88.2 91.8 86.5 75.8 55 92.6 84.3 99.1 90.6 96.4 92.3 
45 66.1 49.9 88.9 80.7 96.3 90.4 94.2 89.9 80.4 55.5 94.3 87.7 99.1 88.6 97.6 94.8 
50 72.4 40.7 91.5 78.2 97.7 88.6 96.3 90.5 85.3 35.7 96.2 82.4 99.3 62.4 98.2 93.6 
55 76.1 40.5 92.5 79.8 97.4 89.4 96.9 91.3 87.4 33.4 96.8 80.4 99.3 53.5 98.2 93.3 
60 79.2 41.8 94.5 81.3 98.8 87.8 97.6 92.1 89.3 27 97.7 77.4 99.9 41.5 99.4 92.3 
65 79 42.2 95.5 82 98.3 87.9 97.6 92.5 89.6 23 97.8 73.5 99.5 34.4 99.2 90.5 
70 85 44.2 95.3 84.7 97.7 88.4 97.5 92.9 90.9 19.2 97.4 71.8 100 27.5 99.4 89.5 
75 84.7 38.7 97.1 84.5 99.1 87 98.9 93.8 92.9 11.5 98.9 62.5 99.9 16.9 99.4 88.5 












Probability of target attainment, % 
Short-term infusion regimens2 Prolonged infusion regimens2 
SI1.212 SI1.812 SI1.88 SI2.412 PI1.212 PI1.812 PI1.88 PI2.412 
Plasma ISF Plasma ISF Plasma ISF Plasma ISF Plasma ISF Plasma ISF Plasma ISF Plasma ISF 
2 
 
35 28.2 12.5 62.5 46.8 79.3 61.8 76.6 67 41.1 10.8 75.1 52.3 91.8 43.8 86.8 75.1 
40 35.8 13.1 70.3 54.1 85.5 66.6 84.1 73.3 50.4 9.5 82 54.2 94.9 31.3 91.7 78.7 
45 38.6 13.5 75.2 55.5 88.8 66.1 87.8 77.4 53.3 6.7 85.8 51.4 95.8 20.6 93.8 79.6 
50 43.3 5.2 80.8 44.6 90.3 44.8 90.6 71.2 55.4 0.7 88.3 23 96.6 1.8 96.3 57.4 
55 44.1 5.2 82.3 43 91.2 38.7 91.9 72.4 56 0.3 89.9 15.8 96.5 0.7 96.3 52.2 
60 46.6 3.4 84.9 41.3 92.9 35 93.8 71.9 55.1 0.2 91 9.4 96.4 0.3 97.2 38.8 
65 46.3 3.1 83.5 40.7 93.2 32.1 94.6 72.8 53.5 0.1 91.8 6.9 95.4 0.3 97.2 34.9 
70 48.5 2.9 87.9 42 93 30.2 94.2 74.7 57.2 0.1 92.5 4.9 94 0.1 97 29.4 
75 44.9 2.3 88.3 33.3 94.1 19 96.2 71.2 51.1 0 94.1 2 92.4 0 98.1 18.2 
80 48.8 2.8 88.7 36.4 94.7 21.5 96.5 72.3 52.2 0 94.7 2.1 87.7 0 97.8 14.1 
4 
35 6.4 0.3 39 14.6 53.5 14.6 61.1 41.1 9.6 0 52.8 6.7 63.3 0.4 73.2 32.9 
40 4.7 0.3 45.4 14.9 55.6 12.5 68.6 45.4 6.3 0 55.7 3.8 54.1 0.1 79.2 27.5 
45 5.3 0.3 46.7 13.2 54.8 9.1 73.2 42.9 5.9 0 56.1 2.1 42.3 0.1 81.6 17.9 
50 5.3 0 51.6 3.4 54.7 1 76.5 28 4.3 0 58.6 0 34.1 0 84.2 1.7 
55 4.6 0 48.7 3.3 47.3 0.8 77 22.9 3.4 0 55.4 0 18.7 0 85.2 0.5 
60 4.1 0 48.9 1.8 43.9 0.2 78.5 20.9 1.5 0 50.8 0.1 11.4 0 86.1 0.5 
65 3.8 0 46.5 1.4 39.4 0.2 78.4 19.5 1.3 0 45.5 0 6.3 0 84 0.2 
70 3.4 0 49.2 0.8 36.7 0.1 82.3 18.9 0.7 0 44.9 0 3.6 0 86.4 0.1 
75 1.8 0 41.8 0.5 26.6 0 79.2 9.7 0.1 0 32.5 0 1.4 0 82.3 0 
80 2.6 0 45 0.6 24.9 0.1 81.8 11.9 0.3 0 28.7 0 1.3 0 80.6 0 
1All other covariates in the NLME model were set to median values of the patient population (for detailed information on patient characteristics see Table 2.4 B). 2Dosing regimens: SI1.212: 600 mg 
30-min i.v. infusion, q12h; SI1.812: 900 mg 30-min i.v. infusion, q12h; SI1.88: 600 mg 30-min i.v. infusion, q8h; SI1.212: 1200 mg 30-min i.v. infusion, q12h; PI1.212: 600  mg 4-h i.v. infusion, q12h; 
PI1.812: 900 mg 4-h i.v. infusion, q12h; PI1.88: 600 mg 4-h i.v. infusion, q8h; PI2.412: 1200 mg 4-h i.v. infusion, q12h.  
Horizontal dashed line: Separates obese from nonobese patients according to LBW obesity threshold of 47.1 kg (translating into the BMI obesity threshold of 30 kg/m2 for a 1.65 m tall female patient).
  
Colour coding: Green: PTA≥90%, Yellow: PTA 80-<90%, Orange: PTA>50-<80%, Red: PTA≤50%  
Abbreviations: fT>MIC: Time period that unbound drug concentration exceeds the MIC; ISF: Interstitial space fluid; LBW: Lean body weight; MIC: Minimum inhibitory concentration; PTA: Probability 







Table S11: (Project II) Probability of target (95%fT>MIC) attainment for typical patients.   
PTA given for plasma and ISF of the s.c. adipose tissue for selected short-term and prolonged linezolid dosing regimen and selected MIC values for the typical obese and non-obese patient1, during 





Probability of target attainment, % 
Short-term infusion regimens2 Prolonged infusion regimens2 
SI1.212 SI1.812 SI1.88 SI2.412 PI1.212 PI1.812 PI1.28 PI2.412 
Plasma ISF Plasma ISF Plasma ISF Plasma ISF Plasma ISF Plasma ISF Plasma ISF Plasma ISF 
“obese &  
intra-anae-
sthetic” 
0.5 88.6 73.4 96.9 90.7 99.4 97.1 98.6 96.2 95.7 79.6 98.9 95 100 95.1 99.6 98.1 
1 74 39.3 92.2 77.6 97.2 85.9 96.7 89.5 85.5 29.1 96.8 75.8 99.5 47.7 98.8 91 
2 42.4 3.8 79.8 39.2 89.5 36.7 90.7 69.6 52.6 0.2 88.5 12.3 95.8 0.7 95.4 44.9 





0.5 78.2 70.5 91.8 87.5 97.9 96.4 96.2 94 88.5 81.3 97.1 94.4 99.5 98.4 98.2 96.7 
1 63.2 47.7 84.2 77.3 95.2 89.1 91.9 86.5 76.7 55.6 92.3 84.6 98.2 90.3 96.8 93.5 
2 37.7 14.4 71.7 53.7 85.2 66.4 83.9 74.7 51 9.4 81.7 53.5 95.1 27.6 92.4 78.3 
4 6.4 0.1 45.1 15.1 54.8 11.5 69.5 43.2 8.1 0 54.9 3.2 50.6 0 78.8 25.1 
“obese &  
post-anae-
sthetic” 
0.5 75.9 62.2 92.4 88.7 97.4 96.7 96.7 95.7 87.4 74.6 97.1 94.2 99.6 98.6 98.2 97.4 
1 51.3 32.3 83.4 73.1 93.9 86.6 92.9 86.9 68.2 29.2 92.1 79.3 98.1 69.5 97.1 93.5 
2 23.4 2.8 65 35.8 80.3 37.1 83.4 67.6 31.4 0.4 77.5 18.5 90.6 1.7 91.2 59.7 





0.5 64.7 60.4 85.2 83.8 96.3 96 92.7 91.9 79.7 77.5 93.5 92.5 99.6 99.5 97.5 96.7 
1 44.4 38.5 75.8 71.9 89.7 88.1 85.4 83.5 60.7 49.9 86.1 82.3 98 95.2 93.7 92.2 
2 19 10.7 56.2 46.7 76.3 65.5 76 70.1 31.4 9.2 72.4 55.2 90.3 44.8 86.1 79.4 
4 2 0.1 27.9 11.7 36.5 10.9 54.8 42 3.2 0 37.7 4.9 37.5 0.1 68.1 33.8 
1Detailed information on patient characteristics: Table 2.4 A. 2Dosing regimens: SI1.212: 600 mg 30-min i.v. infusion, q12h; SI1.812: 900 mg 30-min i.v. infusion, q12h; SI1.88: 600 mg 30-min i.v. 
infusion, q8h; SI1.212: 1200 mg 30-min i.v. infusion, q12h; PI1.212: 600 mg 4-h i.v. infusion, q12h; PI1.812: 900 mg 4-h i.v. infusion, q12h; PI1.88: 600 mg 4-h i.v. infusion, q8h; PI2.412: 1200 mg 4-
h i.v. infusion, q12h.  
Colour coding: Green: PTA≥90%, Yellow: PTA 80-<90%, Orange: PTA>50-<80%, Red: PTA≤50%  




Table S12: (Project II) Impact of intensification of daily dose (DD) on the attainment of adequate PTA (i.e. 
PTA ≥90%).  
For details on comparison scenarios see Table S9. 
1Combinations of investigated dosing regimen, matrix (i.e. plasma, ISF), LBW, MIC (see Table S9).   
Abbreviations: DD: Daily dose; INF: Infusion duration; ISF: Interstitial space fluid; ncomb: number of investigated combinations 
of dosing regimen, matrix, LBW and MIC; PTA: Probability of target attainment.  
Table S13: (Project II) Impact of prolongation of infusion duration (INF) on the attainment of adequate PTA 
(i.e. PTA ≥90%).  
For details on comparison scenarios see Table S9. 
1Combinations of investigated dosing regimen, matrix (i.e. plasma, ISF), LBW, MIC (see Table S9).   
Abbreviations: DD: Daily dose; INF: Infusion duration; ISF: Interstitial space fluid; ncomb: number of investigated combinations 
of dosing regimen, matrix, LBW and MIC; PTA: Probability of target attainment; 𝜏: Dosing interval.  
Table S14: (Project II) Impact of shortening of the dosing interval (𝜏) on the attainment of adequate PTA 
(i.e. PTA≥90%).  
For details on comparison scenarios see Table S9. 
1Combinations of investigated dosing regimen, matrix (i.e. plasma, ISF), LBW, MIC (see Table S9).  
Abbreviations: DD: Daily dose; INF: Infusion duration; ISF: Interstitial space fluid; ncomb: number of investigated combinations 






per DD (ncomb) 
Number (%) of investigated combinations  
attaining PTA ≥90%   r DD 
DD=1200 mg DD=1800 mg DD=2400 mg 
A1 (all)  160 16 (10) 57 (35.6) 87 (54.4) 
B1 (INF=30 min) 80 5 (6.25) 24 (30.0) 42 (52.5) 
C1 (INF=4 h) 80 11 (13.8) 33 (41.3) 45 (56.3) 
D1 (plasma) 80 16 (20) 40 (50.0) 55 (68.8) 
E1 (ISF) 80 0 (0.00) 17 (21.3) 32 (40) 
Comparison scenario 
(details) 
Number of investigated 
combinations per INF 
(ncomb) 
Number (%) of investigated combinations  
attaining PTA ≥90%   r DD 
INF=30 min INF=4 h 
A2 (all)  320 109 (34.1) 127 (39.7) 
B2 (DD=1200 mg) 80 5 (6.25) 16 (20.0) 
C2 (DD=1800 mg) 160 24 (15.0) 33 (20.6) 
D2 (DD=2400 mg) 80 42 (52.5) 45 (56.3) 
E2 (𝜏=12h) 240 71 (29.6) 94 (39.2) 
F2 (𝜏=8h) 80 38 (47.5) 38 (47.5) 
G2 (plasma) 160 74 (46.3) 92 (57.5) 
H2 (ISF) 160 35 (21.9) 35 (21.9) 
Comparison scenario 
(details) 
Number of investigated 
combinations per 𝜏 (ncomb) Number of (%) investigated combinations          g P A≥90%   r 𝜏  𝜏=12 h 𝜏=8 h 
A3 (all)  160 57 (35.6) 76 (47.5) 
B3 (INF=30 min) 80 24 (30) 38 (47.5) 
C3 (INF=4 h) 80 33 (41.3) 38 (47.5) 
D3 (plasma) 80 40 (50) 55 (68.5) 
E3 (ISF) 80 17 (21.3) 21 (26.3) 
Appendix 
201 
Table S15: (Project II) Overview of adequacy of different dosing regimens to attain PK/PD target 
(95%fT>MIC) in plasma (A) or both in plasma and ISF (B) for typical patients.   
Results given for selected short-term and prolonged dosing regimens, selected MIC values and varying LBW values. Dosing 
regimens resulting in adequate PTA for plasma (A) or plasma and ISF (B) are highlighted with . 
Typical 
patient1 MIC [mg/L] 
Dosing regimens3 
A: …r  ul   g     d quate PTA2  
in plasma 
B: …r  ul   g     d qu    P A2  
in plasma and ISF 





































































       
 
   
 
   
1  
   
 
   
none    
 










   
 




   
1   
  
 
   
none   
  
2 none   
  
none none 
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none    
 
2 none   
  
none none 




0.5   
  
 




   
1 none   
  
none   
  
2 none   
 
 none none 
4 none none none none 
1All other covariates in the NLME PK model were set to median values of the patient population (for detailed information on 
patient characteristics see Table 2.4 A). 2Adequate PTA is defined as PTA≥90%, for the PK/PD target 95%fT>MIC (for detailed 
information on PTA see Table S11); 3Dosing regimens: SI1.212: 600 mg 30-min i.v. infusion, q12h; SI1.812: 900 mg 30-min 
i.v. infusion, q12h; SI1.88: 600 mg 30-min i.v. infusion, q8h; SI2.412: 1200 mg 30-min i.v. infusion, q12h; PI1.212: 600 mg 4-h 
i.v. infusion, q12h; PI1.812: 900 mg 4-h i.v. infusion, q12h; PI1.88: 600 mg 4-h i.v. infusion, q8h; PI2.412: 1200 mg 4-h i.v. 
infusion, q12h.   
Horizontal dashed line: Separates obese from nonobese patients according to LBW obesity threshold of 47.1 kg (translating 
into the BMI obesity threshold of 30 kg/m2 for a 1.65 m tall female patient).  
Abbreviations: fT>MIC: Time period that unbound drug concentration exceeds the MIC; ISF: Interstitial space fluid; LBW: Lean 




Table S16: (Project III) PK/PD target attainment for all non-CRRT patients after standard meropenem 
dosing (1000 mg, i.v. 30 min, every 8 h) for different MIC values (modified from [233]). 
MIC [mg/L] PK/PD target attainment, % 
50%T>4xMIC 
C4h ≥ 4xMIC 
100%T>MIC 
C4h ≥ MIC 
0.25  99.6 95.5 
0.5 96.9 91.9 
1 91.0 78.0 
2 56.1 48.4 
4 27.4 38.1 
8 7.17 20.6 
Colour coding: Target attainment ≥90% (green), 80-<90% (yellow), >50-<80% (orange), ≤50 (red)  
Abbreviations: CX: Concentration at specific time point X of concentration-time profile (here: calculated meropenem serum 
concentrations); MIC: Minimum inhibitory concentration; PK/PD: Pharmacokinetic/pharmacodynamic; T>MIC: Time period 









Table S17: (Project IV) Summary of preselected covariates1 (n=27) of non-CRRT patients (n=41) and results of covariate modelling. [continued on next pages] 





























Sex, male CAT, 2 - 1 58.5   0 + - V1 (male> 
female) 
ECMO CAT, 2 - 1 4.88   0 - -  
Lung 
transplantation 
CAT, 2 - 1 40   0 - -  
ARDS CAT, 2 - 1 9.76   0 - -  
Peritonitis CAT, 2 - 1 12.2   0 - -  
Mean arterial 
pressure5 









  0 - -  

















Table S17 [continued] 




































  0 + - V1 (↓),  
 L (↓) 
Age [years] CONT  1 56 32 70 0 + - V1 (↓) 
Body weight [kg] CONT  1 70 47 121 0 + + V1 (↑) 
Serum creatinine 
[mg/dL] 
CONT  4 1.0 0.6 1.9 0 - -  
Serum albumin 
[g/L] 
CONT  4 2.8 2.2 3.6 0 + + V2 (↓) 
Serum urea 
[mg/dL] 
CONT  4 41 20 92 0 + -  L (↓) 
CLCRUC [mL/min] CONT  4 81 19 171 4.88 - -  
CLCRCG [mL/min] CONT  4 80.8 39.4 170 0 + +  L (↑) 
Fibrinogen 
[mg/dL] 
CONT  4 340 187 647 0 - -  
Antithrombin, % CONT  4 74 49 94 0 - +  




CONT  4 3.99 2.11 6.63 0 + -  L (↑) 










Table S17 [continued] 































CONT  8 88.3 24.0 1460 0  -  
C-reactive protein 
[mg/dL] 
CONT  8 8.9 2.1 32. 0 + - V2 (↑) 
CD64 index CONT  4 1.23 0.53 3.73 19.5 - -  
Sodium [mmol/L] CONT  4 143 138 149 0 - -  
pH CONT  4 7.41 7.30 7.51 0 + - V2 (↓) 
Lactate [mmol/L] CONT  4 1.51 0.680 3.64 0 + - V1 (↓) 
Hydrogencarbo-
nate [mmol/L]  
CONT  4 27.4 20.5 37.0 0 + -  L (↓) 
158 patient-specific characteristics: 27 preselected covariates (Table S17) + body height, body mass index, urine volume, fluid balance, urine creatinine, urine albumin, anuria, erythrocytes, 
haemoglobin, haematocrit, thrombocytes, prothrombin time, partial thromboplastin time, aspartate aminotransferase, alanine aminotransferase, cholinesterase enzyme, factor V, leucocytes, 
potassium, glucose, inorganic phosphate, sepsis, cause of sepsis, liver transplantation, 28-day mortality, APACHE II score, SOFA score, Glasgow coma score, body temperature (extracted 
from APACHE II score), respiratory rate (extracted from APACHE II score), PaO2/FiO2 ratio (extracted from APACHE II score).   
2Number of covariate observations planned per patient within the study period of 4 days.   
3Related to total number of observations planned (i.e. Nobservations_planned/patient 41 patients).   
4Direction of covariate-parameter relationship; for CONT covariates: the higher the covariate value, the higher (↑) or the lower (↓) the PK parameter; for ordered CAT covariates: the higher 
the category class of the covariate, the higher (↑) or the lower (↓) the PK parameter; for dichotomous CAT covariates: specification for which covariate class PK parameter is higher)  
5Extracted from APACHE II score (blood pressure [mmHg]: CAT=1 ≤49, CAT=2: n.a., CAT=3: 50-69, CAT=4: n.a., CAT=5: 70-109, CAT=6: n.a., CAT=7: 110-129, CAT=8 130-159, 
CAT=9: ≥160).   
6Extracted from APACHE II score (heart rate [1/min]: CAT=1: ≤39, CAT=2: 40-54, CAT=3: 55-69, CAT=4: n.a., CAT=5: 70-109, CAT=6: n.a., CAT=7: 110-139, CAT=8: 140-179, CAT=9: 
≥180).   
7Extracted from SOFA score (CVS: CAT=1 no hypotension, CAT=2: MAP < 70 mmHg, CAT=3: dop <= 5 or dob (any dose), CAT=4: dop > 5 OR epi <= 0.1 OR nor <= 0.1, CAT=5: dop > 15 
OR epi > 0.1 OR nor > 0.1).  
Abbreviations: APACHE: Acute Physiology And Chronic Health Evaluation [1]; ARDS: Acute respiratory distress syndrome; CAT: Categorical; CONT: Continuous; CLCRCG: Creatinine 
clearance estimated according to Cockcroft and Gault [2]; CRRT: Continuous renal replacement therapy; dop: Dopamine; CVS: Cardiovascular system; ECMO: Extracorporeal membrane 




Table S18: (Project IV) Comparison of NLME base model including interoccasion variability, when 
defining an occasion as study day or intensively monitored dosing interval.  
Parameter [unit] Estimate (RSE1, %) 
‘Base model’ Base model + IOV 
(occasion=study day) 




OFV 6090.465 5653.12 5517.641 
ΔOFV -- -437.345 -572.824 
Fixed-effects parameters 
θ CL [L/h] 8.31 (7.30) 8.21 (7.30) 8.31 (7.30) 
θ V1 [L] 8.62 (10.9) 8.54 (8.30) 9.04 (8.40) 
θ Q [L/h] 30.6 (13.7) 28.8 (10.8) 25.8 (12.9) 
θ V2 [L] 18.7 (6.70) 16.9 (5.80) 16.3 (6.40) 
Interindividual variability parameters, %CV 
ω  L
 
54.1 (7.80) 53.3 (8.10) 53.4 (8.40) 
ω V1 43.2 (11.7) 41.7 (10.3) 39.8 (10.20) 
ω V2 25.4 (16.0) 22.7 (13.9) 24.4 (13.8) 
Interoccasion variability parameters, %CV 
К CL -- 16.0 (9.90) 17.6 (10.2) 
К V1 -- 13.9 (34.0) 16.1 (28.6) 
Residual variability parameters, %CV 
prop, %CV 24.8 (6.60) 18.9 (5.40) 16.1 (8.20) 
add, SD [mg/L] 0.378 (34.0) 0.308 (19.7) 0.273 (31.8) 
1RSE of random-effects parameter estimates ω and  are reported on approximate standard deviation scale.  
Abbreviations: CL: Clearance; CMT: Compartment; CRRT: Continuous renal replacement therapy; CV: Coefficient of variation 
(calculated for random-effects parameters according to Eq. 2.6); NLME: Nonlinear mixed-effects; Q: Intercompartmental 
clearance; RSE: Relative standard error; SD: Standard deviation; V1, V2: Volume of distribution parameters of central and 
peripheral CMTs; θ: Fixed-effects parameter; 𝜔: Random-effects parameter: Interindividual variability; К: Random-effects 




Table S19: (Project IV) Comparison of imputation/interpolation strategies for CLCRCG (Subtable A) and 
comparison of NLME base model for all patients and non-CRRT patients (Subtable B).   
Subtable A: Parameter estimates of NLME base model and NLME model including stepwise imputed/interpolated CLCRCG 
(strategy A) and linear imputed/interpolated CLCRCG (strategy B) as covariate on meropenem clearance.  
Subtable B: Parameter estimates of NLME base model based on all patients (n=48) and based on non-CRRT patients only 
(n=41). 
Parameter [unit] Estimate (RSE1, %) 
Subtable A Subtable B 











OFV 6090.465 5856.377 5689.452 6090.465 4913.332 
Fixed-effects parameters 
θ CL2 [L/h] 8.31 (7.30) 8.85 (4.50) 9.14 (3.90) 8.31 (7.30) 8.82 (8.00) 
θ V1 [L] 8.62 (10.9) 7.94 (9.40 8.31 (9.50) 8.62 (10.9) 8.41 (12.1) 
θ Q [L/h] 30.6 (13.7) 31.7 (11.1) 30.4 (10.6) 30.6 (13.7) 30.9 (15.7) 
θ V2 [L] 18.7 (6.70) 17.0 (6.40) 17.6 (5.30) 18.7 (6.70) 17.8 (7.80) 
θ CLCRCG_CL2, % -- 0.856 (11.9) 1.05 (6.50) -- -- 
Interindividual variability parameters, %CV 
ω  L
 
54.1 (7.80) 30.5 (15.4) 25.7 (16.5) 54.1 (7.80) 55 (9.00) 
ω V1 43.2 (11.7) 46.4 (10.3) 45.1 (10.5) 43.2 (11.7) 41.5 (13.3) 
ω V2 25.4 (16.0) 25.2 (18.1) 24.8 (15.5) 25.4 (16.0) 21.6 (14.3) 
Residual variability parameters, %CV 
prop, %CV 24.8 (6.60) 19.0 (9.80) 20.8 (10.0) 24.8 (6.60) 24.1 (27.9) 
add, SD [mg/L] 0.378 (34.0) 1.11 (39.3) 0.534 (71.5) 0.378 (34.0) 0.367 (27.9) 
1RSE of random-effects parameter estimates ω and  are reported on approximate standard deviation scale, 2Given for a 
CLCRCG value of 80.8 mL/min; 2Change of clearance per mL/min deviation of CLCRCG from 80.8 mL/min.  
Abbreviations: CL: Clearance; CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]; CLCRCG_CL: 
Effect of CLCRCG on CL; CMT: Compartment; CRRT: Continuous renal replacement therapy; CV: Coefficient of variation 
(calculated for random-effects parameters according to Eq. 2.6); NLME: Nonlinear mixed-effects; Q: Intercompartmental 
clearance; RSE: Relative standard error; SD: Standard deviation; V1, V2: Volume of distribution parameters of central and 
peripheral CMTs; θ: Fixed-effects parameter; 𝜔: Random-effects parameter: Interindividual variability; 𝜎: Random-effects 




Table S20: (Project IV) Parameter estimates of NLME model of meropenem in critically ill non-CRRT 
(n=41) vs. CRRT (n=7) patients (modified from [243]). 
Parameter [unit] 
Parameter estimate (RSE1, %) 
Non-CRRT patients CRRT patients 
Fixed-effects parameters  
θ CL2 [L/h] 9.25 (4.60) 9.82 (9.90) 
θ V13 [L] 7.89 (11.9) 8.09 (16.8) 
θ Q [L/h] 28.4 (16.1) 27.4 (10.9) 
θ V24 [L] 16.1 (7.40) 19.1 (16.2) 
θ CLCRCG_CL5, % 0.977 (9.20) 1.29 (8.00) 
θ CLCRCG_INF [mL/min] 154 (6.90) 154* 
θ WT_V16 0.945 (16.6) 1* 
θ ALB_V27 -0.202 (36.6) -0.211 (122.3) 
Interindividual variability parameters, %CV 
ω  L 27.1 (19.3) 18.8 (32.7) 
ω V1 31.5 (14.3) 62.7 (16.1) 
ω V2 16.9 (18.1) 30.9 (37.8) 
Interoccasion variability parameters8, %CV 
К CL 12.5 (12.0) 16.4 (13.8) 
Residual variability parameters  
prop, %CV 16.6 (6.60) 11.4 (10.8) 
add, SD [mg/L] 0.246 (29.0) 1.75 (10.6) 
1RSE of random-effects parameter estimates ω and  are reported on approximate standard deviation scale; 2CL given for 
median CLCRCG of non-CRRT patients on first study day (80.8 mL/min); 3V1 given for median WT of non-CRRT patients (70 
kg); 4V2 given for median ALB of non-CRRT patients at first study day (2.8 g/dL); 5Change of clearance per mL/min deviation 
of CLCRCG from 80.8 mL/min ; 6Estimated exponent in power WT-V1 relationship, centred to median in overall population (70 
kg); 7Change of V2 per g/dL deviation of ALB from 2.79 g/dL; 8Occasion was defined as intensively monitored dosing interval. 
*Fixed parameters: CLCRCG_INF fixed to inflection point of non-CRRT patients, as no information on high CLCRCG values 
available in CRRT patients; WT_V1 fixed to allometry exponent of 1, as implausible estimate below 0, probably due to the low 
number of patients.  
Abbreviations: ALB: Serum albumin concentration; ALB_V2: ALB effect on V2; CI: Confidence interval; CL: Clearance; 
CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]; CLCRCG_CL: CLCRCG effect on CL; 
CLCRCG_INF: CLCRCG value serving as inflection point for meropenem CL (Figure S30); CMT: Compartment; 
CRRT: Continuous renal replacement therapy, CV: Coefficient of variation (calculated for random-effects parameters according 
to Eq. 2.6); IIV: Interindividual variability; IOV: Interoccasion variability; Q: Intercompartmental clearance; RSE: Relative 
standard error; SD: Standard deviation; V1, V2: Volume of distribution parameters of central and peripheral CMTs; WT: Body 
weight; WT_V1: WT effect on V1; θ: Fixed-effects parameter; 𝜔: Random-effects parameter: Interindividual variability; К: 
Random-effects parameter: Interoccasion variability; 𝜎: Random-effects parameter: Residual unexplained variability. 
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Table S21: (Project IV): Probability of target (98%T>MIC) attainment on the first day of standard meropenem 
treatment (1000 mg, 30-min i.v. infusion, q8h) (modified from [243]). PTA is given for varied values of one 
covariate and for selected MIC values and is presented as the median (P0.5), 5th (P0.05) and 95th percentile (P0.95) of the 1000 PTA 














0.06 0.12 0.25 0.5 1 2 4 8 16 32 
P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 
10 70 2.8 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.6 100 100 96.8 100 100 78.2 98 100 16 54.6 93.6 0 0 0.8 
20 70 2.8 100 100 100 100 100 100 100 100 100 100 100 100 99.6 100 100 98.4 100 100 90.6 99 100 59.2 86.2 98.6 4.6 19.4 44.4 0 0 0 
30 70 2.8 100 100 100 100 100 100 100 100 100 99.8 100 100 99 100 100 95.6 99.4 100 81.2 94.2 99.4 39 62.8 81.2 0.6 4.8 13.4 0 0 0 
40 70 2.8 100 100 100 100 100 100 99.8 100 100 99.4 100 100 97.6 99.6 100 90.2 97 99.6 68.8 82.6 93.2 21.6 37.4 51 0 1 4.6 0 0 0 
50 70 2.8 100 100 100 99.8 100 100 99.6 100 100 98.4 99.8 100 94.6 98.4 99.8 82.8 91.2 97.2 52.4 65.6 77 8.39 18.7 30.2 0 0.2 1.8 0 0 0 
60 70 2.8 99.8 100 100 99.6 100 100 98.8 99.8 100 96.8 99.2 100 90 95.6 98.8 73 81.8 89.8 34.8 47.2 57.8 2.2 8.8 18.2 0 0 0.8 0 0 0 
70 70 2.8 99.8 100 100 99.4 100 100 98 99.6 100 94.2 97.8 99.6 84.2 90.6 96 59.6 69.2 78.2 19.4 31.8 43.4 0.4 4 11.2 0 0 0.4 0 0 0 
80 70 2.8 99.6 100 100 98.8 99.8 100 96.4 98.8 100 90.2 95 98.4 75.4 83 90 43.8 55.6 66.2 8.19 19.9 32.2 0 1.6 6.8 0 0 0.2 0 0 0 
90 70 2.8 99.2 99.8 100 97.8 99.4 100 94 97.4 99.4 84.4 90.8 95.6 64 73.6 81.8 29.2 42.8 54.8 3 12.2 23.6 0 0.6 4.2 0 0 0 0 0 0 
100 70 2.8 98.6 99.8 100 96.2 98.8 100 90 95.2 98.4 77.4 85.2 91.4 51.4 63.2 73.4 16.8 31.6 44.8 1 7 17.2 0 0.2 2.4 0 0 0 0 0 0 
110 70 2.8 97.8 99.4 100 94.4 97.6 99.4 85.8 92 96.6 68.8 78.2 86.2 39.4 53 65.2 9.2 22.7 37 0.39 4.1 12.6 0 0 1.6 0 0 0 0 0 0 
120 70 2.8 96.6 98.8 100 92 96.2 98.8 81 87.6 94 59.6 71.2 81 28.4 44.1 58.2 5.2 16.4 30.8 0 2.4 9.6 0 0 1 0 0 0 0 0 0 
130 70 2.8 95 98 99.8 88.6 94 98 74.2 83.4 91.8 50.4 63.6 76.8 19.4 36 52 2.6 11.8 25.8 0 1.4 7.2 0 0 0.6 0 0 0 0 0 0 
140 70 2.8 93 97.2 99.6 85 91.8 97.6 67.8 78.8 90.4 41 56.8 74.2 14 29.8 49.2 1.4 8.8 23 0 0.8 6.2 0 0 0.6 0 0 0 0 0 0 
150 70 2.8 90.6 96 99.4 80.2 89.4 97.2 60 74.4 89.4 32.8 51 73.4 9.99 24.5 46.6 0.8 6.4 20.6 0 0.6 5 0 0 0.4 0 0 0 0 0 0 
≥154 70 2.8 90 95.4 99.4 78.2 88.2 97.4 57.4 72 89.6 30.8 48.8 73.6 8.79 23.2 47 0.79 6 20.6 0 0.4 4.6 0 0 0.4 0 0 0 0 0 0 
80.8 40 2.8 99.2 99.8 100 97.6 99.4 100 93.4 97.2 99.4 84 90.6 95.6 63.4 73.6 82.2 28.6 43 54.8 3.4 12.6 24.2 0 0.8 4.8 0 0 0.2 0 0 0 
80.8 50 2.8 99.2 100 100 98 99.6 100 94.6 97.8 99.6 86.2 92 97 67.2 76.8 85 33.8 47 58.2 4.8 14.8 26.4 0 1 5.2 0 0 0.2 0 0 0 
80.8 60 2.8 99.4 100 100 98.4 99.6 100 95.4 98.4 99.8 88.2 93.6 97.6 71.4 79.8 87 37.8 51 61.8 6.2 17 29 0 1.2 5.6 0 0 0.2 0 0 0 
80.8 70 2.8 99.6 100 100 98.8 99.8 100 96.2 98.8 99.8 89.8 94.6 98.2 74.6 82.2 89.2 42.6 54.4 64.6 7.59 19.2 31.4 0 1.6 6.6 0 0 0.2 0 0 0 
80.8 80 2.8 99.6 100 100 98.8 99.8 100 96.6 99 100 91 95.6 98.6 77.4 84.6 90.8 46.6 57.8 67.6 9.39 21.3 33.6 0 1.8 7 0 0 0.2 0 0 0 
80.8 90 2.8 99.6 100 100 99.2 99.8 100 97.4 99.2 100 92.2 96.4 99 79.4 86.4 92.4 50.6 61.4 71 11.4 23.8 36 0 2 7.4 0 0 0.2 0 0 0 
80.8 100 2.8 99.6 100 100 99.2 100 100 97.6 99.4 100 92.8 97 99.2 81.2 88 94 53.8 64 73.8 13.2 26.2 38.6 0 2.2 8.4 0 0 0.2 0 0 0 
80.8 110 2.8 99.8 100 100 99.4 100 100 97.8 99.5 100 94 97.6 99.4 83 89.6 94.6 56.2 67.2 76.4 15.4 28.3 40.8 0.2 2.6 9 0 0 0.2 0 0 0 
80.8 120 2.8 99.8 100 100 99.4 100 100 98.2 99.6 100 94.6 98 99.6 84.2 91 95.6 59.4 69.8 78.8 17.2 30.6 43.4 0.2 2.8 9.6 0 0 0.2 0 0 0 
80.8 130 2.8 99.8 100 100 99.4 100 100 98.4 99.6 100 95 98.2 99.8 85.8 92 96.8 61.8 72 80.8 18.6 33 45.6 0.2 3.2 10 0 0 0.2 0 0 0 
80.8 140 2.8 99.8 100 100 99.6 100 100 98.4 99.8 100 95.6 98.6 99.8 87 93 97.2 64 74.2 83.4 21 35.2 48.6 0.2 3.4 10.6 0 0 0.2 0 0 0 
80.8 150 2.8 99.8 100 100 99.6 100 100 98.8 99.8 100 95.8 98.6 99.8 87.6 93.8 97.8 66 76 84.8 22 36.8 50.8 0.2 3.4 11 0 0 0 0 0 0 
80.8 160 2.8 99.8 100 100 99.6 100 100 98.8 99.8 100 96.4 99 100 88.8 94.4 98.2 67.6 77.8 86.6 24 39 52.6 0.39 3.8 11.4 0 0 0 0 0 0 
80.8 70 1 100 100 100 99.6 100 100 98.8 99.8 100 96 98.8 100 86.4 93.6 98 60 73 83.2 15.8 31.4 44 0 2.4 8.61 0 0 0 0 0 0 
80.8 70 1.2 99.8 100 100 99.6 100 100 98.8 99.8 100 95.4 98.6 100 85.4 92.8 97.8 59.6 71.6 81.8 15.2 30 42.8 0 2.2 8 0 0 0.2 0 0 0 
80.8 70 1.4 99.8 100 100 99.6 100 100 98.4 99.8 100 95 98.4 99.8 84.4 92.1 97.4 57.8 70 80.2 14.4 28.6 41.8 0 2.2 8.4 0 0 0 0 0 0 
80.8 70 1.6 99.8 100 100 99.6 100 100 98.4 99.8 100 94.2 98.2 99.8 83.2 90.8 96.4 56 68.2 77.6 13.4 27.2 40.4 0 2.2 8.2 0 0 0.2 0 0 0 
80.8 70 1.8 99.8 100 100 99.4 100 100 98 99.6 100 94 97.6 99.6 82 89.6 95.6 53.8 66.2 75.6 12.6 26.2 38.4 0 2.1 7.6 0 0 0.2 0 0 0 
80.8 70 2 99.8 100 100 99.4 100 100 97.8 99.4 100 93.2 97.4 99.6 81.2 88.8 94.6 52.6 63.8 73.6 11.4 24.6 36.8 0 2 7.41 0 0 0.2 0 0 0 
80.8 70 2.2 99.8 100 100 99.2 100 100 97.6 99.4 100 92.6 97 99.2 79.6 87.6 93.4 50 61.8 71.4 11.2 23.6 36.2 0 1.8 7.4 0 0 0.2 0 0 0 
80.8 70 2.4 99.6 100 100 99 99.8 100 97.2 99.2 100 92 96.2 99 78.4 85.8 92.2 48.2 59.6 69.6 9.8 22 35 0 1.8 7.2 0 0 0.2 0 0 0 
80.8 70 2.6 99.6 100 100 99 99.8 100 96.6 99 100 90.8 95.6 98.6 76 84.2 90.6 45.8 57 66.4 9 20.4 33.2 0 1.6 6.6 0 0 0.2 0 0 0 
80.8 70 2.8 99.4 100 100 98.8 99.8 100 96.2 98.6 99.8 89.6 94.6 98 74.2 82.2 89.2 42.4 54.6 64.4 7.79 19 31.2 0 1.6 6.8 0 0 0.2 0 0 0 
80.8 70 3 99.2 100 100 98.4 99.6 100 95.4 98.2 99.8 88.2 93.6 97.6 71.6 80 87.2 38.8 51.8 62.6 6.8 17.8 29.8 0 1.4 6.4 0 0 0.2 0 0 0 
80.8 70 3.2 99.2 100 100 98 99.6 100 94.4 97.8 99.6 86 92.4 97 68.4 77.5 86.2 35.4 48.6 60.8 5.79 16.2 28.8 0 1.2 5.8 0 0 0.2 0 0 0 
80.8 70 3.4 98.8 99.8 100 97.4 99.4 100 93 97.2 99.4 84 90.8 96.2 64.2 74.8 84.6 31.4 45.8 59.2 4.6 14.8 27.2 0 1.2 5.6 0 0 0.2 0 0 0 
80.8 70 3.6 98.6 99.8 100 96.4 99 100 91.4 96.4 99.2 80.2 89 95.6 59.2 72 83.2 27 43 57 3.8 13.2 26.2 0 1 5.2 0 0 0.2 0 0 0 
80.8 70 3.8 98 99.6 100 95.2 98.8 100 88.6 95.4 99 75.8 87 94.8 53.2 68.8 82 22.2 39.8 55.8 3 12 25 0 0.8 4.8 0 0 0.2 0 0 0 
Italic values: Highlight rows based on comparable covariate values of CLCRCG, body weight and serum albumin concentration. 
Colour coding: Green: PTA≥90%, Yellow: PTA 80-<90%, Orange: PTA>50-<80%, Red: PTA≤50%; Grey shaded values: 
Extrapolated covariate range not covered by the study population or CLCRCG ≥154 mL/min (=inflection point of CLCRCG-CL 
relationship).  
Abbreviations: CL: Clearance; CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]; MIC: Minimum 
inhibitory concentration; P0.05: 5th percentile; P0.5: 50th percentile = median; P0.95: 95th percentile, q8h: Every 8 hours; T>MIC: 
Time period that total drug concentration exceeds the MIC.  
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Table S22: (Project IV) Cumulative fraction of response (98%T>MIC) for the first day of standard meropenem 
treatment (1000 mg, 30-min i.v. infusion, q8h) (modified from [243]). CFR is given for varied values of one 
covariate and for selected MIC values and is presented as the median (P0.5), 5th (P0.05) and 95th percentile (P0.95) of the 1000 PTA 









Cumulative fraction of response % 
 
Full MIC distribution1 
 
MIC distribution of isolates 
belonging to the S category1 
MIC distribution of isolates 




























P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 
10 70 2.8 100 100 100 99.8 99.9 100 99.8 99.9 100 91.2 95.2 98 88.2 94 99.1 100 100 100 99.9 100 100 88.2 99.1 100 89.5 99.2 100 
20 70 2.8 100 100 100 99.8 99.8 99.9 99.7 99.8 99.9 88.8 92.1 94.6 85.4 89.1 92.8 99.7 100 100 99.6 100 100 76.1 93.1 99.4 78.3 94 99.5 
30 70 2.8 100 100 100 99.7 99.8 99.8 99.6 99.7 99.8 86.4 89.4 91.4 83 86 88.2 99.3 99.9 100 98.8 99.9 100 61.7 79.7 91 64.7 81.9 92.3 
40 70 2.8 100 100 100 99.6 99.7 99.8 99.5 99.6 99.7 83.7 86.6 88.7 80.4 83.5 85.5 98.2 99.6 100 97.1 99.2 99.9 47 61.7 73.7 50.4 65 76.7 
50 70 2.8 100 100 100 99.5 99.6 99.7 99.4 99.5 99.6 80.5 83.7 86 77 80.6 83.1 96.5 98.6 99.6 94.5 97.7 99.3 32 43.9 55.3 35.2 47.3 58.7 
60 70 2.8 99.9 100 100 99.2 99.5 99.6 99.1 99.4 99.5 76.9 80.4 83.1 72.9 76.9 80 93.8 96.8 98.6 90.8 94.8 97.5 19.7 29.4 39.5 22.1 32.2 42.3 
70 70 2.8 99.9 99.9 100 99.1 99.4 99.5 98.8 99.3 99.4 72.9 76.9 80.2 68 72.5 76.4 90.3 94 96.6 85.7 90.5 94.2 10.6 18.9 28.5 12 20.9 30.8 
80 70 2.8 99.8 99.9 100 98.8 99.3 99.4 98.3 99 99.3 68.2 72.9 77 62.1 67.5 72.2 85.3 90.1 93.8 79 85 89.9 4.4 11.4 20.5 4.99 12.8 22.3 
90 70 2.8 99.6 99.9 99.9 98.2 99 99.3 97.6 98.6 99.1 63 68.5 73.3 55.8 62.2 67.6 79.2 85.3 90.1 71.3 78.7 84.8 1.61 6.83 14.6 1.83 7.67 16 
100 70 2.8 99.4 99.9 99.9 97.5 98.8 99.1 96.6 98.2 98.8 57.4 63.9 69.5 49.4 56.7 63.1 72.3 79.9 86 63.2 72.2 79.5 0.537 3.85 10.4 0.61 4.35 11.4 
110 70 2.8 99.2 99.7 99.9 96.6 98.2 99 95.5 97.4 98.5 52.1 59.1 65.7 43.6 51.4 58.8 65.6 74.2 81.6 55.9 65.6 74.4 0.21 2.2 7.51 0.238 2.5 8.31 
120 70 2.8 98.8 99.6 99.8 95.4 97.6 98.8 94 96.5 98.1 46.9 54.6 62.2 38.4 46.7 55 59.1 68.7 77.5 49.2 59.6 69.7 0 1.29 5.62 0 1.46 6.24 
130 70 2.8 98.2 99.3 99.8 93.9 96.7 98.6 92.1 95.4 97.7 41.6 50.3 59.2 33.5 42.3 51.7 52.5 63.2 74 42.9 54 65.7 0 0.752 4.15 0 0.853 4.62 
140 70 2.8 97.5 99.1 99.8 92.1 95.9 98.3 90 94.3 97.4 37.1 46.5 57.6 29.5 38.6 50 46.7 58.5 72.1 37.7 49.4 63.6 0 0.43 3.61 0 0.488 4.01 
150 70 2.8 96.7 98.8 99.8 89.9 94.8 98.2 87.5 93 97.1 32.6 43.1 56.5 25.7 35.3 48.7 41.1 54.2 70.8 32.9 45.2 62.1 0 0.322 2.87 0 0.366 3.2 
≥154 70 2.8 96.2 98.7 99.8 89.2 94.3 98.2 86.7 92.3 97.2 31.3 41.8 56.7 24.6 34.2 48.9 39.4 52.6 71 31.5 43.8 62.2 0 0.215 2.66 0 0.244 2.96 
80.8 40 2.8 99.6 99.9 99.9 98.2 99 99.3 97.5 98.6 99.1 62.7 68.5 73.4 70.8 78.7 84.9 78.7 85.2 90.1 55.5 62.2 67.8 1.83 7.14 15.2 2.07 7.99 16.6 
80.8 50 2.8 99.7 99.9 99.9 98.3 99.1 99.3 97.8 98.8 99.1 64.5 69.9 74.6 73.6 80.8 86.6 80.9 86.8 91.5 57.7 63.9 69.3 2.58 8.41 16.6 2.93 9.41 18.1 
80.8 60 2.8 99.7 99.9 99.9 98.5 99.2 99.4 98 98.9 99.2 66.3 71.4 75.6 76.1 82.8 88 83 88.4 92.5 59.7 65.6 70.5 3.33 9.69 18.2 3.78 10.8 19.9 
80.8 70 2.8 99.8 99.9 99.9 98.7 99.2 99.4 98.3 99 99.2 67.8 72.5 76.5 78.4 84.4 89.3 84.8 89.7 93.4 61.6 67 71.7 4.08 11.1 19.9 4.63 12.3 21.7 
80.8 80 2.8 99.8 99.9 100 98.8 99.3 99.4 98.4 99.1 99.3 69 73.6 77.4 80.3 86 90.4 86.2 90.8 94.2 63.2 68.4 72.7 5.04 12.3 21.3 5.72 13.7 23.2 
80.8 90 2.8 99.8 99.9 100 98.8 99.3 99.4 98.5 99.1 99.3 70.3 74.5 78.2 82.1 87.4 91.6 87.6 91.8 95 64.7 69.6 73.8 6.12 13.7 22.8 6.94 15.3 24.8 
80.8 100 2.8 99.8 99.9 100 98.9 99.4 99.5 98.6 99.2 99.4 71.1 75.4 78.9 83.4 88.5 92.7 88.5 92.7 95.7 65.8 70.6 74.8 7.09 15.1 24.6 8.05 16.8 26.8 
80.8 110 2.8 99.9 99.9 100 99.1 99.4 99.5 98.8 99.2 99.4 72.1 76.2 79.5 84.6 89.8 93.4 89.6 93.5 96.1 66.9 71.7 75.5 8.37 16.4 26.1 9.47 18.3 28.4 
80.8 120 2.8 99.9 99.9 100 99.1 99.4 99.5 98.8 99.3 99.4 72.9 76.9 80.1 85.8 90.8 94.2 90.4 94.2 96.6 68 72.6 76.3 9.33 17.7 27.8 10.6 19.7 30.2 
80.8 130 2.8 99.9 100 100 99.1 99.4 99.5 98.9 99.3 99.4 73.6 77.5 80.7 86.8 91.5 95 91.1 94.7 97.1 68.8 73.4 77.1 10.1 19.2 29.1 11.4 21.4 31.7 
80.8 140 2.8 99.9 100 100 99.2 99.4 99.5 98.9 99.3 99.5 74.2 78.1 81.2 87.8 92.4 95.7 91.8 95.3 97.5 69.7 74.2 77.8 11.4 20.5 31 12.9 22.8 33.8 
80.8 150 2.8 99.9 100 100 99.2 99.5 99.6 99 99.3 99.5 74.7 78.5 81.6 88.5 92.9 96.1 92.3 95.7 97.8 70.3 74.7 78.2 11.9 21.3 32.4 13.5 23.8 35.3 
80.8 160 2.8 99.9 100 100 99.2 99.5 99.6 99 99.4 99.5 75.3 79 82 89.2 93.6 96.6 92.9 96.1 98.1 71 75.3 78.8 13.1 22.7 33.5 14.8 25.3 36.5 
80.8 70 1 99.9 100 100 99.3 99.4 99.5 99 99.3 99.5 73.6 77.9 80.9 86.9 92.3 95.8 91.4 95.3 97.7 68.7 73.9 77.6 8.49 18 27.6 9.63 20.1 30.2 
80.8 70 1.2 99.9 100 100 99.1 99.4 99.5 98.9 99.3 99.4 73.2 77.5 80.7 86.5 91.7 95.5 91 95 97.5 68.3 73.4 77.2 8.17 17.1 26.7 9.27 19.1 29.2 
80.8 70 1.4 99.9 100 100 99.1 99.4 99.5 98.9 99.3 99.4 72.7 77.1 80.4 85.7 91.2 95 90.4 94.6 97.2 67.7 72.8 76.8 7.74 16.4 26.4 8.78 18.3 28.8 
80.8 70 1.6 99.9 99.9 100 99.1 99.4 99.5 98.8 99.3 99.4 72.1 76.6 79.9 84.8 90.4 94.2 89.8 94.1 96.7 67 72.2 76.1 7.19 15.6 25.5 8.16 17.4 27.8 
80.8 70 1.8 99.9 99.9 100 99.1 99.4 99.5 98.8 99.2 99.4 71.6 76 79.4 83.9 89.6 93.5 89.1 93.4 96.3 66.2 71.4 75.4 6.77 15 24.1 7.68 16.8 26.4 
80.8 70 2 99.9 99.9 100 99 99.4 99.5 98.7 99.2 99.4 71 75.5 78.9 83.2 88.8 92.9 88.6 92.9 95.9 65.6 70.7 74.8 6.12 14.1 23.2 6.95 15.8 25.3 
80.8 70 2.2 99.8 99.9 100 99 99.3 99.5 98.7 99.2 99.3 70.4 74.9 78.4 82.1 88 92 87.8 92.3 95.3 64.7 70 74.1 6.02 13.5 22.9 6.83 15.1 25 
80.8 70 2.4 99.8 99.9 100 98.8 99.3 99.4 98.5 99.1 99.3 69.7 74.1 77.9 81.2 86.8 91.3 87 91.5 94.8 63.9 69.1 73.5 5.27 12.7 22.1 5.97 14.1 24.1 
80.8 70 2.6 99.8 99.9 100 98.8 99.3 99.4 98.4 99 99.3 68.7 73.4 77.2 79.7 85.7 90.1 85.8 90.7 94 62.8 68.1 72.5 4.84 11.7 20.9 5.49 13.1 22.8 
80.8 70 2.8 99.8 99.9 99.9 98.6 99.2 99.4 98.2 99 99.2 67.7 72.5 76.5 78.2 84.4 89.2 84.7 89.6 93.3 61.5 67 71.6 4.19 10.9 19.9 4.75 12.2 21.7 
80.8 70 3 99.8 99.9 99.9 98.4 99.2 99.4 97.9 98.9 99.2 66.4 71.5 75.8 76.3 83 88.2 83.1 88.5 92.6 60 65.8 70.8 3.65 10.2 19 4.15 11.4 20.7 
80.8 70 3.2 99.6 99.9 99.9 98.3 99.2 99.3 97.7 98.8 99.2 64.9 70.4 75.2 74.1 81.4 87.4 81.3 87.3 92 58.2 64.5 70.1 3.11 9.26 18.2 3.53 10.3 19.8 
80.8 70 3.4 99.6 99.9 99.9 97.9 99 99.3 97.3 98.6 99.1 63 69.1 74.5 71.5 79.6 86.5 79 85.8 91.3 56.1 63 69.3 2.47 8.51 17.2 2.8 9.49 18.8 
80.8 70 3.6 99.4 99.9 99.9 97.6 98.9 99.3 96.9 98.4 99.1 60.6 67.8 73.9 68.1 77.8 85.5 76 84.2 90.5 53.4 61.5 68.4 2.04 7.55 16.5 2.32 8.44 18 
80.8 70 3.8 99.2 99.9 99.9 97 98.7 99.3 96.1 98.2 99 57.6 66.3 73.3 64.1 75.7 84.8 72.3 82.5 89.9 50.2 59.8 67.8 1.61 6.82 15.7 1.83 7.63 17.1 
1According to EUCAST [390].   
Italic values: Highlight rows based on comparable covariate values of CLCRCG, body weight and serum albumin concentration. 
Colour coding: Green: CFR≥90%, Yellow: CFR 80-<90%, Orange: CFR>50-<80%, Red: CFR≤50%; Grey shaded values: 
Extrapolated covariate range not covered by the study population or CLCRCG ≥154 mL/min (=inflection point of CLCRCG-CL 
relationship).   
Abbreviations: CL: Clearance; CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]; I category: 
Category ‘susceptible at increased exposure’ [4]; MIC: Minimum inhibitory concentration; P0.05: 5th percentile; P0.5: 50th 
percentile = median; P0.95: 95th percentile, q8h: Every 8 hours; S category: Category ‘susceptible at normal dosing’ [4]; T>MIC: 










Table S23: (Project IV): Probability of target (98%T>MIC) attainment (PTA, %) for different short-term infusion dosing regimens of meropenem for the first day of 
treatment (modified from [243]). PTA is given for varied values of creatinine clearance and for selected MIC values and is presented as the median (P0.5), 5th (P0.05) and 95th percentile 
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10 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.6 100 100 98 100 100 92 99.8 100 73.4 96.8 100 30.6 74.3 98.6 0.79 9.9 47.2 0 0 0 
20 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.4 100 100 98 100 100 93.6 99.4 100 81.6 96.4 100 52.6 81 97 12.6 36.6 66.2 0 1 6.2 0 0 0 
30 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.4 100 100 98.2 99.8 100 95 99.2 100 86 96.2 99.6 67.4 85.4 96.2 34 55.4 75.4 3.6 13.2 26 0 0 1 0 0 0 
40 100 100 100 100 100 100 99.8 100 100 99.8 100 100 99.4 100 100 98.4 99.8 100 96 99.2 100 90 96.6 99.6 76.2 88.2 96.4 50.6 67.3 80.6 16.6 31 43.8 0.6 3.8 10.4 0 0 0.2 0 0 0 
50 100 100 100 99.8 100 100 99.8 100 100 99.4 100 100 98.6 99.8 100 96.6 99.2 100 91.8 97 99.4 82.2 90.8 96.6 63.2 75.2 85.4 33.2 47 58.6 6.2 15 25.4 0 1 4.4 0 0 0 0 0 0 
60 99.8 100 100 99.6 100 100 99.4 100 100 98.6 99.8 100 97 99.2 100 93.6 97.6 99.6 86.6 92.6 97.2 72.2 81.2 89.6 48.2 59.6 70.2 18.2 29.6 40.8 1.6 7 15 0 0.2 2 0 0 0 0 0 0 
70 99.6 100 100 99.4 100 100 98.6 99.8 100 97.2 99.2 100 94.4 97.8 99.6 89 94.2 98 78.2 85.6 92.4 59.4 69.2 78.4 31.8 43.8 54.8 7.8 17.8 28.8 0.2 3 8.8 0 0 1 0 0 0 0 0 0 
80 99.4 100 100 98.8 99.8 100 97.6 99.4 100 95.2 98.2 99.6 90.8 95.4 98.6 82.8 89.2 95 68.2 76.2 84.4 44.6 56 65.6 18.4 30.8 42.6 2.99 10.2 20.2 0 1.2 5.4 0 0 0.6 0 0 0 0 0 0 
90 98.8 99.8 100 97.8 99.4 100 96 98.6 99.8 92.4 96.4 99 85.8 92 96.4 74.6 82.9 89.8 54.8 66.3 75.6 30.8 43.7 55.2 9.4 20.8 33.6 0.8 5.4 14 0 0.4 3.2 0 0 0.2 0 0 0 0 0 0 
100 98.2 99.6 100 96.4 98.8 100 93.8 97.2 99.4 88.6 93.8 97.6 79.6 86.8 93 64.8 74.8 83.4 42 55.4 66.6 19.4 33 45.8 4.4 13.4 25 0.2 3 9.8 0 0.2 2.01 0 0 0.2 0 0 0 0 0 0 
110 97 99 100 94.4 97.6 99.6 90.4 95.2 98.6 83.6 90 95.6 71.6 80.8 89 54 66 76.8 30.4 45.2 58.2 11 24.3 37.6 1.8 8.6 19.6 0 1.6 6.8 0 0 1.2 0 0 0 0 0 0 0 0 0 
120 95.6 98.4 99.8 92.2 96.2 99 87.2 92.6 97.4 77.6 85.6 93.4 63.2 74.2 84.6 43.8 57.9 70.4 22 36.6 51.6 6.4 18 32.2 0.8 5.8 15.2 0 0.8 5 0 0 0.8 0 0 0 0 0 0 0 0 0 
130 93.8 97.4 99.6 89 94.4 98.6 82.2 89.6 96.2 71 80.8 90.6 54.8 67.4 80.4 34.4 50 65.4 14.8 29.4 46.6 3.6 13 27.2 0.4 3.8 12 0 0.4 3.6 0 0 0.41 0 0 0 0 0 0 0 0 0 
140 91.6 96 99.4 86 92.2 98 77.4 86.3 95.2 64.2 76 89 46.6 61.4 77.8 26.8 43.4 62 10.6 24.2 42.8 2.2 10 23.8 0.2 2.6 10.2 0 0.2 2.8 0 0 0.4 0 0 0 0 0 0 0 0 0 
150 88.6 94.8 99.2 81.2 89.8 97.6 71.2 82.8 94.6 56.6 71.6 88.4 39 55.8 77 20.8 37.8 60.6 6.8 19.8 40.4 1.4 7.4 21.4 0 1.6 8.6 0 0.2 2.4 0 0 0.2 0 0 0 0 0 0 0 0 0 









10 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.6 100 100 96.8 100 100 78.2 98 100 16 54.6 93.6 0 0 0.8 
20 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.6 100 100 98.4 100 100 90.6 99 100 59.2 86.2 98.6 4.6 19.4 44.4 0 0 0 
30 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99 100 100 95.6 99.4 100 81.2 94.2 99.4 39 62.8 81.2 0.6 4.8 13.4 0 0 0 
40 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.4 100 100 97.6 99.6 100 90.2 97 99.6 68.8 82.6 93.2 21.6 37.4 51 0 1 4.6 0 0 0 
50 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.6 100 100 98.4 99.8 100 94.6 98.4 99.8 82.8 91.2 97.2 52.4 65.6 77 8.39 18.7 30.2 0 0.2 1.8 0 0 0 
60 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.6 100 100 98.8 99.8 100 96.8 99.2 100 90 95.6 98.8 73 81.8 89.8 34.8 47.2 57.8 2.2 8.8 18.2 0 0 0.8 0 0 0 
70 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.4 100 100 98 99.6 100 94.2 97.8 99.6 84.2 90.6 96 59.6 69.2 78.2 19.4 31.8 43.4 0.4 4 11.2 0 0 0.4 0 0 0 
80 100 100 100 100 100 100 100 100 100 99.8 100 100 99.6 100 100 98.8 99.8 100 96.4 98.8 100 90.2 95 98.4 75.4 83 90 43.8 55.6 66.2 8.19 19.9 32.2 0 1.6 6.8 0 0 0.2 0 0 0 
90 100 100 100 100 100 100 99.8 100 100 99.6 100 100 99.2 99.8 100 97.8 99.4 100 94 97.4 99.4 84.4 90.8 95.6 64 73.6 81.8 29.2 42.8 54.8 3 12.2 23.6 0 0.6 4.2 0 0 0 0 0 0 
100 100 100 100 99.8 100 100 99.8 100 100 99.4 100 100 98.6 99.8 100 96.2 98.8 100 90 95.2 98.4 77.4 85.2 91.4 51.4 63.2 73.4 16.8 31.6 44.8 1 7 17.2 0 0.2 2.4 0 0 0 0 0 0 
110 100 100 100 99.8 100 100 99.6 100 100 99.2 99.8 100 97.8 99.4 100 94.4 97.6 99.4 85.8 92 96.6 68.8 78.2 86.2 39.4 53 65.2 9.2 22.7 37 0.39 4.1 12.6 0 0 1.6 0 0 0 0 0 0 
120 99.8 100 100 99.8 100 100 99.4 100 100 98.6 99.6 100 96.6 98.8 100 92 96.2 98.8 81 87.6 94 59.6 71.2 81 28.4 44.1 58.2 5.2 16.4 30.8 0 2.4 9.6 0 0 1 0 0 0 0 0 0 
130 99.8 100 100 99.6 100 100 99.2 99.8 100 97.8 99.4 100 95 98 99.8 88.6 94 98 74.2 83.4 91.8 50.4 63.6 76.8 19.4 36 52 2.6 11.8 25.8 0 1.4 7.2 0 0 0.6 0 0 0 0 0 0 
140 99.8 100 100 99.4 100 100 98.6 99.8 100 97 99 100 93 97.2 99.6 85 91.8 97.6 67.8 78.8 90.4 41 56.8 74.2 14 29.8 49.2 1.4 8.8 23 0 0.8 6.2 0 0 0.6 0 0 0 0 0 0 
150 99.6 100 100 99.2 100 100 98.2 99.6 100 95.8 98.6 100 90.6 96 99.4 80.2 89.4 97.2 60 74.4 89.4 32.8 51 73.4 9.99 24.5 46.6 0.8 6.4 20.6 0 0.6 5 0 0 0.4 0 0 0 0 0 0 






10 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.6 100 100 96.8 100 100 78.4 98 100 15.4 55.3 93.2 
20 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 98.2 100 100 91 99 100 60.4 86 98.4 4.4 19.2 44.2 
30 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99 100 100 95.6 99.4 100 81.2 94 99.4 39.4 62.2 81.4 0.6 4.8 13.2 
40 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.4 100 100 97.6 99.6 100 90.8 97 99.8 68.2 82.6 93 21.6 37.4 51.2 0 1 5 
50 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.6 100 100 98.4 99.8 100 94.8 98.4 99.8 83.2 91.2 97.2 52.6 65.6 77.2 8.59 18.6 30 0 0.2 1.8 
60 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.6 100 100 99 99.8 100 96.6 99.2 100 90.4 95.6 98.8 72.8 81.8 90 34.8 47 58 2.39 8.8 18.2 0 0 0.6 
70 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.8 100 100 99.2 100 100 98 99.6 100 94 97.6 99.6 84 90.6 95.8 58.8 69.2 77.8 18.4 31.4 43 0.4 3.8 11 0 0 0.4 
80 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.6 100 100 98.6 99.8 100 96.4 98.8 99.8 90 95 98.4 75.4 82.8 89.8 43.4 55.6 65.6 8.4 20.2 32 0 1.6 6.8 0 0 0.2 
90 100 100 100 100 100 100 100 100 100 99.8 100 100 99.6 100 100 99.2 99.8 100 97.8 99.4 100 94 97.4 99.4 84.4 90.8 95.8 63.6 73.6 81.8 29 42.6 55 3.4 12 24 0 0.6 4.2 0 0 0 
100 100 100 100 100 100 100 99.8 100 100 99.8 100 100 99.4 100 100 98.6 99.8 100 96.2 98.6 99.8 90.4 95 98.4 77.4 85 91.6 51.2 63.4 73.4 17 31.4 45.2 1 7 17.2 0 0.2 2.6 0 0 0 
110 100 100 100 100 100 100 99.8 100 100 99.6 100 100 99 99.8 100 97.8 99.4 100 94 97.4 99.4 85.8 91.8 96.6 68.8 78.4 86 39.6 53 65 8.6 22.7 37 0.4 4.2 12.8 0 0 1.6 0 0 0 
120 100 100 100 99.8 100 100 99.8 100 100 99.4 100 100 98.4 99.6 100 96.6 98.8 99.8 91.4 95.6 98.6 81 87.8 94 59.6 71 81 28.4 43.6 57.6 5 16.3 30.8 0 2.4 9.2 0 0 1 0 0 0 
130 100 100 100 99.8 100 100 99.6 100 100 99.2 99.8 100 98 99.4 100 95.2 98 99.6 88.6 93.6 97.8 74.8 83.1 91.2 50.2 63.6 76.6 19.6 35.8 52.2 2.8 11.6 25.8 0 1.4 6.8 0 0 0.8 0 0 0 
140 99.8 100 100 99.8 100 100 99.4 100 100 98.6 99.8 100 97 99.2 100 93.2 97 99.6 84 91.4 97.2 67.8 79.2 89.6 41 57 73 14.2 29.6 48.8 1.4 8.4 22.2 0 0.8 5.6 0 0 0.6 0 0 0 
150 99.8 100 100 99.6 100 100 99.2 100 100 98.2 99.6 100 95.4 98.8 100 90.4 96 99.4 79.4 88.6 96.8 60.2 74 89.4 33 50.8 73 9.79 24.4 47 0.8 6.4 21.2 0 0.6 5 0 0 0.4 0 0 0 
≥154 99.8 100 100 99.6 100 100 99 100 100 97.8 99.6 100 95.2 98.6 100 89.6 95.6 99.4 77.6 87.5 97 57.2 72.4 89.4 30.4 49 73.2 8.2 23 46 0.8 5.8 19.6 0 0.4 4.6 0 0 0.4 0 0 0 
1Body weight and albumin set to median of first study day (i.e. 70 kg and 2.8 g/dL). Colour coding: Green: PTA≥90%, Yellow: PTA 80-<90%, Orange: PTA>50-<80%, Red: PTA≤50%; Grey 
shaded values: Extrapolated CLCRCG range not covered by the study population or CLCRCG ≥154 mL/min (=inflection point of CLCRCG-CL relationship).  
Abbreviations: CL: Clearance; CLCRCG: Creatinine clearance estimated according to Cockcroft and Cockcroft and Gault [2]; MIC: Minimum inhibitory concentration; P0.05: 5th percentile; P0.5: 








Table S24: (Project IV): Probability of target (98%T>MIC) attainment (PTA, %) for different prolonged infusion dosing regimens of meropenem for the first day of 
treatment (modified from [243]). PTA is given for varied values of creatinine clearance and for selected MIC values and is presented as the median (P0.5), 5th (P0.05) and 95th percentile 









0.004 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 
P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 
PI212 




10 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.2 100 100 96.4 100 100 83.2 98.8 100 38 79.3 96.8 0 0 0.4 0 0 0 
20 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.2 100 100 97.4 99.8 100 89.8 98.6 100 66.2 89.8 99 19.2 46.8 76.4 0 0 0 0 0 0 
30 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.4 100 100 98 99.8 100 93.4 98.8 100 80.2 93 98.8 47.4 69.6 86.4 6.8 19.4 35.4 0 0 0 0 0 0 
40 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.4 100 100 98.4 99.8 100 95.4 99 100 87 95 99 65.8 80.6 91.2 29 45.6 60.2 1.6 6.4 15 0 0 0 0 0 0 
50 100 100 100 100 100 100 100 100 100 99.8 100 100 99.4 100 100 98.8 99.8 100 96.4 99.2 100 91.2 96.2 99.2 77.4 87 94.4 50.6 63.8 75.2 14.2 26 37 0.2 2 6.8 0 0 0 0 0 0 
60 100 100 100 100 100 100 99.8 100 100 99.6 100 100 99 99.8 100 97.4 99.4 100 93.4 97.2 99.6 84 91.2 96.6 65.8 75.2 84.6 33.6 45.4 56.4 4.8 13.2 23.4 0 0.6 3.2 0 0 0 0 0 0 
70 100 100 100 99.8 100 100 99.6 100 100 99 99.8 100 98 99.4 100 95 98.2 99.8 88.2 94 97.8 75.8 83.4 90.6 50.8 61.6 70.8 18.4 30.4 41.8 1.4 6.6 14.8 0 0.2 1.6 0 0 0 0 0 0 
80 99.8 100 100 99.6 100 100 99.2 100 100 98.2 99.6 100 96.2 98.8 99.8 91.6 96 98.8 81.8 88.6 94.2 64 73.2 81.2 35.6 47.6 58.2 8.39 19.2 31.2 0.2 3 9.41 0 0 0.8 0 0 0 0 0 0 
90 99.6 100 100 99.2 100 100 98.6 99.8 100 97 99 100 94 97.2 99.4 87.6 92.8 97 73.6 81.6 88.6 50.8 62.2 71.6 21.4 35.4 47.6 3.4 11.8 22.6 0 1.4 6 0 0 0.4 0 0 0 0 0 0 
100 99.4 100 100 98.8 99.8 100 97.8 99.4 100 95.4 98.2 99.6 90.2 95 98.4 81.4 87.8 94 63.2 73.2 81.8 38 51.2 62.2 12.4 25.6 38.6 1.4 7 17 0 0.6 4 0 0 0.2 0 0 0 0 0 0 
110 99 99.8 100 98.2 99.6 100 96.4 98.8 99.8 93 96.6 99.2 86.2 91.9 96.6 74 82 89.6 52.4 64.4 74.6 25.8 40.6 54.2 6.6 18 31.4 0.4 4.2 12.4 0 0.2 2.4 0 0 0.2 0 0 0 0 0 0 
120 98.8 99.8 100 97.2 99.2 100 94.8 97.8 99.6 89.8 94.6 98.4 81.6 88 94.6 65.6 75.8 85.6 41.6 55.6 68.2 18 32.4 47.4 3.6 12.4 25.4 0 2.4 9.2 0 0.2 1.8 0 0 0 0 0 0 0 0 0 
130 98 99.4 100 96 98.6 99.8 92.6 96.6 99.4 86.4 92.2 97.6 75.2 83.8 92.2 56.8 69.4 81.4 32.6 47.8 62.8 11.8 25.6 41.6 1.8 9 21.4 0 1.4 6.8 0 0 1.2 0 0 0 0 0 0 0 0 0 
140 97 99.2 100 94.4 98 99.8 90.2 95.4 99 81.8 89.8 96.8 68.4 79.6 90.8 49.2 63.4 79 25.4 41.1 59.4 8.19 20.4 38.2 1 6.4 18.2 0 0.8 5.6 0 0 0.8 0 0 0 0 0 0 0 0 0 
150 96 98.8 100 92.4 97 99.6 86.8 93.6 99 76.6 86.8 96.2 61.2 75 90.6 41 57.4 78.4 19.6 35.4 58.8 5.59 16.4 36.2 0.6 4.8 16.6 0 0.6 5 0 0 0.8 0 0 0 0 0 0 0 0 0 
≥154 95.6 98.6 100 91.8 96.6 99.6 85.6 93 98.8 74.2 85.6 96 58.4 73 90.4 37.4 55.8 78.6 17.2 33.8 58.2 4.6 15.2 35.2 0.4 4.2 16.2 0 0.4 4.61 0 0 0.6 0 0 0 0 0 0 0 0 0 
PI38 




10 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.2 100 100 82.8 95 99.2 0 0 0.8 0 0 0 
20 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.6 100 100 97 99.8 100 70 89.6 97.4 0 0 0.2 0 0 0 
30 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 98.8 100 100 92.4 98.6 100 53.8 74.8 89.4 0 0 0.2 0 0 0 
40 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.4 100 100 96.8 99.6 100 84.8 94.2 99 35.8 53.2 68 0 0 0 0 0 0 
50 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 98.8 99.8 100 94 98.2 99.8 74.4 84.8 93 19.6 32.3 44.2 0 0 0 0 0 0 
60 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.4 100 100 97.4 99.4 100 88.8 94.8 98.6 60.8 71.4 80.8 7.6 18 29 0 0 0 0 0 0 
70 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.6 100 100 98.8 99.8 100 94.8 98.2 99.8 82 88.8 94.8 44.2 56 65.6 2.2 9.2 19.2 0 0 0 0 0 0 
80 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.4 100 100 97.6 99.4 100 91.2 95.8 98.8 72.2 80.2 87.8 27 41.4 52.4 0.4 4.6 12.6 0 0 0 0 0 0 
90 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.8 100 100 98.8 99.8 100 95.8 98.6 99.8 85.6 92.2 96.4 59.6 69.8 79 14.8 28.8 42.6 0 2.2 8.4 0 0 0 0 0 0 
100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.4 100 100 97.8 99.6 100 93.2 97 99.2 79.8 86.8 92.6 45.6 58.9 69.6 6.8 19.2 33.6 0 1 5.6 0 0 0 0 0 0 
110 100 100 100 100 100 100 100 100 100 99.8 100 100 99.8 100 100 99 99.8 100 96.8 99 99.8 89.8 94.8 98 71.2 80.2 87.6 33.2 48 61 3 12.8 26.6 0 0.4 3.4 0 0 0 0 0 0 
120 100 100 100 100 100 100 100 100 100 99.8 100 100 99.6 100 100 98.4 99.6 100 95.2 98 99.6 86 91.6 96.4 63 73 82.8 22.8 38.7 54.4 1.4 8.6 20.8 0 0.2 2.4 0 0 0 0 0 0 
130 100 100 100 100 100 100 100 100 100 99.8 100 100 99.2 100 100 97.8 99.4 100 93 97 99.2 80.6 88 94.2 52 65.6 78 14.6 31.2 47.6 0.4 5.6 16.8 0 0 1.6 0 0 0 0 0 0 
140 100 100 100 100 100 100 99.8 100 100 99.6 100 100 99 99.8 100 96.8 99.2 100 90.8 95.6 98.8 75.2 84.2 93.2 43.6 59.2 75.8 10.4 25.1 43.8 0.2 3.8 14 0 0 1 0 0 0 0 0 0 
150 100 100 100 100 100 100 99.8 100 100 99.6 100 100 98.6 99.8 100 95.6 98.6 100 87.4 93.6 98.8 68.4 80.1 92.4 34.8 52.8 75.2 6.79 20.6 42 0 2.8 12.8 0 0 1 0 0 0 0 0 0 
≥154 100 100 100 100 100 100 99.8 100 100 99.4 100 100 98.4 99.8 100 95 98.4 100 85.6 93 98.8 65.4 78.6 92.6 32.6 51 74.4 5.8 19.2 41.8 0 2.4 12.6 0 0 1 0 0 0 0 0 0 
PI68 




10 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.2 100 100 82.8 95 99 0 0 0.8 
20 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.6 100 100 97 99.8 100 71 89.4 97.6 0 0 0.2 
30 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 98.8 100 100 92 98.6 100 54 74.6 89.4 0 0 0.2 
40 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.4 100 100 97 99.6 100 84.2 94.2 98.8 35.6 53.4 67.8 0 0 0 
50 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 98.6 99.8 100 93.6 98 99.8 74.4 84.9 93.4 19.2 32.6 44.8 0 0 0 
60 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.4 100 100 97.2 99.4 100 88.6 94.6 98.4 60.8 71.4 80.8 7.8 18 29.4 0 0 0 
70 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.6 100 100 98.8 99.8 100 94.8 98.2 99.8 82 88.6 94.8 44.4 55.6 65.2 2.4 9 19.2 0 0 0 
80 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.4 100 100 97.4 99.4 100 91.4 95.8 98.8 72.2 80 87.8 27.2 41 52.6 0.59 4.6 12.6 0 0 0 
90 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.6 100 100 98.8 99.8 100 96 98.6 99.8 86.6 92 96.4 59.8 69.8 78.6 14.2 29.2 42.6 0 2 8.4 0 0 0 
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.4 100 100 98 99.4 100 93.2 97 99.2 79.4 86.6 92.4 45.8 58.8 69.4 6.99 19.4 34 0 1 5.2 0 0 0 
110 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.6 100 100 99 99.8 100 96.8 99 100 89.8 94.8 97.8 72 80.2 87.8 33.2 48.2 61 3 13.4 26.2 0 0.4 3.4 0 0 0 
120 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.6 100 100 98.4 99.6 100 95.2 98 99.6 86 91.6 96.4 62 73.2 82.2 22.4 39.2 53.4 1.4 8.6 21 0 0.2 2.2 0 0 0 
130 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 99.4 100 100 97.6 99.4 100 93 96.8 99.2 80.8 88.2 94.2 53 65.6 78 14.6 31.2 48.2 0.6 5.6 17.2 0 0 1.8 0 0 0 
140 100 100 100 100 100 100 100 100 100 99.8 100 100 99.6 100 100 99 99.8 100 96.6 99 100 90.2 95.6 98.8 74.4 84.6 92.8 44.2 59 75.6 9.99 25.3 44.8 0.2 4 14.4 0 0 1.2 0 0 0 
150 100 100 100 100 100 100 100 100 100 99.8 100 100 99.4 100 100 98.6 99.8 100 95.4 98.4 100 87 93.8 98.8 68 80.2 92.8 34.8 52.8 73.8 6.4 21 41.2 0 2.8 13 0 0 1 0 0 0 
≥154 100 100 100 100 100 100 100 100 100 99.8 100 100 99.4 100 100 98.4 99.6 100 95 98.4 100 85.8 93.2 98.6 65.4 78.4 92.4 33.4 50.8 74.2 5.6 18.8 42 0 2.4 12.4 0 0 1 0 0 0 
1Body weight and serum albumin concentration set to median of first study day (i.e. 70 kg and 2.8 g/dL). Colour coding: Green: PTA≥90%, Yellow: PTA 80-<90%, Orange: PTA>50-<80%, 
Red: PTA≤50%; Grey shaded values: Extrapolated CLCRCG range not covered by the study population or CLCRCG ≥154 mL/min (=inflection point of CLCRCG-CL relationship).  
Abbreviations: CL: Clearance; CLCRCG: Creatinine clearance estimated according to Cockcroft and Cockcroft and Gault [2]; Minimum inhibitory concentration; P0.05: 5th percentile; P0.5: 50th 







Table S25: (Project IV): Probability of target attainment (PTA, %) for different continuous infusion dosing regimens of meropenem for the first day of treatment 
(modified from [243]). PTA is given for varied values of creatinine clearance and for selected MIC values and is presented as the median (P0.5), 5th (P0.05) and 95th percentile (P0.95) of the 
1000 PTA values derived from the 1000 Monte Carlo simulations considering PK parameter uncertainty.   










0.004 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 
P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 
CI3 









10 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 95.2 99.4 100 0 0.2 1.6 0 0 0 0 0 0 
20 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 89.4 97.8 100 0 0 0.6 0 0 0 0 0 0 
30 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 79.6 93 98.8 0 0 0.2 0 0 0 0 0 0 
40 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.6 100 100 68.4 82.6 93 0 0 0 0 0 0 0 0 0 
50 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99 100 100 54 67.6 79.2 0 0 0 0 0 0 0 0 0 
60 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 98 99.6 100 38 50.8 62 0 0 0 0 0 0 0 0 0 
70 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 95.6 98.6 100 22.6 35.4 47.2 0 0 0 0 0 0 0 0 0 
80 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 92.6 96.8 99.2 11.8 23.5 36 0 0 0 0 0 0 0 0 0 
90 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 88 93.6 97.4 5.39 14.9 27.6 0 0 0 0 0 0 0 0 0 
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 82.4 88.8 94 2.2 9.4 20 0 0 0 0 0 0 0 0 0 
110 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.6 100 100 75.2 82.8 89.2 0.8 5.6 15.2 0 0 0 0 0 0 0 0 0 
120 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.4 100 100 66.4 75.8 83.6 0.2 3.4 11.4 0 0 0 0 0 0 0 0 0 
130 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99 99.8 100 57.4 68.6 79 0 2 8.6 0 0 0 0 0 0 0 0 0 
140 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 98.6 99.8 100 48.2 62 76.6 0 1.2 7.41 0 0 0 0 0 0 0 0 0 
150 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 97.8 99.6 100 39.4 55.8 76.2 0 1 6.2 0 0 0 0 0 0 0 0 0 
≥154 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 97.6 99.4 100 36.2 53.4 75.8 0 0.8 6 0 0 0 0 0 0 0 0 0 
CI 









10 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 95.2 99.4 100 0 0.2 1.6 
20 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 89.4 97.8 100 0 0 0.6 
30 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 79.6 93 98.8 0 0 0.2 
40 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.6 100 100 68.4 82.6 93 0 0 0 
50 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99 100 100 54 67.6 79.2 0 0 0 
60 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 98 99.6 100 38 50.8 62 0 0 0 
70 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 95.6 98.6 100 22.6 35.4 47.2 0 0 0 
80 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 92.6 96.8 99.2 11.8 23.5 36 0 0 0 
90 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 88 93.6 97.4 5.39 14.9 27.6 0 0 0 
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 82.4 88.8 94 2.2 9.4 20 0 0 0 
110 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.6 100 100 75.2 82.8 89.2 0.8 5.6 15.2 0 0 0 
120 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.4 100 100 66.4 75.8 83.6 0.2 3.4 11.4 0 0 0 
130 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99 99.8 100 57.4 68.6 79 0 2 8.6 0 0 0 
140 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 98.6 99.8 100 48.2 62 76.6 0 1.2 7.41 0 0 0 
150 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 97.8 99.6 100 39.4 55.8 76.2 0 1 6.2 0 0 0 

















0.004 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 
P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 P0.05 P0.5 P0.95 
CI6 







10 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 94.8 99.4 100 0 0 1.8 0 0 0 
20 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 89.2 97.8 100 0 0 0.4 0 0 0 
30 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 80 93 98.8 0 0 0.2 0 0 0 
40 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.6 100 100 67.8 82.6 93 0 0 0 0 0 0 
50 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99 100 100 53.4 67.4 79.2 0 0 0 0 0 0 
60 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 97.8 99.6 100 38 50.8 62.2 0 0 0 0 0 0 
70 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 95.6 98.6 99.8 22.8 35.2 47.2 0 0 0 0 0 0 
80 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 92.8 96.8 99.2 11.8 23.5 35.4 0 0 0 0 0 0 
90 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 88.4 93.6 97.4 5 15.2 27 0 0 0 0 0 0 
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 82.2 88.8 94.2 2 9.1 20 0 0 0 0 0 0 
110 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.6 100 100 74.6 82.6 89 0.8 5.6 14.8 0 0 0 0 0 0 
120 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.4 100 100 66.6 75.8 84.2 0.2 3.4 11.4 0 0 0 0 0 0 
130 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99 99.8 100 57.4 68.6 79.2 0 2.2 9.2 0 0 0 0 0 0 
140 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 98.6 99.8 100 48.6 61.6 76.4 0 1.4 7 0 0 0 0 0 0 
150 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 97.8 99.6 100 39.2 55.8 76.4 0 0.8 6.01 0 0 0 0 0 0 
≥154 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 97.8 99.4 100 36.2 53.4 76.4 0 0.8 6 0 0 0 0 0 0 
CI6 







10 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 94.8 99.4 100 
20 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 89.2 97.8 100 
30 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 80 93 98.8 
40 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.6 100 100 67.8 82.6 93 
50 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99 100 100 53.4 67.4 79.2 
60 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 97.8 99.6 100 38 50.8 62.2 
70 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 95.6 98.6 99.8 22.8 35.2 47.2 
80 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 92.8 96.8 99.2 11.8 23.5 35.4 
90 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 88.4 93.6 97.4 5 15.2 27 
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.8 100 100 82.2 88.8 94.2 2 9.1 20 
110 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.6 100 100 74.6 82.6 89 0.8 5.6 14.8 
120 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.4 100 100 66.6 75.8 84.2 0.2 3.4 11.4 
130 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99 99.8 100 57.4 68.6 79.2 0 2.2 9.2 
140 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 98.6 99.8 100 48.6 61.6 76.4 0 1.4 7 
150 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 97.8 99.6 100 39.2 55.8 76.4 0 0.8 6.01 
≥154 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 97.8 99.4 100 36.2 53.4 76.4 0 0.8 6 
1Body weight and serum albumin concentration set to median of first study day (i.e. 70 kg and 2.8 g/dL); 2PTA for the target 98%T>4xMIC was derived by shifting the results for the target 
98%T>MIC two MIC values to the left.  
Colour coding: Green: PTA≥90%, Yellow: PTA 80-<90%, Orange: PTA>50-<80%, Red: PTA≤50%; Grey shaded values: Extrapolated CLCRCG range not covered by the study population 
or CLCRCG ≥154 mL/min (=inflection point of CLCRCG-CL relationship).  
Abbreviations: CL: Clearance; CLCRCG: Creatinine clearance estimated according to Cockcroft and Cockcroft and Gault [2]; MIC: Minimum inhibitory concentration; P0.05: 5th percentile; P0.5: 
50th percentile = median; P0.95: 95th percentile, q8h: Every 8 hours; T>MIC: Time period that total drug concentration exceeds the MIC; T>4xMIC: Time period that unbound drug concentration 
exceeds four times the MIC. 
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Table S26: (Project IV): Cumulative fraction of response (98%T>MIC, CFR, %) for different short-term 
infusion dosing regimens of meropenem for the first day of treatment (modified from [243]). PTA is given for 
varied values of creatinine clearance and for selected MIC values and is presented as the median (P0.5), 5th (P0.05) and 95th 





Full MIC distribution2 
 
MIC distribution of isolates 
belonging to the S category2
 
MIC distribution of isolates 



































10 100 100 100 99.7 99.8 99.9 99.6 99.8 99.9 84.8 90.6 94.8 81.5 87.3 93.1 98.6 100 100 97.7 100 100 53.6 86.4 99.4 56.7 88 99.5 
20 100 100 100 99.5 99.7 99.8 99.4 99.6 99.7 80.3 86.4 89.9 76.7 83.2 86.6 96 99.5 100 93.9 99.1 100 34.1 60.5 82.7 37 63.7 85 
30 99.9 100 100 99.2 99.6 99.7 98.9 99.5 99.6 75.3 81.6 85.5 70.8 78.2 82.6 91.8 97.4 99.5 88.1 95.7 99.1 19.9 35.9 52.6 22.1 38.9 56.1 
40 99.7 99.9 100 98.6 99.4 99.5 98.2 99.2 99.4 69.3 76 80.5 63.8 71.5 76.8 86 92.9 97 80.5 89.2 94.8 9.2 18.4 28.4 10.4 20.4 30.8 
50 99.5 99.9 99.9 97.7 99 99.3 97 98.6 99.1 62.4 69.2 74.5 55.7 63.3 69.2 78.2 86 91.4 71 79.9 86.7 3.33 8.52 15.7 3.78 9.53 17.2 
60 98.8 99.7 99.9 96.1 98.2 99.1 95.1 97.5 98.6 55 61.7 67.8 47.5 54.6 61.2 69.2 77.2 84.1 60.7 69.4 77.2 0.86 3.85 8.99 0.975 4.35 9.93 
70 97.7 99.3 99.8 93.6 96.7 98.5 92.2 95.6 97.7 46.6 53.7 60.5 38.8 46.1 53.2 58.8 67.4 75.4 49.7 58.8 67.5 0.107 1.61 5.19 0.122 1.83 5.75 
80 96.3 98.5 99.5 90.2 94.4 97.3 88.4 92.8 96 38.4 45.8 53.1 31 38.2 45.7 48.3 57.6 66.4 39.7 48.9 58.2 0 0.645 3.18 0 0.732 3.53 
90 94.1 97.3 99.1 85.6 91.3 95.3 83.4 89.3 93.5 30.3 38.5 46.5 23.9 31.5 39.4 38.2 48.5 58.3 30.6 40.3 50.2 0 0.215 1.81 0 0.244 2.03 
100 91.2 95.3 98.2 80 86.7 92.3 77.5 84.4 90.2 23.4 31.8 40.3 18.1 25.5 33.5 29.4 40 50.5 23.2 32.6 42.8 0 0.107 1.17 0 0.122 1.3 
110 87.2 92.6 96.8 72.9 81.3 88.8 70.4 78.9 86.4 17.5 25.9 34.9 13.4 20.6 28.8 22.1 32.7 43.9 17.2 26.3 36.8 0 0 0.645 0 0 0.732 
120 83 89.4 95.2 65.5 75.5 85 63.3 73.2 82.6 13.3 21.3 30.8 10.2 16.7 25.1 16.8 26.9 38.8 13 21.5 32.1 0 0 0.43 0 0 0.488 
130 77.6 85.8 93.4 57.9 69.4 81.3 56 67.4 79 9.95 17.5 27.5 7.59 13.6 22.2 12.5 22 34.6 9.72 17.4 28.4 0 0 0.22 0 0 0.25 
140 72.2 82 92.2 50.5 64 79 49.3 62.2 76.7 7.65 14.7 25.2 5.85 11.4 20.3 9.64 18.5 31.7 7.49 14.6 25.9 0 0 0.215 0 0 0.244 
150 65.8 78.3 91.6 43.3 58.9 78.2 42.7 57.4 75.8 5.73 12.3 23.8 4.38 9.49 19 7.22 15.5 30 5.61 12.2 24.3 0 0 0.107 0 0 0.122 










10 100 100 100 99.8 99.9 100 99.8 99.9 100 91.2 95.2 98 88.2 94 99.1 100 100 100 99.9 100 100 88.2 99.1 100 89.5 99.2 100 
20 100 100 100 99.8 99.8 99.9 99.7 99.8 99.9 88.8 92.1 94.6 85.4 89.1 92.8 99.7 100 100 99.6 100 100 76.1 93.1 99.4 78.3 94 99.5 
30 100 100 100 99.7 99.8 99.8 99.6 99.7 99.8 86.4 89.4 91.4 83 86 88.2 99.3 99.9 100 98.8 99.9 100 61.7 79.7 91 64.7 81.9 92.3 
40 100 100 100 99.6 99.7 99.8 99.5 99.6 99.7 83.7 86.6 88.7 80.4 83.5 85.5 98.2 99.6 100 97.1 99.2 99.9 47 61.7 73.7 50.4 65 76.7 
50 100 100 100 99.5 99.6 99.7 99.4 99.5 99.6 80.5 83.7 86 77 80.6 83.1 96.5 98.6 99.6 94.5 97.7 99.3 32 43.9 55.3 35.2 47.3 58.7 
60 99.9 100 100 99.2 99.5 99.6 99.1 99.4 99.5 76.9 80.4 83.1 72.9 76.9 80 93.8 96.8 98.6 90.8 94.8 97.5 19.7 29.4 39.5 22.1 32.2 42.3 
70 99.9 99.9 100 99.1 99.4 99.5 98.8 99.3 99.4 72.9 76.9 80.2 68 72.5 76.4 90.3 94 96.6 85.7 90.5 94.2 10.6 18.9 28.5 12 20.9 30.8 
80 99.8 99.9 100 98.8 99.3 99.4 98.3 99 99.3 68.2 72.9 77 62.1 67.5 72.2 85.3 90.1 93.8 79 85 89.9 4.4 11.4 20.5 4.99 12.8 22.3 
90 99.6 99.9 99.9 98.2 99 99.3 97.6 98.6 99.1 63 68.5 73.3 55.8 62.2 67.6 79.2 85.3 90.1 71.3 78.7 84.8 1.61 6.83 14.6 1.83 7.67 16 
100 99.4 99.9 99.9 97.5 98.8 99.1 96.6 98.2 98.8 57.4 63.9 69.5 49.4 56.7 63.1 72.3 79.9 86 63.2 72.2 79.5 0.537 3.85 10.4 0.61 4.35 11.4 
110 99.2 99.7 99.9 96.6 98.2 99 95.5 97.4 98.5 52.1 59.1 65.7 43.6 51.4 58.8 65.6 74.2 81.6 55.9 65.6 74.4 0.21 2.2 7.51 0.238 2.5 8.31 
120 98.8 99.6 99.8 95.4 97.6 98.8 94 96.5 98.1 46.9 54.6 62.2 38.4 46.7 55 59.1 68.7 77.5 49.2 59.6 69.7 0 1.29 5.62 0 1.46 6.24 
130 98.2 99.3 99.8 93.9 96.7 98.6 92.1 95.4 97.7 41.6 50.3 59.2 33.5 42.3 51.7 52.5 63.2 74 42.9 54 65.7 0 0.752 4.15 0 0.853 4.62 
140 97.5 99.1 99.8 92.1 95.9 98.3 90 94.3 97.4 37.1 46.5 57.6 29.5 38.6 50 46.7 58.5 72.1 37.7 49.4 63.6 0 0.43 3.61 0 0.488 4.01 
150 96.7 98.8 99.8 89.9 94.8 98.2 87.5 93 97.1 32.6 43.1 56.5 25.7 35.3 48.7 41.1 54.2 70.8 32.9 45.2 62.1 0 0.322 2.87 0 0.366 3.2 







10 100 100 100 99.9 100 100 99.9 100 100 96.9 98.7 99.1 97 99.7 100 100 100 100 100 100 100 98.3 100 100 98.5 100 100 
20 100 100 100 99.9 100 100 99.9 99.9 100 95.1 97.6 98.7 94.4 98.1 99.7 100 100 100 100 100 100 94.9 99.5 100 95.4 99.6 100 
30 100 100 100 99.9 99.9 99.9 99.8 99.9 99.9 92.8 95.5 97.2 91 94.8 97.5 99.8 100 100 99.7 100 100 88.9 96.9 99.7 90 97.3 99.8 
40 100 100 100 99.8 99.9 99.9 99.7 99.8 99.9 90.3 93 94.7 87.7 91.1 93.4 99.6 100 100 99.3 99.9 100 80.3 90.3 96.7 82 91.4 97.1 
50 100 100 100 99.7 99.8 99.8 99.7 99.8 99.8 87.6 90.2 92.2 84.3 87.5 90 98.9 99.8 100 98.4 99.6 100 69 79.4 87.9 71.3 81.2 89.4 
60 100 100 100 99.6 99.7 99.8 99.5 99.7 99.7 84.6 87.4 89.7 81.1 84.4 87.2 97.9 99.3 99.9 96.8 98.8 99.7 55.2 65.7 75.2 58 68.2 77.5 
70 99.9 100 100 99.4 99.6 99.7 99.3 99.6 99.7 81.3 84.6 87.2 77.7 81.4 84.5 96.3 98.4 99.4 94.5 97.3 99 40.1 51.7 61.7 43 54.4 64.2 
80 99.9 100 100 99.3 99.6 99.6 99.1 99.4 99.6 77.9 81.7 84.7 73.9 78 81.6 93.9 96.7 98.5 91.2 94.8 97.3 27.2 39.2 50.1 29.7 41.8 52.5 
90 99.8 99.9 100 99 99.4 99.6 98.7 99.3 99.5 74 78.4 82.2 69.3 74.2 78.5 90.6 94.4 97 86.6 91.4 94.9 17.1 28.4 40.7 19 30.7 42.9 
100 99.7 99.9 100 98.6 99.3 99.5 98.3 99.1 99.4 69.8 74.9 79.4 64.3 70 75.1 86.5 91.3 94.9 81.1 87.1 91.8 9.59 20.1 32.2 10.7 21.9 34.3 
110 99.6 99.9 99.9 98.2 99 99.4 97.6 98.7 99.2 65.4 71.3 76.5 59 65.7 71.6 81.6 87.6 92.3 75 82.3 88.2 4.81 14.1 25.8 5.4 15.5 27.6 
120 99.4 99.9 99.9 97.5 98.8 99.3 96.8 98.3 99 61 67.5 73.7 53.9 61.3 68.3 76.5 83.6 89.6 68.7 77.2 84.7 2.69 9.87 20.8 3.05 10.9 22.4 
130 99.2 99.8 99.9 97 98.4 99.2 96.1 97.8 98.8 56.7 63.9 71.3 49 57.2 65.5 71.2 79.4 87.2 62.6 72.3 81.7 1.5 6.88 17 1.71 7.62 18.4 
140 98.8 99.7 99.9 96 98.1 99.1 94.8 97.3 98.7 52.1 60.7 69.7 44.3 53.6 63.7 65.6 75.8 85.5 56.6 68.1 79.6 0.752 4.88 14.5 0.853 5.43 15.7 
150 98.4 99.6 99.9 94.5 97.7 99.1 93.1 96.7 98.7 47.6 57.4 69.3 39.8 50.1 63.2 60 71.8 85.2 51 63.7 79.1 0.43 3.72 13.7 0.488 4.14 14.9 
≥154 98.2 99.6 99.9 94.2 97.5 99.1 92.7 96.4 98.7 46 56.4 69.1 38.2 49 63 57.9 70.5 85.1 48.9 62.4 79 0.43 3.3 12.7 0.488 3.69 13.8 
1Body weight and serum albumin concentration set to median of first study day (i.e. 70 kg and 2.8 g/dL).   
2According to EUCAST [390].  
Colour coding: Green: CFR≥90%, Yellow: CFR 80-<90%, Orange: CFR >50-<80%, Red: CFR ≤50%; Grey shaded values: 
Extrapolated creatinine CLCRCG range not covered by the study population or creatinine clearance ≥154 mL/min (=inflection 
point of CLCRCG-CL relationship).  
Abbreviations: CL: Clearance; CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]; MIC: Minimum 
inhibitory concentration; I category: Category ‘susceptible at increased exposure’ [4]; P0.05: 5th percentile; P0.5: 50th percentile 
= median; P0.95: 95th percentile, q8h: Every 8 hours; S category: Category ‘susceptible at normal dosing’ [4]; T>MIC: Time period 
that total drug concentration exceeds the MIC.  
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Table S27: (Project IV): Cumulative fraction of response (98%T>MIC, CFR, %) for different prolonged 
infusion dosing regimens of meropenem for the first day of treatment (modified from [243]). PTA is given for 
varied values of creatinine clearance and for selected MIC values and is presented as the median (P0.5), 5th (P0.05) and 95th 





Full MIC distribution2 
 
MIC distribution of isolates 
belonging to the S category2
 
MIC distribution of isolates 



































10 100 100 100 99.7 99.8 99.8 99.6 99.8 99.8 86.5 90.3 91.4 83.2 86.3 87.1 99.4 100 100 99 100 100 62.3 89.8 98.5 65.5 91.2 98.8 
20 100 100 100 99.6 99.7 99.8 99.5 99.7 99.8 83.3 87.8 90.2 80 84.4 86.3 98.1 99.8 100 96.9 99.6 100 44.4 69.9 88.5 47.8 73 90.2 
30 100 100 100 99.5 99.6 99.7 99.3 99.6 99.7 79.5 84.2 86.9 75.9 81.2 83.9 95.8 98.9 99.9 93.5 98.1 99.7 28.6 46.4 62.8 31.6 50 66.5 
40 99.9 100 100 99.2 99.5 99.6 98.9 99.4 99.5 74.9 80 83.2 70.4 76.4 80.2 91.9 96.5 98.8 88.1 94.3 97.8 16.3 27.5 39.3 18.3 30.3 42.6 
50 99.8 99.9 100 98.7 99.3 99.5 98.3 99.1 99.4 69.7 75 78.9 64.1 70.2 75 86.7 92.2 95.9 81.1 88 93.1 7.72 14.9 23 8.73 16.6 25.2 
60 99.6 99.9 99.9 98.1 99 99.3 97.5 98.6 99.1 63.6 69.1 74 56.8 63 68.6 79.7 86 91.1 72.4 79.7 86 2.58 7.37 14.1 2.93 8.28 15.5 
70 99.1 99.8 99.9 96.9 98.4 99.1 96 97.8 98.7 56.7 62.8 68.3 48.9 55.7 61.7 71.3 78.6 84.7 62.6 70.8 77.9 0.752 3.64 8.69 0.853 4.1 9.65 
80 98.5 99.6 99.8 95.2 97.6 98.7 93.9 96.6 98 49.3 56 62.3 41.1 48.3 55.1 62.1 70.4 77.6 52.7 61.6 69.9 0.107 1.61 5.43 0.122 1.83 6.05 
90 97.6 99.2 99.8 93 96.1 98.1 91.3 94.7 97.1 41.8 49.4 56.4 33.9 41.5 48.9 52.7 62.1 70.5 43.4 53.1 62.2 0 0.752 3.41 0 0.853 3.81 
100 96.4 98.5 99.5 89.6 94 97.1 87.6 92.2 95.6 34.8 42.9 50.8 27.6 35.4 43.3 43.9 54 63.6 35.4 45.2 55.2 0 0.322 2.24 0 0.366 2.52 
110 94.5 97.4 99.1 85.9 91.2 95.4 83.5 89 93.6 28.3 36.8 45.6 22.1 29.9 38.3 35.7 46.4 57.2 28.3 38.2 48.9 0 0.107 1.38 0 0.122 1.54 
120 92.3 96 98.6 81.7 87.7 93.6 78.9 85.3 91.5 23 31.6 41.2 17.8 25.3 34.2 29 39.8 51.7 22.8 32.3 43.7 0 0.107 0.967 0 0.122 1.1 
130 89.6 94.3 98.1 76.1 84 91.6 73.4 81.5 89.2 18.5 27.2 37.5 14.2 21.5 30.9 23.4 34.3 47.2 18.2 27.6 39.5 0 0 0.645 0 0 0.732 
140 86.4 92.6 97.5 70.2 80.3 90.3 67.7 77.7 87.9 15.2 23.6 35.2 11.6 18.5 28.8 19.2 29.8 44.3 14.9 23.7 36.8 0 0 0.43 0 0 0.488 
150 82.4 90.4 97.3 63.8 76.3 90 61.7 73.8 87.5 12.3 20.6 34.3 9.38 16.1 27.9 15.5 26 43.2 12 20.6 35.7 0 0 0.43 0 0 0.488 







10 100 100 100 99.8 99.8 99.8 99.8 99.8 99.8 90.6 91.3 91.6 86.5 87 87.2 100 100 100 100 100 100 91.6 97.7 99.6 92.8 98 99.7 
20 100 100 100 99.8 99.8 99.8 99.7 99.8 99.8 89.7 91 91.5 85.8 86.8 87.1 100 100 100 99.9 100 100 84.5 95.1 98.8 86.4 95.8 99 
30 100 100 100 99.8 99.8 99.8 99.7 99.8 99.8 88.3 90.1 91 84.8 86.2 86.8 99.8 100 100 99.7 100 100 74.5 87.6 95.1 77.3 89.3 95.9 
40 100 100 100 99.7 99.8 99.8 99.6 99.7 99.7 86.5 88.5 89.7 83.3 85.1 86 99.5 100 100 99.1 99.9 100 62.1 75.2 84.7 65.7 78.2 86.9 
50 100 100 100 99.7 99.7 99.8 99.6 99.6 99.7 84.6 86.6 88 81.6 83.6 84.7 99 99.8 100 98.4 99.6 100 49 60.5 70.4 53 64.3 74 
60 100 100 100 99.6 99.6 99.7 99.5 99.6 99.6 82.2 84.5 86.2 79.2 81.7 83.3 98 99.3 99.8 96.8 98.7 99.7 36.2 46.7 56.8 40 50.6 60.6 
70 100 100 100 99.5 99.6 99.6 99.4 99.5 99.6 79.6 82.2 84.3 76.3 79.2 81.5 96.5 98.3 99.4 94.5 97.1 98.8 24.8 34.3 44.1 27.8 37.7 47.5 
80 99.9 100 100 99.4 99.5 99.6 99.2 99.4 99.5 76.7 79.8 82.2 72.7 76.3 79.1 94.3 96.8 98.4 91.2 94.5 97 14.7 24.4 34 16.6 27 36.9 
90 99.9 100 100 99.1 99.4 99.5 98.9 99.3 99.4 73.3 77.1 80.1 68.4 72.9 76.4 91.2 94.6 96.9 86.6 91.2 94.5 7.95 16.5 26.8 9.02 18.4 29.2 
100 99.9 99.9 100 99 99.3 99.4 98.7 99.1 99.3 69.9 74.2 77.8 63.9 69.1 73.4 87.5 91.9 94.9 81.4 87.2 91.4 3.65 10.8 20.6 4.15 12.1 22.7 
110 99.8 99.9 99.9 98.8 99.2 99.4 98.4 98.9 99.2 66.3 71.2 75.4 59.3 65.2 70.3 83.3 88.6 92.6 75.7 82.6 88.1 1.61 7.06 15.9 1.83 7.96 17.5 
120 99.8 99.9 99.9 98.5 99.1 99.3 98 98.7 99.1 62.8 68.1 73.3 55 61.4 67.7 79 85.1 90.5 70.3 78 85.1 0.752 4.71 12.3 0.853 5.32 13.6 
130 99.7 99.9 99.9 98.1 99 99.2 97.4 98.5 99 58.7 65.1 71.1 50.2 57.8 65 74 81.6 88.1 64.3 73.6 81.9 0.215 3.01 9.77 0.244 3.41 10.9 
140 99.5 99.9 99.9 97.8 98.7 99.2 96.8 98.2 98.9 55.4 62.4 69.9 46.6 54.6 63.5 69.8 78.3 86.9 59.7 69.7 80.3 0.107 2.04 7.98 0.122 2.32 8.92 
150 99.5 99.8 99.9 97.3 98.6 99.1 96.1 97.9 98.8 51.5 59.7 69.4 42.6 51.6 62.9 64.9 74.9 86.4 54.6 65.9 79.6 0 1.5 7.35 0 1.71 8.2 







10 100 100 100 99.9 100 100 99.9 100 100 97.2 98.1 98.4 97.7 99.2 99.8 100 100 100 100 100 100 99.6 100 100 99.7 100 100 
20 100 100 100 99.9 100 100 99.9 100 100 96.3 97.7 98.3 96.1 98.5 99.6 100 100 100 100 100 100 98.4 99.9 100 98.6 99.9 100 
30 100 100 100 99.9 99.9 100 99.9 99.9 100 94.8 96.6 97.7 93.6 96.6 98.5 100 100 100 100 100 100 95.7 99.4 100 96.1 99.5 100 
40 100 100 100 99.9 99.9 99.9 99.8 99.9 99.9 92.9 94.9 96.2 90.8 93.7 95.7 99.9 100 100 99.9 100 100 91.1 97.1 99.4 92 97.5 99.5 
50 100 100 100 99.8 99.9 99.9 99.8 99.8 99.9 90.9 92.8 94.3 88 90.6 92.6 99.8 100 100 99.6 100 100 84.7 91.9 96.8 86.1 92.9 97.3 
60 100 100 100 99.8 99.8 99.9 99.7 99.8 99.8 88.8 90.8 92.4 85.5 88 90.1 99.5 99.9 100 99.2 99.9 100 75.7 83.9 90.3 77.7 85.5 91.5 
70 100 100 100 99.7 99.8 99.8 99.6 99.7 99.8 86.7 88.8 90.6 83.3 85.7 88 99.1 99.8 100 98.5 99.6 100 64.6 73.3 81.1 67.3 75.7 83.2 
80 100 100 100 99.6 99.7 99.8 99.5 99.6 99.7 84.3 86.8 88.9 81 83.7 86.2 98.3 99.4 99.9 97.3 98.9 99.7 51.4 62 71.5 54.6 64.8 74.1 
90 100 100 100 99.6 99.7 99.7 99.4 99.6 99.7 81.9 84.8 87.2 78.6 81.6 84.3 97.3 98.8 99.6 95.8 97.9 99.2 38.7 51 61.9 42 54 64.5 
100 100 100 100 99.5 99.6 99.7 99.3 99.5 99.6 79.3 82.6 85.4 75.6 79.2 82.3 95.7 97.7 99 93.3 96.2 98.1 27.8 40.6 53 30.6 43.4 55.6 
110 99.9 100 100 99.4 99.5 99.6 99.2 99.4 99.5 76.7 80.5 83.6 72.6 76.7 80.3 93.7 96.4 98.2 90.6 94.2 96.8 19.2 32.1 44.9 21.4 34.6 47.4 
120 99.9 100 100 99.2 99.4 99.6 98.9 99.3 99.5 74 78.2 82 69.2 74 78.3 91.3 94.7 97.2 87 91.6 95.2 12.7 25 38.4 14.2 27.3 40.8 
130 99.9 99.9 100 99 99.4 99.5 98.7 99.2 99.4 71.2 76 80.6 65.8 71.3 76.6 88.5 92.8 96.2 83.2 88.9 93.6 8.12 19.4 33.9 9.13 21.2 36.1 
140 99.8 99.9 100 98.8 99.3 99.5 98.4 99.1 99.4 68.3 74.1 79.6 62.2 68.9 75.5 85.2 91 95.5 78.9 86.2 92.7 5.46 15.4 30.7 6.17 17 32.9 
150 99.8 99.9 100 98.5 99.2 99.5 98 98.9 99.4 65.2 72 79.2 58.4 66.3 74.9 81.7 88.8 95.3 74.4 83.3 92.3 3.44 12.6 28.2 3.9 13.9 30.2 
≥154 99.8 99.9 100 98.5 99.2 99.5 97.9 98.9 99.4 64.3 71.2 79.1 57.4 65.4 74.9 80.6 88 95.2 73.1 82.3 92.3 3.01 11.2 28.3 3.41 12.4 30.4 
1Body weight and serum albumin concentration set to median of first study day (i.e. 70 kg and 2.8 g/dL).   
2According to EUCAST [390].  
Colour coding: Green: CFR≥90%, Yellow: CFR 80-<90%, Orange: CFR >50-<80%, Red: CFR ≤50%; Grey shaded values: 
Extrapolated creatinine CLCRCG range not covered by the study population or creatinine clearance ≥154 mL/min (=inflection 
point of CLCRCG-CL relationship).  
Abbreviations: CL: Clearance; CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]; MIC: Minimum 
inhibitory concentration; I category: Category ‘susceptible at increased exposure’ [4]; P0.05: 5th percentile; P0.5: 50th percentile 
= median; P0.95: 95th percentile, q8h: Every 8 hours; S category: Category ‘susceptible at normal dosing’ [4]; T>MIC: Time period 
that total drug concentration exceeds the MIC.  
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Table S28: (Project IV): Cumulative fraction of response (CFR, %) for different continuous infusion dosing 
regimens of meropenem for the first day of treatment (modified from [243]).   
PTA is given for varied values of creatinine clearance and for selected MIC values and is presented as the median (P0.5), 5th 
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10 100 100 100 99.7 99.7 99.7 99.6 99.6 99.6 85.6 85.9 86 83.3 83.6 83.7 100 100 100 100 100 100 51.1 53.5 54.5 58 60.7 61.6 
20 100 100 100 99.7 99.7 99.7 99.6 99.6 99.6 85.2 85.8 86 83 83.5 83.6 100 100 100 100 100 100 48 52.5 54 54.5 59.6 61.2 
30 100 100 100 99.7 99.7 99.7 99.6 99.6 99.6 84.6 85.5 85.9 82.4 83.2 83.5 100 100 100 100 100 100 42.8 50 53.2 48.5 56.7 60.3 
40 100 100 100 99.6 99.7 99.7 99.6 99.6 99.6 83.8 84.8 85.5 81.8 82.6 83.2 100 100 100 99.9 100 100 36.7 44.4 50 41.7 50.4 56.7 
50 100 100 100 99.6 99.6 99.7 99.5 99.6 99.6 82.8 83.8 84.6 80.9 81.8 82.5 99.9 100 100 99.8 100 100 29 36.3 42.6 32.9 41.2 48.3 
60 100 100 100 99.6 99.6 99.6 99.5 99.5 99.6 81.7 82.7 83.4 79.8 80.8 81.5 99.8 100 100 99.6 99.9 100 20.4 27.3 33.3 23.2 31 37.8 
70 100 100 100 99.5 99.6 99.6 99.5 99.5 99.5 80.4 81.6 82.5 78.6 79.8 80.7 99.5 99.8 100 99 99.7 100 12.1 19 25.4 13.8 21.6 28.8 
80 100 100 100 99.5 99.5 99.6 99.4 99.5 99.5 79.5 80.6 81.6 77.5 78.8 79.9 99.2 99.6 99.9 98.4 99.3 99.8 6.34 12.6 19.3 7.19 14.3 22 
90 100 100 100 99.5 99.5 99.5 99.4 99.5 99.5 78.6 79.8 80.9 76.3 77.8 79.2 98.6 99.3 99.7 97.3 98.6 99.4 2.9 8.01 14.8 3.29 9.08 16.8 
100 100 100 100 99.4 99.5 99.5 99.4 99.4 99.5 77.9 79 80.1 75.1 76.7 78.2 98 98.7 99.3 96.1 97.5 98.7 1.18 5.05 10.7 1.34 5.73 12.2 
110 100 100 100 99.4 99.5 99.5 99.4 99.4 99.4 77.1 78.2 79.4 73.8 75.4 77.1 97.1 98 98.8 94.5 96.2 97.6 0.43 3.01 8.17 0.488 3.41 9.27 
120 100 100 100 99.4 99.4 99.5 99.3 99.4 99.4 76.2 77.4 78.6 72.2 74.1 75.9 96.1 97.2 98.1 92.5 94.7 96.4 0.107 1.83 6.13 0.122 2.07 6.96 
130 100 100 100 99.4 99.4 99.5 99.3 99.3 99.4 75.4 76.6 78 70.6 72.8 75 95 96.4 97.6 90.4 93.1 95.4 0 1.07 4.62 0 1.22 5.24 
140 100 100 100 99.3 99.4 99.4 99.2 99.3 99.4 74.5 76 77.7 68.9 71.6 74.5 93.8 95.6 97.3 88.3 91.6 94.9 0 0.645 3.98 0 0.732 4.52 
150 100 100 100 99.3 99.4 99.4 99.2 99.3 99.4 73.5 75.4 77.6 67.3 70.5 74.3 92.7 94.9 97.3 86.2 90.2 94.8 0 0.537 3.33 0 0.61 3.78 














10 100 100 100 100 100 100 100 100 100 98.1 98.4 98.5 99.3 99.8 99.9 100 100 100 100 100 100 100 100 100 100 100 100 
20 100 100 100 100 100 100 100 100 100 97.7 98.3 98.5 98.5 99.6 99.9 100 100 100 100 100 100 100 100 100 100 100 100 
30 100 100 100 99.9 100 100 99.9 100 100 97.1 98 98.4 97.3 99 99.7 100 100 100 100 100 100 99.9 100 100 99.9 100 100 
40 100 100 100 99.9 99.9 100 99.9 99.9 100 96.3 97.3 98 95.8 97.7 99 100 100 100 100 100 100 99.8 100 100 99.8 100 100 
50 100 100 100 99.9 99.9 99.9 99.9 99.9 99.9 95.3 96.2 97 94 95.8 97.2 100 100 100 100 100 100 99.5 100 100 99.6 100 100 
60 100 100 100 99.9 99.9 99.9 99.9 99.9 99.9 94.1 95.1 95.9 91.9 93.6 95 100 100 100 100 100 100 99.1 99.8 100 99.2 99.8 100 
70 100 100 100 99.9 99.9 99.9 99.8 99.9 99.9 92.9 94 94.8 89.9 91.6 93.2 100 100 100 100 100 100 98 99.4 100 98.3 99.5 100 
80 100 100 100 99.9 99.9 99.9 99.8 99.8 99.9 92 93 94 88.4 90 91.7 100 100 100 100 100 100 96.6 98.5 99.6 97.1 98.8 99.7 
90 100 100 100 99.8 99.9 99.9 99.8 99.8 99.8 91.3 92.3 93.3 87.4 88.8 90.6 100 100 100 100 100 100 94.3 97 98.8 95.2 97.5 99 
100 100 100 100 99.8 99.8 99.9 99.8 99.8 99.8 90.7 91.6 92.6 86.8 87.9 89.5 100 100 100 100 100 100 91.7 94.8 97.2 93 95.6 97.7 
110 100 100 100 99.8 99.8 99.8 99.8 99.8 99.8 90.2 91 92 86.3 87.2 88.7 100 100 100 100 100 100 88.3 92 95 90.1 93.3 95.8 
120 100 100 100 99.8 99.8 99.8 99.7 99.8 99.8 89.7 90.5 91.5 85.9 86.7 88 100 100 100 100 100 100 84.1 88.8 92.4 86.5 90.6 93.6 
130 100 100 100 99.8 99.8 99.8 99.7 99.7 99.8 89.1 89.9 91 85.6 86.3 87.5 100 100 100 100 100 100 79.8 85.4 90.3 82.8 87.6 91.8 
140 100 100 100 99.8 99.8 99.8 99.7 99.7 99.8 88.6 89.5 90.8 85.2 85.9 87.3 100 100 100 100 100 100 75.3 82.3 89.2 78.9 85 90.9 
150 100 100 100 99.8 99.8 99.8 99.7 99.7 99.8 88 89.1 90.7 84.9 85.7 87.1 100 100 100 100 100 100 70.8 79.3 89 75 82.5 90.7 













10 100 100 100 99.8 99.8 99.8 99.8 99.8 99.8 91.3 91.6 91.7 87 87.1 87.4 100 100 100 100 100 100 97.6 99.7 100 98 99.8 100 
20 100 100 100 99.8 99.8 99.8 99.8 99.8 99.8 91 91.5 91.6 86.8 87.1 87.2 100 100 100 100 100 100 95 99 100 95.8 99.1 100 
30 100 100 100 99.8 99.8 99.8 99.8 99.8 99.8 90.5 91.2 91.5 86.4 86.9 87.1 100 100 100 100 100 100 90.6 96.8 99.4 92.1 97.3 99.5 
40 100 100 100 99.8 99.8 99.8 99.7 99.8 99.8 89.7 90.6 91.2 86 86.5 86.9 100 100 100 100 100 100 84.9 91.9 96.8 87.2 93.2 97.3 
50 100 100 100 99.8 99.8 99.8 99.7 99.7 99.8 88.9 89.7 90.4 85.4 86 86.4 100 100 100 100 100 100 77.9 84.9 90.4 81.2 87.3 91.9 
60 100 100 100 99.8 99.8 99.8 99.7 99.7 99.7 87.9 88.8 89.5 84.8 85.4 85.8 100 100 100 100 100 100 70.1 77 82.5 74.5 80.5 85.2 
70 100 100 100 99.7 99.7 99.8 99.7 99.7 99.7 86.9 87.8 88.6 84.2 84.8 85.3 100 100 100 100 100 100 61.9 69.3 75.5 67.2 73.8 79.3 
80 100 100 100 99.7 99.7 99.8 99.6 99.7 99.7 86.1 87.1 87.9 83.6 84.3 84.8 100 100 100 100 100 100 55.3 62.9 69.7 61.2 68.2 74.3 
90 100 100 100 99.7 99.7 99.7 99.6 99.6 99.7 85.4 86.4 87.3 83.1 83.8 84.4 100 100 100 100 100 100 49.8 57.3 64.8 55.8 63 69.9 
100 100 100 100 99.7 99.7 99.7 99.6 99.6 99.6 84.9 85.7 86.7 82.7 83.3 84 100 100 100 100 100 100 45.1 51.9 59.9 50.9 57.7 65.2 
110 100 100 100 99.6 99.7 99.7 99.6 99.6 99.6 84.3 85.1 86 82.2 82.8 83.5 100 100 100 99.9 100 100 40.5 47 54.7 45.8 52.5 60 
120 100 100 100 99.6 99.7 99.7 99.6 99.6 99.6 83.7 84.5 85.5 81.7 82.4 83.1 99.9 100 100 99.9 100 100 35.9 42.3 50.5 40.7 47.5 55.8 
130 100 100 100 99.6 99.6 99.7 99.5 99.6 99.6 83 84 85.1 81.1 81.9 82.8 99.9 100 100 99.8 100 100 30.8 37.9 46.8 35 42.7 51.9 
140 100 100 100 99.6 99.6 99.7 99.5 99.6 99.6 82.4 83.5 84.8 80.5 81.5 82.5 99.8 100 100 99.7 100 100 26.1 33.7 44.3 29.6 38.1 F 
150 100 100 100 99.6 99.6 99.7 99.5 99.5 99.6 81.7 83 84.7 79.9 81.1 82.5 99.7 100 100 99.5 99.9 100 21.1 30.4 43.8 23.9 34.3 48.9 












10 100 100 100 100 100 100 100 100 100 99.1 99.1 99.2 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
20 100 100 100 100 100 100 100 100 100 99.1 99.1 99.2 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
30 100 100 100 100 100 100 100 100 100 99 99.1 99.1 99.9 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
40 100 100 100 100 100 100 100 100 100 98.9 99 99.1 99.9 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
50 100 100 100 100 100 100 100 100 100 98.8 98.9 99 99.8 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
60 100 100 100 100 100 100 100 100 100 98.6 98.8 98.9 99.6 99.9 99.9 100 100 100 100 100 100 100 100 100 100 100 100 
70 100 100 100 100 100 100 100 100 100 98.3 98.6 98.8 99.3 99.7 99.9 100 100 100 100 100 100 100 100 100 100 100 100 
80 100 100 100 100 100 100 100 100 100 98.1 98.4 98.7 99 99.5 99.8 100 100 100 100 100 100 100 100 100 100 100 100 
90 100 100 100 100 100 100 100 100 100 97.7 98.1 98.5 98.4 99.1 99.6 100 100 100 100 100 100 99.9 100 100 99.9 100 100 
100 100 100 100 99.9 100 100 99.9 100 100 97.2 97.8 98.2 97.6 98.5 99.2 100 100 100 100 100 100 99.9 100 100 99.9 100 100 
110 100 100 100 99.9 100 100 99.9 99.9 100 96.7 97.3 97.8 96.6 97.7 98.5 100 100 100 100 100 100 99.8 100 100 99.8 100 100 
120 100 100 100 99.9 99.9 100 99.9 99.9 99.9 96.1 96.8 97.5 95.6 96.8 97.9 100 100 100 100 100 100 99.7 100 100 99.8 100 100 
130 100 100 100 99.9 99.9 99.9 99.9 99.9 99.9 95.5 96.3 97.1 94.4 95.9 97.2 100 100 100 100 100 100 99.5 99.9 100 99.6 99.9 100 
140 100 100 100 99.9 99.9 99.9 99.9 99.9 99.9 94.9 95.8 96.9 93.3 95 96.9 100 100 100 100 100 100 99.4 99.9 100 99.5 99.9 100 
150 100 100 100 99.9 99.9 99.9 99.9 99.9 99.9 94.2 95.4 96.9 92.1 94.2 96.9 100 100 100 100 100 100 99 99.8 100 99.1 99.8 100 
1Body weight and serum albumin concentration fixed to median of first study day (i.e. 70 kg and 2.8 g/dL). 2According to 
EUCAST [390]; 3PTA for the target 98%T>4xMIC was derived by shifting the results for the target 98%T>MIC two MIC values to 
the left. Colour coding: Green: CFR≥90%, Yellow: CFR 80-<90%, Orange: CFR >50-<80%, Red: CFR ≤50%; Grey shaded 
values: Extrapolated creatinine CLCRCG range not covered by the study population or creatinine clearance ≥154 mL/min 
(=inflection point of CLCRCG-CL relationship). Abbreviations: T>4xMIC: Time period that total drug concentration exceeds four 






Table S29: (Project IV) Comparison of selected dosing regimens based on PTAa analyses (A) considering versus (B) not considering uncertainty in the 




0.004 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 
SI PI CI SI PI CI SI PI CI SI PI CI SI PI CI SI PI CI SI PI CI SI PI CI SI PI CI SI PI CI SI PI CI SI PI CI SI PI CI 
A: Dosing regimens selected based on PTA analyses considering PK parameter uncertaintyb 
10 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI38 CI3c SI68 PI68 CI6d -- -- - 
20 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI6d SI68 PI68 -- - - - 
30 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI68 PI38 CI6d -- PI68 -- - - - 
40 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI68 CI6d - -- - - - - 
50 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI68 PI38 CI3c -- PI68 CI6d - - - - - - 
60 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI68 CI3c - -- CI6d - - - - - - 
70 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI38 CI3c -- PI68 CI3c - - CI6d - - - - - - 
80 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI38 CI3c - PI68 CI3c - - CI6d - - - - - - 
90 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI38 CI3c -- PI68 CI3c - -- CI6d - - -- - - - - - - 
100 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI38 CI3c - PI68 CI3c - - CI6d - - - - - - - - - 
110 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI38 CI3c -- PI68 CI3c - -- CI3c - - CI6d - - - - - - - - - 
120 SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI38 CI3c - PI68 CI3c - -- CI3c - - CI6d - - - - - - - - - 
130 SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI38 CI3c -- PI38 CI3c - PI68 CI3c - - CI3c - - CI6d - - - - - - - - - 
140 SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI38 CI3c - PI38 CI3c - PI68 CI3c - - CI3c - - CI6d - - - - - - - - - 
150 SI38 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI38 CI3c - PI68 CI3c - -- CI3c - - CI3c - - CI6d - - - - - - - - - 
≥154 SI38 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI38 PI38 CI3c -- PI38 CI3c - PI68 CI3c - -- CI3c - - CI3c - - CI6d - - - - - - - - - 
B: Dosing regimens selected based on PTA analyses not considering PK parameter uncertaintyb 
10 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI38 CI6d SI68 PI68 - 
20 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI38 CI3c SI68 PI68 CI6d - - - 
30 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI68 PI68 CI6d - - - 
40 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI68 PI38 CI6d - PI68 - - - - 
50 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI68 CI6d - - - - - - 
60 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI68 PI38 CI3c - PI68 CI6d - - - - - - 
70 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI68 CI3c - - CI6d - - - - - - 
80 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI38 CI3c - PI68 CI3c - - CI6d - - - - - - 
90 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI38 CI3c - PI68 CI3c - - CI6d - - - - - - 
100 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI38 CI3c - PI68 CI3c - - CI6d - - - - - - - - - 
110 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI38 CI3c - PI68 CI3c - - CI6d - - - - - - - - - 
120 SI212 PI212 CI3c SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI38 CI3c - PI38 CI3c - PI68 CI3c - - CI6d - - - - - - - - - 
130 SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI38 CI3c - PI68 CI3c - - CI3c - - CI6d - - - - - - - - - 
140 SI212 PI212 CI3c SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI38 CI3c - PI68 CI3c - - CI3c - - CI6d - - - - - - - - - 
150 SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI38 CI3c - PI38 CI3c - PI68 CI3c - - CI3c - - CI6d - - - - - - - - - 
≥154 SI212 PI212 CI3c SI38 PI212 CI3c SI38 PI212 CI3c SI38 PI38 CI3c SI38 PI38 CI3c SI68 PI38 CI3c - PI38 CI3c - PI68 CI3c - - CI3c - - CI6d - - - - - - - - - 
aFor SI and PI the PK/PD target 98%T>MIC was evaluated, for CI 98%T>4xMIC. bLowest possible dosing regimen for which the 5th percentile of the 1000 Monte Carlo simulations considering 
PK parameter uncertainty achieved PTA≥90% (A); Lowest possible dosing regimen for which the 50th percentile (=median) of the 1000 Monte Carlo simulations considering PK parameter 
uncertainty (comparable to PTA not considering PK parameter uncertainty) achieved PTA≥90% (B). cFor first day of treatment: Daily dose of 3412.5 mg incl. loading dose. dFor first day of 
treatment: Daily dose of 6875 mg incl. loading dose. eBody weight and albumin fixed to median of first study day (i.e. 70 kg and 2.8 g/dL).  
Grey shaded areas: Extrapolated covariate range not covered by the study population or CLCRCG ≥154 mL/min (=inflection point of CLCRCG-CL relationship). Blue shaded areas: Differences 
between dosing regimens suggested based on PTA analyses considering PK parameter uncertainty (A) and dosing regimens suggested based on PTA analyses not considering PK parameter 
uncertainty (B). Dosing regimens: SI212: 1000 mg, 30-min i.v. infusion, q12h; SI38: 1000 mg, 30-min i.v. infusion, q8h (=standard dosing; highlighted in bold); SI68: 2000 mg, 30-min i.v. 
infusion, q8h; PI212: 1000 mg, 3-h i.v. infusion, q12h; PI38: 1000 mg, 3-h i.v. infusion, q8h; PI68: 2000 mg, 3-h i.v. infusion, q8h; CI3: 3000 mg, CI, q24h following 500 mg, 30-min loading 
dose; CI6: 6000 mg, CI, q24h following 1000 mg, 30-min loading dose. Colour coding: light blue: Daily dose of 2000 mg; blue: Daily dose of 3000 mg (3412.5 mg for first day of CI, incl. 
loading dose); pink: Daily dose of 6000 mg (6875 mg for first day of CI, incl. loading dose).  Abbreviations: CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]; h: 
Hours; MIC: Minimum inhibitory concentration; min: Minutes; PI: Prolonged infusion; PK: Pharmacokinetics; PTA: Probability of target attainment; SI: Short-term infusion; q8h: Every 8 
hours; q12h: Every 12 hours; q24h: Every 24 hours; T>MIC: Time period that total drug concentration exceeds the MIC; T>4xMIC: Time period that total drug concentration exceeds four times 
the MIC.  
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 Supplementary figures 
 
Figure S1: (Project I) Individual graphical evaluation of the micro- and retrodialysis sampling schedule for 
linezolid, illustrated as an example for two selected patients.  
Colour coding and symbols: Green circles: Total plasma concentrations; Purple circles: Unbound plasma concentrations; Red 
circles: Microdialysate concentrations determined with CAT1, Blue circles: Microdialysate concentrations determined with 
CAT2; Blue arrow: Start of linezolid infusion; Red vertical lines: Start and end of micro- (thin lines) retrodialysis (bold lines) 
and collection interval of CAT1; Blue vertical lines: Start and end of micro- (thin lines) retrodialysis (bold lines) and collection 
interval of CAT2.  
Abbreviation: CAT1: Catheter 1; CAT2: Catheter 2; TINT: Micro-/Retrodialysis collection interval.  
 
Figure S2: (Project IV) Graphical assessment of the two imputation/interpolation strategies ‘stepwise’ (A) 
and ‘linear’ (B), demonstrated by the example of creatinine clearance (A) and CD64 (B) for one selected 
individual. 
Colour coding: Green circles: Observed values; Red circles: Imputed values; Blue circles: Interpolated values for time points 
in dataset.  




Figure S3: (Project IV) Index plot demonstrated by the example of creatinine clearance. 
Blue circles: Observed CLCRCG values; Pink dashed line: Median of observed CLCRCG values; Green dashed lines: Limit 
values of reference range.  




Figure S4: (Project I) Frequency distributions of body size descriptors (A), haemodynamic markers (B) and 
a renal function marker (C) of obese (red) and nonobese (green) patients. 
B: Summary statistics based on individual median observed intra-anaesthetic data and post-anaesthetic data, respectively. 
Colour coding: Red: Obese patients; Green: Nonobese patients.  
Abbreviations: CLCRCG_LBW: Creatinine clearance estimated according to Cockcroft and Gault [2] using LBW; COLZ: Cardiac 





Figure S5: (Project I) Individual relative recovery values for linezolid (A) and boxplots stratified by obesity 
status (B) and catheter and retrodialysis repetition (C). 
Colour coding: Red: Obese patients; Green: Nonobese patients.  
Abbreviations: CAT1: Catheter 1; CAT2: Catheter 2; CAT1_1: Catheter 1, Retrodialysis repetition 1; CAT1_2: Catheter 1, 
Retrodialysis repetition 2; CAT2_1: Catheter 2, Retrodialysis repetition 1; CAT2_2: Catheter 2, Retrodialysis repetition 2;  
 
 
Figure S6: (Project I) Total vs. unbound linezolid plasma concentrations stratified by the obesity status of 
the patient.  
Symbols: Line: Linear regression line; Grey shaded area: 95% confidence interval around regression line; Red circles: Observed 
plasma linezolid concentration for obese patients; Green circles: Observed plasma linezolid concentration for nonobese patients. 




Figure S7: (Project I) Individual linezolid concentration-time profiles in the ISF of the s.c. adipose tissue of 
selected patients, in which the two catheters result in similar profiles (left column), different profiles (middle 
column: catheter 1 < catheter 2; right column: catheter 1 > catheter 2). ISF concentrations are displayed at 
mid time of the respective collection intervals. 
Colour coding: Red: Obese patients; Green: Nonobese patients.  




Figure S8: (Project I) Linezolid concentration-time profiles in plasma and ISF of the s.c. adipose tissue for 
selected patients including the intra- and post-anaesthetic time period.  
Colour coding: Green circles/lines: ISF concentration determined with CAT1; Red circles/lines: ISF concentration determined 
with CAT2; Dark blue circles/lines: Total plasma concentrations; Light blue circles/lines: Unbound plasma concentrations; 
Green shaded area: Intra-anaesthetic time period; Red shaded area: Post-anaesthetic timer period.  




Figure S9: (Project I) Observed vs. population predicted linezolid concentrations (1) and CWRES vs. time 
(2) and population predicted linezolid concentrations (3) for a one-CMT model (A) and a two-CMT (B) 
structural model without IIV and with combined RUV, for the total linezolid plasma concentrations. 
Lines: Black lines: Line of identity (1), reference lines at y=0 (2, 3); Grey, red and green lines: Loess smoothers for all patients, 
obese patients and nonobese patients, respectively [250].   
Colour coding: Red: Obese; Green: nonobese.  
Abbreviations: CMT: Compartment; CWRES: Conditional weighted residuals; IIV: Interindividual variability; RUV: Residual 
unexplained variability. 
 
Figure S10: (Project I) Residuals vs. population predicted linezolid concentrations (A) and CWRES over 
time (B, C) for the two-CMT linezolid model (incl. IIV) with a combined (A, B) and proportional RUV 
model (C) for total linezolid concentrations.  
Lines: Black lines: Line of identity; Grey, red and green lines: Loess smoothers for all patients, obese patients and nonobese 
patients, respectively [250].  
Colour coding: Red: Obese; Green: nonobese.  
Abbreviations: CMT: Compartment; CWRES: Conditional weighted residuals; IIV: Interindividual variability; RUV: Residual 







Figure S11: (Project I) Graphical illustration of evaluation of undulating pattern in “CWRES versus time” plot for the linezolid plasma 
concentrations, to assess whether the pattern is linked to the observed nonlinearity in the linezolid concentration-time profile.  
A: Graphical sketch to illustrate how the undulating pattern in the CWRES could be explained by observed nonlinearity in the concentration-time profile (i.e. third steep 
phase in the terminal phase), which is not captured in the model predicted concentration-time profile by a classical (mammalian) two-CMT model. 
B: Workflow of first evaluation to assess the above described relation between the pattern and the nonlinearity. The individual linezolid concentration-time profiles were 
visually stratified by whether the patients showed a clear nonlinearity. The ‘CWRES vs. time” plot was stratified accordingly and evaluated. The observed pattern (Loess 
smoother [250]) was more pronounced for the patient group for which a clear pattern in the CWRES was observed.  
C: Workflow of second evaluation to assess the above described relation between the pattern and the nonlinearity. Only the linezolid concentration data which were 
collected <6 h after start of infusion were subset to exclude the third steep phase in the profile. The model was re-executed and the “CWRES vs. time” plot evaluated. 
The observed pattern in the CWRES (Loess smoother [250]) was clearly reduced in comparison to the model based on all available linezolid concentration data.  





Figure S12 (Project I) Graphical illustration and mathematical equations for the six investigated ‘anaesthesia 
models’ (A-F) which describe a change of linezolid clearance at the end of anaesthesia.  
Change of linezolid clearance after end of anaesthesia: Stepwise increase (A); Linear increase (B); Increase according to Emax 
model (C); Sigmoidal increase (D); Exponential increase (E); Hyperbolic change (F).  
Abbreviations: ANAE: Anaesthesia status; CL: Clearance; max: Maximum; t: Time; t50: Time to reach half-maximum of time-
varying clearance; tANAE: Time since anaesthesia start; tANAE_STOP: Time of anaesthesia end.  
 
Figure S13: (Project I) CWRES over time for the plasma base models for linezolid with different clearance 
models. 
A: Linear CL; B: Heart rate as covariate on CL; C: Time-varying CL according to an Emax model after end of anaesthesia; D: 
Concentration-dependent parallel linear and nonlinear Michaelis-Menten clearance.  
Lines: Black lines: Reference lines at y=0; Grey, red and green lines: Loess smoothers [250] for all patients, obese patients and 
nonobese patients, respectively.  
Colour coding: Red: Obese; Green: nonobese.  




Figure S14: (Project I) Sketch of two-CMT model with an empirical inhibition CMT causing a time- and 
concentration-dependent CL. 
Abbreviations: CL: Clearance; CMT: Compartment; IC50: Concentration in INH yielding 50% of CL inhibition; INH: Inhibition 
CMT; i.v.: Intravenous; KIC: Rate constant for the transfer into INH; Q: Intercompartmental clearance; RFCL: Remaining 
fraction of CL at maximum CL inhibition; V1, V2: Central and peripheral volume of distribution.  
 
Figure S15: (Project I) Comparison of the two most adequate clearance models in Step 1 with respect to 
extrapolation of linezolid plasma concentration to higher doses (A) and predictive performance (B, C). 
A: Deterministic simulations of linezolid plasma concentrations resulting from a dose of 600 mg (red), 900 mg (blue) and 1200 
mg (green) linezolid administered as 30-min i.v. infusion using the NLME model with linear CL (solid line), time-varying 
increase of CL according to an Emax model after end of anaesthesia (dashed line) and concentration-dependent parallel linear 
and nonlinear Michaelis-Menten clearance (dotted line).   
B, C: VPCs (n=1000 simulations) for the NLME model with time-varying increase of CL according to an Emax model after end 
of anaesthesia (B) and concentration-dependent parallel linear and nonlinear Michaelis-Menten clearance (C); Circles: 
Observed linezolid concentrations; Lines: 5th, 95th percentile (dashed), 50th percentile (solid) of the observed (blue) and 
simulated (green) data. Green shaded areas: 95% confidence interval around 5th, 50th and 95th percentile of simulated data.  




Figure S16: (Project I) Selected results of the external evaluation of a pooled NLME linezolid model [45] 
for the applicability to predict plasma (A) and microdialysate PK data (B) in the obese and nonobese patient 
population. 
A.1, B.1: VPCs (n=1000 simulations) for plasma (A.1) and microdialysate data of catheter 1 (B.1). Circles: Observed linezolid 
concentrations; Lines: 5th, 95th percentile (dashed), 50th percentile (solid) of the observed (blue) and simulated (green) data. 
Green shaded areas: 95% confidence interval around 5th, 50th and 95th percentile of simulated data.  
A.2, B.2: Distribution of relative prediction errors (Section 2.3.3.8) for plasma (t=0.5 h after infusion start, A.2) and 
microdialysate data of catheter 1 (t=0-1.5 h after infusion start, B.2) for obese (red) and nonobese patients (green).  
Abbreviations: NLME: Nonlinear mixed-effects; PK: Pharmacokinetics; VPC: Visual predictive check. 
 
Figure S17: (Project I) Comparison of model predicted linezolid concentrations in the peripheral 






Figure S18: (Project I) Observed vs. population predicted (a) and individual predicted (b) total plasma 
linezolid concentrations (1), unbound plasma (2), microdialysate of catheter 1 (3) and retrodialysate linezolid 
concentrations for Model B (A) and Model C (B). 
Model B: Assignment of ISF of the s.c. adipose tissue to the already existing peripheral compartment of the plasma base model 
and estimation of additional tissue scaling factor; Model C: Assignment of ISF of the s.c. adipose tissue to a new separate 
peripheral compartment and estimation of intercompartmental clearance and the volume of distribution of the respective 
compartment (Figure 3.3). Black lines: Line of identity.  
Colour coding: Red: Obese; Green: nonobese.   




Figure S19: (Project I) Conditional weighted residuals vs. time for linezolid microdialysate (1) and plasma 
concentrations (2) for the base (A) and final joint NLME model (B).  
Symbols: Circles: Conditional weighted residuals of plasma and microdialysate concentrations of catheter 1; Triangles: 
Conditional weighted residuals of microdialysate concentrations of catheter 2.   
Lines: Black solid line: Reference lines at y=0; Grey, red and green lines: Loess smoothers [250] for all patients, obese patients 
and nonobese patients, respectively.  
Colour coding: Red: Obese; Green: nonobese.  
Abbreviations: NLME: Nonlinear mixed-effects. 
 
Figure S20: (Project I) Log-likelihood profiling of the interindividual variability parameter of the Michaelis-
Menten constant of unbound linezolid (ω2 Km,u) of the final joint NLME model for linezolid.  
Lines: Blue solid line: Log-likelihood profile, Red dashed line: ΔOFV=+3.84 with respect to the final joint NLME model. 
X-axis values at the intersection of blue solid line with the red dashed line represent the limits of the 95% confidence interval 
of ω2 Km,u.  




Figure S21: (Project II) Probability of target (95%fT>MIC) attainment vs. LBW in plasma (1) and ISF of the 





Figure S21 [continued]: (Project II) Probability of target (95%fT>MIC) attainment vs. LBW in plasma (1) and 
ISF of the s.c. adipose tissue (2) for different prolonged infusion regimens (E-H). 
All other covariates in the NLME model were set to median values of the patient population (for detailed information on patient 
characteristics see Table 2.4 B). Deterministic simulations for different linezolid dosing regimens: Appendix Figure S22.  
Vertical line: LBW obesity threshold of 47.1 kg (translating into the BMI obesity threshold of 30 kg/m2 for a 1.65 m tall female 
patient).  
Dosing regimens: SI1.212: 600 mg 30-min i.v. infusion, q12h; SI1.812: 900 mg 30-min i.v. infusion; SI1.88: 600 mg 30-min 
i.v. infusion, q8h; SI2.412: 1200 mg 30-min i.v. infusion, q12h; PI1.212: 600 mg 4-h i.v. infusion, q12h; PI1.812: 900 mg 4-h i.v. 
infusion, q12h; PI1.88: 600 mg 4-h i.v. infusion, q8h; PI2.412: 1200 mg 4-h i.v. infusion, q12h.  
Abbreviations: CU: Unbound concentration; ISF: Interstitial space fluid; LBW: Lean body weight; q8h: Every 8 h; q12h: Every 





Figure S22: (Project II) Simulated unbound linezolid concentration-time profiles in plasma (1) and ISF of 
the s.c. adipose tissue (2) for patients with varying LBW, following different short-term infusion regimens 





Figure S22 [continued]: (Project II) Simulated unbound linezolid concentration-time profiles in plasma (1) 
and ISF of the s.c. adipose tissue (2) for patients with varying LBW, following different prolonged infusion 
regimens (E-H). 
All other covariates in the NLME model were set to median values of the patient population (for detailed information on patient 
characteristics see Table 2.4 B). Note the different y-axis scales in the subfigures.  
Horizontal lines: Solid: MIC=4 mg/L; Long dashed: MIC=2 mg/L; Short-dashed: MIC=1 mg/L; Dotted=0.5 mg/L.   
Dosing regimens: SI1.212: 600 mg 30-min i.v. infusion, q12h; SI1.812: 900 mg 30-min i.v. infusion, q12h; SI1.88: 600 mg 30-
min i.v. infusion, q8h; SI2.412: 1200 mg 30-min i.v. infusion, q12h; PI1.212: 600 mg 4-h i.v. infusion, q12h; PI1.812: 900 mg 4-
h i.v. infusion, q12h; PI1.88: 600 mg 4-h i.v. infusion, q8h; PI2.412: 1200 mg 4-h i.v. infusion, q12h.  
Abbreviations: CU: Unbound concentration; ISF: Interstitial space fluid; LBW: Lean body weight; q8h: Every 8 h; q12h: Every 




Figure S23: (Project II) Simulated unbound linezolid concentration-time profiles in plasma (1) and ISF of 
the s.c. adipose tissue (2) for selected typical patients, following different short-term (left panel: A-D) and 
prolonged infusion regimens (right panel: E-H).  
Note the different y-axis scales in the subfigures   
Dashed horizontal line: Exemplary MIC value of 4 mg/L.  
Dosing regimens: SI1.212: 600 mg 30-min i.v. infusion, q12h; SI1.812: 900 mg 30-min i.v. infusion, q12h; SI1.88: 600 mg 30-
min i.v. infusion, q8h; SI2.412: 1200 mg 30-min i.v. infusion, q12h; PI1.212: 600 mg 4-h i.v. infusion, q12h; PI1.812: 900 mg 4-
h i.v. infusion, q12h; PI1.88: 600 mg 4-h i.v. infusion, q8h; PI2.412: 1200 mg 4-h i.v. infusion, q12h.  
Colour coding: Red: Obese and intra-anaesthetic patient; Dark green: Nonobese and intra-anaesthetic patient; Orange: Obese 
and post-anaesthetic patient; Light green: Nonobese and post-anaesthetic patient (for detailed information on patient 
characteristics see Table 2.4 A).  
Abbreviations: CU: Unbound concentration; ISF: Interstitial space fluid; i.v.: Intravenous; q8h: Every 8 h; q12h: Every 12 h; 




Figure S24: (Project III) Distribution of time of study start relative to time of meropenem therapy. Each colour 




Figure S25: (Project III) Individual meropenem serum concentration-time profiles (modified from [233]).   
Number above individual plot: Patient identifier; Circles: Measured meropenem concentrations; Red circles: Meropenem 
concentrations excluded from analyses (0.36%, Section 3.3.1.2); Lines: Connection of consecutively sampled meropenem 




Figure S26: (Project III) Quantified relationship between meropenem serum concentrations and creatinine 
clearance on logarithmic scale, including confidence and prediction intervals (modified from [233]).  
Logarithmised meropenem serum concentrations 8 h after start of infusion (C8h) in non-CRRT patients vs. logarithmised 
CLCRCG are shown. Colour of symbols: Respective renal function (RF) class of a patient at time of determined C8h value; 
Dashed vertical lines/horizontal arrows: Separation of renal function classes; Data points labelled with 36: Four C8h values of 
patient 36; Black solid line: Quantified log(CLCRCG) - log(C8h) relationship (representing log(C8h, pred), excluding data of patient 
36); Black dashed/dotted lines: 95% confidence interval/95% prediction interval (excluding data of patient 36).  
Abbreviations: CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]; CRRT: Continuous renal 
replacement therapy; C8h: Concentration 8 h after start of infusion; RF: Renal function. 
 
Figure S27: (Project III) Comparison of C8h meropenem predictions including or excluding patient 36 in 
model parameter estimation (modified from [233]).   
Solid/dashed/dotted lines: Quantified log(CLCRCG) - log(C8h) relationship/95% confidence interval/95% prediction interval; 
Red: Excluding patient 36; Blue: Including patient 36.  





Figure S28: (Project IV) Meropenem serum concentration vs. time after last dose for all patients and all 
monitored infusions on semilogarithmic scale. 
 
Figure S29: (Project IV) Observed vs. population predicted meropenem concentrations (1), CWRES vs. time 
(2) and population predicted meropenem concentrations (3) and residuals vs. population predicted 
meropenem concentrations (4) for a one-CMT model (A), two-CMT (B) and three-CMT (C) structural model 
without IIV and with combined RUV. 
Circles: Observed vs. population predicted meropenem concentrations (1), conditional weighted residuals vs. time (2) and 
population predicted meropenem concentrations (3).   
Lines: Line of identity (1), reference lines at y=0 (2, 3).  





Figure S30: (Project IV): Meropenem clearance vs. creatinine clearance, including a piecewise (A) and 
linear (B) relationship (modified from [243]). 
Blue circles: Individual meropenem clearance (base model); Red line: A: Identified piecewise linear relationship between 
CLCRCG and meropenem clearance of final NLME model, B: Identified linear relationship of the competing model; Dashed 
black lines: Inflection point of CLCRCG (vertical) and maximum meropenem clearance (horizontal).  
Abbreviations: CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]. 
 
Figure S31: (Project IV) Forrest plot for the final NLME model, illustrating the impact of the covariates on 
the PK parameters. 
Vertical line: Reference (x=1); Blue shaded area: ±20% change from reference (x=0.8-1.2); Grey distribution (upper panel): 
Distribution of the PK parameter for the reference covariate value; Grey distribution (lower thee panels): Distribution of relative 
change from the reference PK parameter, for a specific covariate value.  
Abbreviations: ALB: Serum albumin concentration; CL: Clearance; CLCRCG: Creatinine clearance according to Cockcroft and 
Gault; CMT: Compartment; max.: Maximum; med.: Median; min.: Minimum, Q: Intercompartmental clearance between CMT 




Figure S32: (Project IV) Visual predictive check (n=1000 simulations) for the final NLME model of 
meropenem in critically ill patients, using CLCRCG as independent variable. 
Abbreviations: CLCRCG: Creatinine clearance according to Cockcroft and Gault 
 
Figure S33: (Project IV) Case deletion diagnostic for the inflection point of CLCRCG (A) and meropenem 
clearance vs. CLCRCG, highlighting the influential individuals detected in A (B). 
A: Blue circles: CLCRCG_INF estimate after exclusion of a specific patient; Black line: Original parameter estimate (including 
all patients); Red lines: Limits of 95% confidence interval computed based as parameter estimate (154 mL/min) ± 1.96 ∙ SE 
(10.6 mL/min). B: Red and blue circles: Individual meropenem clearance (base model) of the influential patients identified in 
A and the non-influential patient, respectively.  
Abbreviations: CLCRCG: Creatinine clearance according to Cockcroft and Gault; CLCRCG_INF: CLCRCG value serving as 




Figure S34: (Project IV) Probability of target (98%T>MIC) attainment vs. different covariates given selected 
MIC values for standard meropenem treatment (1000 mg, 30-min i.v. infusion, q8h) (modified from [243]).  
A: Varied CLCRCG, body weight and serum albumin concentration set to median of first study day (i.e. 70 kg, 2.8 g/dL); 
B: Varied body weight, CLCRCG and serum albumin concentration set to median of first study day (i.e. 80.8 mL/min, 2.8 g/dL); 
C: Varied serum albumin concentration, CLCRCG and body weight set to median of first study day (i.e. 80.8 mL/min, 70 kg). 
Left panel (A.1, B.1, C.1): Treatment day 1; Right panel (A.2, B.2, C.2): Treatment day 4.  
Dashed horizontal line: PTA of 90%; Coloured circles and lines + shaded areas: Median + 90%CI of 1000 PTA values derived 
from Monte Carlo simulations considering PK parameter uncertainty; Grey shaded areas: Extrapolated covariate range not 
covered by the study population or CLCRCG ≥154 mL/min (=inflection point of CLCRCG -CL relationship).  
Abbreviations: MIC: Minimum inhibitory concentration; CI: Confidence interval; CL: Clearance; CLCRCG: Creatinine 
clearance according to Cockcroft and Gault; PTA: Probability of target attainment, q8h: Every 8 hours; T>MIC: Time period that 




Figure S35: (Project IV) Probability of target (98%T>MIC) attainment vs. MIC for different covariate 
combinations on the first day of standard meropenem treatment (1000 mg, 30-min i.v. infusion, q8h) 
(modified from [243]). 
A: Solid line: Best, typical, worst case based on all three covariates (i.e. Best case: CLCRCG 25 mL/min, body weight 121 kg, 
serum albumin concentration 2.2 g/dL; Typical case: CLCRCG 80.8 mL/min, body weight 70 kg, serum albumin concentration 
2.8 g/dL; Worst case: CLCRCG 154 mL/min, body weight 47 kg, serum albumin concentration 3.6 g/dL); Dashed line: Best, 
typical, worst case based on CLCRCG only (i.e. Best case: CLCRCG 25 mL/min, body weight 70 kg, serum albumin concentration 
2.8 g/dL; Typical case: CLCRCG 80.8 mL/min, body weight 70 kg, serum albumin concentration 2.8 g/dL; Worst case: CLCRCG 
154 mL/min, body weight 70 kg, serum albumin concentration 2.8 g/dL).  
B: Varied body weight, serum albumin concentration set to median of first study day (i.e. 2.8 g/dL), CLCRCG set to minimum, 
median and inflection point of CLCRCG -CL relationship (i.e. squares: minimum=25 mL/min; circles: median=80.8 mL/min; 
triangles: inflection point=154 mL/min).  
C: Varied serum albumin concentration, body weight set to median of first study day (i.e. 70 kg), CLCRCG set to minimum, 
median and inflection point of CLCRCG -CL relationship (i.e. squares: minimum=25 mL/min; circles: median=80.8 mL/min; 
triangles: inflection point=154 mL/min).  
Dashed horizontal line: PTA of 90%; Coloured circles and solid lines + shaded areas: Median + 90%CI of 1000 PTA values 
derived from Monte Carlo simulations considering PK parameter uncertainty. Coloured circles and dashed lines: For 
comparison: median of PTA simulations (n=1000) including parameter uncertainty for best, typical and worst-case scenario 
based on CLCRCG only (body weight and serum albumin concentration set to median of first study day).   
Abbreviations: MIC: Minimum inhibitory concentration; CI: Confidence interval; CL: Clearance; CLCRCG: Creatinine 
clearance according to Cockcroft and Gault; PTA: Probability of target attainment, q8h: Every 8 hours; T>MIC: Time period that 




Figure S36: (Project IV) Probability of target (98%T>MIC) attainment vs. MIC given selected covariate values 
for standard meropenem treatment (1000 mg, 30-min i.v. infusion, q8h) (modified from [243]).  
A: Varied CLCRCG, body weight and serum albumin concentration set to median of first study day (i.e. 70 kg, 2.8 g/dL); 
B: Varied body weight, CLCRCG and serum albumin concentration set to median of first study day (i.e. 80.8 mL/min, 2.8 g/dL); 
C: Varied serum albumin concentration, CLCRCG and body weight set to median of first study day (i.e. 80.8 mL/min, 70 kg). 
Left panel (A.1, B.1, C.1): Treatment day 1; Right panel (A.2, B.2, C.2): Treatment day 4.  
Dashed horizontal line: PTA of 90%; Dashed vertical line: Non-species-related EUCAST PK/PD breakpoints for meropenem 
(S breakpoint: 2 mg/L, R breakpoint: 8 mg/L; [5]); Coloured dots and lines + shaded areas: Median + 90%CI of 1000 PTA 
values derived from Monte Carlo simulations considering PK parameter uncertainty.  
Abbreviations: MIC: Minimum inhibitory concentration; CI: Confidence interval; CLCRCG: Creatinine clearance according to 
Cockcroft and Gault; PTA: Probability of target attainment, q8h: Every 8 hours; R category: Category ‘resistant’ [4]; R 
breakpoint: MIC breakpoint separating I and R category [5]; S category: Category ‘susceptible at normal dosing’ [4]; S 







Figure S37: (Project IV) Typical simulated meropenem concentration-time profile for varying CLCRCG, following standard and alternative dosing 
regimens.  
Deterministic exposure simulations were performed for short-term (1), prolonged (2) and continuous dosing regimens (3), for daily meropenem dose of 2000 mg (A), 3000 
mg (3412.5 mg for first day of CI, incl. loading dose) (B) and 6000 mg (6875 mg for first day of CI, incl. loading dose) (C).   
Colour coding indicates CLCRCG value: green: 24.8 mL/min (=minimum of first study day), blue: 80.8 mL/min (=median of first study day), red: 154 mL/min (=inflection 
point of CLCRCG-CL relationship).   




Figure S38: (Project III) Relation between meropenem serum C8h and CLCRCG (A) or CLCRUC (B) 
(modified from [233]).  
Blue solid line: Quantified relationship between renal function marker and meropenem serum C8h. The relationship was 
quantified using a weighted (1/CLCR) linear least square regression on (A) double logarithmic (log(CLCRCG) and log(C8h)) 
and (B) semilogarithmic scale (CLCRUC and log(C8h)) for CLCRCG and CLCRUC, respectively; Blue dotted line: 95% confidence 
interval around relationship.   
Abbreviations: CLCRCG: Creatinine clearance estimated according to Cockcroft and Gault [2]; CLCRUC: Creatinine clearance 





 Supplementary formulae 
7.3.1 General statistics 
This section summarises general statistical measures to characterise a distribution with respect to 
the central tendency (Section 7.3.1.1) and the dispersion (Section 7.3.1.2). 
7.3.1.1 Measures of central tendency 
The following measures of central tendency can be used to describe the typical value of a 
distribution 
Mean ?̅? = ∑ 𝑥𝑖𝑛𝑖=1𝑛  ( Eq. 7.1) 
Median 
If 𝑛 is odd:                      ?̃? = 𝑥 𝑛+12  
( Eq. 7.2) 
If 𝑛 is even:                    ?̃? = 0.5 ∙ (𝑥 𝑛2 + 𝑥 𝑛+12 ) 
Geometric mean ?̅?𝑔𝑒𝑜𝑚 = √∏𝑥𝑖𝑛𝑖=1𝑛  ( Eq. 7.3) 
7.3.1.2 Measures of dispersion 
The following measures of dispersion can be used to describe the variability of a distribution: 
Variance 𝜎2 = 1𝑛 − 1 ∙∑(𝑥𝑖 − ?̅?)2𝑛𝑖=1  ( Eq. 7.4) 
Standard deviation 𝜎 = √𝜎2 ( Eq. 7.5) 
Coefficient of 
variation 
𝐶𝑉,% = 𝜎?̅? ∙ 100 ( Eq. 7.6) 
Geometric standard 
deviation 
𝜎𝑔𝑒𝑜𝑚 = exp (√1𝑛 ∙∑[𝑙𝑛 ( 𝑥𝑖?̅?𝑔𝑒𝑜𝑚)]𝑛𝑖=1 ) ( Eq. 7.7) 
Range 𝑅 = 𝑥𝑚𝑖𝑛 − 𝑥𝑚𝑎𝑥 ( Eq. 7.8) 
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Percentile If 𝑛 is odd:                     𝑃 = 𝑥𝑛∙𝑝 ( Eq. 7.9) 
If 𝑛 is even:                    𝑃 = 0.5 ∙ (𝑥𝑛∙𝑝 + 𝑥𝑛∙𝑝+1)  
For computation of CV in the log-normal domain Eq. 2.6 can be used. 
7.3.2 Body size descriptors 
A variety of descriptors exist to characterise the body size of a patient. The descriptors are 
computed based on patient-specific characteristics such as total body weight (WT), body height 
(HT) or sex.  
Body mass index 
(BMI) [391] 𝐵𝑀𝐼 [𝑘𝑔𝑚2] =  𝑊𝑇[𝑘𝑔](𝐻𝑇[𝑚])2 ( Eq. 7.10) 
Lean body weight 
(LBW) [392] 
If male:               𝐿𝐵𝑊𝑚[𝑘𝑔] = 9270∙𝑊𝑇[𝑘𝑔]6680+216 ∙𝐵𝑀𝐼[𝑘𝑔𝑚2] 
( Eq. 7.11) 
If female:           𝐿𝐵𝑊𝑓[𝑘𝑔] = 9270∙𝑊𝑇 [𝑘𝑔]8780+244∙𝐵𝑀𝐼[𝑘𝑔𝑚2] 
Fat mass (FM) 𝐹𝑀 = 𝑊𝑇 − 𝐿𝐵𝑊 ( Eq. 7.12) 
Ideal body weight 
(IBW) [393] 
If male:      𝐼𝐵𝑊𝑚[𝑘𝑔] = 50 + 0.89 ∙ (𝐻𝑇[𝑐𝑚] − 152.4) 
( Eq. 7.13) 
If female:   𝐼𝐵𝑊𝑓[𝑘𝑔] = 45.5 + 0.89 ∙ (𝐻𝑇 [𝑐𝑚] − 152.4) 
Adjusted body 
weight (ABW) 
𝐴𝐵𝑊[𝑘𝑔] = 𝐼𝐵𝑊[𝑘𝑔] + 0.4 ∙ (𝑊𝑇[𝑘𝑔] − 𝐼𝐵𝑊[𝑘𝑔]) 
( Eq. 7.14) 
Equation used if WT>IBW+30%, otherwise IBW used 
7.3.3 Renal function markers 
Creatinine clearance (CLCR) is a marker to describe the renal function of a patient, which can be 
determined in different ways. CLCR can be measured by urine collection over a defined time 
interval (𝛥𝑡) and determination of the urine volume (𝑉𝑢𝑟𝑖𝑛𝑒) as well as the creatinine concentrations 
in serum (𝐶𝑐𝑟𝑒𝑎_𝑠𝑒𝑟𝑢𝑚) and urine (𝐶𝑐𝑟𝑒𝑎_𝑢𝑟𝑖𝑛𝑒). Alternatively, CLCR can be estimated e.g. 
according to the Cockcroft and Gault equation based on the determinants age, total body weight 






𝐶𝐿𝐶𝑅𝑈𝐶 [𝑚𝐿𝑚𝑖𝑛] = 𝐶𝑐𝑟𝑒𝑎_𝑢𝑟𝑖𝑛𝑒[𝑚𝑔/𝑑𝐿] ∙ 𝑉𝑢𝑟𝑖𝑛𝑒[𝑚𝐿]𝐶𝑐𝑟𝑒𝑎_𝑠𝑒𝑟𝑢𝑚[𝑚𝑔/𝑑𝐿] ∙ 𝛥𝑡[𝑚𝑖𝑛]  ( Eq. 7.15) 
Creatinine clearance, 
Cockcroft and Gault 
(CLCRCG) [2] 
𝐶𝐿𝐶𝑅𝐶𝐺 [𝑚𝐿𝑚𝑖𝑛] = (140 − 𝑎𝑔𝑒[𝑦𝑒𝑎𝑟𝑠]) ∙ 𝑊𝑇[𝑘𝑔]72 ∙ 𝐶𝑐𝑟𝑒𝑎𝑠𝑒𝑟𝑢𝑚[𝑚𝑔/𝑑𝐿]  ( ∙  0.85 𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒) ( Eq. 7.16) 
7.3.4 Haemodynamic markers 
Different markers exist to describe the haemodynamic of a patient, e.g. heart rate, blood pressure 
(diastolic blood pressure (DP), systolic blood pressure (SP)), mean arterial pressure (MAP), cardiac 
output (CO), which can be measured and/or estimated based on different determinants: 
MAP 𝑀𝐴𝑃 [𝑚𝑚𝐻𝑔] = (2 ∙ 𝐷𝑃 [𝑚𝑚𝐻𝑔]) + 𝑆𝑃 [𝑚𝑚𝐻𝑔]3  ( Eq. 7.17) 
COLZ (Liljestrand and 
Zander; unadjusted) 
[3] 
𝐶𝑂𝐿𝑍 [ 𝐿𝑚𝑖𝑛] = 𝑆𝑉𝐸𝑠𝑡 [𝐿] ∙ 𝐻𝑅 [ 1𝑚𝑖𝑛] 
𝑆𝑡𝑟𝑜𝑘𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 [𝐿] (𝑆𝑉𝐸𝑠𝑡) = 𝑆𝑃 − 𝐷𝑃𝑆𝑃 + 𝐷𝑃  ( Eq. 7.18) 
7.3.5 Linear interpolation of covariates 
Linear interpolation was used in Project IV for 
longitudinally measured continuous covariates (2.9.2.1 
Dataset generation: Handling of missing covariate data: 
Imputation and interpolation). A graphical illustration is 
provided in Figure S39 in a generic manner and in 
Appendix Figure S2 for selected exemplary covariates. The 
formula for the linear interpolation between two 
longitudinally measured continuous covariate values is 
stated as follows (Eq. 7.17): 
𝐶𝑜𝑣𝑥 = 𝐶𝑜𝑣2  −  𝐶𝑜𝑣1𝑡2  −  𝑡1 ∙ (𝑡𝑥  −  𝑡1) + 𝐶𝑜𝑣1 ( Eq. 7.19) 
In Eq. 7.17, 𝐶𝑜𝑣1 and 𝐶𝑜𝑣2 represent the measured covariate values at the time points 𝑡1 and 𝑡2, 
respectively. 𝐶𝑜𝑣𝑥 is the linearly interpolated covariate value of interest at a given time 𝑡𝑥, which 
lies between the two measured covariate values.  
 
Figure S39: Graphical illustration of 
linear interpolation of covariates . 














 NONMEM® dataset and model script 






Table S30: (Project I) Subset of NONMEM® dataset for linezolid PK data exemplified for a generic obese patient. 
ID TIME AMT RATE DV MDV EVID CMT FLAG CIN TIN ANAE ANSTOP MAP OBE WT HT LBW BMI SEX … 
1 0 600 1200 . 1 1 1 0 . . 1 3.82 97.0 1 119 1.65 56.7 43.7 2 … 
1 0.02 . . . 1 2 3 0 . 0.5 1 3.82 96.3 1 119 1.65 56.7 43.7 2 … 
1 0.02 . . . 1 2 4 0 . 0.5 1 3.82 96.3 1 119 1.65 56.7 43.7 2 … 
1 0.48 . . 27.1 0 0 1 3 . . 1 3.82 92.1 1 119 1.65 56.7 43.7 2 … 
1 0.48 . . 23.4 0 0 1 6 . . 1 3.82 92.1 1 119 1.65 56.7 43.7 2 … 
1 0.53 . . 0.99 0 0 3 1 . 0.5 1 3.82 93.8 1 119 1.65 56.7 43.7 2 … 
1 0.53 . . 1.11 0 0 4 4 . 0.5 1 3.82 93.8 1 119 1.65 56.7 43.7 2 … 
1 0.53 . . . 1 2 -3 0 . 0.5 1 3.82 93.8 1 119 1.65 56.7 43.7 2 … 
1 0.53 . . . 1 2 -4 0 . 0.5 1 3.82 93.8 1 119 1.65 56.7 43.7 2 … 
1 0.53 . . . 1 2 3 0 . 0.52 1 3.82 93.8 1 119 1.65 56.7 43.7 2 … 
1 0.53 . . . 1 2 4 0 . 0.52 1 3.82 93.8 1 119 1.65 56.7 43.7 2 … 
1 0.98 . . 13.4 0 0 1 3 . . 1 3.82 77.5 1 119 1.65 56.7 43.7 2 … 
1 1.04 . . 1.88 0 0 3 1 . 0.52 1 3.82 72.3 1 119 1.65 56.7 43.7 2 … 
1 1.04 . . 3.12 0 0 4 4 . 0.52 1 3.82 72.3 1 119 1.65 56.7 43.7 2 … 
1 1.04 . . . 1 2 -3 0 . 0.52 1 3.82 72.3 1 119 1.65 56.7 43.7 2 … 
1 1.04 . . . 1 2 -4 0 . 0.52 1 3.82 72.3 1 119 1.65 56.7 43.7 2 … 
1 1.04 . . . 1 2 3 0 . 0.48 1 3.82 72.3 1 119 1.65 56.7 43.7 2 … 







Table S30 [continued] 
ID TIME AMT RATE DV MDV EVID CMT FLAG CIN TIN ANAE ANSTOP MAP OBE WT HT LBW BMI SEX … 
1 1.51 . . 2.25 0 0 3 1 . 0.48 1 3.82 67.0 1 119 1.65 56.7 43.7 2 … 
1 1.51 . . 2.89 0 0 4 4 . 0.48 1 3.82 67.0 1 119 1.65 56.7 43.7 2 … 
1 1.51 . . . 1 2 -3 0 . 0.48 1 3.82 67.0 1 119 1.65 56.7 43.7 2 … 
1 1.51 . . . 1 2 -4 0 . 0.48 1 3.82 67.0 1 119 1.65 56.7 43.7 2 … 
1 1.51 . . . 1 2 3 0 . 0.5 1 3.82 67.0 1 119 1.65 56.7 43.7 2 … 
1 1.51 . . . 1 2 4 0 . 0.5 1 3.82 67.0 1 119 1.65 56.7 43.7 2 … 
1 1.98 . . 13 0 0 1 3 . . 1 3.82 66.8 1 119 1.65 56.7 43.7 2 … 
1 2.03 . . 2.61 0 0 3 1 . 0.5 1 3.82 65.1 1 119 1.65 56.7 43.7 2 … 
1 2.03 . . 2.44 0 0 4 4 . 0.5 1 3.82 65.1 1 119 1.65 56.7 43.7 2 … 
1 2.03 . . . 1 2 -3 0 . 0.5 1 3.82 65.1 1 119 1.65 56.7 43.7 2 … 
1 2.03 . . . 1 2 -4 0 . 0.5 1 3.82 65.1 1 119 1.65 56.7 43.7 2 … 
1 2.03 . . . 1 2 3 0 . 0.98 1 3.82 65.1 1 119 1.65 56.7 43.7 2 … 
1 2.03 . . . 1 2 4 0 . 0.98 1 3.82 65.1 1 119 1.65 56.7 43.7 2 … 
1 2.97 . . 8.71 0 0 1 3 . . 1 3.82 68.8 1 119 1.65 56.7 43.7 2 … 
1 2.97 . . 7.49 0 0 1 6 . . 1 3.82 68.8 1 119 1.65 56.7 43.7 2 … 
1 3.02 . . 2.13 0 0 3 1 . 0.98 1 3.82 68.8 1 119 1.65 56.7 43.7 2 … 
1 3.02 . . 2.08 0 0 4 4 . 0.98 1 3.82 68.8 1 119 1.65 56.7 43.7 2 … 






Table S30 [continued] 
ID TIME AMT RATE DV MDV EVID CMT FLAG CIN TIN ANAE ANSTOP MAP OBE WT HT LBW BMI SEX … 
1 3.02 . . . 1 2 -4 0 . 0.98 1 3.82 69.3 1 119 1.65 56.7 43.7 2 … 
1 3.02 . . . 1 2 3 0 . 1 1 3.82 69.3 1 119 1.65 56.7 43.7 2 … 
1 3.02 . . . 1 2 4 0 . 1 1 3.82 69.3 1 119 1.65 56.7 43.7 2 … 
1 3.83 . . . 1 2 . 8 . . 1 3.82 69.3 1 119 1.65 56.7 43.7 2 … 
1 3.83 . . . 1 2 . 8 . . 1 3.82 69.3 1 119 1.65 56.7 43.7 2 … 
1 3.97 . . 8.79 0 0 1 3 . . 0 3.82 69.0 1 119 1.65 56.7 43.7 2 … 
1 4.01 . . 2.35 0 0 3 1 . 1 0 3.82 68.4 1 119 1.65 56.7 43.7 2 … 
1 4.01 . . 2.04 0 0 4 4 . 1 0 3.82 68.4 1 119 1.65 56.7 43.7 2 … 
1 4.01 . . . 1 2 -3 0 . 1 0 3.82 68.4 1 119 1.65 56.7 43.7 2 … 
1 4.01 . . . 1 2 -4 0 . 1 0 3.82 68.4 1 119 1.65 56.7 43.7 2 … 
1 4.01 . . . 1 2 3 0 . 1.02 0 3.82 68.4 1 119 1.65 56.7 43.7 2 … 
1 4.01 . . . 1 2 4 0 . 1.02 0 3.82 68.4 1 119 1.65 56.7 43.7 2 … 
1 4.97 . . 7.31 0 0 1 3 . . 0 3.82 82.2 1 119 1.65 56.7 43.7 2 … 
1 5.02 . . 2.21 0 0 3 1 . 1.02 0 3.82 82.2 1 119 1.65 56.7 43.7 2 … 
1 5.02 . . 2.00 0 0 4 4 . 1.02 0 3.82 82.2 1 119 1.65 56.7 43.7 2 … 
1 5.02 . . . 1 2 -3 0 . 1.02 0 3.82 82.2 1 119 1.65 56.7 43.7 2 … 
1 5.02 . . . 1 2 -4 0 . 1.02 0 3.82 82.2 1 119 1.65 56.7 43.7 2 … 







Table S30 [continued] 
ID TIME AMT RATE DV MDV EVID CMT FLAG CIN TIN ANAE ANSTOP MAP OBE WT HT LBW BMI SEX … 
1 5.02 . . . 1 2 4 0 . 0.98 0 3.82 82.2 1 119 1.65 56.7 43.7 2 … 
1 5.97 . . 6.32 0 0 1 3 . . 0 3.82 99.8 1 119 1.65 56.7 43.7 2 … 
1 6.03 . . 1.45 0 0 3 1 . 0.98 0 3.82 99.8 1 119 1.65 56.7 43.7 2 … 
1 6.03 . . 1.77 0 0 4 4 . 0.98 0 3.82 99.8 1 119 1.65 56.7 43.7 2 … 
1 6.03 . . . 1 2 -3 0 . 0.98 0 3.82 99.8 1 119 1.65 56.7 43.7 2 … 
1 6.03 . . . 1 2 -4 0 . 0.98 0 3.82 99.8 1 119 1.65 56.7 43.7 2 … 
1 6.03 . . . 1 2 3 0 . 1 0 3.82 99.8 1 119 1.65 56.7 43.7 2 … 
1 6.03 . . . 1 2 4 0 . 1 0 3.82 99.8 1 119 1.65 56.7 43.7 2 … 
1 7 . . 1.33 0 0 3 1 . 1 0 3.82 97.1 1 119 1.65 56.7 43.7 2 … 
1 7 . . 1.30 0 0 4 4 . 1 0 3.82 97.1 1 119 1.65 56.7 43.7 2 … 
1 7 . . . 1 2 -3 0 . 1 0 3.82 97.1 1 119 1.65 56.7 43.7 2 … 
1 7 . . . 1 2 -4 0 . 1 0 3.82 97.1 1 119 1.65 56.7 43.7 2 … 
1 7 . . . 1 2 3 0 . 1.02 0 3.82 97.1 1 119 1.65 56.7 43.7 2 … 
1 7 . . . 1 2 4 0 . 1.02 0 3.82 97.1 1 119 1.65 56.7 43.7 2 … 
1 7.99 . . 4.97 0 0 1 3 . . 0 3.82 102 1 119 1.65 56.7 43.7 2 … 
1 7.99 . . 4.22 0 0 1 6 . . 0 3.82 102 1 119 1.65 56.7 43.7 2 … 
1 8.03 . . 0.98 0 0 3 1 . 1.02 0 3.82 103 1 119 1.65 56.7 43.7 2 … 






Table S30 [continued] 
ID TIME AMT RATE DV MDV EVID CMT FLAG CIN TIN ANAE ANSTOP MAP OBE WT HT LBW BMI SEX … 
1 8.03 . 
. 
. 1 2 -3 0 . 1.02 0 3.82 103 1 119 1.65 56.7 43.7 2 … 
1 8.03 . 
. 
. 1 2 -4 0 . 1.02 0 3.82 103 1 119 1.65 56.7 43.7 2 … 
1 8.89 . 
. 
105 0 0 2 2 154 0.5 0 3.82 103 1 119 1.65 56.7 43.7 2 … 
1 8.89 . 
. 
99.8 0 0 2 5 154 0.5 0 3.82 103 1 119 1.65 56.7 43.7 2 … 
Abbreviations: ID: Patient identifier; AMT: Amount (here: linezolid dose [mg]); RATE: Infusion rate (here: [mg/h]); DV: Dependent variable (here: linezolid concentration [mg/L]); MDV: Missing 
dependent variable; EVID: Event identification (here: 0=observation event, 1=dosing event, 2=turn on/switch off compartment); CMT: Compartment (here: 1=Central compartment; 2=Peripheral 
compartment; 3=Microdialysis compartment of catheter 1; 4=Microdialysis compartment of catheter 2); FLAG (here: 0=dose or turn on/switch off CMT, 1=microdialysate observation of catheter 
1, 2=Retrodialysis observation of catheter 1, 3=total plasma observation, 4=microdialysate observation of catheter 2, 5=Retrodialysis observation of catheter 1, 6=unbound plasma observation, 
8=Covariate event); CIN: Retroperfusate concentration (here: linezolid concentration in retroperfusate [mg/L]); TIN: Time interval (here: Micro-/retrodialysis collection interval [h]); ANAE: 
Anaesthesia status (here: 0=post-anaesthetic, 1=intra-anaesthetic); MAP: Mean arterial pressure (here: [mmHg]); OBE: Obesity status (here: 1=Obese, 2=Non-obese), WT: Total body weight (here: 




7.4.2 Project I: NONMEM® script 
;; 1. Based on: run256c 
;; 2. Description: Final joint NLME model, project 1 
;; 3. Label: Final model, all PK data (plasma total&unbound; MD catheter 1&2; RD catheter 1&2) 
;; 4. Structural Model: 2 CMT PK model, ISF part of peripheral CMT; 2 MD dummy CMTs 
;; 5. Covariate model: OBE on RR, TF; LBW on V1, V2, Q; ANAE on TF, MAP on CLTot 
;; 6. Interindividual variability: CL, Km, V1, Q, V2, TF, ANAE_TF 
;; 7. Further levels of variability: Intercatheter&Intracatheter variability on RR 
;; 8. Residual variability: Separate proportional for PK matrices 
;; 9. Estimation: FOCE-I 
;; 10. Author: Lisa Ehmann 
 
$PROBLEM     Final joint NLME model 
$INPUT       ID TIME AMT RATE DV MDV EVID CMT FLAG CIN TINT ANAE ANSTOP MAP OBE WT HT 
LBW BMI SEX (...) 
$DATA       KP-MDL01_FinalNONMEMDataset.csv 
             IGNORE=@ 
$SUBROUTINE  ADVAN6 TOL=6 
 
;;;;; Model compartments --------------------------------------------------------------------- 
 




COMP=(MDCAT1,INITIALOFF)           
COMP=(MDCAT2,INITIALOFF) 
 
$PK    
IF(NEWIND.LE.1) TANAE=ANSTOP 
   
;;;;; Inter- and intracatheter variabilities --------------------------------------------------  
 
; Intercatheter variability in RR (catheter 1)    
INTERCV_CAT1=ETA(10) ; if RD or MD catheter 1 
 
; Intercatheter variability in RR (catheter 2) 
INTERCV_CAT2=ETA(11) ; if RD or MD catheter 2  
 
; Intracatheter variability in RR (catheter 1) 
IF (SAM.EQ.201) THEN ; If catheter 1 (RD1)   
INTRACV=ETA(12) 
ENDIF 




; Intracatheter variability in RR (catheter 2) 
IF (SAM.EQ.501) THEN ; If catheter 2 (RD1)    
INTRACV=ETA(14) 
ENDIF 



















TVV1=THETA(2)*(LBW/51.9)**1                                       
V1=TVV1*EXP(ETA(2)) 
 
TVQ2=THETA(3)*(LBW/51.9)**0.75                                      
Q2=TVQ2*EXP(ETA(3)) 
 























































;;;;; Ordinary differential equations -------------------------------------------------------- 
 




DADT(1)=-K12*A(1)+K21*A(2)-C1*CLT                 ; Central 
CMT 
DADT(2)=K12*A(1)-K21*A(2)        ; 
Peripheral CMT 
CISF=(A(2)/V2)*TF 
DADT(3)=CISF*RRL         ; MDCAT1 
s.c. CMT 



































IF(FLAG.EQ.3) THEN ; plasma total 
IPRED=(A(1)/V1)/FU 
RVA=THETA(8)  ; RUV additive 
RVP=THETA(9)  ; RUV proportional 
ENDIF 
 
IF(FLAG.EQ.6) THEN ; plasma unbound 
IPRED=(A(1)/V1) 
RVA=THETA(10)  ; RUV additive 
RVP=THETA(11)  ; RUV proportional 
ENDIF 
 
IF(FLAG.EQ.1) THEN ; MD catheter 1 
IPRED=A(3)/TIN 
RVA=THETA(12)  ; RUV additive 
RVP=THETA(13)  ; RUV proportional 
ENDIF 
 
IF(FLAG.EQ.4) THEN ; MD catheter 2 
IPRED=A(4)/TIN 
RVA=THETA(12)  ; RUV additive 
RVP=THETA(13)  ; RUV proportional 
ENDIF 
 
IF(FLAG.EQ.2) THEN ; RD catheter 1  
IPRED=CUT1 
RVA=THETA(14)  ; RUV additive 
RVP=THETA(15)  ; RUV proportional 
ENDIF 
 
IF(FLAG.EQ.5) THEN ; RD  catheter 2 
IPRED=CUT2 
RVA=THETA(14)  ; RUV additive 












;;;;; Initial estimates ---------------------------------------------------------------------- 
 
$THETA   
 (0,3.47)     ; CL 
 (0,17)      ; V1 
 (0,62.8)     ; Q2 
 (0,33.4)     ; V2 
 (0,0.856,1)     ; FU 
 (0,0.374,1)     ; RR_OBE 
 (0,0.543)     ; TF_OBE 
 (0) FIX      ; PLTot_RVadd 
 (0,0.0469)     ; PLTot_RVprop 
 (0) FIX      ; PLUnb_RVadd 
 (0,0.0452)     ; PLUnb_RVprop 
 (0) FIX      ; MD_RVadd 
 (0,0.124)     ; MD_RVprop 
 (0) FIX      ; RD_RVadd 
 (0.019) FIX     ; RD_RVprop 
 (0,44.1)     ; VMax 
 (0,2.84)     ; KM 
 (0,0.575,1)     ; RR_NOBE 
 (0,0.691,1)     ; TF_NOBE 
 (0.00825)     ; MAP_CLT 
 (-0.137)     ; ANAE_TF 
 
$OMEGA   
 0.337       ; IIV_CL 
 0.162       ; IIV_V1 
 0.193       ; IIV_Q2 
 0.0284      ; IIV_V2 
 0  FIX       ; IIV_FU 
 0.0213      ; IIV_TF 
 0  FIX       ; IIV_VM 
 0.519       ; IIV_KM 
 0  FIX       ; IIV_RR 
$OMEGA  BLOCK(1) 0.066    ; InterCV_RR (catheter 1) 
$OMEGA  BLOCK(1) SAME  ; InterCV_RR (catheter w) 
$OMEGA  BLOCK(1) 0.0723    ; IntraCV_RR (RD:1, catheter 1) 
$OMEGA  BLOCK(1) SAME  ; IntraCV_RR (RD:2, catheter 1) 
$OMEGA  BLOCK(1) SAME  ; IntraCV_RR (RD:1, catheter 2) 
$OMEGA  BLOCK(1) SAME  ; IntraCV_RR (RD:2, catheter 2) 
$OMEGA  0.511      ; IIV_ANAE_TF 
 





;;;;; Estimation and table output  ----------------------------------------------------------- 
 




$TABLE ID OBE FLAG TIME PRED IPRED C2 CISF DV MDV IWRES 
            CWRES WRES IRES EVID AMT NOPRINT ONEHEADER FILE=sdtab256f 
$TABLE ID OBE FLAG TIME DV CL VM VM_T TVVM_T KM KM_T 
            TVKM_T CLL CLL_T CLN CLN_T CLT CLT_T V1 V1_T TVV1_T Q2 
            Q2_T TVQ2_T V2 V2_T TVV2_T FU TVRR RR_ID RR_ID_CAT1 
            RR_ID_CAT2 RR1 RR2 TF TF_T TVTF_T MAP_CLT ANAE_TF ETA1 
            ETA2 ETA3 ETA4 ETA5 ETA6 ETA7 ETA8 ETA9 ETA10 ETA11 ETA12 
            ETA13 ETA14 ETA15 ETA16 NOPRINT NOAPPEND ONEHEADER FILE=patab256f 
$TABLE ID TIME OBE NOPRINT NOAPPEND ONEHEADER FILE=catab256f 




7.4.3 Project IV: NONMEM® script 
;; 1. Based on: run262 
;; 2. Description: Final NLME model, project 4 
;; 3. Label: Final model with covariates 
;; 4. Structural Model: 2 CMT PK model 
;; 5. Covariate model: CLCRCG on CL, WT on V1, ALB on V2 
;; 6. Interindividual variability: CL, V1, V2 
;; 7. Interoccasion variability: CL 
;; 8. Residual variability: Combined 
;; 9. Estimation: FOCE-I 
;; 10. Author: Lisa Ehmann 
 
$PROBLEM     Final NLME model 
$INPUT       ID TIME AMT RATE DV MDV EVID ID OCC SEX AGE WT HT BMI CLCRCG ALB (…)  
$DATA       KP-MDL01_FinalNONMEMDataset.csv 
             IGNORE=@ 
$SUBROUTINE  ADVAN6 TOL=6 
 
;;;;; Model compartments --------------------------------------------------------------------- 
 





$PK    
 
;;;;;  Interoccasion variability --------------------------------------------------  
 
IF (OCC2.EQ.1) THEN 
 IOVCL=ETA(5) 
ENDIF 
IF (OCC2.EQ.2) THEN 
 IOVCL=ETA(6) 
ENDIF 
IF (OCC2.EQ.3) THEN 
 IOVCL=ETA(7)  
ENDIF 
IF (OCC2.EQ.4) THEN 
 IOVCL=ETA(8) 
ENDIF 
IF (OCC2.EQ.5) THEN 
 IOVCL=ETA(9) 
ENDIF 







;;;;; PK parameters -------------------------------------------------------------------------- 
 
CLCRCG_INF = THETA(10)    ; estimated CLCRCG inflection point  
CLCRCG_IND = 0      ; indicator value 
IF(CLCRCG.GE.CLCRCG_INF) CLCRCG_IND = 1 
 
TVCL = (THETA(1)*( 1 + THETA(7)*(CLCRCG - 80.8))*(1-CLCRCG_IND))   
             + (THETA(1)*( 1 + THETA(7)*(CLCRCG_INF - 80.8))*CLCRCG_IND) 
 
CL = TVCL*EXP(ETA(1)+IOVCL) 
 
TVV1 = THETA(2)*((WT/70)**THETA(8)) 
V1 = TVV1*EXP(ETA(2)) 
 
TVQ = THETA(3) 
Q = TVQ*EXP(ETA(3)) 
 
TVV2 = THETA(4)*( 1 + THETA(9) * (ALB - 2.79)) 





S1 = V1 
S2 = V2 
 
;;;;; Ordinary differential equations -------------------------------------------------------- 
 























;;;;; Initial estimates ---------------------------------------------------------------------- 
 
$THETA 
(0, 9.22)      ; THETA(1) = CL 
(0.001, 9.19)      ; THETA(2) = V1 
(0, 23.2)      ; THETA(3) = Q 
(0.001, 14.5)      ; THETA(4) = V2 
(0, 0.149)      ; THETA(5) = RVProp 
(0, 0.261)      ; THETA(6) = RVadd 
(0, 0.0098)      ; THETA(7) = CL_CLCR_2 
(0.783)       ; THETA(8) = V1_WT_5 
(-0.2)       ; THETA(9) = V2_ALB_2 
(0, 154, 250)      ; THETA(10) = CLCRCG_INF 
 
$OMEGA  
 0.0711       ; ETA(1) = IIV on CL  
 0.0721       ; ETA(2) = IIV on V1  
 0 FIX        ; ETA(3) = IIV on Q 
 0.0317       ; ETA(4) = IIV on V2  
 
$OMEGA BLOCK(1)  
0.0167      ; ETA(5) = IOV on CL (OCC: 1) 
$OMEGA BLOCK (1) SAME    ; ETA(6) = IOV on CL (OCC: 2) 
$OMEGA BLOCK (1) SAME    ; ETA(7) = IOV on CL (OCC: 3) 
$OMEGA BLOCK (1) SAME    ; ETA(8) = IOV on CL (OCC: 4) 
$OMEGA BLOCK (1) SAME    ; ETA(9) = IOV on CL (OCC: 5) 




 1 FIX  ; EPS(1)  
 
;;;;; Estimation and table output  ----------------------------------------------------------- 
 
$ESTIMATION METHOD=1 INTER NOABORT MAXEVAL=9999 PRINT=5 MSFO=MSF262e 
 
$COVARIANCE PRINT = E 
 
$TABLE ID TIME TALD DV MDV EVID PRED RES WRES CWRES IPRED C2 IRES IWRES CIWRES 
ONEHEADER NOPRINT FILE=sdtab262e 
$TABLE ID TIME OCC DV CL V1 Q V2 ETA1 ETA2 ETA3 ETA4 ETA5 ETA6 ETA7 ETA8 ETA9 ETA10 IOVCL 
CLCRCG_INF CLCRCG_IND   
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